

Cochrane Database of Systematic Reviews

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia (Review)

Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L

Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. *Cochrane Database of Systematic Reviews* 2013, Issue 6. Art. No.: CD003038. DOI: 10.1002/14651858.CD003038.pub2.

www.cochranelibrary.com



TABLE OF CONTENTS

ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	3
BACKGROUND	5
OBJECTIVES	5
METHODS	6
RESULTS	7
Figure 1	10
Figure 2	11
Figure 3	11
DISCUSSION	12
AUTHORS' CONCLUSIONS	13
ACKNOWLEDGEMENTS	14
REFERENCES	15
CHARACTERISTICS OF STUDIES	23
DATA AND ANALYSES	85
Analysis 1.1. Comparison 1 Overall effectiveness, Outcome 1 All cause mortality.	85
Analysis 1.2. Comparison 1 Overall effectiveness, Outcome 2 Infection-related mortality.	87
Analysis 1.3. Comparison 1 Overall effectiveness, Outcome 3 Treatment failure.	88
Analysis 2.1. Comparison 2 Superinfections, Outcome 1 Bacterial superinfections.	90
Analysis 2.2. Comparison 2 Superinfections, Outcome 2 Fungal superinfections.	91
Analysis 3.1. Comparison 3 Adverse events, Outcome 1 Any adverse event (monotherapy).	92
Analysis 3.2. Comparison 3 Adverse events, Outcome 2 Discontinuation due to adverse event.	94
Analysis 3.3. Comparison 3 Adverse events, Outcome 3 Any nephrotoxicity - Ag dosing regimen.	95
Analysis 3.4. Comparison 3 Adverse events, Outcome 4 Severe nephrotoxicity - Ag dosing regimen.	96
Analysis 5.4. Comparison 5 Adverse events, outcome 4 severe nephrotoxicity 7 Ag dosing regiment and a severe nephrotoxicity 7 Ag dosing	97
Analysis 4.2. Comparison 4 Documented infections (subgroup analysis), Outcome 2 Treatment failure.	98
Analysis 4.2. Comparison 4 Documented infections (subgroup analysis), Outcome 1 All cause mortality.	99
Analysis 5.2. Comparison 5 Bacteraemia (subgroup analysis), Outcome 2 Treatment failure.	100
Analysis 5.2. Comparison 5 Bacteraemia (subgroup analysis), Outcome 2 Treatment failure	100
Analysis 6.2. Comparison 6 Gram-negative infections (subgroup analysis), Outcome 1 Air Cause mortainty.	101
	102
Analysis 7.1. Comparison 7 Pseudomonas infections (subgroup analysis), Outcome 1 All cause mortality.	
Analysis 7.2. Comparison 7 Pseudomonas infections (subgroup analysis), Outcome 2 Treatment failure.	103
Analysis 8.1. Comparison 8 Haematological cancer patients (subgroup analysis), Outcome 1 All cause mortality.	104
Analysis 8.2. Comparison 8 Haematological cancer patients (subgroup analysis), Outcome 2 Treatment failure.	105
Analysis 9.1. Comparison 9 Severe neutropenia (subgroup analysis), Outcome 1 All cause mortality.	106
Analysis 9.2. Comparison 9 Severe neutropenia (subgroup analysis), Outcome 2 Treatment failure.	107
Analysis 10.1. Comparison 10 Monotherapy, Outcome 1 All cause mortality.	108
Analysis 10.2. Comparison 10 Monotherapy, Outcome 2 Treatment failure.	110
Analysis 11.1. Comparison 11 Adults vs. children, Outcome 1 All cause mortality.	113
Analysis 11.2. Comparison 11 Adults vs. children, Outcome 2 Treatment failure.	115
Analysis 12.1. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 1 Allocation concealment (mortality)	120
Analysis 12.2. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 2 Intention-to-treat vs. efficacy analysis	121
(mortality) Analysis 12.3. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 3 Unit of randomisation (mortality)	123
Analysis 12.4. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 4 Publication status (mortality).	124
Analysis 12.5. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 5 Trial size (mortality).	125
Analysis 12.6. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 6 Allocation concealment (failure)	127
Analysis 12.7. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 7 Intention to treat vs. efficacy analysis (failure).	129
Analysis 12.8. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 8 Intention to treat vs. efficacy analysis, assuming dropouts=failures (failure).	131



Analysis 12.10. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 10 Unit of randomisation (failure).135Analysis 12.11. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 11 Blinding (failure).137Analysis 12.12. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 12 Publication status (failure).139APPENDICES141WHAT'S NEW143HISTORY143CONTRIBUTIONS OF AUTHORS143DECLARATIONS OF INTEREST144NDEX TERMS144	Analysis 12.9. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 9 Trial size (failure).	133
Analysis 12.12. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 12 Publication status (failure).139APPENDICES141WHAT'S NEW143HISTORY143CONTRIBUTIONS OF AUTHORS143DECLARATIONS OF INTEREST144SOURCES OF SUPPORT144	Analysis 12.10. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 10 Unit of randomisation (failure)	135
APPENDICES	Analysis 12.11. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 11 Blinding (failure).	137
WHAT'S NEW143HISTORY143CONTRIBUTIONS OF AUTHORS143DECLARATIONS OF INTEREST144SOURCES OF SUPPORT144	Analysis 12.12. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 12 Publication status (failure)	139
HISTORY 143 CONTRIBUTIONS OF AUTHORS 143 DECLARATIONS OF INTEREST 144 SOURCES OF SUPPORT 144	APPENDICES	141
CONTRIBUTIONS OF AUTHORS143DECLARATIONS OF INTEREST144SOURCES OF SUPPORT144	WHAT'S NEW	143
DECLARATIONS OF INTEREST	HISTORY	143
SOURCES OF SUPPORT	CONTRIBUTIONS OF AUTHORS	143
	DECLARATIONS OF INTEREST	144
INDEX TERMS	SOURCES OF SUPPORT	144
	INDEX TERMS	144



[Intervention Review]

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia

Mical Paul¹, Yaakov Dickstein², Agata Schlesinger³, Simona Grozinsky-Glasberg⁴, Karla Soares-Weiser⁵, Leonard Leibovici³

¹Division of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel. ²Medicine A and Unit of Infectious Diseases, Rambam Health Care Center, Haifa, Israel. ³Department of Medicine E, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel. ⁴Neuroendocrine Tumors Unit, Endocrinology & Metabolism Service, Dept of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. ⁵Cochrane Editorial Unit, Cochrane, London, UK

Contact: Mical Paul, Division of Infectious Diseases, Rambam Health Care Campus, Ha-aliya 8 St, Haifa, 33705, Israel. paulm@post.tau.ac.il, m_paul@rambam.health.gov.il.

Editorial group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. **Publication status and date:** Edited (no change to conclusions), published in Issue 9, 2016.

Citation: Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L. Beta-lactam versus beta-lactamaminoglycoside combination therapy in cancer patients with neutropenia. *Cochrane Database of Systematic Reviews* 2013, Issue 6. Art. No.: CD003038. DOI: 10.1002/14651858.CD003038.pub2.

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Continued controversy surrounds the optimal empirical treatment for febrile neutropenia. New broad-spectrum beta-lactams have been introduced as single treatment, and classically, a combination of a beta-lactam with an aminoglycoside has been used.

Objectives

To compare beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for cancer patients with fever and neutropenia.

Search methods

The Cochrane Central Register of Controlled Trials (CENTRAL) (*The Cochrane Library*, Issue 7, 2012), LILACS (August 2012), MEDLINE and EMBASE (August 2012) and the Database of Abstracts of Reviews of Effects (DARE) (Issue 3, 2012). We scanned references of all included studies and pertinent reviews and contacted the first author of each included trial, as well as the pharmaceutical companies.

Selection criteria

Randomised controlled trials (RCTs) comparing any beta-lactam antibiotic monotherapy with any combination of a beta-lactam and an aminoglycoside antibiotic, for the initial empirical treatment of febrile neutropenic cancer patients. All cause mortality was the primary outcome assessed.

Data collection and analysis

Data concerning all cause mortality, infection related mortality, treatment failure (including treatment modifications), super-infections, adverse effects and study quality measures were extracted independently by two review authors. Risk ratios (RRs) with their 95% confidence intervals (CIs) were estimated. Outcomes were extracted by intention-to-treat (ITT) analysis whenever possible. Individual domains of risk of bias were examined through sensitivity analyses. Published data were complemented by correspondence with authors.

Main results

Seventy-one trials published between 1983 and 2012 were included. All cause mortality was lower with monotherapy (RR 0.87, 95% CI 0.75 to 1.02, without statistical significance). Results were similar for trials comparing the same beta-lactam in both trial arms (11 trials, 1718



episodes; RR 0.74, 95% CI 0.53 to 1.06) and for trials comparing different beta-lactams — usually a broad-spectrum beta-lactam compared with a narrower-spectrum beta-lactam combined with an aminoglycoside (33 trials, 5468 episodes; RR 0.91, 95% CI 0.77 to 1.09). Infection related mortality was significantly lower with monotherapy (RR 0.80, 95% CI 0.64 to 0.99). Treatment failure was significantly more frequent with monotherapy in trials comparing the same beta-lactam (16 trials, 2833 episodes; RR 1.11, 95% CI 1.02 to 1.20), and was significantly more frequent with combination therapy in trials comparing different beta-lactams (55 trials, 7736 episodes; RR 0.92, 95% CI 0.88 to 0.97). Bacterial super-infections occurred with equal frequency, and fungal super-infections were more common with combination therapy. Adverse events were more frequent with combination therapy (numbers needed to harm 4; 95% CI 4 to 5). Specifically, the difference with regard to nephrotoxicity was highly significant. Adequate trial methods were associated with a larger effect estimate for mortality and smaller effect estimates for failure. Nearly all trials were open-label. No correlation was noted between mortality and failure rates and these trials.

Authors' conclusions

Beta-lactam monotherapy is advantageous compared with beta-lactam-aminoglycoside combination therapy with regard to survival, adverse events and fungal super-infections. Treatment failure should not be regarded as the primary outcome in open-label trials, as it reflects mainly treatment modifications.

PLAIN LANGUAGE SUMMARY

Cancer patients with fever and suspected infection can be treated with a single 'new-generation' beta-lactam antibiotic

Cancer chemotherapy or bone marrow transplantation disrupts the immune system, exposing patients to severe infection. The major sign of infection is fever, and the hallmark of damaged immune defences is a decreased white blood cell count. Patients have usually been treated with a combination of two different classes of antibiotics. Evidence shows that treatment with a new single drug (monotherapy), belonging to the beta-lactam class of antibiotics, is associated with better outcomes. Survival is improved when single-drug therapy is used, and side effects, mainly damage to the kidneys, are more frequent with combination therapy.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. beta-lactam monotherapy compared to beta-lactam-aminoglycoside combination therapy for Febrile neutropenic cancer patients

Beta-lactam monotherapy compared with beta-lactam-aminoglycoside combination therapy for febrile neutropenic cancer patients

Patient or population: febrile neutropenic cancer patients.

Settings:

Intervention: beta-lactam monotherapy.

Comparison: beta-lactam-aminoglycoside combination therapy.

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Partici- pants	Quality of the evidence	Comments
	Assumed risk	Corresponding risk		(studies)	(GRADE)	
	Beta-lactam-aminoglyco- side combination therapy	Beta-lactam monotherapy				
All cause mortali-	Study population		RR 0.87 (0.75 to 1.02)	7186 (44 studies)	⊕⊕⊕⊕ high	
ty	83 per 1000	72 per 1000 (62 to 85)	(0.13 (0 1.02)	(++ studies)	ingi	
	Moderate					
	68 per 1000	59 per 1000 (51 to 69)				
Any nephrotoxici-	Study population		RR 0.45 (0.35 to 0.57)	6608 (39 studies)	⊕⊕⊕⊕ high	
ty - Ag dosing regi- men (Copy)	57 per 1000	26 per 1000 (20 to 33)	(0.33 (0.37)	(JJ studies)	ingi	
	Moderate					
	29 per 1000	13 per 1000 (10 to 17)				
Treatment failure - same beta-lac-	Study population		RR 1.11 (1.02 to 1.2)	2833 (10 studies)	⊕⊕⊕⊝	
tam	405 per 1000	449 per 1000 (413 to 485)	(1.02 (0 1.2)	(16 studies)	moderate ¹	

Cochrane Library

	Moderate				
	398 per 1000	442 per 1000 (406 to 478)			
Treatment fail-	Study population		RR 0.92 (0.88 to 0.97)	7736 (55 studies)	⊕⊕⊝⊝ Low 1 2 3 4
ure - different be- ta-lactam 426 per 100	426 per 1000	392 per 1000 (375 to 413)	(0.88 to 0.97)	3 to 0.97) (55 studies) low 1,2,3,4	(OW 1,2,3,7
	Moderate				
	432 per 1000	397 per 1000 (380 to 419)			
Moderate quality: I Low quality: Further Very low quality: W Outcome determine Differences decrease	Further research is likely to er research is very likely to /e are very uncertain abou ed mainly by treatment mo ed with low risk of bias reg s between published and o	difications. Poor correlation with all cause mort arding allocation concealment.	the estimate of effe the estimate of effe	t and is likely to ch	ange the estimate.



BACKGROUND

Cancer patients are prone to infection. Low blood cell count (neutropenia) and disruption of normal barriers to infection, such as skin and mucous membranes, are caused by chemotherapy or underlying malignancy. Both disrupt the normal immune response and predispose patients to infection (Bodey 1966). Pathogens implicated in these infections are Gram-negative bacteria, including *Pseudomonas aeruginosa*, Gram-positive bacteria and fungi (Chow 1991; Hughes 1997). The considerable morbidity and mortality associated with these infections in neutropenic patients led to the routine use of empirical antibiotic treatment, which is given upon suspicion of infection (e.g. fever), before the causative pathogen/s or their susceptibilities are identified (Hughes 1997; Schimpff 1986).

Initial effective empirical treatment for patients with fever and neutropenia consisted of combinations of antibiotics, including double beta-lactam regimens and, more recently, aminoglycoside-beta-lactam combinations (Hughes 1990; Hughes 1997; Schimpff 1971). In the 1980s, third-generation cephalosporins and carbapenems having bactericidal activity against Enterobacteriaceae, *Pseudomonas aeruginosa* and many Gram-positive organisms became available, making monotherapy a reasonable alternative to combination therapy. Neither combination therapy nor monotherapy provides full coverage for the spectrum of infections encountered among neutropenic patients. Notably, resistant Gram-positive bacteria and fungi are left untreated. Nevertheless, current guidelines recommend betalactam monotherapy in clinically stable patients (Freifeld 2011; Tam 2011).

An evident advantage of combination therapy over monotherapy is the higher probability that the infecting pathogen will be covered by at least one of the components of the regimen. Furthermore, the interaction between two antibiotics may be synergistic, resulting in enhanced bacterial kill activity compared with the additive activities of the antibiotics when assessed separately (Giamarellou 1984; Giamarellou 1986; Klastersky 1976; Klastersky 1982). Finally, use of combination therapy has been claimed to suppress the emergence of resistant subpopulations of bacteria (Allan 1985; Milatovic 1987; Wade 1989). On the other hand, benefits of monotherapy may include a lower probability of adverse effects and narrower-spectrum treatment, possibly reducing the chance of developing a super-infection with resistant bacteria (Weistein 1985). Adverse effects may be related to administration of aminoglycosides per se (e.g. nephrotoxicity) or to interactions between antibiotic and underlying disease and/or other drugs. Neutropaenic participants not responding to the initial antibiotic regimen will be given modified treatment, which usually includes vancomycin to cover resistant Gram-positive bacteria and/or amphotericin-based preparations or azoles to treat fungal infection (Hughes 1997), thus increasing the chance for adverse events and drug interactions.

Although neutropenia itself is the single most important risk factor for infection, other factors can alter the risk. The probability and severity of infection are inversely proportional to the absolute neutrophil count, and patients with neutrophil counts below 100/ mm³ are at highest risk for severe infection (Bodey 1966; Schimpff 1986). Underlying malignancy may affect outcome. Patients with acute leukaemia and other haematological malignancies have a worse prognosis than solid tumour patients (Rolston 1992; Rossini 1994; Talcott 1992). The severity and nature of the infection (e.g. bacteraemia, Gram-positive and *Pseudomonas aeruginosa* infections, resistant organisms) as well as the patient's age may underlie heterogeneity (Elting 1997; Hann 1997; Rolston 1992). More recent guidelines for empirical treatment of febrile neutropenia have emphasized the importance of risk stratification, both for deciding on the setting of therapy (out-patient versus hospitalisation) and for choosing among empirical antibiotics (monotherapy versus combination therapy) (Freifeld 2011; Tam 2011).

We undertook this systematic review to assess the evidence for combination therapy versus monotherapy in patients with febrile neutropenia in clinical trials. In 2002, the first version of this review was published. Results showed no advantage of combination therapy with regard to all cause mortality, the primary outcome assessed and an increased rate of nephrotoxicity with the combined regimen. Most trials compared a broadspectrum beta-lactam with an older beta-lactam combined with an aminoglycoside; however comparisons performed to directly assess our research question, that is, trials comparing the same beta-lactam with or without an aminoglycoside, were rare. We called for further studies assessing directly the clinical implications of synergism, and further trials comparing different beta-lactams were discouraged in our recommendations (Paul 2003). In 2008 we updated our systematic review with new evidence that had accumulated since publication of the first version of our review; no significant differences were presented in terms of outcomes or subsequent recommendations. At present we are undertaking to update the review to include new evidence that has accumulated since the previous version.

OBJECTIVES

To compare the effectiveness of beta-lactam monotherapy versus that of beta-lactam-aminoglycoside combination therapy in febrile neutropenic cancer patients. In addition, to compare the effectiveness of the two treatment modalities in the following subgroups of neutropenic participants:

- Participants with an absolute neutrophil count of less than 100/ mm³
- · Participants with microbiologically documented infection
- Participants with documented *Pseudomonas aeruginosa* infection
- Bacteraemic participants
- Participants with an underlying haematological malignancy or bone marrow transplantation

The following hypotheses were tested for the comparison between participants treated with beta-lactam monotherapy and those treated with beta-lactam-aminoglycoside combination therapy:

- There is no difference in the number of deaths in febrile neutropenic patients
- There is no difference in the number of deaths in the above subgroups of febrile neutropenic patients
- There is no difference in the number of treatment failures in all febrile neutropenic patients and in the defined subgroups
- There is no difference in the number and severity of adverse effects among all patients



• There is no difference in the rate of resistant colonisation and super-infection among all neutropenic patients

METHODS

Criteria for considering studies for this review

Types of studies

Randomised or quasi-randomised trials comparing any betalactam antibiotic monotherapy with any combination of a betalactam and an aminoglycoside antibiotic, for the treatment of febrile neutropenia in cancer patients. Allocation to these regimens had to occur initially, before administration of any other antibiotics for the specific febrile episode and, empirically, before detection of pathogen/s or their susceptibilities.

Trials with randomly assigned participants with microbiologically documented infection (e.g. *Pseudomonas aeruginosa* infection, Gram-negative bacteraemia) were excluded, as were trials comparing short versus long courses of aminoglycoside treatment, because in both cases randomisation to combination treatment versus monotherapy did not occur empirically (referred to as semiempirical studies).

Types of participants

Febrile cancer patients with neutropenia, as defined in the study, induced by chemotherapy or bone marrow transplantation. Neonates and preterm babies were excluded.

Types of interventions

The following antibiotic regimens were compared:

- Intravenous beta-lactam antibiotic given as monotherapy, including:
 - Antipseudomonal carboxy-penicillins or ureido-penicillins ± beta-lactamase inhibitor (piperacillin, piperacillin/ clavulanate, ticarcillin-clavulanate, azlocilin, mezlocillin)
 - Cephalosporins (ceftazidime, ceftriaxone, cefoperazone, cefoxitin, cefuroxime, cefepime, cefpiramide)
 - Carbapenems (imipenem/cilastatin, meropenem)

Studies comparing the same beta-lactam, with the addition of an aminoglycoside to one arm ('same beta-lactam'), were analysed separately from studies comparing different beta-lactams ('different beta-lactam').

- Combination duotherapy of an intravenous beta-lactam antibiotic (as specified) with one of the following aminoglycosides given intravenously:
 - Gentamicin
 - Tobramycin
 - Amikacin
 - Netilmicin
 - Kanamycin

Types of outcome measures

Primary outcomes

Death at end of follow-up for the infectious episode, up to 30 days (all cause mortality).

Secondary outcomes

- Treatment failure: a composite end point comprising one or more of the following: death; persistence, recurrence or worsening of clinical signs or symptoms of presenting infection; any modification of the assigned empirical antibiotic treatment.
- Infection related mortality, as reported in the study.
- Duration of hospital stay.
- Dropouts before end of study.
- Super-infection: new, persistent or worsening symptoms and/ or signs of infection associated with the isolation of a new pathogen (different, or different susceptibilities) or the development of a new site of infection.
- Colonisation: isolation during or after therapy of Gram-negative bacteria resistant to the beta-lactam included in the empirical regimen, without symptoms or signs of infection.

Adverse effects

- Life threatening or associated with permanent disability.
- Serious requiring discontinuation of therapy.
- Any other.

Search methods for identification of studies

Electronic searches

Relevant randomised trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (*The Cochrane Library*, Issue 7, 2012), LILACS to August 2012, Database of Abstracts of Reviews of Effects (DARE) (Issue 3, 2012) and MEDLINE and EMBASE to August 2012. We conducted a wide search targeting all randomised trials for the treatment of infection in neutropenic patients for this and other systematic reviews conducted by our group. The detailed search strategies for each database are provided in Appendix 1, Appendix 2 and Appendix 3.

Searching other resources

References of all identified studies as well as major reviews were inspected for more studies. We checked the conference proceedings of the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) 1995 to 2011, the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2001 to 2012) and the American Society of Hematology (ASH) 2003 to 2011. Letters, abstracts and unpublished trials were accepted to reduce the influence of publication bias. Additionally, the first or corresponding author of each included study and pharmaceutical companies were contacted for complementary information or information regarding unpublished trials.

Data collection and analysis

Selection of studies

One review author inspected the abstract of each reference identified by the search and applied inclusion criteria. For possibly relevant articles, the full article was obtained and inspected by two review authors.

Data extraction and management

Two review authors independently extracted data from included trials. In cases of disagreement between the two review authors, a third review author extracted the data. In addition the third

review author extracted 10% of the studies, selected randomly. Data extractions were discussed, decisions documented and all authors of included studies contacted for clarification. Justification for excluding studies from the review was also documented. Differences in the data extracted were resolved by discussion. All data were collected on an intention-to-treat (ITT) basis whenever possible.

Assessment of risk of bias in included studies

Trials fulfilling the review inclusion criteria were assessed for risk of bias by two review authors working independently. For the 2012 update, this was done using the criteria described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). We primarily assessed the effect of allocation concealment on results, based on the evidence of a strong association between poor allocation concealment and overestimation of effect (Schulz 1995), as defined below:

- Low risk of bias (adequate allocation concealment).
- Moderate risk of bias (uncertainty regarding allocation concealment).
- High risk of bias (inadequate allocation concealment).

In addition to the adequacy of allocation concealment, methods of allocation generation, blinding, incomplete outcome data, selective reporting, the unit of randomisation (patient or febrile episode) and publication status were recorded independently by the two review authors.

Assessment of heterogeneity

Heterogeneity in the results of the trials was initially graphically inspected and assessed by calculating a test of heterogeneity (Chisquare). We anticipated between-trial variation in estimation of morbidity and mortality for studies comparing the same betalactam and studies comparing different beta-lactams (Elphick 2001). These were separated when heterogeneity was observed. Further heterogeneity was explored through subgroup analysis, assessing the above-defined patient subgroups (Objectives).

A funnel plot estimating the precision of trials (plots of the log of the risk ratio for efficacy against the sample size) was examined to estimate potential selection bias (such as publication bias) and to assess whether effect estimates are associated with study size.

Adjusted means were calculated and corrected by the inverse of the variance. We searched for the correlation between mortality and treatment failure, to assess the clinical relevance of treatment failure and infection related mortality outcomes in these studies. Correlations were tested for significance using a non-parametric test (Spearman) using the Statistical Package for the Social Sciences (SPSS) version 14.0. Numbers needed to treat or harm were calculated as 1/(CER-CER*RR), where CER is the control event rate and RR is the risk ratio.

Data synthesis

Dichotomous data were analysed by calculating the risk ratio (RR) for each trial with the uncertainty in each result expressed with the use of 95% confidence intervals (CIs). A fixed-effect model was used throughout the review, unless significant heterogeneity was observed (P < 0.1 or I² > 50%) where the random-effects model was used.

RESULTS

Description of studies

The computerised search strategy identified a large number of randomised trials assessing the treatment of febrile neutropenia — not all of which were relevant for the present review. These were screened for trials assessing beta-lactam-aminoglycoside combination therapy versus beta-lactam monotherapy. Ninety-five publications of RCTs were considered eligible for this review.

Twenty-three publications of 22 trials were excluded (Characteristics of excluded studies). Allocation to monotherapy versus combination therapy was non-random in five studies, randomisation to monotherapy versus combination therapy was semi-empirical in three trials (Bodey 1976; EORTC 1987; Pegram 1989), the comparator regimens were incompatible with our inclusion criteria in nine trials, and non-neutropenic patients were included in three trials (D'Antonio 1992; Fainstein 1983; Hoepelman 1988), in which results for neutropenic patients only could not be extracted. One trial randomly assigned participants to treatment with ticarcillin-clavulanate versus ticarcillin-clavulanate +amikacin; however participants who had undergone bone marrow transplantation were allocated to combination therapy only, overriding the random allocation (Bru 1986); another trial comparing imipenem versus ceftazidime versus amikacin was excluded, because it was presented as an ongoing study in a conference in 1986, no further publication of the study was found and we were not able to contact the authors (Moreno-Sanchez 1992).

We could not yet obtain the full text of one trial, which is awaiting assessment (Li 1998). Another trial was presented at a conference in 2005 and is listed as ongoing (Bilgir 2005).

Seventy-one trials described in 89 publications are included in the review (Characteristics of included studies; secondary publications are listed under their primary reference). The trials were published between 1983 and 2012. Three trials were added since the previous version of this review, all published between 2007 and 2012. Forty-three trials reported data on all cause mortality and 41 reported on infection related mortality. Data regarding treatment failure were available for all trials. Thirty-one trials contained usable information for super-infections, and 49 trials are included in the adverse event analysis.

Eight included trials, presented in conference proceedings between 1987 and 2002, were published in abstract form only. Supplementary data from the authors were available for two of these (Cornely 2001, Hense 2000). Additional information on trial methods and/or on mortality was available from 24 full-text publications ('unpublished data' in the reference description).

Patient and infection characteristics

Most trials included adult cancer patients. Fourteen trials included only children, and another 14 trials included both adults and children. Most trials included participants with haematological cancer: 35 trials included only patients with haematological malignancies, and in another 32 trials most patients had haematological cancer. Bone marrow transplant patients were excluded from three trials. Patients with septic shock were specifically excluded from four trials; most trials did not refer to patients with septic shock, and in the few trials that did report patients with septic shock, only a few patients were included (1%



to 6% of patients in five trials reporting the number of patients with shock on admission).

The ratio between Gram-negative and Gram-positive bacteria among all included studies was 0.69. The adjusted mean rate of infection caused by Gram-negative bacteria was 11.5% of participants. *Pseudomonas aeruginosa*, a commonly implicated pathogen of febrile neutropenia in the past, was isolated in only 1.7% of included participants, constituting 15.3% of all documented Gram-negative isolates.

Surveillance cultures were performed in nine trials.

Antibiotic regimens

The same beta-lactam was compared in 16 of 71 included trials. In these trials the beta-lactam was ceftazidime (seven trials), piperacillin-tazobactam (four trials), cefepime (three trials), imipenem (two trials—one of which included four arms and assessed both ceftazidime and imipenem) and cefoperazone (one trial). All other trials compared one beta-lactam (usually a new drug) with a narrower-spectrum beta-lactam combined with an aminoglycoside. The most common mono-combi beta-lactam comparison was between a carbapenem and a cephalosporin (18 trials). Other comparisons included cephalosporin-cephalosporin (11 trials), cephalosporin-penicillin (nine trials), new trials), penicillin-cephalosporin (four trials) and penicillin-penicillin (three trials), respectively.

The most commonly tested aminoglycoside was amikacin (43 trials), followed by tobramycin (14 trials), gentamicin (11 trials) and netilmicin (three trials). Aminoglycosides were administered once daily in 16 trials. Aminoglycosides were administered for the duration of treatment in all trials, except Tamura 2004, where amikacin was administered only for the first 3 days of combination therapy.

Treatment duration was reported as means or medians. The mean treatment duration ranged from 7 to 15 days (most commonly 9 days); median treatment duration varied between 4 and 9 days (most commonly 9 days).

Risk of bias in included studies

Adequate allocation concealment, using sealed opaque envelopes or central randomisation, was described in 27 trials (Ahmed 2007; Akova 1999; Alanis 1983; Behre 1998; Cometta 1996; Cornely 2001; De la Camara 1997; Del Favero 2001; De Pauw 1994; Gibson 1989; Gorschluter 2003; Hess 1998; Jimeno 2006; Kinsey 1990; Leyland 1992; Lieschke 1990; Marie 1991; Matsui 1991; Norrby 1987; Novakova 1991; Novakova 1990; Petrilli 1991; Pickard 1983; Tamura 2002; Tamura 2004; Wrzesien-Kus 2001; Yamamura 1997). Allocation generation was adequate in a similar number of studies. These studies used tables of random numbers or computer-generated lists. Allocation concealment was inadequate in two trials describing the randomisation only as consecutive (Corapcioglu 2005; Zengin 2011). Randomisation methods were not described in all other trials. Four trials were double-blinded (Del Favero 2001; Ozyilkan 1999; Schuchter 1988; Wade 1989), four single-blinded (Cometta 1996; Duzova 2001; Leyland 1992; Rolston 1992) and the remainder open-randomised trials.

Intention-to-treat (ITT) analysis was presented in 23 of 68 trials included for treatment failure analysis and in 25 of 47 trials included

for mortality analysis. Dropouts were reported by their allocation group in 26 of the 45 trials presenting per protocol analysis for treatment failure, permitting a secondary ITT analysis in which dropouts were assumed to be failures (see later, sensitivity analyses for failure). The number of patients excluded from analysis in studies in which ITT analysis was impossible ranged between 3% and 30% and the median rate of excluded patients was 10%. Twelve trials, mostly presented as conference proceedings, addressed 'treated' or 'evaluated' patients, without specifying a different figure for the number of randomly assigned participants (Agaoglu 2001; Borbolla 2001; Duzova 2001; El Haddad 1995; Esteve 1997; Gaytan-Martinez 2002; Kliasova 2001; Marie 1991; Pegram 1984; Pellegrin 1988; Schuchter 1988; Wade 1987). The analysis presumed for these studies was per-protocol.

A pre-determined, defined follow-up period was available from the publication or through author contact for 14 included trials (Behre 1998; Cometta 1996; De la Camara 1997; Del Favero 2001; Gorschluter 2003; Hess 1998; Kojima 1994; Leyland 1992; Norrby 1987; Ozyilkan 1999; Smith 1990; Tamura 2002; Tamura 2004; Yamamura 1997). Follow-up ranged from 72 hours to 1 month following the end of treatment. The observation time was longer than 1 month in two trials (De la Camara 1997; Ozyilkan 1999), both of which reported the outcomes at 1 month post-therapy. In five trials the time of outcome assessment was described more generally as end of treatment, fever, episode or neutropenia (De Pauw 1994; Erjavec 1994; Lieschke 1990; Matsui 1991; Piguet 1988). Two additional trials reported the average follow-up period of their trials (8 and 14 days) but a fixed time for outcome assessment was not specified (Akova 1999; Rolston 1992).

The unit of randomisation was the patient in 23 of the 71 trials (Characteristics of included studies). Episodes comprised the unit of randomisation in all the other trials, which allowed patient reentry for recurrent episodes of fever and neutropenia. The number of participating patients was given in 74% of trials analysing episodes, and the mean episode-to-patient ratio in these trials was 1.3 (range 1.02 to 2.07). Trials that allowed repeat randomisation of participants for separate episodes of febrile neutropenia did not adjust their analyses to the 'cluster' effect of episodes within single participants and did not provide an intra-patient correlation estimate to allow for adjusted analyses in the meta-analysis. All trials were included in the main analysis and the effect of episode randomisation was assessed through sensitivity analyses.

Effects of interventions

See: Summary of findings for the main comparison betalactam monotherapy compared to beta-lactam-aminoglycoside combination therapy for Febrile neutropenic cancer patients

Overall effectiveness

All cause mortality :

All cause mortality was reported in 44 trials, including 7186 episodes. A difference in favour of monotherapy was observed overall (RR 0.87, 95% CI 0.75 to 1.02) (Analysis 1.1). This difference was not statistically significant, but there was no heterogeneity (P = 0.95, $I^2 = 0$) among trials for this combined effect estimate. Similar results were obtained using the random-effects model (RR 0.88, 95% CI 0.75 to 1.04). Among trials comparing the same beta-lactam, the RR was 0.74 (95% CI 0.53 to 1.06, 11 trials, 1718 episodes). Among trials comparing different beta-lactams, the RR was 0.91



(95% CI 0.77 to 1.09, 33 trials, 5468 episodes). Results were similar for trials comparing same and different beta-lactams with regard to all cause mortality; therefore these trials were combined in all subsequent subgroup and sensitivity analyses for mortality.

No significant differences between monotherapy and combination therapy were observed for the planned subgroups. The trend observed was similar for all comparisons, with RRs favouring monotherapy, with no statistical significance. Moreover, effect estimates favouring monotherapy were larger in subgroups designating participants with a potential worst prognosis:

- Participants with microbiologically documented infection: 13 trials, 1188 episodes, RR 0.81 (95% CI 0.56 to 1.17) (Analysis 4.1).
- Participants with bacteraemia: 14 trials, 676 episodes, RR 0.74 (95% CI 0.46 to 1.18) (Analysis 5.1).
- Participants with microbiologically documented Gram-negative infection: 16 trials, 376 episodes, RR 0.64 (95% CI 0.37 to1.11) (Analysis 6.1).
- Participants with documented *Pseudomonas aeruginosa* infection: 9 trials, 71 episodes, RR 0.87 (95% CI 0.34 to 2.24) (Analysis 7.1).
- Participants with haematological cancer: 22 trials 3463 episodes, RR 0.88 (95% CI 0.68 to 1.13) (Analysis 8.1).
- Participants with severe neutropenia on admission: 6 trials, 737 episodes, RR 0.68 (95% CI 0.37 to 1.24) (Analysis 9.1).

When the analysis was separated by the monotherapy betalactam (Analysis 10.1), only piperacillin-tazobactam was associated with significantly improved survival compared with combination therapy (RR 0.62, 95% CI 0.40 to 0.96, 5 trials, 1093 episodes). In studies including only children, the RR was 0.80 (95% CI 0.29 to 1.64), and in trials including only adults, the RR was 0.90 (95% CI 0.75 to 1.09) (Analysis 11.1).

In summary, monotherapy was associated with a trend toward improved survival overall and in all subgroups assessed.

Infection related mortality and treatment failure

Infection related mortality was reported in 41 trials (Analysis 1.2). No deaths related to infection were reported in nine trials (which did not contribute to the meta-analysis). Monotherapy was associated with a significantly lower rate of infection related mortality compared with combination therapy (RR 0.80, 95% CI 0.64 to 0.99). Results were similar for trials comparing same and different beta-lactams. The number of participants needed to treat with monotherapy to prevent one death related to infection was 95 participants, but 95% CIs were large (49 to 1241 participants).

Studies performed in recent years based their definitions for treatment success and failure on recommendations of the Immuncompromised Host Society (Consensus 1990). Treatment failure reported here is the inverse of "success without modification". It should be noted that we defined *treatment failure* more broadly in our protocol as death, lack of clinical improvement or any modification of the assigned empirical antibiotic treatment (see earlier, outcomes). Death judged as unrelated to infection was not included in the consensus definitions for failure. Thus other than infection related deaths, treatment failure reflected mainly treatment modifications in trials that were open-label in the vast majority.

In trials comparing the same beta-lactam, a significant advantage was seen with combination therapy (RR 1.11, 95% CI 1.02 to 1.20) with minor heterogeneity (I² = 12%). In trials comparing different beta-lactams, a significant advantage was observed with beta-lactam monotherapy (RR 0.92, 95% CI 0.88 to 0.97, I² = 16%) (Analysis 1.3). Results diverged for trials comparing same and different beta-lactams with regard to treatment failure; therefore these data were not pooled for the main and all subsequent analyses of treatment failure.

Subgroup analyses for trials comparing the same beta-lactams (Analysis 4.2; Analysis 5.2; Analysis 6.2; Analysis 7.2; Analysis 8.2; Analysis 9.2) demonstrated significant differences in favour of combination therapy for patients with Gram-negative infection (RR 1.34) and severe neutropenia (RR 1.48). No significant differences were observed for the subgroups of participants with any microbiologically documented infection, *Pseudomonas aeruginosa* infection, bacteraemia and haematological cancer. No specific beta-lactam monotherapy was associated with increased risk for failure (Analysis 10.2). All subgroup analyses for trials comparing the same beta-lactam were limited by the paucity of trials and participants included.

Similar subgroup analyses for trials comparing different betalactams showed that the significant advantage associated with monotherapy persisted in all tested subgroups, except for cases of documented *Pseudomonas aeruginosa* infection, severe neutropenia and haematological cancer. Similar RRs in favour of monotherapy were observed with the different specific betalactams.

No correlation was noted between rates of treatment failure and all cause or infection related mortality in these studies (r = 0.27, P = 0.11, 38 trials, and r = 0.21, P = 0.27, 30 trials, respectively). As expected, infection related mortality was significantly correlated with all cause mortality (r = 0.63, P < 0.001, 29 trials). No significant correlation was noted between publication year and the RRs for mortality or treatment failure.

Super-infections

Twenty-nine trials, including 4961 episodes, reported on the development of bacterial super infections during and after antibiotic treatment (Analysis 2.1), and 20 trials, including 3437 episodes, reported on fungal super infections (Analysis 2.2). Equivalence was demonstrated with regard to bacterial super infections (RR 1.02, 95% CI 0.87 to 1.19). Fungal super infections developed more frequently in the combination treatment group (RR 0.70, 95% CI 0.49 to 1.00). Data concerning resistant colonisation were scarce. Five trials supplied data regarding any colonisation (Alanis 1983; Cornelissen 1992; Erjavec 1994; Kojima 1994; Norrby 1987), and comparison of colonisation with resistant Gram-negative bacteria was possible in only two studies (Cornelissen 1992; Norrby 1987). In these studies, resistant Gramnegative bacteria were detected in 5 of 152 participants in the monotherapy group versus 1 of 152 in the combination group. Notably, none of the newer trials included in the updated review performed surveillance cultures, nor did they report on colonisation with resistant bacteria.

Adverse events

Adverse events were significantly more frequent in the combination treatment group. The difference was most remarkable when

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



development of renal failure was compared (RR 0.45, 95% CI 0.35 to 0.57) for any nephrotoxicity (Analysis 3.3) and (RR 0.16, 95% CI 0.05 to 0.49) for severe nephrotoxicity (Analysis 3.4). Nephrotoxicity was more common in the combination therapy than in the monotherapy arm also in studies using a once-daily dosing regimen for the aminoglycoside (RR 0.31, 95% CI 0.15 to 0.63, 8 trials, 1707 participants). In assessment of any adverse effect in all trials and in studies grouped by their monotherapy (Analysis 3.1), an advantage of monotherapy was seen overall (RR 0.87, 95% CI 0.81 to 0.94), and with ceftazidime monotherapy (RR 0.64, 95% CI 0.53 to 0.76). Likewise, discontinuation of study medication due to adverse events occurred more often in the combination group (Analysis 3.2) (RR 0.61, 95% CI 0.40 to 0.93). The number needed to harm with combination therapy was 34 participants (95% CI, 20 to 104) with regard to any adverse event and 31 participants (95% Cl, 24 to 42) with regard to nephrotoxicity.

outcome: mean 24.8 days (standard deviation (SD) 21 to 31) versus 27.3 days (SD 23 to 56) (De la Camara 1997, data availed through personal correspondence), median 8.6 \pm 4 versus 11.8 \pm 5.6 (Corapcioglu 2005), mean 9.96 versus 11.93 days (Jimeno 2006) and mean 12.6 \pm 5.3 versus 10.6 \pm 4.7 (Yildirim 2008) for monotherapy versus combination therapy, respectively. The data were not pooled because variable reporting measures were used.

Selection bias

Funnel plot analyses were undertaken for the two main comparisons: failure and mortality. The funnel plot for mortality was symmetrical (Figure 1). The funnel plots for trials comparing same and different beta-lactams for failure were separated. Among trials comparing the same beta-lactam, the funnel plot was approximately symmetrical (Figure 2); among trials comparing different beta-lactams, an indication that small trials favouring combination therapy are missing may be present (Figure 3).

Other outcomes

Duration of hospital stay was non-significantly shorter in the monotherapy group in each of the four trials that reported this

Figure 1. All cause mortality.




Figure 2. Failure-same BL.





Figure 3. Failure-different BL.



Copyright @ 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Sensitivity analyses

Sensitivity analyses were performed for the primary outcomes — mortality and failure — to assess the impact of study quality on our results.

For mortality, results from studies with adequate allocation concealment (RR 0.88) were similar to results from studies with unclear allocation concealment (RR 0.87; Analysis 12.1), as were results for trials reporting ITT (RR 0.87) versus efficacy analysis (RR 0.88; Analysis 12.2). The effect size was smaller in trials assessing episodes (RR 0.90) compared with trials assessing participants (RR 0.84), although the 95% CI overlapped (Analysis 12.3). Small and large trials provided similar results, with no study size effect for mortality (comparison 12.5). Unpublished trials and those published only in conference proceedings showed no advantage of monotherapy (RR 1.07, 95% CI 1.07 to 0.72 to 1.59), and trials published in peer reviewed journals showed an advantage of monotherapy (RR 0.84, 95% CI 0.71 to 1.00) (Analysis 12.4).

For failure among trials comparing the same beta-lactams, no significant differences in the pooled effect estimate were observed for the different methodological measures assessed. In an ITT analysis counting all dropouts as failures, the advantage of combination therapy decreased (RR 1.07; Analysis 12.8). Analysis by episodes was associated with a larger effect estimate in favour of combination therapy (RR 1.16; Analysis 12.10). The only doubleblinded trial showed similar results for combination therapy versus monotherapy (Del Favero 2001, Analysis 12.11).

Among trials comparing different beta-lactams, adequate allocation concealment was associated with a smaller effect estimate in favour of monotherapy than was seen with unclear methods (RR 0.94 versus RR 0.87, respectively; Analysis 12.6). ITT analysis in the publication was associated with a smaller effect estimate than was seen with efficacy analysis (RR 0.80, 95% CI 0.71 to 0.91 versus RR 0.95, 95% CI 0.88 to 1.01, respectively; Analysis 12.7), and an ITT analysis assuming that all dropouts were failures did not alter results significantly (RR 0.92, 95% CI 0.86 to 0.97; Analysis 12.8). Analysis by episodes was associated with a smaller effect estimate than analysis by participants (RR 0.95 versus RR 0.89; Analysis 12.10). Smaller trials were associated with a significantly larger effect estimate than was noted in the bigger trials (RR 0.75, 95% CI 0.67 to 0.84 versus RR 0.98, 95% CI 0.92 to 1.03; Analysis 12.9), pointing at the same small studies for effects observed in the corresponding funnel plot analysis (Figure 3). No advantage was seen with monotherapy in double-blind trials (Analysis 12.11).

For trials comparing same and different beta-lactams, unpublished trials showed no difference between monotherapy and combination therapy, but published trials showed a significant difference favouring combination therapy for trials comparing the same beta-lactams, and favouring monotherapy for trials comparing different beta-lactams (Analysis 12.12).

DISCUSSION

Seventy one trials that included more than 10,000 participants were analysed to compare beta-lactam monotherapy with betalactam-aminoglycoside combination therapy for the empirical treatment of febrile neutropenic cancer patients. The same betalactam was compared in 16 trials, but all other trials compared a broad-spectrum beta-lactam with a narrower-spectrum betalactam combined with an aminoglycoside. Most of the participants included in these trials were haematological cancer patients. We assessed all cause mortality as the primary outcome.

Monotherapy was associated with a statistically non-significant lower all cause mortality rate at end of follow-up (30 days) (RR 0.87, 95% CI 0.75 to 1.02). Results for trials comparing same and different beta-lactams were similar. Appropriate trial methods (adequate allocation concealment, ITT analysis and analysis by participants) were associated with similar effect estimates in favour of monotherapy, and no small studies effect was observed. Mortality attributed in the primary studies to infection was significantly lower with monotherapy (RR 0.80, 95% CI 0.64 to 0.99).

Treatment failure was assessed as the primary outcome in all included trials. By definition, its main addition on the rather subjective outcome of infection related mortality is treatment modifications (Consensus 1990). Among trials comparing the same beta-lactams, treatment failure was significantly more frequent with monotherapy. This difference likely reflects mainly physicians' tendency for treatment modifications in open trials comparing one antibiotic regimen with a broader-spectrum regimen. Among trials comparing different beta-lactams, a significant advantage was seen with monotherapy. Adequate trial methods were associated with smaller effect estimates for both 'same' and 'different' comparisons. Notably, in the single double-blind trial comparing the same beta-lactams, failure was equal with combination treatment and with monotherapy, and in three double-blind trials assessing different beta-lactams, the RRs were in the opposite direction compared with those in the other trials. We detected a small studies effect for trials comparing different beta-lactams. This may reflect a publication bias related to trials that assessed a newer monotherapy without showing its advantage.

Bacterial super infections occurred with equal frequency with monotherapy and combination therapy. Fungal super-infections were more common with combination therapy. All adverse events were more common with combination therapy, with a highly significant difference for nephrotoxicity. The pooled effect estimate translated to a number needed to harm of 34 participants (95% CI 20 to 104 participants).

To explain the advantage of monotherapy with regard to all cause mortality, several of the secondary outcomes may be used. Infection related mortality was significantly lower with monotherapy, and fungal super infections occurred more frequently with combination treatment. Fungal infections developing during neutropenia are highly lethal (Lin 2001). Thus, the improvement in survival may indeed be infection related. On the other hand, nephrotoxicity associated with combination therapy is a risk factor for subsequent adverse outcomes. Given these results and those of the methodological quality assessment, it is likely that the both mechanisms contribute to an unbiased advantage in overall survival with monotherapy.

Several hypotheses underlie the use of beta-lactamaminoglycoside combination therapy for patients with neutropenia and suspected infection. Synergism is usually claimed as the major reason for combination therapy. Synergism was assessed most directly in trials comparing the same beta-lactam. We did not detect the beneficial effects of synergism. A wider spectrum of coverage may be the incentive for the addition of

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



an aminoglycoside depending on local patterns of resistance. Studies included in the review did not supply enough data to allow determination of whether coverage is indeed improved with combination therapy. However, the efficacy of aminoglycosides alone for the treatment of neutropenic patients is doubtful (Bodey 1972; Klastersky 1986); therefore this potential advantage does not seem substantial. Finally, combination therapy is claimed to prevent emergence of resistant pathogens. Development of resistance after antibiotic treatment is difficult to quantify. We intended to extract data regarding colonisation with resistant pathogens following antibiotic treatment, but these data were rarely available. Resistance was therefore indirectly examined through super infections, under the assumption that infection that develops under antibiotic treatment involves resistant pathogens. No difference was noted in the rate of bacterial super infections between monotherapy and combination therapy, and this analysis resulting in an RR close to 1. Fungal super infections developed more frequently with combination therapy, perhaps as a reflection of increased antibiotic spectrum or burden with combination therapy. Thus we could not show an advantage of combination therapy from this aspect.

We chose all cause mortality as the primary outcome, rather than treatment failure or infection related mortality, and have drawn our conclusions from the analysis for all cause mortality. Only a small part of the variance in mortality is explained by infection and its treatment; however, appropriate randomisation should ensure similar distribution of non-infection related risk factors for death between the study groups. Infection related mortality may be prone to bias in that the cause of death is difficult to determine in severely ill cancer patients. Moreover, ignoring deaths due to treatmentrelated adverse effects and super infections is inappropriate. Early empirical antibiotic treatment is the standard of practice for febrile neutropenic patients because it has been proven to decrease mortality (Hughes 1997; Schimpff 1986). Survival is indeed the objective when an acute infection is treated in cancer patients. Treatment failure indicates mainly modifications of the initial antibiotic regimen, and possibly a longer time to defervescence. The implications of such an outcome are not clear from the clinical point of view. Finally, deaths are objective, but failures cannot be objective when the trials are open. It is important to note that we could demonstrate in this review that assessing treatment failure is probably inappropriate, because no correlation between failure and mortality could be shown.

Our results are congruent with those of several other analyses of beta-lactam-aminoglycoside combination therapy versus betalactam monotherapy, showing no advantage associated with combination therapy. We conducted a similar analysis in nonneutropenic participants with sepsis, showing an advantage of monotherapy in trials comparing different beta-lactams, and no difference in trials comparison the same beta-lactam (Paul 2004; Paul 2006a). In an analysis of all RCTs comparing the same beta-lactam in the combination and monotherapy arms, in both neutropenic and non-neutropenic participants, and including semi-empirical studies, we did not find a significant difference in all cause mortality, but we noted significantly more bacterial super infections and increased renal failure with the addition of aminoglycosides (Marcus 2011). An analysis focusing on the development of resistance did not find an advantage associated with combination therapy (Bliziotis 2005). Finally, an analysis of observational studies focusing on Pseudomonas aeruginosa infection (mainly bacteraemia), a pathogen with special relevance to neutropenic cancer patients, did not find an advantage for combination therapy (Vardakas 2013).

The major limitations of this review include the lack of complete data concerning mortality (all cause mortality was available for 44 of 71 included trials, 62%) and the paucity of available data regarding specific patient subgroups, such as those with Pseuomonas aeruginosa infection. Other limitations stem from those of the primary studies. Allocation concealment was at low risk of bias in less than 35% of the trials, and nearly all were nonblinded. Many of the trials did not adhere to the principle of ITT analysis, resulting in incomplete data reporting. Most studies used febrile episodes as the unit of randomisation, although recurrent episodes are not independent for any for the outcomes assessed. Finally, follow-up did not seem pre-determined in many of the studies. Reported mortality may have been biased because the time of assessment was not defined in advance. We included trials regardless of their publication status. The differences detected in our review, namely, the advantage of monotherapy with regard to survival and the divergent advantages with regard to failure, existed with larger effect estimates in trials published in peer reviewed journals. The RRs were close to 1 for these outcomes in unpublished trials, mainly conference proceedings. Their inclusion in the metaanalysis tipped the overall RRs toward equivalence.

AUTHORS' CONCLUSIONS

Implications for practice

Monotherapy can be regarded as the standard of care for the empirical treatment of febrile neutropenic patients. The addition of an aminoglycoside does not improve survival. On the contrary, it is associated with significant morbidity incurred mainly through aminoglycoside-associated nephrotoxicity.

The monotherapies assessed in recent years have included imipenem, meropenem, ceftazidime, piperacillin-tazobactam and cefepime. These beta-lactams have also been assessed in headto-head trials comparing different monotherapies and have shown similar efficacies, but for cefepime this was associated with increased all cause mortality (Paul 2006). Thus, individual centres should select the best matching monotherapy according to local epidemiology and susceptibility patterns.

RCTs do not support an advantage of combination therapy for *Pseudomonas aeruginosa* infection and other more severely ill patient subgroups. However the paucity of data precludes firm conclusions regarding these patient subgroups.

Implications for research

Assessment of new beta-lactams for febrile neutropenia should not be performed by comparison with a narrower-spectrum betalactam combined with an aminoglycoside. The results of these trials are uniformly unfavourable for patients. Assessment of new beta-lactam monotherapies should be performed by comparison with established monotherapies for febrile neutropenia. This design can and does show the advantages and disadvantages of specific beta-lactams (Paul 2006).

The need for further trials assessing the addition of an aminoglycoside to the same beta-lactam is doubtful given the results of our review, spanning more than two decades of

clinical trials in febrile neutropenia and without a change in RRs throughout the years. We can foresee such a need if a reduction in aminoglycoside-related adverse effects is expected, or if new data will point toward drug combinations with a marked synergistic effect — much greater than that observed in current studies. Trials targeting specific patient subgroups, such as those with severe sepsis and septic shock, documented *Pseudomonas aeruginosa* infection, etc. are warranted.

Future trials should report all cause mortality. The primary outcome used in these studies should be re-defined because with current definitions, no correlation can be noted between failure and the ultimate outcome: survival. This outcome should be defined in a consensus statement and applied universally to permit comparisons and compilation of different studies. The unit of randomisation should be the patient — not the episode. If recurrent episodes are allowed, results for the first randomisation of each patient should be reported separately, or the analysis should be adjusted to the clustering effect of patient episodes. Length of follow-up should be uniform and should be determined before the study is begun.

ACKNOWLEDGEMENTS

We would like to thank warmly the Cochrane Gynaecological Cancer Review Group, for their helpful advice and for their assistance in obtaining articles from abroad. We would like to express our appreciation to all the authors who responded to our letters and supplied additional information on their studies: Drs. Will (Smith 1990 trial), Wrzesien-Kus, Ahmed, Jimeno, Pettrili, Tamura and Vallejos (Rodriguez 1995), Gibson, Donnelly and De Pauw (De Pauw 1983; De Pauw 1994 trials), Pickard and Rotstein (Yamamura 1997 trial), Kojima, Kinsey, Norrby, Matsui, Ozyilkan, Dincol, Doyen and Michaux (Doyen 1983 trial), Duzova, Agaoglu and Karakas (Agaoglu 2001 trial), Jacobs, De la Camara and Sarper (Zengin 2011), Drs. Glasmacher, Hense and Lieschke, who supplied their full unpublished manuscripts, Drs. Keddie and Wilks of the AstraZeneca Company for supplying their data for the Behre 1998 and De la Camara 1997 trials, Dr. Sawae for clarifying the details of his study, and Dr. Cornelly for supplying full results for his yet unpublished trial (Cornely 2001). We would also like to thank Professor Bodey for his response and comments on the previous version of this review.

In addition we would like to thank the authors who responded even though additional data were unavailable: Drs. Morgan, Piccart, Rehm (Alanis 1983 trial),

The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Gynaecological Cancer Group.

The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health

REFERENCES

References to studies included in this review

Agaoglu 2001 {published and unpublished data}

Agaoglu L, Devecioglu O, Anak S, Karakas Z, Yalman N, Biner B, et al. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. *Journal of Chemotherapy* 2001;**13**(3):281-7.

Ahmed 2007 {published and unpublished data}

Ahmed N, Borollosy N, Beshlawy A, Mahallawy H, Haddad A. Outpatient single dose ceftriaxone and amikacin vs. imipenem/ cilastatin monotherapy in the empiric treatment of pediatric patients with high risk fever and neutropenia: a randomized, prospective clinical trial. Proceedings of Meeting of the American Society of Hematology; Abstract No. 887. 2003.

Ahmed N, Borollosy N, Beshlawy A, Mahallawy H, Haddad A. Outpatient single dose ceftriaxone and amikacin vs. imipenem/ cilastatin monotherapy in the empiric treatment of pediatric patients with high risk fever aneutropenia: a randomized, prospective clinical trial. Proceedings of ASCO Meeting; Abstract No. 8520. 2004.

* Ahmed N, Mahallawy HA, Ahmed IA, Nassif S, Beshlawy A, Haddad A. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. *Pediatric Blood Cancer* 2007;**49**:786-92.

Akova 1999 {published and unpublished data}

Akova M, Akan H, Korten V, Biberoglu K, Hayran M, Unal S, et al. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. *International Journal of Antimicrobial Agents* 1999;**13**(1):15-9.

Alanis 1983 {published data only}

Alanis A, Rehm S, Weinstein AJ. Comparative efficacy and toxicity of moxalactam and the combination of nafcillin and tobramycin in febrile granulocytopenic patients. *Cleveland Clinic Quarterly* 1983;**50**(4):385-95.

Antmen 2001 {published data only}

Antmen B, Sasmaz I, Tanyeli A, Yaman A, Kocabas E, Bayram I, et al. Initial empiric antibiotic treatments in childhood febrile neutropenia: meropenem versus ceftazidime plus amikacin combination. Proceedings of the 11th European Congress of Clinical Microbiology and Infectious Diseases Apr 1-4; Istanbul, Turkey. 2001:Poster 1087. [MEDLINE: http://www.akm.ch/ eccmid2001]

Au 1994 {published data only}

Au E, Tow A, Allen DM, Ang PT. Randomised study comparing imipenem/cilastatin to ceftriaxone plus gentamicin in cancer chemotherapy-induced neutropenic fever. *Annals of the Academy of Medicine Singapore* 1994;**23**(6):819-22.

Behre 1998 {published and unpublished data}

Behre G, Link H, Maschmeyer G, Meyer P, Paaz U, Wilhelm M, et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. *Annals of Hematology* 1998;**76**(2):73-80.

Bezwoda 1985 {published data only}

Bezwoda WR, Derman DP, Perkins S, Cassel R. Treatment of neutropenic infection: a randomized trial comparing latamoxef (moxalactam) with cephradine plus tobramycin. *Journal of Antimicrobial Chemotherapy* 1985;**15**(2):239-45.

Borbolla 2001 {published data only}

Borbolla JR, Lopez-Hernandez MA, Gonzalez-Avante M, DeDiego J, Trueba E, Alvarado ML, et al. Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients. *Chemotherapy* 2001;**47**(5):381-4.

Cometta 1996 {published data only}

Cometta A, Calandra T, Gaya H, Zinner SH, De Bock R, Del Favero A, et al (EORTC). Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. *Antimicrobial Agents and Chemotherapy* 1996;**40**(5):1108-15.

Conte 1996 {published data only}

Conte G, Flores C, Alfaro J, Araos D, Thompson L, Barahona O, et al. Single agent sulperazone vs. two agent ceftazidime-amikacin in high risk febrile neutropenic patients. *Blood* 1996;**88(10)**:30b.

Corapcioglu 2005 {published data only}

Corapcioglu F, Sarper N. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. *Pediatric Hematologic Oncology* 2005;**22**(1):59-70.

Cornelissen 1992 {published data only}

Cornelissen JJ, de Graeff A, Verdonck LF, Branger T, Rozenberg-Arska M, Verhoef J, et al. Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropenic patients. *Antimicrobial Agents and Chemotherapy* 1992;**36**(4):801-7.

Cornely 2001 {unpublished data only}

* Cornely OA, Reichert D, Buchheidt D, Maschmeyer G, Wilhelm M, Chiel X (for the Paul-Erlich-Gesellschaft). Threearmed multicenter randomized study on the empiric treatment of neutropenic fever in a high risk patient population (PEG study III). Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy;Abstract L-775. 2001.

Maschmeyer G. Cefepime in the empirical initial treatment of febrile neutropenic cancer patients [Cefepim in der empirischen Initial therapie bei febrilen neutropenischen Patienten mit mignen erkankungen]. *Chemotherapie Journal* 2004;**13**:174-180.



De la Camara 1997 {published and unpublished data}

De la Camara R, Figuera A, Sureda A, Hermida G, Verge G, Olalla I, et al. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study. *Haematologica* 1997;**82**(6):668-75.

Del Favero 2001 {published data only}

* Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. *Clinical Infectious Diseases* 2001;**33**(8):1295-301.

Del Favero A, Micozzi A, Bucaneve G, Martino P. Doubleblind, randomised, clinical trial comparing monotherapy with piperacillin-tazobactam vs piperacillin-tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; Abstract No. 1092. 1999.

Micozzi A, Bucaneve G, Menichetti F, Martino P, Del Favero A, G.I.M.E.M.A.Infection Program. Double blind, randomized, clinical trial comparing monotherapy with piperacillintazobactam versus piperacillin-tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients.. *Supportive Care in Cancer* 2000;**8 Suppl**:160, Abstract 63.

De Pauw 1983 {published data only}

De Witte T. Antibiotic treatment in patients with haematological malignancies and bone marrow transplantation. Perspectives on Therapeutics in Northern Europe. Vol. **46**, London: Glaxo, 26 September 1986:6-7.

* de Pauw BE, Kauw F, Muytjens H, Williams KJ, Bothof T. Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. *Journal of Antimicrobial Chemotherapy* 1983;**12 Suppl A**:93-9.

De Pauw 1994 {published and unpublished data}

* De Pauw BE, Deresinski SC, Feld R, Lane Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. The Intercontinental Antimicrobial Study Group. *Annals of Internal Medicine* 1994;**120**(10):834-44.

De Pauw BE, Feld R, Deresinski S, Donnelly JP, Lane-Allman E. Multicentre, randomised, comparative study of ceftazidime vs piperacillin as empirical therapy for febrile granulocytic patients. Proceedings of the Sixth International Symposium of Infections in the Immunocompromised Host. Abstract No 116. 1990.

Dompeling EC, Donnelly JP, Deresinski SC, Feld R, Lane Allman EF, De Pauw BE. Early identification of neutropenic patients at risk of gram positive bacteraemia and the impact of empirical administration of vancomycin. *European Journal of Cancer* 1996;**32a**(8):1332-9.

Dincol 1998 {published and unpublished data}

Dincol D, Arican A, Aydin F, Samur M, Willke A, Akbulut H, et al. A comparison of imipenem monotherapy versus cefoperazone/ sulbactam plus amikacin combination treatment in febrile neutropenic cancer patients. *Cancer Journal* 1998;**11**(2):89-93.

Doyen 1983 {published and unpublished data}

Doyen C, Tepantondele JM, Wauters G, Michaux JL. A randomized therapeutic trial for ceftazidime versus ceftazidime and amikacin in febrile granulopenic patients. Proceedings of the 13th International Congress of Chemotherapy. Vienna: Spitzy KH, 1983:26-29.

Duzova 2001 {published and unpublished data}

Duzova A, Kutluk T, Kanra G, Buyukpamukcu M, Akyuz C, Secmeer G, Ceyhan, M. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. *The Turkish Journal of Pediatrics* 2001;**43**(2):105-9.

El Haddad 1995 {published data only}

El Haddad AMA. Comparison of cefoperazone-sulbactam versus piperacillin plus amikacin as empiric therapy in pediatric febrile neutropenic cancer patients. *Current Therapeutic Research Clinical and Experimental* 1995;**56**(10):1094-9.

Erjavec 1994 {published data only}

Erjavec Z, de Vries Hospers HG, van Kamp H, van der Waaij D, Halie MR, Daenen SM. Comparison of imipenem versus cefuroxime plus tobramycin as empirical therapy for febrile granulocytopenic patients and efficacy of vancomycin and aztreonam in case of failure. *Scandinavian Journal of Infectious Diseases* 1994;**26**(5):585-95.

Esteve 1997 {published data only}

Esteve J, Nomdedeu B, Mensa J, Guardia R, Marco F, Montserrat E. Piperacillin/tazobactam vs. piperacillin/ tazobactam plus amikacin as empiric therapy for fever in neutropenic patients. *Blood* 1997;**10**(Suppl 1 (Pt 2)):229b. Abstract 3767.

Gaytan-Martinez 2002 {published data only}

Gaytan-Martinez JE, Mateos-Garcia E, Casanova LJ, Fuentes-Allen JL, Sanchez-Cortes E, Manjarrez-Tellez B, et al. Efficacy of empirical therapy with cefepime compared with ceftazidime plus amikacin in febrile neutropenic patients. Proceedings of the Annual Meeting of the American Society of Hematology. 2002:Abstract No. 3655.

Gibson 1989 {published data only}

Gibson J, Date L, Joshua DE, Young GA, Wilson A, Benn R, et al. A randomised trial of empirical antibiotic therapy in febrile neutropenic patients with hematological disorders: ceftazidime versus azlocillin plus amikacin. *Australian and New Zealand Journal of Medicine* 1989;**19**(5):417-25.

Gorschluter 2003 {published data only}

Glasmacher A, Hahn C, Molitor E, Fixson A, Mey U, Sauerbruch T, et al. A randomized comparison of piperacillin-tazobactam vs. ceftriaxone and gentamicin in 172 severely neutropenic patients with hematologic malignancies. Proceedings of the

39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999:Abstract 1090.

* Gorschluter M, Hahn C, Fixson A, Mey U, Ziske C, Molitor E, et al. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. *Supportive Care in Cancer* 2003;**11**(6):362-70.

Gribble 1983 {published data only}

Gribble MJ, Chow AW, Naiman SC, Smith JA, Bowie WR, Sacks SL, et al. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. *Antimicrobial Agents and Chemotherapy* 1983;**24**(3):388-93.

Hansen 1986 {published data only}

Hansen SW, Friis H, Ernst P, Vejlsgaard R, Hansen HH. Latamoxef versus carbenicillin plus gentamicin or carbenicillin plus mecillinam in leukopenic, febrile patients with solid tumors. *Acta Med Scand* 1986;**220**(3):249-54.

Hense 2000 {published and unpublished data}

* Hense J, Bertz H, Leifert J, Meusers P, Mertelsmann R, Brittinger G. Final results of a prospective randomized trial of bolus meropenem versus infusion meropenem versus ceftazidime/amikacin as empiric initial therapy for infections and fever of unknown origin in neutropenic patients with hematologic malignancies. *Supportive Care in Cancer* 2000;**8**:Suppl:160. Abstract 64.

Hense J, Uppenkamp M, Meusers P, Hofeler H, Brittinger G. Prospective randomized trial of bolus meropenem versus infusion meropenem versus ceftazidime/amikacin as empiric initial therapy for infections and fever of unknown origin in neutropenic patients with hematologic malignancies. *Annals of Hematology* 1998;**77**:Suppl 2:S199.

Hess 1998 {published data only}

Hess UBC, Rey K, Senn HJ. Monotherapy with piperacillin/ tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. *Supportive Care in Cancer* 1998;**6**:402-9.

Hung 2003 {published data only}

Hung KC, Chiu HH, Tseng YC, Wang JH, Lin HC, Tsai FJ, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy. *Journal of Microbiology, Immunology, and Infection* 2003;**36**(4):254-9.

Jacobs 1993 {published data only}

Jacobs RF, Vats TS, Pappa KA, Chaudhary S, Kletzel M, Becton DL. Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic children. *Infection* 1993;**21**(4):223-8.

Jimeno 2006 {published and unpublished data}

* Jimeno A, Arcediano A, Bazares S, Amador ML, Gonzalez-Cortijo L, Ciruelos E, et al. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia. *Clinical Transplantation and Oncology* 2006;**8**(12):889-95.

Jimeno A, Arcediano A, Gomez C, Bezares S, Castellano D, Paz-Ares L, et al. Randomized study of cefepime versus ceftazidime plus amikacin in febrile neutropenic patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS). Proceedings of the Annual Meeting of the American Society of Clinical Oncology; Abstract 3387. 2003.

Kiehl 2001 {published data only}

Kiehl MG, Bischoff M, Basara N, Guenzelmann S, Fauser AA. A prospective randomized trial comparing the efficacy and safety of piperacillin/tazobactam versus piperacillin/tazobactam plus netilmicin in the treatment of tebrile neutropenia in allogeneic stem cell recipients. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 2001.

Kinsey 1990 {published data only}

Kinsey SE, Machin SJ, Goldstone AH. Ceftazidime monotherapy is as effective as ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients. *Journal of Hospital Infection* 1990;**15**:49-53.

Kliasova 2001 {published data only}

Kliasova G, Savchenko V, Lubimova L, Mendeleeva L, Parovichnikova E, Tolkacheva T, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for febrile neutropenic bone marrow transplant patients. Proceedings of the 11th European Congress of Clinical Microbiology and Infectious Diseases. 2001. [MEDLINE: http://www.akm.ch/eccmid2001/]

Koehler 1990 {published data only}

Koehler M, Bubala H, Sonta-Jakimczyk D, Wieczorek M, Janik-Moszant A, Kuder K. [Assessment of the efficacy of treating infections in hematopoietic proliferative diseases: monotherapy with ceftazidime and tobramycin combined with amoxycillin/ ampicillin]. *Pol Tyg Lek* 1990;**45**(21-22):417-20.

Kojima 1994 {published and unpublished data}

Kojima A, Shinkai T, Soejima Y, Okamoto H, Eguchi K, Sasaki Y, et al. A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients. *American Journal of Clinicial Oncology* 1994;**17**(5):400-4.

Leyland 1992 {published data only}

Leyland MJ, Bayst K, Cohen J, Warren R, Newland AC, Bint AJ, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. *Journal of Antimicrobial Chemotherapy* 1992;**30**(6):843-54.

Lieschke 1990 {published and unpublished data}

Lieschke GJ, Bell D, Rawlinson W, Green M, Sheridan W, Morstyn G, et al. Imipenem/cilastatin versus tobramycin and piperacillin as initial empiric therapy for febrile episodes in neutropenic patients: interim analysis of a prospective

randomized comparison. *Australian and New Zealand Journal of Medicine* 1990;**3**:Suppl 1:424.

Liu 1989 {published data only}

Liu CY, Wang FD. A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients. *Chemotherapy* 1989;**35**:Suppl 2:16-22.

Marie 1991 {published data only}

* Marie JP, Pico J, Lapierre V, Maulard C, Pappo M, Chiche D, et al. Comparative trial of ceftazidime alone, ceftazidime + amikacin and ceftazidime + vancomycin as empiric therapy of febrile cancer patients with induced prolonged neutropenia [Traitement empirique des episodes febriles survenant chez les patients cancereux presentant une neutropenie prolongee: essai comparatif ceftazidime seule, ceftazidime+amikacine et ceftazidime+vancomycine]. *Medicine et Maladies Infectieuses* 1991;**21**:386-8.

Marie JP, Pico JL, Chiche D, Fitoussi F, Delmer A, Baume D, et al. [Antibiotic therapy protocol using ceftazidime 3g/day alone or in combination with vancomycin or amikacin. In febrile episodes in neutropenic patients]. [French] [Protocole d'antibiotherie utilisant la ceftazidime a la dose de 3g/jour seule ou en association avec la vancomycin ou l'amikacin]. *Presse Medicale* 1988;**17**(37):1968-70.

Marie JP, Vekhoff A, Pico JL, Guy H, Andremont A, Richet H. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. *Journal of Antimicrobial Chemotherapy* 1998;**41**(Suppl D):57-64.

Pico JL, Marie JP, Chiche D, Guiguet M, Andremont A, Lapierre V, et al. Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial. *Eur J Med* 1993;**2**(5):275-80.

Matsui 1991 {published and unpublished data}

Matsui K, Masuda N, Takada M, Kusunoki Y, Fukuoka M. A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer. *Jpn J Clin Oncol* 1991;**21**(6):428-34.

Miller 1993 {published data only}

Miller JA, Butler T, Beveridge RA, Kales AN, Binder RA, Smith LJ, et al. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients. *Clinical Therapeutics* 1993;**15**(3):486-99.

Morgan 1983 {published data only}

Morgan G, Duerden BI, Lilleyman JS. Ceftazidime as a single agent in the management of children with fever and neutropenia. *Journal of Antimicrobial Chemotherapy* 1983;**12**:Suppl A:347-51.

Norrby 1987 {published and unpublished data}

* Norrby SR, Vandercam B, Louie T, Runde V, Norberg B, Anniko M, et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multiclinic study. Scandinavian Journal of Infectious Diseases Supplement 1987;**52**:65-78.

Vandercam B, Ezzeddine H, Agaliotis D, Gala JL, Gigi J, Wauters G, et al. Imipenem/cilastatin versus piperacillin plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with haematologic malignancies. *Acta Clinica Belgica* 1989;**44**(2):99-109.

Novakova 1990 {published data only}

Novakova I, Donnelly P, De Pauw B. Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia. *Scandinavian Journal of Infectious Diseases* 1990;**22**(6):705-11.

Novakova 1991 {published data only}

Novakova IR, Donnelly JP, de Pauw BE. Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients. *Annals of Hematology* 1991;**63**(4):195-200.

Ozyilkan 1999 {published and unpublished data}

Ozyilkan O, Yalcintas U, Baskan S. Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients. *The Korean Journal of Internal Medicine* 1999;**14**(2):15-9.

Papachristodoulou 96 {published data only}

Papachristodoulou A, Vaslamatzis M, Xynogalos S, Papacharalambous A, Alexopoulos CG. Ceftazidime (CFZ) monotherapy as empirical initial treatment of febrile neutropenia cancer patients (Pts). *Annals of Oncology* 1996;**7**:Suppl 5:140. Abstract 676.

Pegram 1984 {published data only}

Pegram SP, Muss HB, McGall CE, Cooper RM, White DR, Richards F, et al. A comparative study of moxalactam vs. ticarcillin and tobramycin in febrile, neutropenic cancer patients. Proceedings of the Annual Meetings of the American Society of Clinical Oncology; Abstract No. 255. 1982.

* Pegram SP, Muss HB, McGall CE, Cooper RM, White DR, Richards T, et al. A comparative study of moxalactam vs. ticarcillin and tobramycin in febrile, neutropenic cancer patients. Proceedings of the Annual Meetings of the American Society of Clinical Oncology; Abstract No. 391. 1984.

Pellegrin 1988 {published data only}

Pellegrin JL, Marit G, Fourche J, Broustet A, Texier MJ, Leng B, et al. Response to infection in patients with acute leukemia during remission induction treatment: ceftazidime versus cefotaxime + tobramycin [Etude prospective randomisee de la ceftazidime versus l'association cefotaxime-tobramycine, dans les leucemies aigues en aplasie therapeutique]. *Presse Med* 1988;**17**(37):1960-3.

Pereira 2009 {published data only (unpublished sought but not used)}

Pereira CAP, Petrilli AS, Carlesse FA, Luisi FAV, da Silva KVTB, Lee MLM. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk

febrile neutropenia in a randomized comparison. *Journal of Microbiology, Immunology and Infection* 2009;**42**(2):141-7.

Perez 1995 {published data only}

Perez C, Sirham M, Labarca J, Grebe G, Lira P, Oliva J, et al. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients] [Imipenem/ cilastatina versus ceftazidima-amikacina para el tratmiento de pacientes neutropenicos febriles]. *Revista Medica de Chile* 1995;**123**(3):312-20.

Petrilli 2003 {published and unpublished data}

Petrilli AS, Cypriano M, Dantas LS, Lee LM, Vercillo Luisi MF, Torres B, et al. Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma.. *Brazilian Journal of Infectious Diseases* 2003;**7**(2):111-20.

Piccart 1984 {published data only}

Piccart M, Klastersky J, Meunier F, Lagast H, Van Laethem Y, Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. *Antimicrobial Agents and Chemotherapy* 1984;**26**(6):870-5.

Pickard 1983 {published and unpublished data}

* Pickard W, Durack D, Gallis H. A randomized trial of empiric therapy with moxalactam versus tobramycin plus ticarcillin in febrile, neutropenic patients. Current Choices in Antibiotic Therapy for Febrile Episodes in Neutropenic Patients. 1983.

Pickard W, Durack D, Gallis H. A randomized trial of moxalactam versus tobramycin plus ticarcillin in 50 febrile neutropenic patients. Proceedings of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Abstract No. 66. 1982.

Pickard W, Gallis HA, Durack DT. A randomized trial of empiric therapy with moxalactam versus tobramycin plus ticarcillin in febrile neutropenic patients. Proceedings of the Second International Symposium in Infections in the Immunocompromised Host. 1982.

Piguet 1988 {published data only}

Piguet H, Pappo M. First-line treatment of febrile episodes in leukemia in adults: randomized, multicenter study of ceftazidime in single antibiotic therapy versus a cefotaximeamikacin combination [Traitment de premiere intention des episodes febriles des leucemies de l'adulte. Etude randomisee, multicentrique de la ceftazidime en monoantibiotherapie versus l'association cefotaxime-amikacine]. *Presse Med* 1988;**17**(37):1954-9.

Rodjer 1987 {published data only}

Rodjer S, Alestig K, Bergmark J, Bergstrom T, Hultberg B, Jagenburg R, et al. Treatment of septicaemia in immunocompromised patients with ceftazidime or with tobramycin and cefuroxime, with special reference to renal effects. *Journal of Antimicrobial Chemotherapy* 1987;**20**(1):109-16.

Rodriguez 1995 {published data only}

Rodriguez W, Gomez H, Silva ME, Vallejos C, Valdivia S, Casanova L, et al. Cefotaxime vs cephalotin-gentamicin in the first febrile episode of patients having solid tumors and shortterm neutropenia. *Acta Cancer* 1995;**25**:61-8.

Rolston 1992 {published data only}

Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. *Archives of Internal Medicine* 1992;**152**(2):283-91.

Schuchter 1988 {published data only}

Schuchter L, Kaelin W, Petty B, Wingard J, Altomonte V, Dick J, et al. Ceftazidime vs ticalcillin and gentamicin in febrile neutropenic bone marrow transplant patients: a prospective, randomized, double-blind trial. *Blood* 1988;**Abstract 1534**(Suppl 1):1:406a.

Smith 1990 {published and unpublished data}

Smith L, Will AM, Williams RF, Stevens RF. Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children. *The Journal of Infection* 1990;**20**(3):201-6.

Tamura 2002 {published and unpublished data}

Tamura K, Matsuoka H, Tsukada J, Masuda M, Ikeda S, Matsuishi E, et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study. *Am J Hematol* 2002;**71**:248-55.

Tamura 2004 {published and unpublished data}

Tamura K, Imajo K, Akiyama N, Suzuki K, Urabe A, Ohyashiki K, et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. *Clinical Infectious Diseases* 2004;**39**:S15-24.

Wade 1987 {published data only}

Bustamante CI. Initial empiric therapy for fever in neutropenia. *Recent Results in Cancer Research* 1993;**132**:45-56.

Wade JC. Antibiotic therapy for the febrile granulocytopenic cancer patient: combination therapy versus monotherapy. *Reviews of Infectious Diseases* 1989;**11**:Suppl 7:S1572-81.

* Wade JC, Delin A, Finely R, Drusano G, Thompson B. Imipenem versus piperacillin plus amikacin, empiric therapy for febrile neutropenic patients: a double blind trial. Proceedings of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1987:Abstract No. 1251.

Wrzesien-Kus 2001 {published and unpublished data}

Wrzesien-Kus A, Jamroziak K, Wierzbowska A, Robak T. Cefepime in monotherapy or in combination with amikacine as the empirical treatment of febrile neutropenic patients. *Acta Haematologica Polonica* 2001;**32**(2):165-72.

Yamamura 1997 {published and unpublished data}

Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experience with single agent and combination regimens in the

management of infection in the febrile neutropenic patient. *American Journal of Medicine* 1996;**100**(6a):83s-9s.

* Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. *Antimicrobial Agents and Chemotherapy* 1997;**41**(8):1704-8.

Yildirim 2008 {published data only (unpublished sought but not used)}

Yildirim I, Aytac S, Ceyhan M, Cetin M, Tuncer M, Cengiz AB, et al. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies. *Pediatric Hematology and Oncology* 2008;**25**:291-9.

Zengin 2011 {published and unpublished data}

Zengin E, Sarper N, Kiliç S. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. *Pediatric Hematology and Oncology* 2011;**28**:311-20.

References to studies excluded from this review

Berezin 2003 {published data only}

Berezin EN, Almeida FJ, Santos AG, Arnoni M, Safadi M, Peixoto F, et al. Asessment of cefepime monotherapy versus combined therapy with ceftriaxone and aminoglycoside in oncologic children and adolescents with febrile neutropenia. Proceedings of the 13th European Congress of Clinical Microbiology and Infectious Diseases. 2003:UK. Poster 836. [MEDLINE: http://www.akm.ch/eccmid2003/]

Bodey 1976 {published data only}

Bodey GP, Feld R, Burgess MA. Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients. *American Journal of Medicine* 1976;**271**(2):179-86.

Bru 1986 {published data only}

Bru JP, Michallet M, Legrand C, Swierz P, Stahl JP, Leautet JB, et al. A prospective randomized study comparing the efficacy of timentin alone or in combination with amikacin in the treatment of febrile neutropenic patients. *Journal of Antimicrobial Chemotherapy* 1986;**17**:Suppl C:203-9.

Cetto 1983 {published data only}

Cetto GL, Todeschini G, Caramaschi G, Vinante F, Benini F, Perona G. Empiric therapy of infections in hematologic malignancies: a prospective, randomized trial. *Tumori* 1983;**69**:155-60.

D'Antonio 1992 {published data only}

D'Antonio D, Fioritoni G, Iacone A, Dell'Isola M, Natale D, D'Arcangelo L, et al. Randomized comparison of ceftriaxone versus ceftriaxone plus amikacin for the empirical treatment of infections in patients with altered host defense: microbiological and clinical evaluation. *Chemotherapy* 1992;**38**(6):420-7.

Drusano 1985 {published data only}

Drusano GL, Joshi J, Forrest A, Ruxer R, Standiford H, Leslie J, et al. Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients. *Antimicrobial Agents and Chemotherapy* 1985;**27**(4):605-7.

EORTC 1987 {published data only}

The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. *New England Journal of Medicine* 1987;**317**(27):1692-8.

Fainstein 1983 {published data only}

Fainstein V, Bodey GP, Elting L, Bolivar R, Keating MJ, McCredie KB, et al. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. *Journal of Antimicrobial Chemotherapy* 1983;**12**:Suppl A:101-10.

Hauer 1990 {published data only}

Hauer C, Urban C, Slavc I, Gamillscheg A, Lackner H. Imipenemantibiotic monotherapy in juvenile cancer patients with neutropenia. *Pediatric Hematology and Oncology* 1990;**7**:229-41.

Hazel 1998 {published data only}

Hazel DL, Phelan L, Kinsey SE, Picton S, Todd N, Hawkey PM, et al. Piperacillin-tazobactam plus tobramycin is safe and effective therapy in children with febrile neutropenic episodes who are colonised with Enterobacteriaceae expressing extended spectrum β -lactamases. *Blood* 1998;**10**:Suppl 1 (Pt 1):612a. Abstract 2526.

Hoepelman 1988 {published data only}

Hoepelman IM, Rozenberg-Arska M, Verhoef J. Comparative study of ceftriaxone monotherapy versus a combination regimen of cefuroxime plus gentamicin for treatment of serious bacterial infections: the efficacy, safety and effect on fecal flora. *Chemotherapy* 1988;**34**:Suppl 1:21-9.

Hoepelman IM, Rozenberg-Arska M, Verhoef J. Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. *Lancet* 1988;**1**(8598):1305-9.

Karthaus 1998 {published data only}

Karthaus M, Wolf H, Egerer G, Kampfe D, Suedhoff T, Ritter J, et al. Ceftriaxone in the treatment of solid tumour patients with febrile neutropenia. *Onkologie* 1998;**21**:212-6.

Moreno-Sanchez 1992 {published data only}

Moreno-Sanchez FGR, Lazaro RM, Tellez E, Torres E. Monotherapy in patients with neutropenic fever. Proceedings of the American Society for Clinical Oncology. 1992:Abstract No. 1364.

Moroni 1987 {published data only}

Moroni C, Viscoli C, Boni L, Garaventa A, Dini G, Haupt R, et al. A randomized study of the empirical antibiotic therapy of the infections in neutropenic patients, affected by neoplastic diseases in paediatric age and under a fever attack. *Giornale*



di Malattie Infettive e Parassitarie (Journal of Infectious and Parasitic Dieases) 1987;**39**:1194-8.

Pegram 1989 {published data only}

Pegram PS, Phair JP, McMahan R, Murphy RL, Gordon LI, Washton H, et al. Prospective comparative trial of short course (four day) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients. *Journal of Antimicrobial Chemotherapy* 1989;**24**(4):591-604.

Petrilli 1991 {published data only}

Petrilli AS, Melarango R, Bianchi A, Kussano E, Barros KVT, Silva AAM. Fever and neutropenia in children: a new therapeutic proposal. *Revista da Associação Médica Brasileira* 1991;**37**(4):173-80.

Pizzo 1986 {published data only}

Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. *New England Journal of Medicine* 1986;**315**:552-8.

Reilly 1983 {published data only}

Reilly JT, Brada M, Bellingham AJ, Hart CA, Bennet C. Ceftazidime compared to tobramycin and ticarcillin in immunocompromised haematological patients. *Journal of Antimicrobial Chemotherapy* 1983;**12**:Suppl A:89-92.

Sampi 1987 {published data only}

Sampi K, Kumai R, Maseki N, Sakurai M, Kaneko Y, Hattori M. Cefmenoxime or piperacillin plus amikacin: a prospective randomized comparison of empiric antibiotic therapy of febrile granulocytopenic cancer patients. *Gan to Kagaku Ryoho Cancer* & Chemotherapy 1987;**14**:674-9.

Sanz 2005 {published data only}

Sanz MA, Bermudez A, Rovira M, Besalduch J, Pascual MJ, Nocea G, et al. Imipenem/cilastatin versus piperacillin/ tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.. *Current Medical Research and Opinion* 2005;**21**(5):645-55.

Sawae 1996 {published data only}

Sawae Y, Niho Y, Okamura T, Gondo H, Kozuru M, Uike N, et al. [Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders]. [Japanese]. Jpn J Antibiot 1996;**49**(12):1049-61.

Wrzesien-Kus 2000 {published data only}

Wrzesien-Kus AL-ME, Robak T. Cefepime or ceftazidime in combination with amikacin as the empirical treatment of febrile neutropenic patients. *Acta Haematologica Polonica* 2000;**31**(1):79-85.

References to studies awaiting assessment

Li 1998 {published data only}

Li HC, Zhang M, Ye X. Evidence of treating febrile neutropenia with netilmicin-ceftazidime. *Clinical Assembly* 1998;**13**(23):1057-8.

References to ongoing studies

Bilgir 2005 {published data only}

Bilgir O, Kadikoylu V, Bilgir F. The comparison of imipenem with piperacillin/tazobactam and amikacin combination in patients with hematological malignancies in the treatment of febrile neutropenia. Proceedings of the 10th Congress of the European Hematology Association. 2005:Abstract No. 1021.

Additional references

Allan 1985

Allan JD, Moellering RC Jr. Management of infections caused by gram negative bacilli: the role of antimicrobial combinations. *Reviews of Infectious Diseases* 1985;**7**:Suppl 4:S559-71.

Bliziotis 2005

Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. *Clinical Infectious Diseases* 2005;**41**(2):149-58.

Bodey 1966

Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Annals of Internal Medicine* 1966;**64**(2):328-40.

Bodey 1972

Bodey GP, Middleman E, Umsawadi T, Rodriguez V. Infections in cancer patients: results with gentamicin sulfate therapy. *Cancer* 1972;**29**(6):1697-701.

Chow 1991

Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. *Annals of Internal Medicine* 1991;**115**(8):585-90.

Consensus 1990

Anonymous. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel. *Journal of Infectious Diseases* 1990;**161**(3):397-401.

Elphick 2001

Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. *Cochrane Database of Systematic Reviews* 2005, Issue 2. [DOI: 10.1002/14651858.CD002007]



Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. *Clinical Infectious Diseases* 1997;**25**(2):247-59.

Freifeld 2011

Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. *Clinical Infectious Diseases* 2011;**52**(4):e56-93.

Giamarellou 1984

Giamarellou H, Zissis P, Tagari G, Bouzos J. In vitro synergistic activities of aminoglycosides and new beta lactams against multiresistant *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy* 1984;**25**(4):534-6.

Giamarellou 1986

Giamarellou H. Aminoglycosides plus beta lactams against gram negative organisms: evaluation of in vitro synergy and chemical interactions. *American Journal of Medicine* 1986;**80**:Suppl 6B:126-37.

Hann 1997

Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). *British Journal of Haematology* 1997;**99**(3):580-8.

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Hughes 1990

Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, et al. From the Infectious Diseases Society of America: guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. *Journal of Infection* 1990;**161**(3):381-96.

Hughes 1997

Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al. From the Infectious Diseases Society of America: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. *Clinical Infectious Diseases* 1997;**25**(3):551-73.

Klastersky 1976

Klastersky J, Meunier-Carpentier F, Prevost JM, Staquet M. Synergism between amikacin and cefazolin against *Klebsiella*. *Journal of Infectious Diseases* 1976;**134**(3):271-6.

Klastersky 1982

Klastersky J, Zinner SH. Synergistic combinations of antibiotics in gram negative bacillary infections. *Review of Infectious Diseases* 1982;**4**(2):294-301.

Klastersky 1986

Klastersky J, Glauser MP, Schimpff SC, Zinner SH, Gaya H. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. *Antimicrobial Agents and Chemotherapy* 1986;**29**(2):263-70.

Lin 2001

Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. *Clinical Infectious Diseases* 2001;**32**:358-66.

Marcus 2011

Marcus R, Paul M, Elphick H, Leibovici L. Clinical implications of -lactam–aminoglycoside synergism: systematic review of randomised trials. *International Journal of Antimicrobial Agents* 2011;**37**(6):491-503.

Milatovic 1987

Milatovic D, Braveny I. Development of resistance during antibiotic therapy. *European Journal of Clinical Microbiology and Infectious Diseases* 1987;**6**(3):234-44.

Paul 2003

Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. *BMJ* 2003;**326**:1111.

Paul 2004

Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. *BMJ* 2004;**328**(7441):668.

Paul 2006

Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. *Antimicrobial Agents & Chemotherapy* 2006;**57**(2):176-89.

Paul 2006a

Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactamaminoglycoside antibiotic combination therapy for sepsis. *Cochrane Database of Systematic Reviews* 2006, Issue 1. [DOI: 10.1002/14651858.CD003344.pub2]

Rossini 1994

Rossini F, Pioltelli P, Mingozzi S, Bregani R, Vigano F, Bolis S, et al. Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors. *Supportive Care in Cancer* 1994;**2**(4):259-65.



Schimpff 1971

Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. *New England Journal of Medicine* 1971;**284**(19):1061-5.

Schimpff 1986

Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. *American Journal of Medicine* 1986;**80**:Suppl 5C:13-20.

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. *JAMA* 1995;**273**(5):408-12.

Talcott 1992

Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. *Journal of Clinical Oncology* 1992;**10**(2):316-22.

Tam 2011

Tam CS, O'Reilly M, Andresen D, Lingaratnam S, Kelly A, Burbury K, et al. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee. *Internal Medicine Journal* 2011;**41**(1b):90-101.

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Vardakas 2013

Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME. β-Lactam plus aminoglycoside or fluoroquinolone combination versus βlactam monotherapy for *Pseudomonas aeruginosa* infections: a meta-analysis. *International Journal of Antimicrobial Agents* 2013;**41**(4):301-10.

Wade 1989

Wade JC. Antibiotic therapy for the febrile granulopenic cancer patient: combination therapy versus monotherapy. *Review of Infectious Diseases* 1989;**11**:Suppl 7:S1572-81.

Weistein 1985

Weistein L. Gram negative bacterial infections: a look at the past, a view of the present, and a glance at the future. *Review of Infectious Diseases* 1985;**7**:Suppl 4:S538-44.

References to other published versions of this review

Paul 2003a

Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. *BMJ* 2003;**326**:1111.

* Indicates the major publication for the study

gaoglu 2001				
Methods	Randomisation: "systematic sampling". Blinding: single. Intention-to-treat: yes. Interim analysis: none. Exclusions from analysis: 0/82.			
Participants	Turkey: 82 children. <18 years with 87 episodes randomly assigned to 3 arms. Underlying haematological cancer in 74/87 episodes. Neutropenia < 1000/mm³ and fever > 38.5°.			
Interventions	Meropenem 20 mg/kg × 3 versus Cefepime 33 mg/kg × 3 + netilmicin 2.5 mg/kg × 2 versus Ceftazidime 33 mg/kg × 3 + amikacin 7.5 mg/kg × 2.			
Outcomes	All cause mortality; infection related mortality. Treatment failure. Adverse events.			
Notes	Journal publication. No outcomes in subgroups. Additional outcome in study: cost.			
Risk of bias				
Bias	Authors' judgement Support for judgement			



Agaoglu 2001 (Continued)

Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All episodes included in analysis.

hmed 2007						
Methods	Randomisation: sealed opaque envelopes drawn at a central phone. Location. Blinding: no information. Intention to treat: possible. Interim analysis: none. Exclusions from analysis: 10/129 episodes. Follow-up period: no information.					
Participants		Egygt: 129 episodes among children < 18 years with haematological cancer mainly (80%), neutropenia < 500/mm³ expected to last > 6 days and fever.				
Interventions	Imipenem 20-25 mg/kg	g × 4 versus Ceftriaxone 100 mg/kg × 1 + amikacin 15 mg/kg × 1.				
Outcomes	All cause mortality. Infection related morta Treatment failure. Adverse events.	Infection related mortality. Treatment failure.				
Notes	Journal publication and correspondence with author. Outcome in subgroups: bacteraemia, Gram-negative bacteraemia, <i>Pseudomonas aeruginosa</i> bacter- aemia, haematological cancer. Additional outcome in study: cost.					
Risk of bias						
Bias	Authors' judgement	Support for judgement				
Random sequence genera- tion (selection bias)	Low risk	Central and sealed opaque envelopes.				
Allocation concealment (selection bias)	Low risk	A—Adequate.				



Ahmed 2007 (Continued)		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	10 patients excluded from analysis.

Akova 1999

Methods	Randomisation: sealed erated list in balanced Blinding: none. Intention-to-treat: pos Interim analysis: none. Exclusions from analys Follow-up period: mea	sible. sis: 12/83 (in study).				
Participants	Turkey: Multicentre. 83 adults > 18 years wi hours were excluded.	83 adults > 18 years with cancer, neutropenia < 500/mm ³ and fever. Patients with life expectancy < 24				
Interventions	Meropenem 1 gr × 3 ve	rsus Ceftazidime 2 gr × 3 + amikacin 1 gr × 1.				
Outcomes	Treatment failure. Adverse events.					
Notes	Journal publication. No outcomes in subgroups.					
Risk of bias						
Bias	Authors' judgement	Support for judgement				
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.				
Allocation concealment (selection bias)	Low risk	A—Adequate.				
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.				
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.				



Akova 1999 (Continued)

Incomplete outcome data High risk (attrition bias) All outcomes 6 patients excluded from analysis.

Methods	Randomisation: random selection of sealed envelopes (opaque not mentioned). Blinding: none.				
	Intention-to-treat: no. Interim analysis: none. Exclusions from analys Follow-up period: no ir				
Participants		les in 86 cancer patients (9-74 years) with neutropenia < 1000/mm ³ . Included h neutropenia unrelated to malignancy.			
Interventions	Moxalactam 50- to 70 mg/kg × 2-3 (max 14 gr/d) versus Nafcillin 30 mg/kg × 6 (max 12 gr/d) + to- bramycin 1.7 mg/kg × 3.				
Outcomes	Treatment failure. Bacterial and fungal su Colonisation. Adverse events. Dropouts after random				
Notes	Journal publication. Outcome in subgroups Bacteraemia, Severe neutropenia.				
Risk of bias					
Bias	Authors' judgement	Support for judgement			
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.			
Allocation concealment (selection bias)	Low risk	A—Adequate.			
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.			
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.			
Incomplete outcome data (attrition bias) All outcomes	High risk	14 episodes excluded from analysis.			



Methods	Randomisation: no information. Blinding: no information. Intention-to-treat: yes. Interim analysis: none. Exclusions from analysis: 0/67 episodes. Follow-up period: no information.					
Participants		Turkey: 67 febrile episodes in 52 children (11 months-15 years) with haematological cancer mainly and neutropenia < 1000/mm ³ .				
Interventions	Meropenem versus cef	tazidime + amikacin (no data on doses).				
Outcomes	Treatment failure.					
Notes	Conference proceeding: no outcomes in subgroups.					
Risk of bias						
Bias	Authors' judgement	Support for judgement				
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.				
Allocation concealment (selection bias)	Unclear risk	B—Unclear.				
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	B—Unclear.				
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	B—Unclear.				
Incomplete outcome data (attrition bias) All outcomes	Low risk	All episodes included in analysis.				

Δ			

Methods	Randomisation: no information.		
	Blinding: no information.		
	Intention-to-treat: no.		
	Interim analysis: none.		
	Exclusions from analysis: 5/56.		
	Follow-up period: no information.		
Participants	Singapore: 50 cancer patients > 14 years with neutropenia < 1000/mm ³ and fever > 38°. Patients with life expectancy < 24 hours were excluded.		
Interventions	Imipenem/cilastatin 500 mg × 4 versus Ceftriaxone 2 gr × 1 + gentamicin 1 mg/kg × 3.		
Outcomes	Treatment failure.		
	Adverse events.		



Au 1994 (Continued)

Notes

Journal publication. Outcome in subgroups.

Documented infections: bacteraemia. Documented Gram-negative and *Pseudomonas* infections.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	6 participants excluded from analysis.

Behre 1998

Bias	Authors' judgement Support for judgement
Risk of bias	
	Documented infections: bacteraemia. Documented Gram-negative and <i>Pseudomonas</i> infections.
Notes	Journal publication and author correspondence. Outcomes in subgroups.
	Adverse events. Dropouts after randomisation.
Outcomes	All cause mortality; infection related mortality. Treatment failure.
Interventions	Meropenem 1 gr × 3 versus Ceftazidime 2 gr × 3 + amikacin 5-7.5 mg/kg × 2-3.
Participants	Germany, multicentre: 78 episodes in 71 adults > 18 years with cancer (excluding allogeneic BMT), neu tropenia < 500/mm³ and fever.
Methods	Randomisation: pre-formed randomisation lists, provided by study centre. Blinding: none. Intention-to-treat: yes. Interim analysis: none. Exclusions from analysis: 7/78 (for efficacy analysis). Follow-up period: 14 days following end of study medication.



Behre 1998 (Continued)

Continued)		
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.
Allocation concealment (selection bias)	Low risk	A—Adequate.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	7 episodes excluded from analysis.
Bezwoda 1985		
Methods	Randomisation: no info Blinding: no informatic Intention-to-treat: no. Interim analysis: none. Exclusions from analys Follow-up period: no ir	on. is: 3/63.
Participants	South Africa: 60 adult c	ancer patients with neutropenia < 1000/mm ³ and fever > 39°.
Interventions	Moxalactam 2 gr × 3 ve	rsus cephradine 2 gr × 3 + tobramycin 1.5 mg/kg × 3.
Outcomes	All cause mortality. Treatment failure. Adverse events.	
Notes	Journal publication. Trial terminated because of increasing resistance to cephradine. Outcomes in subgroups.	
	Documented infections	s: documented Gram-negative and Pseudomonas infections.
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.



Bezwoda 1985 (Continued)			
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.	
Incomplete outcome data (attrition bias) All outcomes	High risk	3 participants excluded from analysis.	

Borbolla 2001

Methods	ethods Randomisation: no information. Blinding: no information. Intention-to-treat: no information.		
	Interim analysis: none. Exclusions from analys included). Follow-up period: no ir	is: no information (the study does not refer to excluded patients, 40 participants	
Participants	Mexico: 40 acute leuka tion.	emia patients included. Neutropenia < 500/mm ³ and fever > 38° or focal infec-	
Interventions	Cefepime 2 gr × 3 versu	us ceftriaxone 17 mg/kg × 3 + amikacin 15 mg/kg × 1.	
Outcomes	Treatment failure. Adverse events.		
Notes	Journal publication. Outcomes in subgroups. Haematological cancer patients.		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.	
Allocation concealment (selection bias)	Unclear risk	B—Unclear.	
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.	
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.	
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants included in analysis.	

Methods	Randomisation: central computer-generated randomisation using minimisation technique for 2 strati- fications: leukaemia or BMT and centre. Blinding: single (assessing committee). Intention-to-treat: no (performed according to study on eligible evaluable patients). Interim analysis: 2. Exclusions from analysis: 76/1034. Follow-up period: 30 days.			
Participants	Europe, multicentre: 1 and a presumed infect	034 cancer or BMT patients aged > 3 months with neutropenia < 1000/mm³, fever ion.		
Interventions	Meropenem 1 gr × 3 or	20 mg/kg × 3 versus ceftazidime 2 gr × 3 or 35 mg/kg × 3 + amikacin 20 mg/kg × 1		
Outcomes	All cause mortality. Infection related mortality. Treatment failure. Adverse events. Super-infections. Dropouts after randomisation.			
Notes	Journal publication. Envelopes used for randomisation in case of computer/connection failure. Outcomes in subgroups. Documented infections: documented Gram-negative, resistant Gram-negative and <i>Pseudomonas</i> infec- tions.			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.		
Allocation concealment (selection bias)	Low risk	A—Adequate.		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No blinding.		
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Outcome assessor blinded.		
Incomplete outcome data (attrition bias) All outcomes	High risk	76 participants excluded from analyses.		

Con	te	1	99	6
COI				•

Methods	Randomisation: no information.	
	Blinding: none.	
	Intention-to-treat: yes.	
Pota lactam vorcus he	ta lastam aminordy control combination therapy in cancer patients with poutropopia (Review)	21



Conte 1996 (Continued)	Exclusions from analysis: 0/40 episodes. Follow-up period: no information.
Participants	Chile: 40 episodes in 25 participants with haematological cancer and high-risk febrile neutropenia (me- dian count < 100/mm³).
Interventions	Cefoperazone-sulbactam 3 gr × 2 versus ceftazidime 1 gr × 3 + amikacin 7.5 mg/kg × 2.
Outcomes	All cause mortality. Treatment failure. Adverse events.
Notes	Conference proceedings.
	Outcomes in subgroups: haematological malignancies. Vitamin K added to cefoperazone-sulbactam group.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants included in analysis.

Corapcioglu 2005	
Methods	Randomisation: consecutive with no further details. Blinding: none. Intention-to-treat: no
	Interim analysis: 0. Exclusions from analysis: 10/60 episodes; follow-up p

	Exclusions from analysis: 10/60 episodes; follow-up period: not specified.		
Participants	Turkey: 60 episodes among 29 children 11 months-17 years, mainly with haematological cancer (74%), with neutropenia < 500/mm ³ or < 1000/mm ³ and expected to decline to < 500/mm ³ within 24-48 hours and fever.		
Interventions	ventions Cefepime 50 mg/kg × 3 versus Ceftazidime 50 mg/kg × 3 + amikacin 15 mg/kg × 1.		
Outcomes	Infection related mortality. Treatment failure.		



Corapcioglu 2005 (Continued)

	Adverse events. Dropouts after randomisation.		
Notes	Journal publication. No outcomes in subgroups.		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	High risk	C—Inadequate.	
Allocation concealment (selection bias)	High risk	C—Inadequate.	
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.	
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.	
Incomplete outcome data (attrition bias) All outcomes	High risk	10 episodes excluded from analysis.	

Randomisation: no information. Blinding: none. Intention-to-treat: no. Exclusions from analysis: 6/100. Follow-up period: no information.		
Netherlands: 100 episodes in 93 adult cancer patients with neutropenia < 500/mm ³ and fever. Alloge ic BMT patients excluded.		
Imipenem 500 mg × 4 versus Cefuroxime 1.5 gr × 3 or cephalotin 1 gr × 6 + gentamicin 80 mg × 3.		
Treatment failure. Colonisation. Adverse events. Dropouts after randomisation.		
Journal publication. Treatment modification suggested by protocol differs between the two treatment groups. Outcomes in subgroups.		
Documented infections: Gram-negative, resistant Gram-negative and <i>Pseudomonas</i> infections; bacter- aemia.		
-		



Cornelissen 1992 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	6 participants excluded from analysis.
Cornely 2001		
Methods	Randomisation: block randomisation with a block length of six (3 arms for first randomisation × 2 arms for second randomisation). Consecutively numbered sealed opaque envelopes, non-used envelopes to be returned (envelopes glued to the binding of the CRF). Blinding: none. Intention-to-treat: yes for mortality. Exclusions from analysis: 73/602 participants for failure patients. Follow-up period: up to 42 days (mortality data given up to 30 days).	
Participants	MC, Germany: 602 adult participants with high-risk haematological malignancies, neutropenia < 500 mm ³ and fever > 38.5° once or > 38 twice within 24 hours. Randomly assigned to 3 arms.	
Interventions	Meropenem 1 gr × 3 versus Cefepime 2 gr × 3 versus Piperacillin-tazobactam 4.5 gr × 3 + aminoglycoside once daily. For the purposes of the meta-analysis, the two monotherapy arms (cefepime and meropenem) were joined.	
Outcomes	All cause mortality.	
	Infection related morta Treatment failure. Adverse events.	ality.
Notes	Conference proceedings: Full methods and results supplied by the author.	
	Outcomes in subgroups: haematological malignancies.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Computer-generated block randomisation.



Cornely 2001 (Continued)

Allocation concealment (selection bias)	Low risk	A—Consecutively numbered sealed opaque envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	73 participants excluded from analysis.

e la Camara 1997				
Methods	Randomisation: consecutive computer-generated, concealed by sealed, opaque envelopes, stratified by centre.			
	Blinding: none.			
	Intention-to-treat: pose Interim analysis: none.	sible for mortality.		
		is: 29/122 episodes (for failure).		
	Follow-up period: 1 month following end of treatment.			
Participants	Spain, multicentre: 122 episodes in 103 participants > 16 years with neutropenia < 500/mm ³ and fever. All participants with underlying haematological malignancy, of which 49% had BMT and an additional 29% acute leukaemia.			
Interventions	Meropenem 1 gr × 3 versus Ceftazidime 2 gr × 3 + Amikacin 5-7.5 mg/kg × 2-3.			
Outcomes	All cause mortality.			
	Infection related mortality.			
	Treatment failure.			
	Adverse events. Bacterial and fungal super infections.			
	Dropouts after randomisation.			
Notes	Journal publication and author correspondence. Outcomes in subgroups. Documented infections: bacteraemia; haematological cancer patients.			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.		
Allocation concealment (selection bias)	Low risk	A—Adequate.		

De la Camara 1997 (Continued) Blinding of participants and personnel (performance bias) All outcomes High risk Open-label. Blinding of outcome assessment (detection bias) All outcomes High risk Open-label.

Incomplete outcome data High risk (attrition bias) All outcomes

De Pauw 1983

Methods	Randomisation: no information. Blinding: none. Intention-to-treat: no. Interim analysis: no. Exclusions from analysis: 4/78. Follow-up period: no information.
Participants	Netherlands: 78 haematological or BMT cancer patients > 15 years with neutropenia < 1000/mm³ and fever.
Interventions	Ceftazidime 2 gr × 3 versus Cefotaxime 2 gr × 4 + gentamicin 80 mg × 3.
Outcomes	Treatment failure. Fungal super infections. Adverse events.
Notes	Journal publication. Surveillance cultures performed. Outcomes in subgroups: Gram-negative and <i>Pseudomonas</i> infections; haematological cancer patients.

10 participants excluded from analysis.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias)	High risk	4 participants excluded from analysis.



De Pauw 1983 (Continued) All outcomes

Blinding of participants

and personnel (perfor-

Blinding of outcome as-

sessment (detection bias)

Incomplete outcome data

mance bias) All outcomes

All outcomes

(attrition bias) All outcomes High risk

High risk

High risk

e Pauw 1994			
Methods	Randomisation: central in blocks of eight, concealed by sealed envelopes (opaque not mentioned). Blinding: none. Intention-to-treat: no. Interim analysis: no. Exclusions from analysis: 74/1086. Follow-up period: end of treatment.		
Participants	Australia, Canada, Europe, multicentre: 968 episodes in 872 participants > 14 years evaluated, with neutropenia < 500/mm ³ and fever. Underlying haematological cancer in 83% of participants.		
Interventions	Ceftazidime 2 gr × 3 versus Piperacillin 3-4 gr × 4-6 + Tobramycin 1.7-2 mg/kg × 3. Supplemented as indicated by Vancomycin 1 gr × 2 or Metronidazole 500 × 3-4.		
Outcomes	All cause mortality. Infection related morta Treatment failure. Super-infections. Adverse events. Dropouts after random		
Notes	Journal publication, conference proceedings and author correspondence. Participants with suspected Gram-positive (n = 113) or anaerobic (n = 71) infections were given van- comycin or metronidazole, respectively, in addition to the randomly allocated antibiotic/s. Outcomes in subgroups. Documented infections: haematological cancer patients.		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.	
Allocation concealment (selection bias)	Low risk	A—Adequate.	

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Open-label.

Open-label.

118 episodes excluded from analysis.

el Favero 2001	
Methods	Randomisation: computer-generated, central, stratified by center and underlying malignancy. Blinding: double, placebo-controlled. Intention-to-treat: possible for failure. Interim analysis: no. Exclusions from analysis: 27/760 (for efficacy analysis and mortality). Follow-up period: 30 days.
Participants	Italy, multicentre: 760 participants > 13 years with neutropenia < 500/mm³ and fever > 38.5°. Underlying haematological cancer in 81%. of participants, and BMT in 52%.
Interventions	Piperacillin-tazobactam 4.5 gr × 3 versus piperacillin-tazobactam 4.5 gr × 3 + amikacin 7.5 mg/kg × 2.
Outcomes	All cause mortality.
	Infection related mortality. Treatment failure. Dropouts after randomisation. Adverse events.
Notes	Journal publication. Outcomes in subgroups. Documented infections: bacteraemia. Documented Gram-negative and <i>Pseudomonas</i> infections.
Risk of bias	
Bias	Authors' judgement Support for judgement

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.
Allocation concealment (selection bias)	Low risk	A—Adequate.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Double-blinded.
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Double-blinded.
Incomplete outcome data (attrition bias) All outcomes	High risk	27 participants excluded from analysis.

Dincol 1998

Methods	Randomisation: no information. Blinding: none.
	Intention-to-treat: yes.
	Interim analysis: no.
	Exclusions from analysis: none.
	Follow-up period: end of treatment.



Dincol 1998 (Continued)

Participants	Turkey: 150 episodes in 97 cancer patients > 14 years, with neutropenia < 500/mm³ and fever > 38.5°. Underlying haematological cancer in 43%.	
Interventions	Imipenem 500 mg × 4 versus cefoperazone-sulbactam 2 gr × 2 + amikacin 15 mg/kg × 1.	
Outcomes	All cause mortality. Infection related mortality. Treatment failure.	
	Adverse events.	
Notes	Journal publication and author correspondence. Outcomes in subgroups.	
	Documented infections: bacteraemia. Documented Gram-negative and <i>Pseudomonas</i> infections.	
Risk of bias		

Authors' judgement Bias Support for judgement Random sequence genera-Low risk A-Adequate. tion (selection bias) Allocation concealment Unclear risk B-Unclear. (selection bias) Blinding of participants High risk Open-label. and personnel (performance bias) All outcomes Blinding of outcome as-High risk Open-label. sessment (detection bias) All outcomes Incomplete outcome data Low risk All episodes included in analysis. (attrition bias) All outcomes

Doyen 1983

Methods	Randomisation: no information. Blinding: none. Intention-to-treat: possible for mortality. Interim analysis: 1. Exclusions from analysis: 7/104 (for failure). Follow-up period: no information.	
Participants	Belgium: 104 episodes in 83 adult haematological cancer with neutropenia < 500/mm ³ and fever > 38°.	
Interventions	Ceftazidime 30 mg/kg × 3 versus ceftazidime 30 mg/kg × 3 + amikacin 5 mg/kg × 3.	
Outcomes	All cause mortality.	
	Infection related mortality. Treatment failure.	



Doyen 1983 (Continued) Bacterial and fungal super infections. Notes Conference proceeding and author correspondence: Study not completed, all randomly assigned participants included in the review. Outcomes in subgroups. Outcomes in subgroups. Documented infections: bacteraemia; haematological cancer patients. Documented Gram-negative infections.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	7 episodes excluded from analysis.

Methods	Randomisation: no information.
	Blinding: single-blinded.
	Intention-to-treat: unknown.
	Interim analysis: no.
	Exclusions from analysis: no information, 90 episodes included.
	Follow-up period: no information.
Participants	Turkey: 90 episodes in children < 16 years with lymphomas or solid tumours (leukaemia excluded), with neutropenia < 500/mm³ and fever > 38.3°.
Interventions	Meropenem 50 mg/kg × 3 versus Piperacillin 200 mg/kg × 4 + Amikaciin 15 mg/kg × 1.
Outcomes	All cause mortality.
	Infection related mortality.
	Treatment failure.
Notes	Journal publication and author correspondence.
	Outcomes in subgroups: haematological cancer patients.

Risk of bias

_



Duzova 2001 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No blinding.
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Outcome assessor blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All episodes included in analysis.

El Haddad 1995

Methods	Randomisation: no information. Blinding: none. Intention-to-treat: no. Interim analysis: no. Exclusions from analysis: unknown, only number of evaluated participants reported. Follow-up period: unknown.		
Participants		hildren < 15 years with leukaemia or lymphoma and neutropenia < 500/mm³ or > 38° thrice during 24 hours.	
Interventions	Randomization 2:1 to cefoperazone-sulbactam 67 mg/kg × 3 versus Piperacillin 100 mg/kg × 4 + Amikacin 5 mg/kg × 3.		
Outcomes	Infection related morta Treatment failure. Adverse events.	ility.	
Notes	Journal publication. Outcomes in subgroup	s: haematological cancer.	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.	
Allocation concealment (selection bias)	Unclear risk	B—Unclear.	



El Haddad 1995 (Continued)		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	B—Unclear.

Erjavec 1994

Methods	Randomisation: no information. Blinding: none. Intention-to-treat: yes. Interim analysis: no. Exclusions from efficacy and subgroup analysis: 36/179. Follow-up period: resolution of neutropenia.	
Participants	Netherlands: 179 episodes in 127 haematological cancer patients > 16 years, with neutropenia < 500/ mm³ and fever.	
Interventions	Imipenem 12.5 mg/kg -1gr × 4 versus Cefuroxime 15 mg/kg × 3 + Tobramycin 2 mg/kg × 2 following a loading dose of 2.5 mg/kg.	
Outcomes	Treatment failure. Bacterial and fungal super-infections.	
Notes	Journal publication. Outcomes in subgroups. Documented infections: documented Gram-negative, <i>Pseudomonas</i> and resistant Gram-negative in- fections; haematological cancer patients.	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.



Erjavec 1994 (Continued)

Incomplete outcome data High risk (attrition bias) All outcomes 36 episodes excluded from analysis.

steve 1997	
Methods	Randomisation: no information. Blinding: none. Intention-to-treat: unknown. Interim analysis: unknown. Exclusions analysis: only the number of treated participants reported. Follow-up period: unknown.
Participants	Spain: 85 episodes in 75 haematological cancer patients (excluding bone marrow transplantation) with neutropenia < 1000/mm ³ and fever.
Interventions	Piperacillin-tazobactam 4 gr × 4 versus Piperacillin-tazobactam 4 gr × 4 + Amikacin 15 mg/kg × 1.
Outcomes	All cause mortality. Treatment failure. Adverse events.
Notes	Conference proceeding.
Risk of bias	Outcomes in subgroups: haematological cancer patients.
Piac	Authorst judgement Support for judgement

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	B—Unclear.

Gaytan-Martinez 2002	
Methods	Randomisation: no information. Blinding: none.



Gaytan-Martinez 2002 (Continued)

Intention-to-treat: no. Interim analysis: unknown. Exclusions from analysis: unknown (only number of evaluated episodes reported). Follow-up period: unknown.	
Mexico: 117 evaluated episodes in participants with non-Hodgkin lymphoma or acute leukaemia with neutropenia and fever > 38.3°.	
Cefepime 2 gr × 2 versus Ceftazidime 2 gr × 3 + Amikacin 1 gr × 1.	
Treatment failure.	
Conference proceeding. No outcomes in subgroups.	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	B—Unclear.

Gibson 1989

Methods	Randomisation: computer-generated random numbers, concealed by sealed envelopes, which were taken in consecutive order (opaque not mentioned). Blinding: none. Intention-to-treat: yes. Interim analysis: none. Exclusions from analysis: 0. Follow-up period: no information.	
Participants	Australia: 102 adults > 14 years. All with underlying haematological malignancy. Neutropenia < 1000/ mm³ and fever or clinically localised site of infection.	
Interventions	Ceftazidime 2 gr × 3 versus Azlocillin 4 gr × 4 + Amikacin 5 mg/kg × 3.	
Outcomes	All cause mortality.	
	Infection related mortality.	



Gibson 1989 (Continued)

Treatment failure.

Journal publication. Additional empirical treatment with flucloxacillin allowed. Outcomes in subgroups: haematological cancer patients.

Risk of bias

Notes

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.
Allocation concealment (selection bias)	Low risk	A—Adequate.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants included in analysis.

Gorschluter 2003	
Methods	Randomisation: computer-generated, concealed by sealed, opaque envelopes. Blinding: none. Intention-to-treat: modified (performed on all eligible participants). Interim analysis: 2. Exclusions from analysis: 29/212 episodes. Follow-up period: 21 days after treatment initiation.
Participants	Germany: 212 episodes in 130 adults > 18 years. All with underlying haematological malignancy, 90% acute leukaemia. Leukopaenia < 1000/mm³ or neutropenia < 500/mm³ and fever > 38.5° (rectal) or > 38′ (axillary).
Interventions	Piperacillin-tazobactam 4.5 gr × 3 versus Ceftriaxone 2 gr × 1 + gentamycin 5 mg/kg × 1.
Outcomes	All cause mortality. Infection related mortality. Treatment failure.
Notes	Journal article. Study discontinued at second interim analysis by protocol because of a significant advantage for monotherapy. Outcomes in subgroups. Documented infections: bacteraemia. Documented: Gram-negative, <i>Pseudomonas</i> and resistant Gram-negative infections; haematological cancer patients.



Gorschluter 2003 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Computer generated lists.
Allocation concealment (selection bias)	Low risk	A – Sealed opaque envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	29 episodes excluded from analysis.

Gribble 1983

tion (selection bias)

Methods	Pandomisation: comp	uter generated concealment net specified	
Methous	Randomisation: computer-generated, concealment not specified. Blinding: none.		
	Intention-to-treat: no.		
	Interim analysis: none.		
	Exclusions from analys	sis: 4/54.	
	Follow-up period: 14 d	ays after treatment cessation.	
Participants	Canada: 50 episodes in 38 adults > 16 years evaluated. Of these, 30 episodes were in neutropenic par- ticipants with neutropenia < 1000/mm³ and fever > 38.3°.		
Interventions	Piperacillin 75 mg/kg × 4 versus Carbenicillin 125 mg/kg × 4 (could be replaced by ticarcillin) + Gentam- icin 1.5 mg/kg × 3 (could be replaced by tobramycin).		
Outcomes	Treatment failure: super-infections. Adverse events.		
Notes	Journal publication.		
	•	eatment with cloxacillin allowed.	
	Study includes both neutropenic and non-neutropenic participants, and only outcomes that can be separated were extracted.		
		bups (for neutropenic participants only).	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera-	Low risk	A—Adequate.	



Gribble 1983 (Continued)

Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	4 participants excluded from analysis.

Hansen 1986

Methods	Randomisation: no information, stratification according to cytotoxic therapy. Blinding: none. Intention-to-treat: no. Interim analysis: none.	
	Exclusions from analysis: 7/40. Follow-up period: no information.	
Participants	Denmark: 80 episodes in 70 solid tumour cancer patients with neutropenia < 1500/mm ³ and fever, ran- domised to 4 arms, of which 2 arms and 40 episodes are included in the review.	
Interventions	Latamoxef 2 gr × 3 versus Carbenicillin 10 gr × 3 +gentamicin 80 mg × 3.	
Outcomes	Treatment failure: dropouts after randomisation.	
Notes	Journal publication. Outcomes in subgroups: severe neutropenia, bacteraemia, documented Gram-negative infections.	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias)	High risk	7 episodes excluded from analysis.



Hansen 1986 (Continued) All outcomes

Methods	Randomisation: no information. Blinding: none. Intention-to-treat: yes for mortality, possible for failure. Interim analysis: none. Exclusions from analysis: in study 3/87. Follow-up period: no information.	
Participants	Germany: 88 adult pati	ents with haematological malignancy, with neutropenia < 500/mm ³ and fever.
Interventions	Meropenem 1 gr × 3 (gi tazidime 2 gr × 3 + Amil	ven either as bolus or infusion—2 arms merged for this review) versus Cef- kacin 5 mg/kg × 3.
Outcomes	All cause mortality. Infection related mortality. Treatment failure: adverse events; dropouts after randomisation.	
Notes	Conference proceeding and results from author. Outcomes in subgroups: haematological malignancy.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	3 participants excluded from analysis.

Hess 1998

Methods	Randomisation: consecutively numbered sealed envelopes (opaque not mentioned) in randomly per- muted blocks, by 24 hours' service. Blinding: none. Intention-to-treat: no. Interim analysis: none. Exclusions from analysis: 11/107.



less 1998 (Continued)	Follow-up period: 30 d	ays after inclusion.	
Participants	Switzerland: 107 episodes in 83 cancer patients > 13 years with neutropenia < 500/mm ³ and fever or documented infection without fever.		
Interventions	Piperacillin-tazobactar	n 4.5 gr × 3 versus Ceftazidime 2 gr × 3 + Amikacin 15 mg/kg × 1.	
Outcomes	All cause mortality.		
	Infection related mortality. Treatment failure: adverse events; dropouts after randomisation.		
Notes	Journal publication. Additional empirical treatment with vancomycin allowed by protocol for non-responders after 48 hours. Discrepancy between tables and text concerning dropouts, disabling analysis by intention-to-treat. Outcomes in subgroups: bacteraemia.		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.	
Allocation concealment (selection bias)	Low risk	A—Adequate.	
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.	
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.	
Incomplete outcome data (attrition bias) All outcomes	High risk	11 episodes excluded from analysis.	

Randomisation: no information, stratified by haematological malignancy. Blinding: none. Intention-to-treat: no. Interim analysis: none. Exclusions from analysis: 24/100 episodes. Follow-up period: no information.
China: 76 episodes in 51 children < 14 years with neutropenia < 500/mm³, fever and suspected infec- tion.
Meropenem 40 mg/kg × 3 versus Ceftazidime 50 mg/kg × 3 + Amikacin 5 mg/kg × 3,
All cause mortality.
-



Hung 2003 (Continued)

Infection related mortality.	
Treatment failure: adverse events;	dropouts after randomisation.

Journal publication. Outcomes in subgroups: severe neutropenia.

Documented infections.

Risk of bias

Notes

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	24 episodes excluded from analysis.

Jacobs 1993

Bias	Authors' judgement Support for judgement		
Risk of bias			
	Documented infections: bacteraemia. Documented Gram-negative and <i>Pseudomonas</i> infections.		
Notes	Journal publication. Outcomes in subgroups.		
Outcomes	Treatment failure: bacterial super-infections; adverse events; dropouts after randomisation.		
Interventions	Ceftazidime 50 mg/kg × 3 versus Ceftazidime 50 mg/kg × 3 + Tobramycin 2.5 mg/kg × 3.		
Participants	USA: multicentre, 107 episodes in 92 children < 18 years treated for cancer with fever > 38° and neu- tropenia > 500/mm ³ .		
Methods	Randomisation: no information, stratified by centre. Blinding: none. Intention-to-treat: no. Interim analysis: none. Exclusions from analysis: 16/107. Follow-up period: no information.		



Jacobs 1993 (Continued)

Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	16 episodes excluded from analysis.

limeno 2006			
Methods	Randomisation: compu	iter-generated, concealed by sealed opaque envelopes.	
	Blinding: none. Intention-to-treat: yes. Interim analysis: study stopped early because cancer treatment protocol changed. Exclusions from analysis: 0/51 episodes. Follow-up period: no information.		
Participants		9 adults with solid malignancies treated with high-dose chemotherapy and pe- ll support, with fever > 38.3° (or > 38° lasting > 1 hour) and neutropenia < 500/	
Interventions	Cefepime 2 gr × 3 versu	ıs Ceftazidime 2 gr × 3 + Amikacin 500 mg × 2.	
Outcomes	All cause mortality. Infection related mortality. Treatment failure: adverse events; hospitalisation duration.		
Notes	Journal publication and correspondence with author. Outcomes in subgroups. Documented infections.		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	A—Computer generated.	
Allocation concealment (selection bias)	Low risk	A—Sealed opaque envelopes.	



Jimeno 2006 (Continued)		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All episodes included in analysis.

Kiehl 2001

Methods	Randomisation: no information. Blinding: none. Intention-to-treat: yes. Interim analysis: unknown. Exclusions from analysis: 0/71 participants. Follow-up period: no information.
Participants	Germany: 71 patients following autologous stem cell transplantation with febrile neutropenia.
Interventions	Piperacillin-tazobactam 4.5 gr × 3 versus Piperacillin-tazobactam 4.5 gr × 3 + Netilmicin 5 mg/kg × 1.
Outcomes	Treatment failure.
Notes	Conference proceeding.
	Outcomes in subgroups: haematological cancer patients.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants included in analysis.



Kinsey 1990

Methods	Randomisation: no information. Blinding: none. Intention-to-treat: no Interim analysis: none. Exclusions from analysis: 45/205. Follow-up period: no information.	
Participants	UK: 205 episodes in 13 and fever.	9 haematological cancer patients, aged 9-74 years with neutropenia < 500/mm ³
Interventions	Ceftazidime versus cef	tazidime + gentamicin (no dosing information).
Outcomes	All cause mortality. Infection related mortality. Treatment failure.	
Notes	Journal publication. No outcomes in subgroups. 11 deaths in 45 excluded participants.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	45 episodes excluded from analysis.

Kliasova 2001

Methods	Randomisation: no information. Blinding: none. Intention-to-treat: unknown. Interim analysis: unknown. Exclusions from analysis: only number evaluated provided. Follow-up period: 60 days after treatment.
	Follow-up period: 60 days after treatment.



Kliasova 2001 (Continued)

Participants	Russia: 43 episodes in 42 haematological cancer patients > 15 years after bone marrow transplantation, with fever and neutropenia.
Interventions	Meropenem 1 gr × 3 versus Ceftazidime 2 gr × 3 + Amikacin 500 mg × 3.
Outcomes	All cause mortality. Infection related mortality. Treatment failure: adverse events.
Notes	Conference proceeding.
	Outcomes in subgroups: haematological cancer patients.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	B—Unclear.

Koehler 1990

Methods	Randomisation: no information. Blinding: none. Intention-to-treat: yes. Interim analysis: none. Exclusions from analysis: 0/120 episodes. Follow-up period: no information.
Participants	Poland: 76 children with haematological cancer with 120 episodes of neutropenia <= 1000/mm ³ and fever >= 38° for > 3 hours.
Interventions	Ceftazidime 50 mg/kg × 3 versus Ampicilin or Amoxycillin 100 mg/kg × 3 + Tobramycin 4 mg/kg × 3.
Outcomes	Treatment failure: bacterial and fungal super-infections; adverse events.
Notes	Journal publication. Outcomes in subgroups: haematological cancer.



Koehler 1990 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All episodes included in analysis.

Kojima 1994

Methods	Randomisation: stratified by use of G-CSF, no further information. Blinding: none. Intention-to-treat: no. Interim analysis: none. Exclusions from analysis: 2/70. Follow-up period: 72 hours after completion of treatment.
	··· ·
Participants	Japan: 70 episodes in 60 solid tumour cancer adult patients with neutropenia < 1000/mm³ and fever. No BMT patients.
Interventions	Imipenem 500 mg × 4 versus Imipenem 500 mg × 4 + Amikacin 200 mg/m ² × 2.
Outcomes	Treatment failure: adverse events; fungal colonisation; dropouts after randomisation.
Notes	Journal publication and author correspondence. Study terminated prematurely because of excess fail- ures in monotherapy. Outcomes in subgroups:
	Documented infections: documented Gram-negative and <i>Pseudomonas</i> infections.
Risk of bias	

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Low risk	A—Adequate.



Kojima 1994 (Continued)						
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.				
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.				
Incomplete outcome data (attrition bias) All outcomes	High risk	3 participants excluded from analysis.				

Leyland 1992

Methods	Randomisation: generation not specified, concealment by sealed envelopes (opaque not mentioned). Blinding: single (outcome assessor). Intention-to-treat: no. Interim analysis: none. Exclusions from analysis: 96/312. Follow-up period: 14 days.
Participants	UK , multicentre: 312 episodes in 234 adults > 18 years with haematological cancer, neutropenia < 1000/mm ³ and fever.
Interventions	Imipenem 0.5-1 gr × 4 versus Piperacillin 4 gr × 4 + Gentamycin 80 mg/kg × 3.
Outcomes	Overall mortality. Treatment failure: bacterial super-infections; adverse events; dropouts after randomisation.
Notes	Journal publication. Exclusion rate 30.8%, with 3 patients not accounted for. Outcomes in subgroups.
	Documented infections: bacteraemia. Documented Gram-negative infections: haematological cancer patients.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Low risk	A—Adequate.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No blinding.
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Outcome assessor blinded.



Leyland 1992 (Continued)

Incomplete outcome data	High risk
(attrition bias)	-
All outcomes	

96 episodes excluded from analysis.

ieschke 1990				
Methods	Randomisation: generated through centre at drug company, concealed by envelopes (sealed or opaque not mentioned). Blinding: none. Intention-to-treat: yes. Interim analysis: 1. Exclusions from analysis: none. Follow-up period: end of fever, infection or neutropenia.			
Participants	Australia: 182 episodes in 150 adult febrile neutropenic cancer patients. Neutropenia < 1000/mm ³ and fever > 38°.			
Interventions	Imipenem 500 mg × 4 v	versus Piperacillin 4 gr × 4 + Tobramycin 1 mg/kg × 3.		
Outcomes	All cause mortality. Infection related mortality. Treatment failure: bacterial super-infections; adverse events.			
Notes	Data from manuscript of unpublished trial supplied by author. Published as an abstract at an interim analysis. No outcomes in subgroups.			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.		
Allocation concealment (selection bias)	Low risk	A—Adequate.		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.		
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.		
Incomplete outcome data (attrition bias) All outcomes	Low risk	All episodes included in analysis.		

Liu 1989

Methods	Randomisation: no information.
---------	--------------------------------

Liu 1989 (Continued)	Blinding: none.				
	Intention-to-treat: no. Interim analysis: none. Exclusions from analys Follow-up period: no ir	sis: 1/28.			
Participants	China: 28 adults > 18 ye arms.	China: 28 adults > 18 years with cancer, neutropenia < 500/mm ³ and fever. Randomised to 3 treatment arms.			
Interventions	Imipenem 500 mg × 4 versus Ceftriaxone 2 gr × 1 + Amikacin 7.5 mg/kg × 2 versus Ceftazidime 2 gr × 3 + Amikacin 7.5 mg/kg × 2.				
Outcomes	Treatment failure: bacterial and fungal super-infections; adverse events; dropouts after randomisation.				
Notes	Journal publication. Outcomes in subgroups: documented infections.				
Risk of bias					
Bias	Authors' judgement	Support for judgement			
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.			
Allocation concealment (selection bias)	Unclear risk	B—Unclear.			
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.			

All outcomes					
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.			
Incomplete outcome data (attrition bias) All outcomes	High risk	1 patient excluded from analysis.			

Μ	2	ri	0	-1	a	a	1
171	а		-	-	-	-	

Methods	Randomisation: "triage a sort" concealed by sealed envelopes (opaque not mentioned).
	Blinding: none.
	Intention-to-treat: unknown. Interim analysis: yes. Exclusions from analysis: no information (the study does not refer to excluded participants). Follow-up period: no information.
Participants	France, bi-centre: 146 episodes in adult cancer patients with cancer, neutropenia < 500/mm ³ and fever. Randomised to 3 treatment arms, of which 2 are relevant for the comparison in the review.
Interventions	Ceftazidime 1 gr × 3 versus Ceftazidime 1 gr × 3 + Amikacin 7.5 mg/kg × 2 versus Ceftazidime 1 gr × 3 + Vancomycin 500 mg × 3 (third treatment arm excluded).



Marie 1991 (Continued)

Outcomes

Treatment failure: bacterial and fungal super-infections; adverse events.

Notes

Journal publication. No outcomes in subgroups.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.
Allocation concealment (selection bias)	Low risk	A—Adequate.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	B—Unclear.

Matsui 1991

Bias	Authors' judgement Support for judgement			
Risk of bias				
Notes	Journal publication and author correspondence. Outcomes in subgroups. Documented infections: documented Gram-negative and <i>Pseudomonas</i> infections; severe neutropenia			
Outcomes	All cause mortality. Infection related mortality. Treatment failure.			
Interventions	Imipenem 1 gr × 2 versus Moxalactam 2 gr × 2 + Tobramycin 90 mg × 2.			
Participants	Japan: 101 episodes in 98 adults with chemotherapy treated lung cancer, leukopenia < 3000/mm³ and fever (80% with neutropenia < 1000/mm³). All participants with clinically or microbiologically docu- mented infection.			
	Intention-to-treat: possible. Interim analysis: none. Exclusions from analysis: 3/101 (in study). Follow-up period: end of treatment.			
Methods	Randomisation: computer generated, concealed with opaque envelopes. Blinding: single.			



Matsui 1991 (Continued)

Random sequence genera- tion (selection bias)	Low risk	A—Adequate.
Allocation concealment (selection bias)	Low risk	A—Adequate.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Only patient blinded.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	No blinding.
Incomplete outcome data (attrition bias) All outcomes	High risk	3 episodes excluded from analysis.

Ailler 1993			
Methods	Randomisation: no information. Blinding: none. Intention-to-treat: no, modified ITT possible for failure. Interim analysis: none. Exclusions from analysis: 45/131 episodes. Follow-up period: end of treatment.		
Participants	USA: 131 episodes in 106 adult patients with haematological or solid cancer from three hospitals, with neutropenia < 500/mm ³ and fever > 38° or a clinically or microbiologically documented source of infection.		
Interventions	Imipenem 500 mg × 4 versus Ceftazidime 2 gr × 3 + Tobramycin 1-1.5 mg/kg × 3-4.		
Outcomes	All cause mortality. Infection related mortality. Treatment failure: bacterial super-infections; adverse events.		
Notes	Journal publication. Outcomes in subgroups. Documented infections: bacteraemia. Documented Gram-negative infections; severe neutropenia.		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.	
Allocation concealment (selection bias)	Unclear risk	B—Unclear.	



Miller 1993 (Continued)		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	45 episodes excluded from analysis.

Morgan 1983

Methods	Randomisation: no information.		
	Blinding: none.		
	Intention-to-treat: no.		
	Interim analysis: none.		
	Exclusions from analysis: 3/50.		
	Follow-up period: no information.		
Participants	England: 50 episodes in 34 children < 15 years with malignancy. Neutropenia < 1000/mm ³ and fever.		
Interventions	Ceftazidime 30 mg/kg × 3 versus Azlocillin 50 mg/kg × 3 + Tobramycin 2 mg/kg × 3.		
Outcomes	All cause mortality.		
	Infection related mortality.		
	Treatment failure: dropouts after randomisation.		
Notes	Journal publication.		
	Outcomes in subgroups: Pseudomonas infections.		

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias)	High risk	3 episodes excluded from analysis.



Morgan 1983 (Continued) All outcomes

Methods	Randomisation: conco	aled by sealed envelopes (onague not mentioned) stratified by centre. No infor		
Methous	Randomisation: concealed by sealed envelopes (opaque not mentioned), stratified by centre. No infor- mation on allocation generation.			
	Blinding: none. Intention-to-treat: yes.			
	Interim analysis: none. Exclusions from analys			
	Follow-up period: 7 da			
Participants		centre: 210 participants > 16 years with neutropenia < 1000/mm ³ and fever. Par- bability of death within 48 hours excluded.		
Interventions	lmipenem 1 gr (or 125 × 2-3.	mg/kg) × 4 versus Piperacillin 4 gr × 4 (or 75 mg/kg × 4-6) + Amikacin 5-7.5 mg/kg		
Outcomes	All cause mortality.			
	Infection related morta			
	Treatment failure: bacterial and fungal super-infections; colonisation and resistant colonisation; ad- verse events.			
Notes	Journal publication and author correspondence.			
	Outcomes in subgroups.			
	Documented infections: bacteraemia			
	Documented Gram-ne	gative and <i>Pseudomonas</i> infections; severe neutropenia.		
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.		
Allocation concealment (selection bias)	Low risk	A—Adequate.		
Blinding of participants	High risk	Open-label.		
and personnel (perfor- mance bias)				
All outcomes				
Blinding of outcome as-	High risk	Open-label.		
sessment (detection bias) All outcomes				
Incomplete outcome data (attrition bias)	Low risk	78 participants excluded from efficacy analysis in study, but ITT analysis also given.		



Methods	Randomisation: computer-generated allocation with sealed envelope concealment (opaque not men- tioned). Blinding: none. Intention-to-treat: possible. Interim analysis: none. Exclusions from analysis: 21/90 (in study). Follow-up period: no information.		
Participants	Netherlands: 90 episoc underlying haematolog	les in 83 adult patients > 15 years with neutropenia < 500/mm ³ and fever. All wit gical malignancy.	
Interventions	Ceftazidime 2 gr × 3 ve	rsus Piperacillin 4 gr × 4 + Amikacin 500 mg × 3.	
Outcomes	All cause mortality. Infectionvrelated mortality. Treatment failure: bacterial and fungal super-infections; dropouts after randomisation.		
Notes	Journal publication. Outcomes in subgroups: bacteraemia; haematological cancer patients. Participants nursed in reverse isolation.		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.	
Allocation concealment (selection bias)	Low risk	A—Adequate.	
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.	
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.	
Incomplete outcome data (attrition bias) All outcomes	High risk	21 episodes excluded from analysis.	

 Novakova 1991

 Methods
 Randomisation: computer-generated, concealed by sealed envelopes (opaque not mentioned). Blinding: none. Intention-to-treat: possible. Interim analysis: none. Exclusions from analysis: 21/90 (in study). Follow-up period: no information.

 Participants
 Netherlands: 90 episodes in 82 adults > 15 years with neutropenia < 1000/mm³, fever and signs of a local infection. All with underlying haematological malignancy or BMT.



Ceftazidime 2 gr × 3 versus Ceftazidime 2 gr × 3 + Amikacin 500 mg × 3.		
All cause mortality.		
Infection×related morta Treatment failure: bact	ality. terial and fungal super-infections; dropouts after randomisation.	
Journal publication. Outcomes in subgroups.		
Documented infections: bacteraemia; haematological cancer patients. Participants nursed in reverse isolation.		
Authors' judgement	Support for judgement	
Low risk	A—Adequate.	
	All cause mortality. Infection×related mort Treatment failure: back Journal publication. Outcomes in subgroup Documented infections Participants nursed in Authors' judgement	

Allocation concealment (selection bias)	Low risk	A—Adequate.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	21 episodes excluded from analysis.

Ozyilkan 1999

Methods	Randomisation: central randomisation with random file number. Blinding: double. Intention-to-treat: yes. Interim analysis: none. Exclusions from analysis: none. Follow-up period: 12 months.	
Participants	Turkey: 30 adult cancer patients with neutropenia < 1000/mm ³ and fever. 93% with underlying haema- tological malignancy.	
Interventions	Imipenem 500 mg × 4 versus Cefoperazone-sulbactam 2 gr × 2 + Amikacin 7.5 mg/kg × 2.	
Outcomes	All cause mortality. Infection related mortality. Treatment failure: bacterial and fungal super-infections; dropouts after randomisation.	
Notes	Journal publication and author correspondence. Outcomes in subgroups.	



Ozyilkan 1999 (Continued)

Documented infections.

Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.
Allocation concealment (selection bias)	Low risk	A—Adequate.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Double-blinded.
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Double-blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants included in analysis.

Papachristodoulou 96				
Methods	Randomisation: no information. Blinding: none. Intention-to-treat: yes. Interim analysis: unknown (results obtain from conference proceeding). Exclusions from analysis: 0/85 episodes. Follow-up period: no information.			
Participants	Greece: 85 episodes in	Greece: 85 episodes in 77 cancer patients with neutropenia <= 1000/mm ³ and fever >= 38°.		
Interventions	Ceftazidime 6 gr/day versus Ceftazidime 6 gr/day + Amikacin 1 gr/day.			
Outcomes	All cause mortality. Treatment failure.			
Notes	Conference proceeding. No outcomes in subgroups.			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.		
Allocation concealment (selection bias)	Unclear risk	B—Unclear.		



Papachristodoulou 96 (Continued)

Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.	
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.	
Incomplete outcome data (attrition bias) All outcomes	Low risk	All episodes included in analysis.	

Pegram 1984

Methods	Randomisation: no information. Blinding: none. Intention-to-treat: unknown. Interim analysis: yes. Exclusions from analysis: no information. Follow-up period: no information.	
Participants	USA: 140 episodes in cancer patients. with neutropenia < 1000/mm ³ and fever.	
Interventions	Moxalactam 4 gr × 3 versus Ticarcillin 50 mg/kg × 6 + Tobramycin 1.5 mg/kg × 3.	
Outcomes	Treatment failure.	
Notes	Conference proceeding. Outcomes in subgroups. Documented <i>Pseudomonas</i> infections.	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	B—Unclear.



Pellegrin 1988

Methods	Randomisation: allocation by table of 20 numbers; no reference to concealment. Blinding: none. Intention-to-treat: no information. Interim analysis: none. Exclusions from analysis: no information (157 participants evaluated, the study does not refer to the number of randomly assigned participants). Follow-up period: no information.
Participants	France: 157 patients with acute leukaemia newly diagnosed or in first remission, with neutropenia < 500/mm ³ for 21 or more days, and fever. All participants > 16 years. BMT patients excluded.
Interventions	Ceftazidime 2 gr × 2 versus Cefotaxime 2 gr × 2 + Tobramycin 1 mg/kg × 2.
Outcomes	Treatment failure: bacterial and fungal super-infections.
Notes	Journal publication: French language. Outcomes in subgroups
	Documented infections: bacteraemia; haematological cancer patients.
	Documented Gram-negative infections. Participants treated in a protected environment.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	B—Unclear.

Pereira 2009

 Methods
 Randomisation: allocation by number list, no reference to concealment.

 Blinding: none.
 Intention-to-treat: no.

 Interim analysis: no.
 Interim analysis: no.

All outcomes

Trusted evidence. Informed decisions. Better health.

Pereira 2009 (Continued)			
	Exclusion from analysis: 5/130 episodes.		
	Follow-up period: not	described.	
Participants	Brazil: 130 episodes in	57 patients with haematological malignancy all \leq 18 years.	
		s/mm ³ or between 500 and 1000 cells/mm ³ before the nadir of chemotherapy temperature > 38.0° C or 3 measurements between 37.5° C and 38.0° C.	
Interventions	Cefepime 50 mg/kg × 3	3 versus Ceftriaxone 50 mg/kg × 2 + Amikacin 15 mg/kg × 1.	
Outcomes	Treatment failure: infe	ction related mortality; bacterial super-infection.	
Notes	Journal publication.		
	Outcome in subgroup: first episode of neutropenic fever.		
	Added AMP-B after 5 days with continued neutropenic fever, vanco for CR-BSI, skin and pulmonary in- fections and hypotension.		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	Allocation by number list.	
Allocation concealment (selection bias)	Unclear risk	Not described.	
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.	
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.	
Incomplete outcome data (attrition bias)	High risk	5 episodes excluded from analysis.	

Methods	Randomisation: allocation by balanced table, no reference to concealment.
	Blinding: none.
	Intention-to-treat: yes.
	Interim analysis: none.
	Exclusions from analysis: 0/60.
	Follow-up period: no information.
Participants	Chile: 60 episodes in 52 cancer patients > 16 years, of whom 88% had underlying haematological malig nancy. Neutropenia < 500/mm³ and fever.
Interventions	Imipenem 500 mg × 4 versus Ceftazidime 1-1.5 gr × 4 + Amikacin 7.5 mg/kg × 2.



Perez 1995 (Continued)	
Outcomes	All cause mortality.
	Infection related mortality. Treatment failure: bacterial super-infections; dropouts after randomisation.
Notes	Journal publication, Spanish language. Outcomes in subgroups.
	Documented infections: bacteraemia.
	Documented Gram-negative infections.
Risk of bias	

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All episodes included in analysis.

Petrilli 2003

Methods	Randomisation: allocation by table of random numbers concealed by sealed opaque envelopes. Blinding: none. Intention-to-treat: no. Interim analysis: none. Exclusions from analysis: 2/138 episodes. Follow-up period: no information.
Participants	Brazil: 138 episodes in 70 children or adolescents with leukaemia or grade III-IV lymphoma, neutrope- nia < 500/mm³ (or < 1000/mm³ expected to decline) and fever.
Interventions	Ticarcillin-clavulanic acid 62.5 mg/kg × 4 versus Ceftriaxone 100 mg/kg × 1 + Amikacin 7.5 mg/kg × 2,
Outcomes	All cause mortality. Infection related mortality; Treatment failure: bacterial super-infections; adverse events; dropouts after randomisation.
Notes	Journal publication. Outcomes in subgroups.



Petrilli 2003 (Continued)

Documented Gram-negative infections: haematological cancer patients; bacteraemia.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	A—Random number table.
Allocation concealment (selection bias)	Low risk	A—Sealed opaque envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	2 episodes excluded from analysis.

Piccart 1984

100111504		
Methods	Randomisation: no information. Blinding: none. Intention-to-treat: no. Interim analysis: none. Exclusions from analysis: 5/49. Follow-up period: no information.	
Participants	Belgium: 154 cancer patients > 17 years randomly assigned, of which 49 patients with neutropenia < 1000/mm³, and with fever > 38.5° are included in the review.	
Interventions	Cefoperazone 6 gr × 2 versus Cefoperazone 2 gr × 2 + Amikacin 500 mg × 2.	
Outcomes	All cause mortality (in bacteraemia only). Infection related mortality. Treatment failure: super-infections; dropouts after randomisation.	
Notes	Journal publication. Outcomes in subgroups. Documented infections: Gram-negative and resistant Gram-negative infections; haematological cancer patients; severe neutropenia.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.



Piccart 1984 (Continued)

Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	5 participants excluded from analysis.

Pickard 1983

Methods	Randomisation: random number table supplied by sponsor, concealed by sealed envelopes (opaque not mentioned). Blinding: none. Intention-to-treat: possible for mortality. Interim analysis: 2. Exclusions from analysis: 5/80. Follow-up period: no information.
Participants	USA: 80 episodes in cancer patients > 18 years with neutropenia < 1000/mm ³ and fever.
Interventions	Moxalactam 2-4 gr × 3 versus Ticarcillin 3 gr × 4 + Tobramycin 1.66 mg/kg × 3.
Outcomes	All cause mortality. Treatment failure: bacterial super-infections; adverse events; dropouts after randomisation.
Notes	Author correspondence and conference proceedings. Outcomes in subgroups.
	Documented infections: documented Gram-negative and <i>Pseudomonas</i> infections. Study not by Intention-to-treat but permits re-analysis by Intention-to-treat. Participants nursed in reverse isolation.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.
Allocation concealment (selection bias)	Low risk	A—Adequate.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.



Pickard 1983 (Continued)		
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	5 episodes excluded from analysis.

Piguet 1988

Methods	Randomisation: envelope selection (sealed or opaque not mentioned). Blinding: none. Intention-to-treat: no. Interim analysis: none. Exclusions from analysis: 5/174. Follow-up period: until resolution of neutropenia.
Participants	France, multicentre: 169 episodes evaluated in participants > 16 years with underlying haematological malignancy, neutropenia < 1000/mm³ and fever. BMT patients excluded.
Interventions	Ceftazidime 2 gr × 3 versus Cefotaxime 2 gr × 3 + Amikacin 5 mg/kg × 3.
Outcomes	All cause mortality. Infection related mortality. Treatment failure.
Notes	Journal publication: French language. Outcomes in subgroups. Documented infections: haematological cancer patients.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	5 episodes excluded from analysis.



Rodjer 1987

Methods	Randomisation: by envelope (sealed or opaque not mentioned). Blinding: none. Intention-to-treat: no. Interim analysis: none. Exclusions from analysis: 16/61 for failure; 3/61 for death. Follow-up period: no information.
Participants	Sweden: 61 febrile episodes in 52 immunocompromised cancer patients > 16 years. Neutropenia not part of inclusion criteria, but 70% of included patients were neutropenic < 1000/mm ³ .
Interventions	Ceftazidime 1-2 gr × 2-3 versus Cefuroxime 1.5 gr × 2-3 + Tobramycin 1.5 mg/kg × 2-3.
Outcomes	All cause mortality. Treatment failure: bacterial and fungal super-infections.
Notes	Journal publication. Outcomes in subgroups. Documented infections: bacteraemia.
	Documented Gram-negative and Pseudomonas infections.
Risk of bias	

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	3 episodes excluded from analysis.

Rodriguez 1995

Intention-to-treat: no. Interim analysis: none. Exclusions from analysis: 14/150 participants. Follow-up period: no information.	Methods	Interim analysis: none. Exclusions from analysis: 14/150 participants.	
---	---------	---	--



Rodriguez 1995 (Continued)

Participants	Peru: 136 participants > 15 years evaluated, with solid cancer or non-Hodgkin lymphoma, neutropenia < 1000/mm ³ expected to last less than 10 days and fever or suspected infection using specific criteria.
Interventions	Cefotaxime 1 gr × 3 versus Cephalotin 1gr × 4 + Gentamicin 4 mg/kg × 1.
Outcomes	Infection related mortality. Treatment failure.
Notes	Journal publication. Outcomes in subgroups.
	Documented infections: bacteraemia; Pseudomonas infections; severe neutropenia.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Table of random numbers.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	14 participants excluded from analysis.

Rolston 1992

Methods	Randomisation: computer-generated sequence of numbers. Blinding: single (outcome assessor). Intention-to-treat: no. Interim analysis: none. Exclusions from analysis: 158/908. Follow-up period: median 8-9 days.	
Participants	USA: 750 episodes in 567 participants > 16 years in 4 arms. 67% underlying haematological malignancy. Neutropenia < 1000/mm³ and fever or documented infection.	
Interventions	Ceftazidime 1 gr × 6 versus Ceftazidime 1 gr × 6 + Amikacin and Imipenem 12.5 mg/kg × 4 versus Imipenem 12.5 mg/kg × 4 + Amikacin. Amikacin given continuously 800 mg/m ² per day after 200 mg/m ² loading dose.	
Outcomes	Treatment failure: bacterial and fungal super-infections; adverse events.	
Notes	Journal publication. Outcomes in subgroups.	



Rolston 1992 (Continued)

Documented infections.

Documented Gram-negative, resistant Gram-negative and *Pseudomonas* infections; severe neutropenia.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No blinding.
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Outcome assessor blinded.
Incomplete outcome data (attrition bias) All outcomes	High risk	158 episodes excluded from analysis.

Schuchter 1988

Methods	Randomisation: no information. Blinding: double-blind. Intention-to-treat: unknown (assumed yes). Interim analysis: unknown. Exclusions from analysis: no information. Follow-up period: no information.		
Participants	USA: 133 patients following bone marrow transplantation between 2 and 57 years (median, 27 years) with neutropenia < 500/mm³ and fever > 38.5° once or > 38° more than once during 24 hours		
Interventions	Ceftazidime 50 mg/kg or 2 gr × 3 versus Ticarcillin 45 mg/kg × 6 + Gentamicin 2 mg/kg × 4.		
Outcomes	Treatment failure: bacterial and fungal super-infections.		
Notes	Conference proceeding. Outcomes in subgroups. Documented infections: haematological cancer patients.		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.	



Schuchter 1988 (Continued)

Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Double-blinded.
Blinding of outcome as- sessment (detection bias)	Low risk	Double-blinded.
All outcomes		

Smith 1990

Methods	Randomisation: no information. Blinding: none. Intention-to-treat: unknown. Interim analysis: none. Exclusions from analysis: no information. Follow-up period: 7 days.	
Participants	UK: 100 episodes in 63 children < 16 years old. Neutropenia < 500/mm³ and fever > 39°.	
Interventions	Ceftriaxone 50 mg/kg × 1 versus Azlocillin 75 mg/kg × 3 + Netilmicin 2.5 mg/kg × 3.	
Outcomes	All cause mortality. Infection related mortality. Treatment failure.	
Notes	Journal publication. No outcomes in subgroups.	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.



Smith 1990 (Continued)

Incomplete outcome data Low risk (attrition bias) All outcomes All episodes included in analysis.

Famura 2002				
Methods	Randomisation: table of random numbers concealed with sealed opaque envelopes.			
	Blinding: none. Intention-to-treat: yes for mortality and possible for failure Interim analysis: yes, number not specified, trial stopped when the interim analysis demonstrated that the number of participants was sufficient for analysis.			
	Exclusions from analysis: 12/206 participants for failure. Follow-up period: 30 days.			
Participants	Japan, multicentre: 206 adult cancer patients with neutropenia < 1000/mm³ and fever >= 37.5°. Nearly all patients with haematological cancer.			
Interventions	Cefepime 1-2 gr × 2 versus Cefepime 1-2 gr × 2 + Amikacin (28 participants) or Isepamicin (36 partici- pants) or Tobramycin or Netilmicin (12 participants).			
Outcomes	All cause mortality. Treatment failure: adverse events; dropouts after randomisation.			
Notes	Journal publication and author correspondence. Outcomes in subgroups.			
	Documented infections. An additional arm of carbapenem monotherapy is not included in this review.			

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.
Allocation concealment (selection bias)	Low risk	A—Adequate.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	12 participants excluded from analysis.

Methods	Randomisation: computer-generated, central. Blinding: none. Intention-to-treat: no. Interim analysis: no information. Exclusions from analysis: 12/201 participants. Follow-up period: 30 days.		
Participants	Japan, multicentre: 201 haematological cancer patients with neutropenia < 1000/mm ³ and fever >= 37.5°.		
nterventions	cefepime 1-2 gr × 2 vers	sus Cefepime 1-2 gr × 2 + Amikacin 100-200 mg × 2.	
Outcomes	All cause mortality.		
	Infection related mortality. Treatment failure: adverse events; dropouts after randomisation.		
Notes	Journal publication. Outcomes in subgroups: haematological malignancy; bacteraemia.		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	A—Computer generated.	
Allocation concealment (selection bias)	Low risk	A—Central.	
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.	
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.	
ncomplete outcome data (attrition bias) All outcomes	High risk	12 participants excluded from analysis.	

Nade 1987	
Methods	Randomisation: no information. Blinding: double. Intention-to-treat: unknown.
	Interim analysis: none. Exclusions from analysis: no information. Follow-up period: no information.
Participants	USA: 460 evaluable episodes in cancer patients with neutropenia < 500/mm ³ and fever > 38°.
Interventions	Imipenem 4 gr/qd versus Piperacillin 300 mg/kg/qd + Amikacin 24 mg/kg/qd.



Wade 1987 (Continued)

 Outcomes
 Treatment failure.

 Notes
 Conference proceeding + review. Outcomes in subgroups.

 Documented infections.
 Documented infections.

 Documented Gram-negative and Pseudomonas infections.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	B—Unclear.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Double-blinded.
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Double-blinded.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	B—Unclear.

Bias	Authors' judgement Support for judgement	
Risk of bias		
Notes	Journal publication in Polish. No outcomes in subgroups.	
	Treatment failure.	
Outcomes	All cause mortality. Infection related mortality.	
Interventions	Cefepime 2 gr × 3 versus Cefepime 2 gr × 3 + Amikacin 500 mg × 2.	
Participants	Poland: 40 adults with cancer (haematological in 95%), neutropenia <= 1000/mm ³ and fever >= 38°.	
Methods	Randomisation: coin toss performed after participants' recruitment into the trial. Blinding: none. Intention-to-treat: yes. Interim analysis: none. Exclusions from analysis: 0/40 participants. Follow-up period: no information.	

Wrzesien-Kus 2001 (Continued)

Random sequence genera- tion (selection bias)	Low risk	A—Coin toss.
Allocation concealment (selection bias)	Low risk	A—Performed after patient recruitment.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants included in analysis.

Yamamura 1997		
Methods	Randomisation: computer-generated code, concealed by sealed, opaque envelopes.	
	Blinding: none. Intention-to-treat: possible. Interim analysis: none. Exclusions from analysis: 11/111 (in study). Follow-up period: no information.	
Participants	USA, multicentre: 111 cancer patients > 18 years. Neutropenia < 1000/mm³ and fever > 38.5°.	
Interventions	Cefepime 2 gr × 3 versus Piperacillin 3 gr × 6 + Gentamicin 1.5 mg/kg × 3.	
Outcomes	Treatment failure: bacterial and fungal super-infections; adverse events; dropouts after randomisation.	
Notes	Journal publication and author correspondence. Vancomycin addition after 72 hours permitted by protocol, not counted as failure (27 participants). Outcomes in subgroups. Documented infections: bacteraemia.	
	Documented Gram-negative and <i>Pseudomonas</i> infections; haematological cancer patients.	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Adequate.
Allocation concealment (selection bias)	Low risk	A—Adequate.
Blinding of participants and personnel (perfor- mance bias)	High risk	Open-label.



Yamamura 1997 (Continued) All outcomes

Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	12 participants excluded from analysis.

Yildirim 2008

Methods	Randomisation: computer-generated random number list.	
	Blinding: open. Intention-to-treat: no. Interim analysis: no. Exclusions from analysis: 12/99 participants. Follow-up period: no information.	
Participants	Turkey: 99 episodes in 99 participants with haematological malignancy all \leq 16.	
	Neutropenia < 500 or < 1000 and expected to decline and fever > 38.5° or 2 measurements > 38°.	
Interventions	Imipenem/meropenem 20 mg/kg × 3; Piperacillin-tazobactam 80 mg/kg × 4 + Amikacin 7.5 mg/kg × 2.	
Outcomes	Treatment failure: duration of fever; neutropenia; hospitalisation; mortality; need for additional antibi- otics or antifungal drugs.	
Notes	Journal publication.	
	Added glycopeptide after 72 hours with persistent fever, added AMP-B after 5 days with continued fever and neutropenia. In participants with monotherapy added aminoglycoside after 72 hours with persistent fever.	
	No outcomes in subgroups.	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	A—Computer-generated random number list.
Allocation concealment (selection bias)	Unclear risk	B—Unclear.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.



Yildirim 2008 (Continued)

Incomplete outcome data High risk (attrition bias) All outcomes 12 participants excluded from analysis.

Methods	Randomisation: no mention.	
	Blinding: open,	
	Intention-to-treat: no,	
	Interim analysis: no.	
	Exclusions from analysis: 7/79 episodes.	
	Follow-up period: no information.	
Participants	Turkey: 79 episodes in 43 participants with haematological malignancy all \leq 19 years.	
	Neutropenia ≤ 500 or ≤ 1000 with decrease to ≤ 500 within 48 hours and fever ≥ 38.5° once or ≥ 8° for longer than 1 hour.	
Interventions	Piperacillin-tazobactam 90 mg/kg × 4; Piperacillin-tazobactam 90 mg/kg × 4 + Amikacin 15 mg/kg × 1.	
Outcomes	Treatment failure.	
Notes	Journal publication.	
	Added teicoplanin after 96 hours with persistent fever, added AMP-B or LipAMP-B or fluconazole after 120 hours with persistent neutropenia and fever.	
	Subgroup analyses: episodes with and without catheter; high-dose cytosine arabinocide in the previous chemotherapy.	

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	High risk	No random sequence — participants randomly assigned by presentation.
Allocation concealment (selection bias)	High risk	No concealment.
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Open-label.
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Open-label.
Incomplete outcome data (attrition bias) All outcomes	High risk	7 episodes excluded from analysis.



Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion		
Berezin 2003	Retrospective comparative study comparing cefepime monotherapy versus ceftriaxone combined with gentamicin or amikacin.		
Bodey 1976	The randomisation to beta-lactam versus beta-lactam + aminoglycoside was semi-empirical, af ter pathogen identification. Empirically the participants all received carbenicillin and cephaloti Following pathogen isolation, participants with <i>Pseudomonas</i> sp. or <i>Proteus mirabilis</i> infec- tion (analysed together) were randomly assigned to carbenicillin monotherapy versus carbeni- cillin-gentamicin combination therapy, and those with other Gram-negative infections were rar domly assigned to cephalotin versus cephalotin with gentamicin.		
Bru 1986	Study randomly assigned participants to ticarcillin-clavulanate versus ticarcillin-clavulanate + amikacin; however, several problems preclude its inclusion: Participants following bone mar- row transplantation were allocated to combination therapy only, over-riding the random alloca tion; only the number of evaluated episodes is reported, numbers of randomly assigned partici pants/episodes unknown; number of episodes described in results is larger than the number of evaluable episodes; most results are reported as percentages and the denominator is unknowr		
Cetto 1983	Participants with haematological malignancies were randomly assigned to receive cefuroxime or tobramycin plus ampicillin. However, all neutropenic participants also received carbenicillin with both regimens.		
D'Antonio 1992	Study included non-neutropenic, haematological cancer patients with altered immune defences.		
Drusano 1985	Study includes monotherapy and combination treatment groups compatible with the protocol, but randomisation was not performed between these groups. Non-neutropenic cancer patients re ceived empirically beta-lactam monotherapy, while neutropenic cancer patients were randomly assigned to double beta-lactam combination therapy versus beta-lactam-aminoglycoside combi- nation therapy.		
EORTC 1987	Randomisation to monotherapy versus beta-lactam-aminoglycoside combination therapy se- mi-empirical. Empirically all participants received beta-lactam-aminoglycoside combination ther py. After 3 days, participants were randomly assigned to continue the combination, or to disconti ue the aminoglycoside (beta-lactam monotherapy).		
Fainstein 1983	Randomized study comparing ceftazidime versus ceftazidime + tobramycin. The study random- ly assigned 321 episodes in 253 cancer patients with or without neutropenia. A subgroup of par- ticipants with neutropenia and documented infection were analysed separately. The number of neutropenic participants per group is not known, only the denominator for the subgroup of par- ticipants with neutropenia and documented infections is given. The outcome assessed in the sub- group is failure but does not include the non–infection related deaths. Author contacted without response.		
Hauer 1990	Non-randomised controlled clinical trial.		
Hazel 1998	Randomised trial presented as a conference proceeding comparing piperacillin-tazobactam + to- bramycin versus imipenem + tobramycin for participants with febrile neutropenia, colonised with ESBL+ Enterobactericeae.		
Hoepelman 1988	Study includes data on neutropenic and non-neutropenic participants combined. Data on neu- tropenic participants are not separated.		
Karthaus 1998	Study not randomised: prospective observational design.		
Moreno-Sanchez 1992	Randomized trial comparing imipenem versus ceftazidime + amikacin presented in conference. The abstract states that the study is in progress, but no further publications were identified. Results		

Study	Reason for exclusion		
	in abstract are given for 31 participants, but the number of dropouts is unknown; only evaluable participants are discussed. Author contacted without response.		
Moroni 1987	Incompatible comparator regimens: ceftazidime + amikacin versus ceftazidime + vancomycin.		
Pegram 1989	Randomisation to monotherapy versus beta-lactam-aminoglycoside combination therapy se- mi-empirical. Empirically all participants were treated with combination therapy. At 4 days, partici- pants were randomly assigned to continue the combination, or to discontinue the aminoglycoside (beta-lactam monotherapy).		
Petrilli 1991	Non-randomised study describing treatment with imipenem and ceftriaxone monotherapy for high-risk and low-risk febrile neutropenic children, respectively.		
Pizzo 1986	Randomised trial comparing ceftazidime monotherapy versus double beta-lactam-aminoglycoside combination therapy.		
Reilly 1983	Study not randomised: patient groups were studied sequentially.		
Sampi 1987	Study compares two combination regimens: cefmenoxime + amikacin versus piperacillin + amikacin.		
Sanz 2005	Study not randomised: prospective observational matched cohort study comparing imipenem monotherapy versus piperacillin-tazobactam + amikacin for febrile neutropenia.		
Sawae 1996	Study randomly assigned participants to imipenem monotherapy or combination therapy. The combination arm included several different combinations (beta-lactam-aminoglycoside combinations, beta-lactam-beta-lactam combinations and other combinations), but the decision as to which combination therapy the patient received was left to the physician's decision. (Personal communication with author.)		
Wrzesien-Kus 2000	Comparison between cefepime and ceftazidime, both combined with amikacin.		

Characteristics of studies awaiting assessment [ordered by study ID]

Li 1998	
Methods	No information
Participants	Febrile neutropenia
Interventions	Ceftazidime and netilmicin
Outcomes	No information
Notes	

Characteristics of ongoing studies [ordered by study ID]

Bilgir 2005

Trial name or title	The comparison of imipenem with piperacillin/tazobactam and amikacin combination in partici-
	pants with haematological malignancies in the treatment of febrile neutropenia.



Bilgir 2005 (Continued)

MethodsParticipantsTurkey: 40 participants with haematological malignancies.InterventionsImipenem versus piperacillin-tazobactam + amikacin.OutcomesTreatment failure and adverse events reported only as percentages, without a denominator per
group.Starting dateUnknown. Results presented in EHA 2005.Contact informationDr. O. Bilgir, Okmeydani Hastanesi, Izmir, Turkey.NotesAuthor's address unknown.

DATA AND ANALYSES

Comparison 1. Overall effectiveness

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 All cause mortality	44	7186	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.75, 1.02]
1.1 same beta-lactam	11	1718	Risk Ratio (M-H, Fixed, 95% CI)	0.74 [0.53, 1.06]
1.2 different beta-lactam	33	5468	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.77, 1.09]
2 Infection-related mortali- ty	41	6872	Risk Ratio (M-H, Fixed, 95% CI)	0.80 [0.64, 0.99]
2.1 same beta-lactam	8	1403	Risk Ratio (M-H, Fixed, 95% CI)	0.68 [0.43, 1.10]
2.2 different beta-lactam	33	5469	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.65, 1.06]
3 Treatment failure	71		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.1 same beta-lactam	16	2833	Risk Ratio (M-H, Fixed, 95% CI)	1.11 [1.02, 1.20]
3.2 different beta-lactam	55	7736	Risk Ratio (M-H, Fixed, 95% CI)	0.92 [0.88, 0.97]

Analysis 1.1. Comparison 1 Overall effectiveness, Outcome 1 All cause mortality.

Study or subgroup	Monotherapy	y Combina- tion therapy		Risk Ratio			Weight	Risk Ratio	
	n/N	n/N		M-H	, Fixed, 95	% CI			M-H, Fixed, 95% Cl
1.1.1 same beta-lactam									
Del Favero 2001	22/364	32/369			-+			10.74%	0.7[0.41,1.18]
	F	avours treatment	0.01	0.1	1	10	100	Favours control	



Cochrane Database of Systematic Reviews

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI	<u>.</u>	M-H, Fixed, 95% Cl
Doyen 1983	8/50	9/54	<u> </u>	2.93%	0.96[0.4,2.2
Esteve 1997	1/39	2/46		0.62%	0.59[0.06,6.2
Kinsey 1990	2/77	7/83		2.28%	0.31[0.07,1.4
Novakova 1991	5/45	5/45		1.69%	1[0.31,3.2
Papachristodoulou 96	1/35	1/42	+	0.31%	1.2[0.08,18.
Piccart 1984	1/22	2/22		0.68%	0.5[0.05,5.1
Tamura 2002	2/42	3/82		0.69%	1.3[0.23,7.4
Tamura 2004	7/95	5/94		1.7%	1.39[0.46,4.2
Wrzesien-Kus 2001	0/19	4/21		1.45%	0.12[0.01,2.1
Zengin 2011	0/37	0/35			Not estimat
Subtotal (95% CI)	825	893	•	23.08%	0.74[0.53,1.0
Total events: 49 (Monotherapy)), 70 (Combination therap	y)			
Heterogeneity: Tau ² =0; Chi ² =5.	29, df=9(P=0.81); I ² =0%				
Test for overall effect: Z=1.66(P	=0.1)				
1.1.2 different beta-lactam					
Agaoglu 2001	2/30	0/57		0.12%	9.35[0.46,188.8
Ahmed 2007	2/63	3/66		0.99%	0.7[0.12,4.0
kova 1999	1/40	0/43		0.16%	3.22[0.13,76.8
Behre 1998	2/35	4/36	+	1.33%	0.51[0.1,2.6
Bezwoda 1985	7/29	11/31	ı	3.59%	0.68[0.31,1.5
Cometta 1996	24/483	22/475	<u> </u>	7.5%	1.07[0.61,1.8
Conte 1996	1/21	1/19		0.35%	0.9[0.06,13.4
Cornely 2001	26/404	9/198		4.08%	1.42[0.68,2.9
De la Camara 1997	1/52	3/51		1.02%	0.33[0.04,3.0
De Pauw 1994	69/488	75/480		25.57%	0.9[0.67,1.2
Dincol 1998	3/78	2/72		0.7%	1.38[0.24,8.0
Duzova 2001	0/45	2/12		0.85%	0.2[0.01,4.0
Gibson 1989	3/52	5/50		1.72%	0.58[0.15,2.2
Gorschluter 2003	5/56			2.83%	
		8/51			0.57[0.2,1.6
Hense 2000	6/61	2/26		0.95%	1.28[0.28,5.9
Hess 1998	1/48	5/48		1.69%	0.2[0.02,1.6
Hung 2003	2/39	3/37		1.04%	0.63[0.11,3.5
limeno 2006	1/23	0/26		0.16%	3.38[0.14,7
(liasova 2001	0/22	0/20			Not estimal
eyland 1992	14/106	11/110		3.65%	1.32[0.63,2.7
_ieschke 1990	13/90	10/92	+ +	3.34%	1.33[0.61,2.8
Matsui 1991	0/51	0/50			Not estimal
Ailler 1993	2/45	2/41		0.71%	0.91[0.13,6.1
lorgan 1983	1/26	3/24		1.05%	0.31[0.03,2.7
Vorrby 1987	7/105	12/105	-+	4.06%	0.58[0.24,1.4
lovakova 1990	5/46	6/44	+	2.07%	0.8[0.26,2.4
Dzyilkan 1999	0/15	0/15			Not estimal
Perez 1995	3/30	4/30		1.35%	0.75[0.18,3.0
Petrilli 2003	2/68	3/68		1.01%	0.67[0.12,3.8
Pickard 1983	2/40	7/40		2.37%	0.29[0.06,1.2
Piguet 1988	7/82	7/87		2.3%	1.06[0.39,2.8
Rodjer 1987	5/29	1/29	+	0.34%	5[0.62,40
Smith 1990	0/47	0/53			Not estimal
Subtotal (95% CI)	2849	2619	♦	76.92%	0.91[0.77,1.0
otal events: 217 (Monotheran	y), 221 (Combination thera	anv)			



Study or subgroup	Monotherapy	Combina- tion therapy			Risk Ratio			Weight	Risk Ratio
	n/N	n/N	_	M-H	, Fixed, 95%	5 CI			M-H, Fixed, 95% Cl
Heterogeneity: Tau ² =0; Chi ² =2	20.83, df=28(P=0.83); I ² =0%								
Test for overall effect: Z=0.99((P=0.32)								
Total (95% CI)	3674	3512			•			100%	0.87[0.75,1.02]
Total events: 266 (Monothera	py), 291 (Combination thera	ару)							
Heterogeneity: Tau ² =0; Chi ² =2	26.67, df=38(P=0.92); I ² =0%								
Test for overall effect: Z=1.65((P=0.1)								
Test for subgroup differences:	: Chi ² =1.05, df=1 (P=0.31), I ²	=4.92%	_						
	F	avours treatment	0.01	0.1	1	10	100	Favours control	

Analysis 1.2. Comparison 1 Overall effectiveness, Outcome 2 Infection-related mortality.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
1.2.1 same beta-lactam					
Del Favero 2001	9/364	19/369	+	10.96%	0.48[0.22,1.05]
Doyen 1983	7/34	6/41		3.16%	1.41[0.52,3.79]
Kinsey 1990	0/77	2/83	├── ।	1.4%	0.22[0.01,4.42]
Novakova 1991	4/45	4/45		2.32%	1[0.27,3.75]
Piccart 1984	1/22	2/22	├ ─── ├ ────	1.16%	0.5[0.05,5.12]
Tamura 2004	4/95	4/94		2.34%	0.99[0.25,3.84]
Wrzesien-Kus 2001	0/19	2/21	<u>⊢ </u>	1.38%	0.22[0.01,4.31]
Zengin 2011	0/37	0/35			Not estimable
Subtotal (95% CI)	693	710		22.73%	0.68[0.43,1.1]
Total events: 25 (Monotherapy),	39 (Combination therapy	<i>y</i>)			
Heterogeneity: Tau ² =0; Chi ² =4.62	2, df=6(P=0.59); I ² =0%				
Test for overall effect: Z=1.57(P=0	0.12)				
1.2.2 different beta-lactam					
Agaoglu 2001	0/30	0/28			Not estimable
Ahmed 2007	2/58	2/61		- 1.13%	1.05[0.15,7.22]
Akova 1999	1/40	0/43	+	0.28%	3.22[0.13,76.82]
Behre 1998	1/35	1/36	•	0.57%	1.03[0.07,15.81]
Cometta 1996	8/483	13/475		7.62%	0.61[0.25,1.45]
Corapcioglu 2005	0/25	0/25			Not estimable
Cornely 2001	20/404	6/198		4.68%	1.63[0.67,4]
De la Camara 1997	1/52	2/51	l	1.17%	0.49[0.05,5.24]
De Pauw 1994	42/551	44/535	_ _	25.94%	0.93[0.62,1.39]
Dincol 1998	2/78	2/72		1.21%	0.92[0.13,6.38]
Duzova 2001	0/45	2/45		1.45%	0.2[0.01,4.05]
El Haddad 1995	1/30	1/16	•	- 0.76%	0.53[0.04,7.97]
Gibson 1989	1/52	3/50	↓	1.78%	0.32[0.03,2.98]
Gorschluter 2003	4/56	6/51	+	3.65%	0.61[0.18,2.03]
Hense 2000	1/61	1/26	•	0.81%	0.43[0.03,6.56]
Hess 1998	0/48	0/48			Not estimable
Hung 2003	1/39	0/37		0.3%	2.85[0.12,67.83]
Jimeno 2006	1/23	0/26	+	0.27%	3.38[0.14,79]
Kliasova 2001	0/22	0/20			Not estimable



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
Lieschke 1990	10/90	10/92		5.75%	1.02[0.45,2.34]
Matsui 1991	0/51	0/50			Not estimable
Miller 1993	2/45	1/41		0.61%	1.82[0.17,19.35]
Morgan 1983	0/26	1/24		0.91%	0.31[0.01,7.23]
Norrby 1987	3/105	11/105	← →	6.39%	0.27[0.08,0.95]
Novakova 1990	3/46	4/44		2.38%	0.72[0.17,3.02]
Ozyilkan 1999	0/15	0/15			Not estimable
Pereira 2009	1/29	1/28	•	0.59%	0.97[0.06,14.7]
Perez 1995	3/30	4/30		2.32%	0.75[0.18,3.07]
Petrilli 2003	1/68	2/68	+ +	1.16%	0.5[0.05,5.39]
Piguet 1988	3/82	4/87		2.26%	0.8[0.18,3.45]
Rodriguez 1995	4/64	6/72	+	3.28%	0.75[0.22,2.54]
Smith 1990	0/47	0/53			Not estimable
Yildirim 2008	0/41	0/46			Not estimable
Subtotal (95% CI)	2871	2598	•	77.27%	0.83[0.65,1.06]
Total events: 116 (Monothera	py), 127 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =1	11.84, df=24(P=0.98); l ² =0%				
Test for overall effect: Z=1.49((P=0.14)				
Total (95% CI)	3564	3308	•	100%	0.8[0.64,0.99]
Total events: 141 (Monothera	py), 166 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =1	16.68, df=31(P=0.98); l ² =0%				
Test for overall effect: Z=2.05((P=0.04)				
Test for subgroup differences	: Chi ² =0.51, df=1 (P=0.48), I ²	=0%	ĺ		
	I	avours treatment	0.1 0.2 0.5 1 2 5	¹⁰ Favours control	

Analysis 1.3. Comparison 1 Overall effectiveness, Outcome 3 Treatment failure.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
1.3.1 same beta-lactam					
Del Favero 2001	188/370	188/384	-	32.38%	1.04[0.9,1.2]
Doyen 1983	13/49	11/48		1.95%	1.16[0.58,2.33]
Esteve 1997	23/39	26/46		4.19%	1.04[0.72,1.5]
Jacobs 1993	14/46	5/45		0.89%	2.74[1.08,6.98]
Kiehl 2001	14/35	12/36		2.08%	1.2[0.65,2.22]
Kinsey 1990	48/77	59/83	-+-	9.97%	0.88[0.7,1.09]
Kojima 1994	10/35	3/32	+	0.55%	3.05[0.92,10.1]
Marie 1991	67/77	50/69		9.26%	1.2[1.01,1.42]
Novakova 1991	19/36	18/33		3.3%	0.97[0.62,1.5]
Papachristodoulou 96	3/39	6/45		0.98%	0.58[0.15,2.16]
Piccart 1984	5/22	6/22		1.05%	0.83[0.3,2.33]
Rolston 1992	130/378	99/372	-+	17.51%	1.29[1.04,1.61]
Tamura 2002	13/38	29/76		3.39%	0.9[0.53,1.52]
Tamura 2004	47/95	39/94	+	6.88%	1.19[0.87,1.63]
Wrzesien-Kus 2001	9/19	10/21	<u> </u>	1.67%	0.99[0.52,1.91]
Zengin 2011	24/37	22/35	+	3.97%	1.03[0.73,1.46]
Subtotal (95% CI)	1392	1441	•	100%	1.11[1.02,1.2]



Cochrane Database of Systematic Reviews

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Total events: 627 (Monotherapy), 583 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =17.	12, df=15(P=0.31); l ² =12.3	6%			
Test for overall effect: Z=2.5(P=0	0.01)				
1.3.2 different beta-lactam					
Agaoglu 2001	8/30	12/57		0.5%	1.27[0.58,2.7
Ahmed 2007	28/58	23/61	++	1.37%	1.28[0.84,1.9
Akova 1999	13/40	28/43		1.64%	0.5[0.3,0.8
Alanis 1983	20/46	27/48	+ <u>+</u> -	1.61%	0.77[0.51,1.1
Antmen 2001	25/38	21/29	-+	1.45%	0.91[0.66,1.2
Au 1994	5/26	9/24	+	0.57%	0.51[0.2,1.3
Behre 1998	15/34	17/37		0.99%	0.96[0.57,1.6
Bezwoda 1985	8/29	11/31		0.65%	0.78[0.36,1.6
Borbolla 2001	2/20	3/20 -	+	0.18%	0.67[0.12,3.5
Cometta 1996	213/483	230/475	-+-	14.12%	0.91[0.79,1.0
Conte 1996	10/21	8/19		0.51%	1.13[0.57,2.2
Corapcioglu 2005	12/25	15/25		0.91%	0.8[0.48,1.3
Cornelissen 1992	4/47	12/47 —		0.73%	0.33[0.12,0.9
Cornely 2001	193/353	92/176	-+-	7.48%	1.05[0.88,1.2
De la Camara 1997	29/46	30/47	<u> </u>	1.81%	0.99[0.73,1.3
De Pauw 1983	11/38	24/45		1.34%	0.54[0.31,0.9
De Pauw 1994	292/488	278/480	+	17.07%	1.03[0.93,1.1
Dincol 1998	17/78	15/72	_	0.95%	1.05[0.57,1.9
Duzova 2001	11/45	16/45	_	0.97%	0.69[0.36,1.3
El Haddad 1995	7/30	9/16		0.71%	0.41[0.19,0
Erjavec 1994	38/94	49/85	+	3.13%	0.7[0.52,0.9
Gaytan-Martinez 2002	9/63	7/54		0.46%	1.1[0.44,2.7
Gibson 1989	16/52	19/50	+	1.18%	0.81[0.47,1.3
Gorschluter 2003	25/56	35/51	_ _	2.23%	0.65[0.46,0.9
Gribble 1983	2/12	3/18		0.15%	1[0.2,5.1
Hansen 1986	4/14	9/19		0.46%	0.6[0.23,1.5
Hense 2000	33/58	16/26		1.35%	0.92[0.63,1.3
Hess 1998	9/48	8/48		0.49%	1.13[0.47,2.6
lung 2003	11/39	16/37		1%	0.65[0.35,1.2
limeno 2006	16/24	23/27	_ _	1.32%	0.78[0.57,1.0
sova 2001	8/23	10/20	_	0.65%	0.7[0.34,1.4
Koehler 1990	16/55	19/65		1.06%	1[0.57,1.7
eyland 1992	48/106	52/110		3.11%	0.96[0.72,1.2
ieschke 1990	19/90	18/92	<u> </u>	1.08%	1.08[0.61,1.9
.iu 1989	1/10	3/17		0.14%	0.57[0.07,4.7
Matsui 1991	9/51	10/50		0.61%	0.88[0.39,1.9
Ailler 1993	25/45	20/41	_ _ _ +	1.27%	1.14[0.76,1.7
Norgan 1983	9/26	13/24		0.82%	0.64[0.34,1.2
lorrby 1987	35/105	46/105	_	2.8%	0.76[0.54,1.0
lovakova 1990	18/46	28/44		1.74%	0.61[0.4,0.9
Dzyilkan 1999	6/15	6/15		0.37%	1[0.42,2
Pegram 1984	21/72	20/68		1.25%	0.99[0.59,1.6
Pellegrin 1988	21/72 23/71	31/86		1.25%	0.99[0.59,1.3
Pereira 2009	26/62	20/63	·	1.71%	
					1.32[0.83,2
Perez 1995	14/30	19/30	'	1.16%	0.74[0.46,1.1



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
Pickard 1983	14/37	23/38	— + — 	1.38%	0.63[0.38,1.02]
Piguet 1988	59/82	63/87	+	3.72%	0.99[0.82,1.2]
Rodjer 1987	5/22	4/23		0.24%	1.31[0.4,4.24]
Rodriguez 1995	15/64	22/72		1.26%	0.77[0.44,1.35]
Schuchter 1988	33/65	30/68	_ ++	1.79%	1.15[0.8,1.65]
Smith 1990	24/47	21/53	++	1.2%	1.29[0.83,1.99]
Wade 1987	16/228	14/232		0.84%	1.16[0.58,2.33]
Yamamura 1997	17/56	17/55		1.04%	0.98[0.56,1.72]
Yildirim 2008	26/46	22/41	— —	1.42%	1.05[0.72,1.54]
Subtotal (95% CI)	3957	3779	•	100%	0.92[0.88,0.97]
Total events: 1593 (Monotherag	py), 1609 (Combination the	erapy)			
Heterogeneity: Tau ² =0; Chi ² =63	8.94, df=54(P=0.17); l ² =15.5	4%			
Test for overall effect: Z=3.15(P	=0)				
	Favo	ours monotherapy 0.1	0.2 0.5 1 2 5	¹⁰ Favours combination	1

Comparison 2. Superinfections

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Bacterial superinfections	29	4961	Risk Ratio (M-H, Fixed, 95% CI)	1.02 [0.87, 1.19]
2 Fungal superinfections	20	3437	Risk Ratio (M-H, Fixed, 95% CI)	0.70 [0.49, 1.00]

Analysis 2.1. Comparison 2 Superinfections, Outcome 1 Bacterial superinfections.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
Alanis 1983	3/46	7/48		2.58%	0.45[0.12,1.63]
Cometta 1996	56/270	58/245	_ _	22.9%	0.88[0.63,1.21]
De la Camara 1997	0/46	1/47	•	0.56%	0.34[0.01,8.15]
De Pauw 1983	0/38	0/45			Not estimable
De Pauw 1994	48/488	39/480	_ + •	14.81%	1.21[0.81,1.81]
Doyen 1983	24/50	20/54		7.24%	1.3[0.82,2.04]
Erjavec 1994	3/94	4/85		1.58%	0.68[0.16,2.94]
Hansen 1986	0/14	0/19			Not estimable
Jacobs 1993	2/46	1/45	• • •	0.38%	1.96[0.18,20.83]
Koehler 1990	2/55	0/65		0.17%	5.89[0.29,120.2]
Leyland 1992	4/106	2/110		0.74%	2.08[0.39,11.09]
Lieschke 1990	9/90	2/92		0.74%	4.6[1.02,20.71]
Liu 1989	0/10	0/17			Not estimable
Marie 1991	20/77	13/69		5.16%	1.38[0.74,2.56]
Miller 1993	8/45	3/41		1.18%	2.43[0.69,8.55]
Norrby 1987	12/105	15/105		5.65%	0.8[0.39,1.63]
Novakova 1990	4/46	7/44	· · · · · · · · · · · · · · · · · · ·	2.69%	0.55[0.17,1.74]
	Favo	ours monotherapy	0.1 0.2 0.5 1 2 5 10	Favours combinatior	ı



Study or subgroup	Monotherapy Combina- tion therapy			Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H, Fixed, 95% Cl			M-H, Fixed, 95% CI
Novakova 1991	6/36	11/33		+		4.32%	0.5[0.21,1.2]
Ozyilkan 1999	3/15	5/15	-			1.88%	0.6[0.17,2.07]
Pellegrin 1988	11/71	18/86				6.13%	0.74[0.37,1.46]
Pereira 2009	14/62	10/63		+		3.74%	1.42[0.68,2.96]
Perez 1995	1/30	2/30	◀—	•	_	0.75%	0.5[0.05,5.22]
Petrilli 2003	7/68	6/68				2.26%	1.17[0.41,3.29]
Piccart 1984	1/22	1/22	-			0.38%	1[0.07,15]
Pickard 1983	2/37	6/38	-			2.23%	0.34[0.07,1.59]
Rodjer 1987	1/22	0/23		+	\rightarrow	0.18%	3.13[0.13,72.99]
Rolston 1992	13/378	12/372				4.55%	1.07[0.49,2.31]
Schuchter 1988	8/65	7/68				2.58%	1.2[0.46,3.11]
Yamamura 1997	10/51	12/49				4.61%	0.8[0.38,1.68]
Total (95% CI)	2483	2478		•		100%	1.02[0.87,1.19]
Total events: 272 (Monotherapy),	262 (Combination thera	ару)					
Heterogeneity: Tau ² =0; Chi ² =23.6	6, df=25(P=0.54); I ² =0%						
Test for overall effect: Z=0.25(P=0	.8)						
	Favo	ours monotherapy	0.1 0	.2 0.5 1 2	5 10	Favours combination	

Analysis 2.2. Comparison 2 Superinfections, Outcome 2 Fungal superinfections.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio M-H, Fixed, 95% Cl
	n/N	n/N	M-H, Fixed, 95% Cl		
Alanis 1983	3/46	1/48		1.37%	3.13[0.34,29.02]
De la Camara 1997	0/46	1/47	+ +	2.08%	0.34[0.01,8.15]
De Pauw 1983	1/38	1/45	+	1.29%	1.18[0.08,18.3]
De Pauw 1994	13/488	21/480		29.73%	0.61[0.31,1.2]
Erjavec 1994	2/75	2/68		- 2.95%	0.91[0.13,6.26]
Hansen 1986	0/14	0/19			Not estimable
Jacobs 1993	0/46	0/45			Not estimable
Koehler 1990	0/65	2/65	< +	3.51%	0.2[0.01,4.09]
Liu 1989	1/10	0/18	+	0.51%	5.18[0.23,116.56]
Marie 1991	0/77	2/69	< +	3.7%	0.18[0.01,3.67]
Norrby 1987	4/105	5/105	+	7.02%	0.8[0.22,2.9]
Novakova 1990	1/46	0/44		0.72%	2.87[0.12,68.68]
Novakova 1991	1/36	0/33		0.73%	2.76[0.12,65.41]
Ozyilkan 1999	2/15	5/15	↓ →	7.02%	0.4[0.09,1.75]
Pellegrin 1988	4/71	6/86	+	7.62%	0.81[0.24,2.75]
Piccart 1984	0/22	2/22	< +	3.51%	0.2[0.01,3.94]
Rodjer 1987	2/22	1/23		1.37%	2.09[0.2,21.45]
Rolston 1992	8/378	7/372		9.91%	1.12[0.41,3.07]
Schuchter 1988	1/65	4/68	↓ →	5.49%	0.26[0.03,2.28]
Yamamura 1997	3/51	8/49	+	11.46%	0.36[0.1,1.28]
Total (95% CI)	1716	1721	•	100%	0.7[0.49,1]
Total events: 46 (Monotherapy),	68 (Combination therapy)			
Heterogeneity: Tau ² =0; Chi ² =11.7	7, df=17(P=0.82); I ² =0%				
Test for overall effect: Z=1.96(P=0	0.05)				

Comparison 3. Adverse events

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Any adverse event (monotherapy)	49	7412	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.81, 0.94]
1.1 imipenem monotherapy	12	1429	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.86, 1.13]
1.2 meropenem monothera- py	9	2003	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.84, 1.06]
1.3 ceftazidime monotherapy	9	1941	Risk Ratio (M-H, Fixed, 95% CI)	0.64 [0.53, 0.76]
1.4 moxalactam monothera- py	5	421	Risk Ratio (M-H, Fixed, 95% CI)	0.71 [0.51, 0.97]
1.5 cefepime monotherapy	8	1079	Risk Ratio (M-H, Fixed, 95% CI)	0.94 [0.75, 1.17]
1.6 other monotherapy	7	539	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.61, 1.44]
2 Discontinuation due to ad- verse event	16	4051	Risk Ratio (M-H, Fixed, 95% CI)	0.61 [0.40, 0.93]
3 Any nephrotoxicity - Ag dosing regimen	39	6608	Risk Ratio (M-H, Fixed, 95% CI)	0.45 [0.35, 0.57]
3.1 Once daily	8	1707	Risk Ratio (M-H, Fixed, 95% CI)	0.31 [0.15, 0.63]
3.2 Multiple daily	31	4901	Risk Ratio (M-H, Fixed, 95% CI)	0.47 [0.36, 0.61]
4 Severe nephrotoxicity - Ag dosing regimen	20	4199	Risk Ratio (M-H, Fixed, 95% CI)	0.16 [0.05, 0.49]
4.1 Once daily	6	1526	Risk Ratio (M-H, Fixed, 95% CI)	0.20 [0.03, 1.14]
4.2 Multiple daily	14	2673	Risk Ratio (M-H, Fixed, 95% CI)	0.14 [0.03, 0.60]

Analysis 3.1. Comparison 3 Adverse events, Outcome 1 Any adverse event (monotherapy).

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio			Weight	Risk Ratio		
	n/N	n/N		M-H, Fixe	d, 95% CI				M-H, Fixed, 95% CI
3.1.1 imipenem monotherapy									
Ahmed 2007	4/58	8/61						0.78%	0.53[0.17,1.65]
Au 1994	0/26	0/24							Not estimable
Cornelissen 1992	9/47	8/47			•			0.8%	1.13[0.47,2.66]
Dincol 1998	5/71	3/72			+		-	0.3%	1.69[0.42,6.81]
Kojima 1994	13/36	11/34						1.13%	1.12[0.58,2.14]
Leyland 1992	31/164	53/148		+				5.57%	0.53[0.36,0.77]
Lieschke 1990	55/90	46/92			+			4.55%	1.22[0.94,1.59]
	Favo	ours monotherapy	0.1 0.2	2 0.5	1 2	5	10	Favours combination	



	Monotherapy Combina- tion therapy		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl	<u>.</u>	M-H, Fixed, 95% CI
Liu 1989	4/10	2/18	+	0.14%	3.6[0.79,16.31
Miller 1993	30/65	28/66		2.78%	1.09[0.74,1.6
Norrby 1987	73/105	67/105	-+-	6.7%	1.09[0.9,1.32
Ozyilkan 1999	2/15	0/15		0.05%	5[0.26,96.13
Perez 1995	4/30	6/30	• • • • • • • • • • • • • • • • • • •	0.6%	0.67[0.21,2.13
Subtotal (95% CI)	717	712	•	23.39%	0.99[0.86,1.13
Total events: 230 (Monotherapy), 232 (Combination thera	іру)			
Heterogeneity: Tau ² =0; Chi ² =20.	45, df=10(P=0.03); l ² =51.1	1%			
Test for overall effect: Z=0.21(P=	-0.83)				
3.1.2 meropenem monotherap	ру				
Agaoglu 2001	3/30	0/57		0.03%	13.1[0.7,245.5
Akova 1999	8/40	9/43	_	0.87%	0.96[0.41,2.23
Behre 1998	13/39	31/39		3.1%	0.42[0.26,0.67
Cometta 1996	151/516	148/511	_ + _	14.87%	1.01[0.83,1.22
Cornely 2001	70/202	62/198	_ +	6.26%	1.11[0.84,1.46
De la Camara 1997	54/62	53/60	+	5.39%	0.99[0.86,1.13
Hense 2000	28/61	13/26		1.82%	0.92[0.57,1.47
Hung 2003	12/39	13/37	,	1.33%	0.88[0.46,1.67
Kliasova 2001	4/23	12/20		1.28%	0.29[0.11,0.76
Subtotal (95% CI)	1012	991	•	34.95%	0.95[0.84,1.06
Total events: 343 (Monotherapy			•		,
Heterogeneity: Tau ² =0; Chi ² =22.					
3.1.3 ceftazidime monotherap					
-	-	2/45		0 1006	
De Pauw 1983	1/42	2/45		0.19%	
De Pauw 1983 De Pauw 1994	1/42 76/551	134/535		13.59%	0.55[0.43,0.71
De Pauw 1983 De Pauw 1994 Doyen 1983	1/42 76/551 3/50	134/535 6/54		13.59% 0.58%	0.55[0.43,0.71 0.54[0.14,2.04
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989	1/42 76/551 3/50 34/52	134/535 6/54 45/50		13.59% 0.58% 4.59%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993	1/42 76/551 3/50 34/52 3/53	134/535 6/54 45/50 0/54		13.59% 0.58% 4.59%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.77
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991	1/42 76/551 3/50 34/52 3/53 7/77	134/535 6/54 45/50 0/54 7/69		13.59% 0.58% 4.59% 0.05% 0.74%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.77 0.9[0.33,2.43
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983	1/42 76/551 3/50 34/52 3/53 7/77 0/26	134/535 6/54 45/50 0/54 7/69 1/24		13.59% 0.58% 4.59% 0.05% 0.74% 0.16%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.5 7.13[0.38,134.77 0.9[0.33,2.43 0.31[0.01,7.23
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45	134/535 6/54 45/50 0/54 7/69 1/24 5/45		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.77 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5% 0.49%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.77 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988 Subtotal (95% CI)	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82 978	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87 963		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.77 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988 Subtotal (95% CI) Total events: 134 (Monotherapy	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82 978), 205 (Combination thera	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87 963		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5% 0.49%	0.54[0.05,5.69 0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.77 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58 0.64[0.53,0.76
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988 Subtotal (95% CI)	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82 978), 205 (Combination thera 5, df=8(P=0.43); I ² =0.57%	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87 963		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5% 0.49%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.77 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988 Subtotal (95% CI) Total events: 134 (Monotherapy Heterogeneity: Tau ² =0; Chi ² =8.0 Test for overall effect: Z=4.86(P<	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82 978), 205 (Combination thera 5, df=8(P=0.43); I ² =0.57% :0.0001)	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87 963		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5% 0.49%	0.55[0.43,0.7] 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134,7] 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988 Subtotal (95% CI) Total events: 134 (Monotherapy Heterogeneity: Tau ² =0; Chi ² =8.0 Test for overall effect: Z=4.86(P<	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82 978), 205 (Combination thera 5, df=8(P=0.43); I ² =0.57% :0.0001)	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87 963		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5% 0.49%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.77 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58 0.64[0.153,0.76
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988 Subtotal (95% CI) Total events: 134 (Monotherapy Heterogeneity: Tau ² =0; Chi ² =8.0 Test for overall effect: Z=4.86(P<	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82 978 •), 205 (Combination thera 5, df=8(P=0.43); l ² =0.57% •0.0001)	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87 963		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5% 0.49% 20.88%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.77 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988 Subtotal (95% CI) Total events: 134 (Monotherapy Heterogeneity: Tau ² =0; Chi ² =8.0	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82 978), 205 (Combination thera 5, df=8(P=0.43); l ² =0.57% 0.0001) Py	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87 963 npy)		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5% 0.49% 20.88%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.77 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58 0.64[0.53,0.76
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988 Subtotal (95% CI) Total events: 134 (Monotherapy Heterogeneity: Tau ² =0; Chi ² =8.0 Test for overall effect: Z=4.86(P< 3.1.4 moxalactam monotheraj Alanis 1983 Bezwoda 1985 Hansen 1986	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82 978), 205 (Combination thera 5, df=8(P=0.43); l ² =0.57% c0.0001) Py 19/53 9/29	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87 963 909) 25/55 17/31		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5% 0.49% 20.88%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.77 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58 0.64[0.53,0.76 0.79[0.5,1.25 0.57[0.3,1.06
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988 Subtotal (95% CI) Total events: 134 (Monotherapy Heterogeneity: Tau ² =0; Chi ² =8.0 Test for overall effect: Z=4.86(P< 3.1.4 moxalactam monothera Alanis 1983 Bezwoda 1985 Hansen 1986 Pegram 1984	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82 978), 205 (Combination thera 5, df=8(P=0.43); l ² =0.57% c0.0001) Py 19/53 9/29 0/14	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87 963 npy) 25/55 17/31 0/19		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5% 0.49% 20.88% 2.45% 1.64%	0.55[0.43,0.7: 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.7: 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58 0.64[0.16,2.58 0.64[0.53,0.76 0.57[0.3,1.00 Not estimabl 0.47[0.17,1.33
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988 Subtotal (95% CI) Total events: 134 (Monotherapy Heterogeneity: Tau ² =0; Chi ² =8.0 Test for overall effect: Z=4.86(P< 3.1.4 moxalactam monotherap Alanis 1983 Bezwoda 1985 Hansen 1986 Pegram 1984 Pickard 1983	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82 978), 205 (Combination thera 55, df=8(P=0.43); l ² =0.57% c0.0001) py 19/53 9/29 0/14 5/72	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87 963 npy) 25/55 17/31 0/19 10/68		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5% 0.49% 20.88% 2.45% 1.64%	0.55[0.43,0.7: 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.7: 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58 0.64[0.16,2.58 0.64[0.53,0.76 0.57[0.3,1.00 Not estimabl 0.47[0.17,1.33 1[0.44,2.26
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988 Subtotal (95% CI) Total events: 134 (Monotherapy Heterogeneity: Tau ² =0; Chi ² =8.0 Test for overall effect: Z=4.86(P 3.1.4 moxalactam monotherap Alanis 1983 Bezwoda 1985 Hansen 1986 Pegram 1984 Pickard 1983 Subtotal (95% CI)	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82 978 0/26 (Combination thera 5, df=8(P=0.43); l ² =0.57% c0.0001) py 19/53 9/29 0/14 5/72 9/40 208	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87 963 ppy) 25/55 17/31 0/19 10/68 9/40 213		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5% 0.49% 20.88% 2.45% 1.64% 1.03% 0.9%	0.55[0.43,0.7: 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.7: 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58 0.64[0.16,2.58 0.64[0.53,0.76 0.57[0.3,1.00 Not estimabl 0.47[0.17,1.33 1[0.44,2.26
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988 Subtotal (95% CI) Total events: 134 (Monotherapy Heterogeneity: Tau ² =0; Chi ² =8.0 Test for overall effect: Z=4.86(P< 3.1.4 moxalactam monotherap Alanis 1983 Bezwoda 1985 Hansen 1986 Pegram 1984 Pickard 1983 Subtotal (95% CI) Total events: 42 (Monotherapy),	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82 978 0/26 7/45 3/82 978 0/26 (Combination thera 9/29 0/14 5/72 9/40 208 ,61 (Combination thera	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87 963 ppy) 25/55 17/31 0/19 10/68 9/40 213		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5% 0.49% 20.88% 2.45% 1.64% 1.03% 0.9%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.77 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58 0.64 [0.53,0.76 0.79[0.5,1.25 0.57[0.3,1.06 Not estimabl
De Pauw 1983 De Pauw 1994 Doyen 1983 Gibson 1989 Jacobs 1993 Marie 1991 Morgan 1983 Novakova 1991 Piguet 1988 Subtotal (95% CI) Total events: 134 (Monotherapy Heterogeneity: Tau ² =0; Chi ² =8.0 Test for overall effect: Z=4.86(P 3.1.4 moxalactam monotherap Alanis 1983 Bezwoda 1985 Hansen 1986 Pegram 1984 Pickard 1983 Subtotal (95% CI)	1/42 76/551 3/50 34/52 3/53 7/77 0/26 7/45 3/82 978 c), 205 (Combination thera 5, df=8(P=0.43); l ² =0.57% c0.0001) py 19/53 9/29 0/14 5/72 9/40 208 , 61 (Combination therap) 9, df=3(P=0.57); l ² =0%	134/535 6/54 45/50 0/54 7/69 1/24 5/45 5/87 963 ppy) 25/55 17/31 0/19 10/68 9/40 213		13.59% 0.58% 4.59% 0.05% 0.74% 0.16% 0.5% 0.49% 20.88% 2.45% 1.64% 1.03% 0.9%	0.55[0.43,0.71 0.54[0.14,2.04 0.73[0.58,0.9 7.13[0.38,134.71 0.9[0.33,2.43 0.31[0.01,7.23 1.4[0.48,4.08 0.64[0.16,2.58 0.64[0.153,0.76 0.57[0.3,1.06 Not estimabl 0.47[0.17,1.31 1[0.44,2.26



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl	
3.1.5 cefepime monotherapy						
Tamura 2002	11/38	12/76		0.8%	1.83[0.89,3.76]	
Corapcioglu 2005	0/25	1/25	↓ ↓	0.15%	0.33[0.01,7.81]	
Cornely 2001	53/202	62/198	-+-	6.26%	0.84[0.61,1.14]	
Jimeno 2006	2/24	5/27	• •	0.47%	0.45[0.1,2.11]	
Tamura 2004	5/95	4/94		0.4%	1.24[0.34,4.46]	
Wrzesien-Kus 2001	0/19	0/20			Not estimable	
Yamamura 1997	12/56	23/55	+	2.32%	0.51[0.28,0.92]	
Pereira 2009	21/62	11/63		1.09%	1.94[1.02,3.68]	
Subtotal (95% CI)	521	558	•	11.49%	0.94[0.75,1.17]	
Total events: 104 (Monotherapy), 118 (Combination thera	ару)				
Heterogeneity: Tau ² =0; Chi ² =14.	28, df=6(P=0.03); I ² =58%					
Test for overall effect: Z=0.56(P=	:0.58)					
3.1.6 other monotherapy						
Conte 1996	1/21	4/19		0.42%	0.23[0.03,1.85]	
El Haddad 1995	0/30	0/16	•	011270	Not estimable	
Hess 1998	17/48	15/48		1.5%	1.13[0.64,2]	
Petrilli 2003	11/68	10/68		1%	1.1[0.5,2.42]	
Piccart 1984	0/25	0/24		270	Not estimable	
Smith 1990	1/47	2/53		0.19%	0.56[0.05,6.02]	
Zengin 2011	0/37	1/35		0.15%	0.32[0.01,7.5]	
Subtotal (95% CI)	276	263		3.26%	0.93[0.61,1.44]	
Total events: 30 (Monotherapy),						
Heterogeneity: Tau ² =0; Chi ² =2.9		,,				
Test for overall effect: Z=0.3(P=0						
Total (95% CI)	3712	3700	•	100%	0.87[0.81,0.94]	
Total events: 883 (Monotherapy), 989 (Combination thera	ару)				
Heterogeneity: Tau ² =0; Chi ² =93.	14, df=44(P<0.0001); I ² =5	2.76%				
Test for overall effect: Z=3.65(P=	:0)					
Test for subgroup differences: C	hi²=18.5, df=1 (P=0), l²=72	2.98%				
	Favo	ours monotherapy	0.1 0.2 0.5 1 2 5	¹⁰ Favours combinatio	n	

Analysis 3.2. Comparison 3 Adverse events, Outcome 2 Discontinuation due to adverse event.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
Agaoglu 2001	0/30	0/57			Not estimable
Borbolla 2001	0/20	0/20			Not estimable
Cometta 1996	3/516	5/511		9.37%	0.59[0.14,2.47]
De la Camara 1997	1/62	1/60	4	1.9%	0.97[0.06,15.12]
De Pauw 1983	0/42	0/45			Not estimable
De Pauw 1994	12/551	16/535		30.29%	0.73[0.35,1.52]
Del Favero 2001	2/364	5/369	↓	9.27%	0.41[0.08,2.08]
Dincol 1998	1/71	1/72	•	1.85%	1.01[0.06,15.9]
El Haddad 1995	0/30	0/16			Not estimable
Hess 1998	1/48	0/48		0.93%	3[0.13,71.85]
	Favo	ours monotherapy	0.1 0.2 0.5 1 2 5	¹⁰ Favours combinatio	n



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio Y			Weight		Risk Ratio		
	n/N	n/N		M-H, I	ixed, 9	5% CI				M-H, Fixed, 95% CI
Hung 2003	0/39	0/37								Not estimable
Koehler 1990	3/55	2/65				+		→	3.42%	1.77[0.31,10.23]
Kojima 1994	1/36	1/34	-					→	1.92%	0.94[0.06,14.51]
Liu 1989	0/10	0/18								Not estimable
Norrby 1987	6/105	20/105			-				37.32%	0.3[0.13,0.72]
Pickard 1983	2/40	2/40	-						3.73%	1[0.15,6.76]
Total (95% CI)	2019	2032		-					100%	0.61[0.4,0.93]
Total events: 32 (Monotherapy)	, 53 (Combination therapy	<i>y</i>)								
Heterogeneity: Tau ² =0; Chi ² =6,	df=9(P=0.74); I ² =0%									
Test for overall effect: Z=2.3(P=	0.02)									
	Favo	ours monotherapy	0.1	0.2 0.5	1	2	5	10	Favours combination	

Analysis 3.3. Comparison 3 Adverse events, Outcome 3 Any nephrotoxicity - Ag dosing regimen.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
3.3.1 Once daily					
Ahmed 2007	0/58	0/61			Not estimable
Borbolla 2001	0/20	0/20			Not estimable
Cometta 1996	1/516	6/511	+	3.06%	0.17[0.02,1.37]
Dincol 1998	0/71	1/72		0.76%	0.34[0.01,8.16]
Esteve 1997	5/39	17/46	- _	7.92%	0.35[0.14,0.85]
Hess 1998	0/48	2/48	+	1.27%	0.2[0.01,4.06]
Pereira 2009	1/62	2/63		1.01%	0.51[0.05,5.46]
Zengin 2011	0/37	1/35	•	0.78%	0.32[0.01,7.5]
Subtotal (95% CI)	851	856		14.8%	0.31[0.15,0.63]
Total events: 7 (Monotherapy)	, 29 (Combination therapy)				
Heterogeneity: Tau ² =0; Chi ² =0	.66, df=5(P=0.99); I ² =0%				
Test for overall effect: Z=3.24(F	P=0)				
3.3.2 Multiple daily					
Agaoglu 2001	0/30	0/57			Not estimable
Alanis 1983	1/53	11/55	↓	5.48%	0.09[0.01,0.71]
Au 1994	0/26	0/24			Not estimable
Behre 1998	0/39	0/39			Not estimable
Bezwoda 1985	0/29	4/31	↓	2.21%	0.12[0.01,2.11]
Conte 1996	0/21	3/19	↓	1.86%	0.13[0.01,2.36]
Cornelissen 1992	0/47	2/47	↓ ↓ ↓ ↓	1.27%	0.2[0.01,4.06]
De la Camara 1997	0/62	2/60	↓	1.29%	0.19[0.01,3.95]
De Pauw 1983	0/42	1/45	←	0.74%	0.36[0.01,8.52]
De Pauw 1994	43/551	76/535		39.15%	0.55[0.39,0.78]
Doyen 1983	0/50	1/54	←	0.73%	0.36[0.01,8.63]
El Haddad 1995	0/30	0/16			Not estimable
Hansen 1986	0/14	0/19			Not estimable
Hung 2003	0/39	0/37			Not estimable
Jacobs 1993	0/53	0/54			Not estimable
Jimeno 2006	2/24	2/27		0.96%	1.13[0.17,7.38]



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Koehler 1990	6/55	7/65		3.26%	1.01[0.36,2.84]
Kojima 1994	1/36	1/34		0.52%	0.94[0.06,14.51]
Leyland 1992	0/164	7/148	↓	4%	0.06[0,1.05]
Lieschke 1990	4/90	5/92		2.51%	0.82[0.23,2.95]
Liu 1989	0/10	0/18			Not estimable
Marie 1991	3/77	5/69		2.68%	0.54[0.13,2.17]
Miller 1993	2/65	6/66	I	3.02%	0.34[0.07,1.62]
Norrby 1987	6/105	8/105	+	4.06%	0.75[0.27,2.09]
Novakova 1991	2/45	0/45		0.25%	5[0.25,101.31]
Pegram 1984	0/71	6/68	↓	3.37%	0.07[0,1.28]
Pickard 1983	0/40	1/40	•	0.76%	0.33[0.01,7.95]
Rolston 1992	0/378	2/372	+	1.28%	0.2[0.01,4.09]
Tamura 2002	2/38	2/76		0.68%	2[0.29,13.65]
Tamura 2004	0/95	1/94	•	0.77%	0.33[0.01,8]
Yamamura 1997	0/56	8/55	↓	4.35%	0.06[0,0.98]
Subtotal (95% CI)	2435	2466	◆	85.2%	0.47[0.36,0.61]
Total events: 72 (Monotherap	y), 161 (Combination therapy	/)			
Heterogeneity: Tau ² =0; Chi ² =2	21.12, df=22(P=0.51); l ² =0%				
Test for overall effect: Z=5.75((P<0.0001)				
Total (95% CI)	3286	3322	•	100%	0.45[0.35,0.57]
Total events: 79 (Monotherap	y), 190 (Combination therapy	/)			
Heterogeneity: Tau ² =0; Chi ² =2	23.51, df=28(P=0.71); l ² =0%				
Test for overall effect: Z=6.55	(P<0.0001)				
Test for subgroup differences	: Chi ² =1.24, df=1 (P=0.27), l ² =	19.34%			
	Favoi	irs monotherapy	0.05 0.2 1 5 20	Favours combinatio	n

Analysis 3.4. Comparison 3 Adverse events, Outcome 4 Severe nephrotoxicity - Ag dosing regimen.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk	Risk Ratio		Risk Ratio
	n/N	n/N	M-H, Fix	ed, 95% CI		M-H, Fixed, 95% CI
3.4.1 Once daily						
Ahmed 2007	0/58	0/61				Not estimable
Borbolla 2001	0/20	0/20				Not estimable
Cometta 1996	1/516	6/511		+	27.719	6 0.17[0.02,1.37]
Dincol 1998	0/71	1/72	+	+	6.85%	6 0.34[0.01,8.16]
Pereira 2009	0/62	0/63				Not estimable
Zengin 2011	0/37	0/35				Not estimable
Subtotal (95% CI)	764	762		•	34.55%	6 0.2[0.03,1.14]
Total events: 1 (Monotherapy)), 7 (Combination therapy)					
Heterogeneity: Tau ² =0; Chi ² =0	0.14, df=1(P=0.71); I ² =0%					
Test for overall effect: Z=1.81(P=0.07)					
3.4.2 Multiple daily						
Agaoglu 2001	0/30	0/57				Not estimable
Alanis 1983	0/53	2/55	+		11.289	6 0.21[0.01,4.22]
Au 1994	0/26	0/24				Not estimable
Behre 1998	0/39	0/39			L	Not estimable
	Favo	ours monotherapy	0.01 0.1	1 10	¹⁰⁰ Favours combin	ation



Trusted evidence. Informed decisions. Better health.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Conte 1996	0/21	3/19	← → <u></u>	16.85%	0.13[0.01,2.36]
De la Camara 1997	0/62	1/60	+	7%	0.32[0.01,7.77]
De Pauw 1983	0/42	0/45			Not estimable
De Pauw 1994	0/551	6/535		30.31%	0.07[0,1.32]
El Haddad 1995	0/30	0/16			Not estimable
Hansen 1986	0/14	0/19			Not estimable
Jacobs 1993	0/53	0/54			Not estimable
Jimeno 2006	0/24	0/27			Not estimable
Liu 1989	0/10	0/18			Not estimable
Rolston 1992	0/378	0/372			Not estimable
Subtotal (95% CI)	1333	1340		65.45%	0.14[0.03,0.6]
Total events: 0 (Monotherapy)	, 12 (Combination therapy)				
Heterogeneity: Tau ² =0; Chi ² =0	.52, df=3(P=0.91); I ² =0%				
Test for overall effect: Z=2.64(F	P=0.01)				
Total (95% CI)	2097	2102		100%	0.16[0.05,0.49]
Total events: 1 (Monotherapy)	, 19 (Combination therapy)				
Heterogeneity: Tau ² =0; Chi ² =0	.72, df=5(P=0.98); I ² =0%				
Test for overall effect: Z=3.21(F	P=0)				
Test for subgroup differences:	Chi ² =0.1, df=1 (P=0.75), I ² =0	0%			
	Favo	urs monotherapy	0.01 0.1 1 10	¹⁰⁰ Favours combinatior	1

Comparison 4. Documented infections (subgroup analysis)

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 All cause mortality	13	1188	Risk Ratio (M-H, Fixed, 95% CI)	0.81 [0.56, 1.17]
2 Treatment failure	35		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 same beta-lactam	8	1043	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.93, 1.19]
2.2 different beta-lactam	27	2740	Risk Ratio (M-H, Fixed, 95% CI)	0.89 [0.82, 0.95]

Analysis 4.1. Comparison 4 Documented infections (subgroup analysis), Outcome 1 All cause mortality.

Study or subgroup	Monotherapy	Combina- tion therapy	Ris	sk Ratio		Weight	Risk Ratio
	n/N	n/N	M-H, Fi	ixed, 95% CI			M-H, Fixed, 95% Cl
Agaoglu 2001	1/9	0/25				0.49%	7.8[0.35,176.01]
Akova 1999	0/1	0/1					Not estimable
De la Camara 1997	1/28	2/23				3.88%	0.41[0.04,4.25]
De Pauw 1994	24/292	33/296		•+-		57.94%	0.74[0.45,1.22]
Dincol 1998	0/29	2/26	↓			4.65%	0.18[0.01,3.58]
Jacobs 1993	1/14	0/15			\rightarrow	0.86%	3.2[0.14,72.62]
Matsui 1991	0/51	0/50					Not estimable
	Favo	ours monotherapy	0.1 0.2 0.5	1 2	5 10	Favours combination	



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio M-H, Fixed, 95% Cl
	n/N	n/N	M-H, Fixed, 95% CI		
Miller 1993	2/15	0/15		0.88%	5[0.26,96.13]
Norrby 1987	3/58	9/62 -	+ +	15.38%	0.36[0.1,1.25]
Novakova 1991	5/45	5/45		8.84%	1[0.31,3.22]
Ozyilkan 1999	0/10	0/11			Not estimable
Perez 1995	3/20	3/21	+	5.17%	1.05[0.24,4.61]
Rodjer 1987	3/14	1/12		1.9%	2.57[0.31,21.59]
Total (95% CI)	586	602	•	100%	0.81[0.56,1.17]
Total events: 43 (Monotherap	y), 55 (Combination therapy	/)			
Heterogeneity: Tau ² =0; Chi ² =8	8.68, df=9(P=0.47); I ² =0%				
Test for overall effect: Z=1.13((P=0.26)				
	Favo	ours monotherapy ^{0.}	1 0.2 0.5 1 2 5 1	¹⁰ Favours combination	

Analysis 4.2. Comparison 4 Documented infections (subgroup analysis), Outcome 2 Treatment failure.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
4.2.1 same beta-lactam					
Del Favero 2001	120/190	121/181		53.8%	0.94[0.81,1.1]
Doyen 1983	8/45	6/46		2.58%	1.36[0.51,3.62]
Jacobs 1993	3/14	4/15		1.68%	0.8[0.22,2.97]
Kojima 1994	7/29	3/16		1.68%	1.29[0.39,4.3]
Novakova 1991	19/45	18/45		7.81%	1.06[0.64,1.73]
Piccart 1984	3/15	6/16		2.52%	0.53[0.16,1.76]
Rolston 1992	77/172	60/177		25.67%	1.32[1.01,1.72]
Tamura 2002	7/14	13/23	+	4.27%	0.88[0.47,1.67]
Subtotal (95% CI)	524	519	*	100%	1.05[0.93,1.19]
Total events: 244 (Monotherapy)	, 231 (Combination ther	ару)			
Heterogeneity: Tau ² =0; Chi ² =6.89	9, df=7(P=0.44); I ² =0%				
Test for overall effect: Z=0.78(P=	0.44)				
4.2.2 different beta-lactam					
Agaoglu 2001	5/9	8/25		0.62%	1.74[0.77,3.93]
Au 1994	2/5	5/9	+	0.52%	0.72[0.21,2.44]
Behre 1998	11/15	7/14	- 	1.05%	1.47[0.8,2.69]
Bezwoda 1985	13/29	14/31		1.97%	0.99[0.57,1.74]
Cometta 1996	136/251	145/240	-+-	21.56%	0.9[0.77,1.05]
Cornelissen 1992	3/39	12/38	↓	1.77%	0.24[0.07,0.8]
De la Camara 1997	20/28	16/23		2.55%	1.03[0.72,1.47]
De Pauw 1994	176/292	186/296	+	26.86%	0.96[0.84,1.09]
Erjavec 1994	23/42	30/37	+	4.64%	0.68[0.49,0.93]
Gorschluter 2003	18/31	21/29	_ + +	3.16%	0.8[0.55,1.17]
Hung 2003	4/13	7/14		0.98%	0.62[0.23,1.62]
Jimeno 2006	4/6	9/9	+- <u>+</u>	1.14%	0.68[0.38,1.2]
Leyland 1992	30/76	24/61	<u> </u>	3.87%	1[0.66,1.52]
Liu 1989	1/7	3/8	• •	0.41%	0.38[0.05,2.88]
Matsui 1991	9/51	10/50		1.47%	0.88[0.39,1.99]
Miller 1993	3/15	4/15	+	0.58%	0.75[0.2,2.79]
	Favo	ours monotherapy	0.1 0.2 0.5 1 2 5	¹⁰ Favours combinatio	n



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Norrby 1987	19/58	29/62	+ _+	4.08%	0.7[0.44,1.1]
Ozyilkan 1999	6/10	6/11		0.83%	1.1[0.52,2.3]
Pellegrin 1988	20/61	25/61	+	3.64%	0.8[0.5,1.28]
Perez 1995	11/20	16/21	— • 	2.27%	0.72[0.45,1.15]
Pickard 1983	7/14	13/15		1.83%	0.58[0.33,1.01]
Piguet 1988	37/48	39/47	-+-	5.73%	0.93[0.76,1.14]
Rodjer 1987	3/14	2/12	+	0.31%	1.29[0.26,6.46]
Rodriguez 1995	10/29	15/41		1.81%	0.94[0.5,1.79]
Schuchter 1988	2/24	1/32		0.12%	2.67[0.26,27.72]
Wade 1987	30/142	39/155	+	5.42%	0.84[0.55,1.28]
Yamamura 1997	6/26	6/29		0.82%	1.12[0.41,3.03]
Subtotal (95% CI)	1355	1385	•	100%	0.89[0.82,0.95]
Total events: 609 (Monotherapy), 6	92 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =23.97,	df=26(P=0.58); l ² =0%				
Test for overall effect: Z=3.24(P=0)					

Comparison 5. Bacteraemia (subgroup analysis)

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 All cause mortality	14	676	Risk Ratio (M-H, Fixed, 95% CI)	0.74 [0.46, 1.18]
2 Treatment failure	26		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 same beta-lactam	6	395	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.90, 1.23]
2.2 different beta-lactam	20	1149	Risk Ratio (M-H, Fixed, 95% CI)	0.86 [0.78, 0.95]

Analysis 5.1. Comparison 5 Bacteraemia (subgroup analysis), Outcome 1 All cause mortality.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
Agaoglu 2001	1/6	0/17			0.74%	7.71[0.35,167.72]
Ahmed 2007	0/25	1/32	-	+	- 3.49%	0.42[0.02,9.96]
De la Camara 1997	1/22	2/19	←		5.66%	0.43[0.04,4.4]
De Pauw 1994	11/163	22/173			56.34%	0.53[0.27,1.06]
Dincol 1998	0/7	2/8	←	-+	6.21%	0.23[0.01,4.02]
Jacobs 1993	1/11	0/10	_		1.38%	2.75[0.12,60.7]
Miller 1993	2/12	0/11		+	1.37%	4.62[0.25,86.72]
Norrby 1987	0/14	2/16	←	+	6.19%	0.23[0.01,4.36]
Novakova 1991	3/12	0/9			1.49%	5.38[0.31,92.73]
Ozyilkan 1999	0/9	0/8				Not estimable
Perez 1995	0/15	1/17	-	+	- 3.73%	0.38[0.02,8.57]
Petrilli 2003	0/5	2/8	-	+	5.28%	0.3[0.02,5.21]
	Favo	ours monotherapy	0.1	0.2 0.5 1 2 5	¹⁰ Favours combination	1



Study or subgroup	Monotherapy	Combina- tion therapy			Ris	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, Fi	ixed, 9	95% CI				M-H, Fixed, 95% CI
Piccart 1984	1/13	2/12	╉		+					5.49%	0.46[0.05,4.46]
Rodjer 1987	3/11	1/11					+			2.64%	3[0.37,24.58]
Total (95% CI)	325	351								100%	0.74[0.46,1.18]
Total events: 23 (Monotherap	y), 35 (Combination therapy	<i>י</i>)									
Heterogeneity: Tau ² =0; Chi ² =	11.2, df=12(P=0.51); l ² =0%										
Test for overall effect: Z=1.26	(P=0.21)										
	Favo	ours monotherapy	0.1	0.2	0.5	1	2	5	10	Favours combination	

Analysis 5.2. Comparison 5 Bacteraemia (subgroup analysis), Outcome 2 Treatment failure.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
5.2.1 same beta-lactam					
Del Favero 2001	98/140	93/137		84.85%	1.03[0.88,1.21]
Doyen 1983	2/19	1/21		0.86%	2.21[0.22,22.47]
Jacobs 1993	3/11	4/10		3.78%	0.68[0.2,2.33]
Novakova 1991	9/12	4/9		4.13%	1.69[0.76,3.76]
Piccart 1984	3/13	4/12		3.75%	0.69[0.19,2.48]
Tamura 2004	3/4	4/7		2.63%	1.31[0.56,3.09]
Subtotal (95% CI)	199	196	•	100%	1.05[0.9,1.23]
Total events: 118 (Monotherapy),	110 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =2.94,	df=5(P=0.71); I ² =0%				
Test for overall effect: Z=0.62(P=0.	54)				
5.2.2 different beta-lactam					
Agaoglu 2001	5/6	5/17		0.76%	2.83[1.25,6.43]
Alanis 1983	11/21	8/14		2.81%	0.92[0.5,1.69]
Au 1994	1/3	4/4		1.17%	0.42[0.11,1.53]
Behre 1998	9/11	6/9	++	1.93%	1.23[0.72,2.1]
Cometta 1996	66/113	80/114		23.32%	0.83[0.68,1.01]
Cornelissen 1992	2/17	6/12	↓	2.06%	0.24[0.06,0.97]
De la Camara 1997	14/22	14/19	— • —	4.4%	0.86[0.57,1.31]
De Pauw 1994	108/163	124/173	-	35.22%	0.92[0.8,1.07]
Gorschluter 2003	14/24	19/25	+ _	5.45%	0.77[0.51,1.15]
Hansen 1986	0/1	0/3			Not estimable
Hess 1998	6/17	7/23		1.74%	1.16[0.48,2.83]
Leyland 1992	18/54	19/49	+	5.83%	0.86[0.51,1.44]
Miller 1993	2/12	3/11		0.92%	0.61[0.12,3]
Norrby 1987	2/14	8/16	↓ + +	2.19%	0.29[0.07,1.13]
Novakova 1990	3/7	11/16	+	1.96%	0.62[0.25,1.56]
Pellegrin 1988	8/24	10/19		3.27%	0.63[0.31,1.29]
Perez 1995	7/15	14/17	+	3.84%	0.57[0.32,1.02]
Rodjer 1987	3/11	2/11		0.59%	1.5[0.31,7.3]
Rodriguez 1995	7/20	3/16		0.98%	1.87[0.57,6.09]
Yamamura 1997	5/14	5/12	+	1.58%	0.86[0.32,2.26]
Subtotal (95% CI)	569	580	•	100%	0.86[0.78,0.95]
Total events: 291 (Monotherapy),	348 (Combination thera	ару)			
	Favo	ours monotherapy	0.1 0.2 0.5 1 2 5	¹⁰ Favours combinatio	n



Study or subgroup	Monotherapy	Combina- tion therapy			Ri	sk Ra	tio			Weight	Risk Ratio
	n/N	n/N			М-Н, F	ixed,	95% CI				M-H, Fixed, 95% Cl
Heterogeneity: Tau ² =0; Chi ² =24.04,	df=18(P=0.15); I ² =25.	13%									
Test for overall effect: Z=3.03(P=0)											
	Fav	ours monotherapy	0.1	0.2	0.5	1	2	5	10	Favours combination	

Comparison 6. Gram-negative infections (subgroup analysis)

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 All cause mortality	16	376	Risk Ratio (M-H, Fixed, 95% CI)	0.64 [0.37, 1.11]
2 Treatment failure	29		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 same beta-lactam	7	261	Risk Ratio (M-H, Fixed, 95% CI)	1.34 [1.03, 1.74]
2.2 different beta-lactam	22	603	Risk Ratio (M-H, Fixed, 95% CI)	0.74 [0.60, 0.90]

Analysis 6.1. Comparison 6 Gram-negative infections (subgroup analysis), Outcome 1 All cause mortality.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Agaoglu 2001	1/2	0/7		• 0.97%	8[0.43,147.24]
Ahmed 2007	0/6	1/7	◀ +	- 5%	0.38[0.02,7.93]
Behre 1998	0/5	0/5			Not estimable
De la Camara 1997	0/6	0/4			Not estimable
De Pauw 1994	6/62	12/61		43.2%	0.49[0.2,1.23]
Dincol 1998	0/16	2/15	< →	9.2%	0.19[0.01,3.63]
Jacobs 1993	1/3	0/2		2.04%	2.25[0.13,38.09]
Matsui 1991	0/14	0/12			Not estimable
Miller 1993	1/8	0/7		1.89%	2.67[0.13,56.63]
Norrby 1987	0/21	2/19	< +	9.35%	0.18[0.01,3.56]
Novakova 1991	2/7	1/4		4.55%	1.14[0.15,8.99]
Ozyilkan 1999	0/2	0/9			Not estimable
Perez 1995	0/9	1/5	↓ · · · · · · · · · · · · · · · · · · ·	6.7%	0.2[0.01,4.17]
Petrilli 2003	0/11	1/9	◀ → │	5.84%	0.28[0.01,6.1]
Piccart 1984	1/12	2/13	◀────	6.86%	0.54[0.06,5.24]
Rodjer 1987	3/8	1/5		4.4%	1.88[0.26,13.42]
Total (95% CI)	192	184		100%	0.64[0.37,1.11]
Total events: 15 (Monotherapy),	23 (Combination therapy)				
Heterogeneity: Tau ² =0; Chi ² =8.5	7, df=11(P=0.66); I ² =0%				
Test for overall effect: Z=1.6(P=0	.11)				

Analysis 6.2. Comparison 6 Gram-negative infections (subgroup analysis), Outcome 2 Treatment failure.

6.2.1 same beta-lactam Del Favero 2001 Doyen 1983 Jacobs 1993 Kojima 1994 Novakova 1991 Piccart 1984 Rolston 1992 Subtotal (95% CI) Total events: 61 (Monotherapy), 44 (C	=6(P=0.11); I ² =41.49		M-H, Fixed, 95% Cl	75% 0.97% 1.26% 3.15% 5.62% 8.47% 5.53% 100%	M-H, Fixed, 95% Cl 1.06[0.81,1.38] 3.82[0.17,84.9] 3.75[0.27,52.64] 2[0.27,14.55] 0.86[0.23,3.15] 0.81[0.23,2.91] 5.11[1.57,16.63] 1.34[1.03,1.74]
Del Favero 2001 Doyen 1983 Jacobs 1993 Kojima 1994 Novakova 1991 Piccart 1984 Rolston 1992 Subtotal (95% CI)	1/10 2/3 5/20 3/7 3/12 11/28 131 combination therapy =6(P=0.11); l ² =41.45	0/13 0/2 1/8 2/4 4/13 3/39 130 /)		0.97% 1.26% 3.15% 5.62% 8.47% 5.53%	3.82[0.17,84.9] 3.75[0.27,52.64] 2[0.27,14.55] 0.86[0.23,3.15] 0.81[0.23,2.91] 5.11[1.57,16.63]
Doyen 1983 Jacobs 1993 Kojima 1994 Novakova 1991 Piccart 1984 Rolston 1992 Subtotal (95% CI)	1/10 2/3 5/20 3/7 3/12 11/28 131 combination therapy =6(P=0.11); l ² =41.45	0/13 0/2 1/8 2/4 4/13 3/39 130 /)		0.97% 1.26% 3.15% 5.62% 8.47% 5.53%	3.82[0.17,84.9] 3.75[0.27,52.64] 2[0.27,14.55] 0.86[0.23,3.15] 0.81[0.23,2.91] 5.11[1.57,16.63]
Jacobs 1993 Kojima 1994 Novakova 1991 Piccart 1984 Rolston 1992 Subtotal (95% CI)	2/3 5/20 3/7 3/12 11/28 131 combination therapy =6(P=0.11); l ² =41.45	0/2 1/8 2/4 4/13 3/39 130 /)		1.26% 3.15% 5.62% 8.47% 5.53%	3.75[0.27,52.64] 2[0.27,14.55] 0.86[0.23,3.15] 0.81[0.23,2.91] 5.11[1.57,16.63]
Kojima 1994 Novakova 1991 Piccart 1984 Rolston 1992 Subtotal (95% CI)	5/20 3/7 3/12 11/28 131 combination therapy =6(P=0.11); l ² =41.49	1/8 2/4 4/13 3/39 130 /)		3.15% 5.62% 8.47% 5.53%	2[0.27,14.55] 0.86[0.23,3.15] 0.81[0.23,2.91] 5.11[1.57,16.63]
Novakova 1991 Piccart 1984 Rolston 1992 Subtotal (95% CI)	3/7 3/12 11/28 131 combination therapy =6(P=0.11); l ² =41.49	2/4 4/13 3/39 130 /)		, 5.62% 8.47% 5.53%	0.86[0.23,3.15] 0.81[0.23,2.91] 5.11[1.57,16.63]
Piccart 1984 Rolston 1992 Subtotal (95% CI)	3/12 11/28 131 combination therapy =6(P=0.11); l ² =41.45	4/13 3/39 130 /)		8.47% 5.53%	0.81[0.23,2.91] 5.11[1.57,16.63]
Rolston 1992 Subtotal (95% CI)	11/28 131 combination therapy =6(P=0.11); I ² =41.49	3/39 130 /)	→ → → → → → → → → → → → → → → → → → →	5.53%	5.11[1.57,16.63]
Subtotal (95% CI)	131 combination therapy =6(P=0.11); I ² =41.49	130	◆	•	
	combination therapy =6(P=0.11); I ² =41.49	/)	•	100%	1.34[1.03,1.74]
Total events: 61 (Monotherapy), 44 (C	=6(P=0.11); I ² =41.49				
		%			
Heterogeneity: Tau ² =0; Chi ² =10.26, df					
Test for overall effect: Z=2.19(P=0.03)					
6.2.2 different beta-lactam					
Agaoglu 2001	1/2	2/7		0.7%	1.75[0.29,10.74]
Au 1994	1/3	2/ · 4/7 —		1.89%	0.58[0.1,3.27]
Behre 1998	1/5	0/5		0.39%	3[0.15,59.89]
Bezwoda 1985	7/16	5/14		4.2%	1.23[0.5,3]
Cometta 1996	11/37	11/24	_	10.51%	0.65[0.34,1.25]
Cornelissen 1992	0/6	1/3		1.5%	0.19[0.01,3.66]
De la Camara 1997	0/6	0/4		1070	Not estimable
De Pauw 1983	0/6	2/8		1.72%	0.26[0.01,4.54]
De Pauw 1994	42/62	40/61		31.77%	1.03[0.8,1.33]
Erjavec 1994	3/9	8/14	+	4.93%	0.58[0.21,1.63]
Gorschluter 2003	0/1	0/1			Not estimable
Hansen 1986	1/4	1/6		0.63%	1.5[0.13,17.67]
Leyland 1992	5/27	6/22	+	5.21%	0.68[0.24,1.93]
Matsui 1991	4/14	5/12	+	4.24%	0.69[0.24,1.99]
Miller 1993	1/5	1/4		0.88%	0.8[0.07,9.18]
Norrby 1987	1/21	7/19	•	5.79%	0.13[0.02,0.96]
Pellegrin 1988	1/29	8/23		7.03%	0.1[0.01,0.74]
Perez 1995	2/9	4/5		4.05%	0.28[0.08,1.02]
Pickard 1983	4/11	7/9	+	6.07%	0.47[0.2,1.1]
Rodjer 1987	3/8	1/5		- 0.97%	1.88[0.26,13.42]
Wade 1987	4/18	12/29		7.24%	0.54[0.2,1.41]
Yamamura 1997	2/7	0/15	+	0.26%	10[0.54,184.55]
Subtotal (95% CI)	306	297	\bullet	100%	0.74[0.6,0.9]
Total events: 94 (Monotherapy), 125 (
Heterogeneity: Tau ² =0; Chi ² =26.4, df=	-				
Test for overall effect: Z=3.01(P=0)	. ,,				
	Four	ours monotherapy 0.3	0.2 0.5 1 2 5 10	Favours combination	

Comparison 7. Pseudomonas infections (subgroup analysis)

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 All cause mortality	9	71	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.34, 2.24]

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2 Treatment failure	16		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 same beta-lactam	3	49	Risk Ratio (M-H, Fixed, 95% CI)	1.41 [0.90, 2.22]
2.2 different beta-lactam	13	99	Risk Ratio (M-H, Fixed, 95% CI)	0.89 [0.60, 1.31]

Analysis 7.1. Comparison 7 Pseudomonas infections (subgroup analysis), Outcome 1 All cause mortality.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
Ahmed 2007	0/1	1/3	•	13.09%	0.67[0.04,10.05]
Behre 1998	0/1	0/1			Not estimable
De Pauw 1994	1/10	3/17		29.09%	0.57[0.07,4.74]
Dincol 1998	0/1	1/5		9.82%	1[0.06,15.99]
Gorschluter 2003	0/3	1/3	•	19.64%	0.33[0.02,5.97]
Norrby 1987	0/2	1/5	•	13.09%	0.67[0.04,11.94]
Ozyilkan 1999	0/1	0/3			Not estimable
Piccart 1984	1/3	0/3		6.55%	3[0.17,53.71]
Rodriguez 1995	1/3	1/6	+	- 8.73%	2[0.18,22.06]
Total (95% CI)	25	46		100%	0.87[0.34,2.24]
Total events: 3 (Monotherapy), 8 (Co	ombination therapy)				
Heterogeneity: Tau ² =0; Chi ² =1.83, df	F=6(P=0.93); I ² =0%				
Test for overall effect: Z=0.28(P=0.78	3)				
	Favo	ours monotherapy	0.05 0.2 1 5 2	¹⁰ Favours combination	ı

Analysis 7.2. Comparison 7 Pseudomonas infections (subgroup analysis), Outcome 2 Treatment failure.

Study or subgroup	Monotherapy	Combina- tion therapy		Risk Ratio	Weight	Risk Ratio
	n/N	n/N		M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
7.2.1 same beta-lactam						
Del Favero 2001	6/7	15/17		- -	78.27%	0.97[0.69,1.38]
Piccart 1984	1/3	2/3	◀		17.89%	0.5[0.08,2.99]
Rolston 1992	5/8	0/11			3.83%	14.67[0.93,232.44]
Subtotal (95% CI)	18	31		-	100%	1.41[0.9,2.22]
Total events: 12 (Monotherapy), 17	(Combination therapy	<i>י</i>)				
Heterogeneity: Tau ² =0; Chi ² =8.47, c	lf=2(P=0.01); I ² =76.39%	ó				
Test for overall effect: Z=1.5(P=0.13)					
7.2.2 different beta-lactam						
Au 1994	0/1	2/4	◀	+	4.92%	0.5[0.04,6.44]
Behre 1998	1/1	0/1			1.72%	3[0.24,37.67]
Bezwoda 1985	2/3	0/2			1.97%	3.75[0.27,52.64]
De Pauw 1983	0/4	2/3	↓		9.56%	0.16[0.01,2.47]
De Pauw 1994	6/10	11/17			28.03%	0.93[0.5,1.72]
	Favo	ours monotherapy	0.1 0.2	0.5 1 2 5	¹⁰ Favours combination	 າ



Study or subgroup	Monotherapy	Combina- tion therapy			Risk Ra	tio			Weight	Risk Ratio
	n/N	n/N		M-H	Fixed,	95% CI				M-H, Fixed, 95% CI
Erjavec 1994	0/1	2/2	-	+					6.88%	0.3[0.03,3.49]
Gorschluter 2003	1/3	3/3		+					12.04%	0.43[0.11,1.6]
Kojima 1994	3/7	0/1	-					-	2.75%	1.75[0.14,21.88]
Norrby 1987	0/2	3/5	←	•			_		8.03%	0.29[0.02,3.92]
Pegram 1984	2/2	2/2		_					8.6%	1[0.49,2.05]
Rodriguez 1995	2/3	5/6			-+				11.47%	0.8[0.33,1.92]
Wade 1987	2/7	0/2	_					\rightarrow	2.5%	1.88[0.12,28.78]
Yamamura 1997	2/3	0/4						\rightarrow	1.53%	6.25[0.4,96.5]
Subtotal (95% CI)	47	52			\blacklozenge				100%	0.89[0.6,1.31]
Total events: 21 (Monotherapy), 30 (Combination therapy	<i>י</i>)								
Heterogeneity: Tau ² =0; Chi ² =9.07, df	=12(P=0.7); I ² =0%									
Test for overall effect: Z=0.59(P=0.55)									
	Favo	ours monotherapy	0.1	0.2 0.5	1	2	5	10	Favours combination	

Comparison 8. Haematological cancer patients (subgroup analysis)

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 All cause mortality	22	3463	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.68, 1.13]
2 Treatment failure	32		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 same beta-lactam	8	778	Risk Ratio (M-H, Fixed, 95% CI)	1.04 [0.91, 1.20]
2.2 different beta-lactam	24	3671	Risk Ratio (M-H, Fixed, 95% CI)	0.94 [0.88, 1.01]

Analysis 8.1. Comparison 8 Haematological cancer patients (subgroup analysis), Outcome 1 All cause mortality.

			Risk Ratio
n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
0/50		0.28%	6.12[0.26,144.92]
2/48		1.72%	0.96[0.14,6.55]
1/19		0.88%	0.9[0.06,13.48]
9/198		10.18%	1.42[0.68,2.96]
2/47	⊢ −−−−−	1.67%	0.51[0.05,5.44]
31/392		26.92%	0.64[0.37,1.09]
9/48	+	7.66%	0.87[0.37,2.07]
2/29		2.03%	0.21[0.01,4.27]
2/46		1.55%	0.59[0.06,6.26]
8/51	+	7.06%	0.57[0.2,1.63]
2/26		2.36%	1.28[0.28,5.92]
7/83	<u>↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ </u>	5.68%	0.31[0.07,1.44]
0/20			Not estimable
11/148		9.74%	1.15[0.54,2.45]
6/44	+	5.17%	0.8[0.26,2.42]
s	11/148 6/44	11/148 ***** 6/44 *****	11/148 9.74% 6/44 5.17%



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Novakova 1991	5/45	5/45		4.21%	1[0.31,3.22]
Ozyilkan 1999	0/14	0/14			Not estimable
Petrilli 2003	2/68	3/68		2.53%	0.67[0.12,3.86]
Piccart 1984	1/13	0/14		0.41%	3.21[0.14,72.55]
Piguet 1988	7/82	7/87		5.72%	1.06[0.39,2.89]
Tamura 2004	7/95	5/94		4.23%	1.39[0.46,4.21]
Zengin 2011	0/37	0/35			Not estimable
Total (95% CI)	1857	1606	•	100%	0.88[0.68,1.13]
Total events: 115 (Monotherap	oy), 112 (Combination thera	ру)			
Heterogeneity: Tau ² =0; Chi ² =1	0.37, df=18(P=0.92); l ² =0%				
Test for overall effect: Z=1.01(H	P=0.31)			_1	
	Favo	ours monotherapy ^{0.}	.1 0.2 0.5 1 2 5 1	¹⁰ Favours combination	

Analysis 8.2. Comparison 8 Haematological cancer patients (subgroup analysis), Outcome 2 Treatment failure.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
8.2.1 same beta-lactam					
Doyen 1983	13/49	11/48		5.99%	1.16[0.58,2.33]
Esteve 1997	23/39	26/46		12.87%	1.04[0.72,1.5]
Kiehl 2001	14/35	12/36		6.38%	1.2[0.65,2.22]
Kinsey 1990	48/77	59/83		30.63%	0.88[0.7,1.09]
Novakova 1991	19/45	18/45		9.71%	1.06[0.64,1.73]
Piccart 1984	2/7	2/7		1.08%	1[0.19,5.24]
Tamura 2004	47/95	39/94		21.15%	1.19[0.87,1.63]
Zengin 2011	24/37	22/35		12.2%	1.03[0.73,1.46]
Subtotal (95% CI)	384	394	•	100%	1.04[0.91,1.2]
Total events: 190 (Monotherapy),	189 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =3.32	, df=7(P=0.85); I ² =0%				
Test for overall effect: Z=0.55(P=0	.58)				
8.2.2 different beta-lactam					
Agaoglu 2001	7/24	10/50		0.74%	1.46[0.63,3.36]
Borbolla 2001	2/20	3/20		0.34%	0.67[0.12,3.57]
Conte 1996	10/21	8/19		0.96%	1.13[0.57,2.26]
Cornely 2001	193/353	92/176	+	14.07%	1.05[0.88,1.24]
De la Camara 1997	29/46	30/47	-+	3.4%	0.99[0.73,1.34]
De Pauw 1983	11/42	24/45		2.65%	0.49[0.28,0.87]
De Pauw 1994	256/417	239/392	+	28.22%	1.01[0.9,1.12]
El Haddad 1995	7/30	9/16		1.34%	0.41[0.19,0.9]
Erjavec 1994	38/94	49/85	+	5.9%	0.7[0.52,0.95]
Gaytan-Martinez 2002	9/63	7/54		0.86%	1.1[0.44,2.76]
Gorschluter 2003	25/56	35/51	— + —	4.2%	0.65[0.46,0.92]
Hense 2000	33/58	16/26	— · —	2.53%	0.92[0.63,1.35]
Kliasova 2001	8/23	10/20		1.23%	0.7[0.34,1.42]
Koehler 1990	16/55	19/65		2%	1[0.57,1.74]
Leyland 1992	48/164	52/148	· · · · · · · · · · · · · · · · · · ·	6.26%	0.83[0.6,1.15]
	Favo	ours monotherapy	0.1 0.2 0.5 1 2 5	¹⁰ Favours combination	<u>ו</u>



Study or subgroup	Monotherapy	Combina- tion therapy			R	isk Rat	io			Weight	Risk Ratio
	n/N	n/N			м-н, і	ixed, 9	95% CI				M-H, Fixed, 95% Cl
Novakova 1990	18/46	28/44			+					3.28%	0.61[0.4,0.94]
Ozyilkan 1999	6/15	6/15				-+				0.69%	1[0.42,2.4]
Pellegrin 1988	23/71	31/86			_	-+				3.21%	0.9[0.58,1.39]
Pereira 2009	26/62	20/63				++				2.27%	1.32[0.83,2.1]
Petrilli 2003	20/68	13/68				_	+			1.49%	1.54[0.83,2.84]
Piguet 1988	59/82	63/87				+				7%	0.99[0.82,1.2]
Schuchter 1988	33/65	30/68				++-	_			3.36%	1.15[0.8,1.65]
Yamamura 1997	8/37	10/27		_						1.32%	0.58[0.27,1.28]
Yildirim 2008	26/46	22/41				-+	-			2.67%	1.05[0.72,1.54]
Subtotal (95% CI)	1958	1713				•				100%	0.94[0.88,1.01]
Total events: 911 (Monotherapy), 826	6 (Combination thera	ру)									
Heterogeneity: Tau ² =0; Chi ² =34.69, d	f=23(P=0.06); I ² =33.70	%									
Test for overall effect: Z=1.76(P=0.08)	1										
	Favo	urs monotherapy	0.1	0.2	0.5	1	2	5	10	Favours combination	

Comparison 9. Severe neutropenia (subgroup analysis)

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 All cause mortality	6	737	Risk Ratio (M-H, Fixed, 95% CI)	0.68 [0.37, 1.24]
2 Treatment failure	11		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 same beta-lactam	2	237	Risk Ratio (M-H, Fixed, 95% CI)	1.48 [1.12, 1.96]
2.2 different beta-lactam	9	871	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.84, 1.10]

Analysis 9.1. Comparison 9 Severe neutropenia (subgroup analysis), Outcome 1 All cause mortality.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Agaoglu 2001	0/2	0/8			Not estimable
De Pauw 1994	12/242	17/232		70.86%	0.68[0.33,1.39]
Matsui 1991	0/12	0/10			Not estimable
Miller 1993	2/33	2/27		8.98%	0.82[0.12,5.43]
Norrby 1987	3/82	5/84		20.16%	0.61[0.15,2.49]
Ozyilkan 1999	0/3	0/2			Not estimable
Total (95% CI)	374	363		100%	0.68[0.37,1.24]
Total events: 17 (Monotherap	oy), 24 (Combination therapy	/)			
Heterogeneity: Tau ² =0; Chi ² =	0.06, df=2(P=0.97); I ² =0%				
Test for overall effect: Z=1.27	(P=0.21)				
	Favo	ours monotherapy 0	.1 0.2 0.5 1 2 5	¹⁰ Favours combination	1

Analysis 9.2. Comparison 9 Severe neutropenia (subgroup analysis), Outcome 2 Treatment failure.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
9.2.1 same beta-lactam					
Piccart 1984	2/8	2/7	+	4.85%	0.88[0.16,4.68]
Rolston 1992	58/101	46/121		95.15%	1.51[1.14,2]
Subtotal (95% CI)	109	128	•	100%	1.48[1.12,1.96]
Total events: 60 (Monotherapy), 48	(Combination therapy	/)			
Heterogeneity: Tau ² =0; Chi ² =0.4, df	=1(P=0.53); I ² =0%				
Test for overall effect: Z=2.75(P=0.0	1)				
9.2.2 different beta-lactam					
Agaoglu 2001	0/2	4/8		1.06%	0.33[0.02,4.55]
Alanis 1983	14/34	17/42		7.19%	1.02[0.59,1.75]
De Pauw 1994	138/242	125/232	#	60.37%	1.06[0.9,1.24]
Hansen 1986	1/4	3/5	+ + +	1.26%	0.42[0.07,2.63]
Hung 2003	8/23	11/22		5.32%	0.7[0.35,1.4]
Matsui 1991	4/12	3/10		1.55%	1.11[0.32,3.84]
Miller 1993	20/33	15/27		7.8%	1.09[0.71,1.69]
Norrby 1987	19/82	31/84		14.49%	0.63[0.39,1.02]
Rodriguez 1995	2/3	3/6		0.95%	1.33[0.43,4.13]
Subtotal (95% CI)	435	436	•	100%	0.96[0.84,1.1]
Total events: 206 (Monotherapy), 2	12 (Combination thera	іру)			
Heterogeneity: Tau²=0; Chi²=7.29, d	f=8(P=0.51); I ² =0%				
Test for overall effect: Z=0.53(P=0.6)				
	Favo	ours monotherapy	0.1 0.2 0.5 1 2 5	¹⁰ Favours combinatio	n

Comparison 10. Monotherapy

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 All cause mortality	43		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.1 ceftazidime monotherapy	10	1868	Risk Ratio (M-H, Fixed, 95% CI)	0.89 [0.70, 1.14]
1.2 imipenem monotherapy	9	1164	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.68, 1.50]
1.3 meropenem monothera- py	9	1921	Risk Ratio (M-H, Fixed, 95% CI)	1.14 [0.77, 1.69]
1.4 moxalactam monothera- py	2	140	Risk Ratio (M-H, Fixed, 95% CI)	0.52 [0.26, 1.06]
1.5 piperacillin-tazobactam monotherapy	5	1093	Risk Ratio (M-H, Fixed, 95% CI)	0.62 [0.40, 0.96]
1.6 cefepime monotherapy	5	802	Risk Ratio (M-H, Fixed, 95% CI)	1.08 [0.61, 1.93]
1.7 other monotherapy	4	320	Risk Ratio (M-H, Fixed, 95% CI)	0.65 [0.19, 2.25]
2 Treatment failure	65		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only

Cochrane Library

Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.1 same BL - ceftazidime	6	647	Risk Ratio (M-H, Fixed, 95% CI)	1.07 [0.94, 1.23]
2.2 same BL - imipenem	1	67	Risk Ratio (M-H, Fixed, 95% CI)	3.05 [0.92, 10.10]
2.3 same BL - piperacillin- tazobactam	3	911	Risk Ratio (M-H, Fixed, 95% CI)	1.04 [0.92, 1.18]
2.4 same BL - cefepime	3	343	Risk Ratio (M-H, Fixed, 95% CI)	1.08 [0.84, 1.39]
2.5 same BL - other monotherapy	1	44	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.30, 2.33]
2.6 different BL - ceftazidime	10	1917	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.89, 1.05]
2.7 different BL - imipenem	14	1964	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.78, 1.01]
2.8 different BL - meropenem	8	1542	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.79, 0.98]
2.9 different BL - moxalactam	5	402	Risk Ratio (M-H, Fixed, 95% CI)	0.77 [0.60, 0.99]
2.10 different BL - piperacillin-tazobactam	2	203	Risk Ratio (M-H, Fixed, 95% CI)	0.74 [0.53, 1.02]
2.11 different BL - cefepime	5	377	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.77, 1.22]
2.12 different BL - other	7	575	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.83, 1.28]

Analysis 10.1. Comparison 10 Monotherapy, Outcome 1 All cause mortality.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
10.1.1 ceftazidime monotherapy					
De Pauw 1994	69/488	75/480		63.51%	0.9[0.67,1.22]
Doyen 1983	8/50	9/54		7.27%	0.96[0.4,2.29]
Gibson 1989	3/52	5/50		4.28%	0.58[0.15,2.29]
Kinsey 1990	2/77	7/83	<	5.66%	0.31[0.07,1.44]
Morgan 1983	1/26	3/24	◀	2.62%	0.31[0.03,2.76]
Novakova 1990	5/46	6/44		5.15%	0.8[0.26,2.42]
Novakova 1991	5/45	5/45		4.2%	1[0.31,3.22]
Papachristodoulou 96	1/35	1/42	•	0.76%	1.2[0.08,18.5]
Piguet 1988	7/82	7/87		5.71%	1.06[0.39,2.89]
Rodjer 1987	5/29	1/29		0.84%	5[0.62,40.2]
Subtotal (95% CI)	930	938	•	100%	0.89[0.7,1.14]
Total events: 106 (Monotherapy), 1	19 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =6.02, o	lf=9(P=0.74); l ² =0%				
Test for overall effect: Z=0.94(P=0.3	5)				
10.1.2 imipenem monotherapy					
Ahmed 2007	2/63	3/66		6.69%	0.7[0.12,4.04]



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Dincol 1998	3/78	2/72		4.75%	1.38[0.24,8.0
Leyland 1992	14/106	11/110		24.65%	1.32[0.63,2.7
Lieschke 1990	13/90	10/92		22.59%	1.33[0.61,2.8
Matsui 1991	0/51	0/50			Not estimab
Miller 1993	2/45	2/41 -	+	4.78%	0.91[0.13,6.1
Norrby 1987	7/105	12/105		27.4%	0.58[0.24,1.4
Ozyilkan 1999	0/15	0/15			Not estimab
Perez 1995	3/30	4/30	•	9.13%	0.75[0.18,3.0
Subtotal (95% CI)	583	581	•	100%	1.01[0.68,1.
Total events: 44 (Monotherapy), 44	4 (Combination therapy)				
Heterogeneity: Tau ² =0; Chi ² =2.92,	df=6(P=0.82); I ² =0%				
Test for overall effect: Z=0.05(P=0.	96)				
10.1.3 meropenem monotherap	y				
Agaoglu 2001	2/30	0/57		0.78%	9.35[0.46,188.8
Akova 1999	1/40	0/43 -		1.09%	3.22[0.13,76.8
Behre 1998	2/35	4/36	• · · · · · · · · · · · · · · · · · · ·	8.89%	0.51[0.1,2.6
Cometta 1996	24/483	22/475		49.98%	1.07[0.61,1.8
Cornely 2001	15/202	9/198		20.48%	1.63[0.73,3.6
De la Camara 1997	1/52	3/51	+	6.83%	0.33[0.04,3.0
Duzova 2001	0/45	2/45		5.63%	0.2[0.01,4.0
Hense 2000	6/61	2/26		6.32%	1.28[0.28,5.9
Kliasova 2001	0/22	0/20			Not estimat
Subtotal (95% CI)	970	951	•	100%	1.14[0.77,1.6
Total events: 51 (Monotherapy), 42	2 (Combination therapy)				- /
Heterogeneity: Tau ² =0; Chi ² =6.54,					
Test for overall effect: Z=0.65(P=0.					
10.1.4 moxalactam monotherap	у				
Bezwoda 1985	7/29	11/31	_	60.3%	0.68[0.31,1.5
Pickard 1983	2/40	7/40	_	39.7%	0.29[0.06,1.2
Subtotal (95% CI)	69	71		100%	0.52[0.26,1.0
Total events: 9 (Monotherapy), 18	(Combination therapy)				
Heterogeneity: Tau ² =0; Chi ² =1.03,					
Test for overall effect: Z=1.8(P=0.0					
10.1.5 piperacillin-tazobactam n	nonotherapy				
Del Favero 2001	22/364	32/369	— — —	67.63%	0.7[0.41,1.1
Esteve 1997	1/39	2/46		3.91%	0.59[0.06,6.2
Gorschluter 2003	5/56	8/51		17.82%	0.57[0.2,1.6
Hess 1998	1/48	5/48	_	10.64%	0.2[0.02,1.6
Zengin 2011	0/37	0/35			Not estimat
Subtotal (95% CI)	544	549		100%	0.62[0.4,0.9
Total events: 29 (Monotherapy), 4 ⁻		2.15	-	20070	
Heterogeneity: Tau ² =0; Chi ² =1.33,					
Test for overall effect: Z=2.13(P=0.					
10.1.6 cefepime monotherapy					
Cornely 2001	11/202	9/198		43.48%	1.2[0.51,2.8
-				N	
Jimeno 2006	1/23	0/26		2.25%	3.38[0.14,7



Study or subgroup	Monotherapy	Combina- tion therapy			Risk Ra	tio		Weight	Risk Ratio
	n/N	n/N		M-H	, Fixed,	95% CI			M-H, Fixed, 95% CI
Tamura 2004	7/95	5/94		_		•		24.04%	1.39[0.46,4.21]
Wrzesien-Kus 2001	0/19	4/21	-					20.5%	0.12[0.01,2.13]
Subtotal (95% CI)	381	421						100%	1.08[0.61,1.93]
Total events: 21 (Monotherapy), 21 (Combination therapy	I.							
Heterogeneity: Tau ² =0; Chi ² =3.02, df	=4(P=0.55); I ² =0%								
Test for overall effect: Z=0.27(P=0.79)								
10.1.7 other monotherapy									
Conte 1996	1/21	1/19	-		-+		\rightarrow	17.36%	0.9[0.06,13.48]
Petrilli 2003	2/68	3/68						49.59%	0.67[0.12,3.86]
Piccart 1984	1/22	2/22	-				_	33.06%	0.5[0.05,5.12]
Smith 1990	0/47	0/53							Not estimable
Subtotal (95% CI)	158	162						100%	0.65[0.19,2.25]
Total events: 4 (Monotherapy), 6 (Co	mbination therapy)								
Heterogeneity: Tau ² =0; Chi ² =0.11, df	=2(P=0.95); I ² =0%								
Test for overall effect: Z=0.67(P=0.5)									
	Fa	avours treatment	0.1	0.2 0.5	1	2	5 10	Favours control	

Analysis 10.2. Comparison 10 Monotherapy, Outcome 2 Treatment failure.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
10.2.1 same BL - ceftazidime					
Doyen 1983	13/49	11/48		7.41%	1.16[0.58,2.33]
Jacobs 1993	14/46	5/45	+	3.37%	2.74[1.08,6.98]
Kinsey 1990	48/77	59/83		37.85%	0.88[0.7,1.09]
Marie 1991	67/77	50/69	-	35.15%	1.2[1.01,1.42]
Novakova 1991	19/36	18/33	_ -	12.52%	0.97[0.62,1.5]
Papachristodoulou 96	3/39	6/45	+	3.71%	0.58[0.15,2.16]
Subtotal (95% CI)	324	323	•	100%	1.07[0.94,1.23]
Total events: 164 (Monotherapy), 14	19 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =9.86, d	f=5(P=0.08); I ² =49.319	6			
Test for overall effect: Z=1.02(P=0.31	1)				
10.2.2 same BL - imipenem					
Kojima 1994	10/35	3/32		100%	3.05[0.92,10.1]
Subtotal (95% CI)	35	32		100%	3.05[0.92,10.1]
Total events: 10 (Monotherapy), 3 (C	Combination therapy)	1			
Heterogeneity: Not applicable					
Test for overall effect: Z=1.82(P=0.07	7)				
10.2.3 same BL - piperacillin-tazol	bactam				
Del Favero 2001	188/370	188/384		79.88%	1.04[0.9,1.2]
Esteve 1997	23/39	26/46	_ 	10.33%	1.04[0.72,1.5]
Zengin 2011	24/37	22/35	_	9.79%	1.03[0.73,1.46]
Subtotal (95% CI)	446	465	•	100%	1.04[0.92,1.18]
Total events: 235 (Monotherapy), 23	86 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =0, df=2	(P=1); I ² =0%				
	Favo	ours monotherapy	0.1 0.2 0.5 1 2 5 10	Favours combination	n



Cochrane Database of Systematic Reviews

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Test for overall effect: Z=0.58(P	=0.56)				
10.2.4 same BL - cefepime					
Tamura 2002	13/38	29/76	_ -	28.41%	0.9[0.53,1.5
Tamura 2004	47/95	39/94		57.62%	1.19[0.87,1.6
Wrzesien-Kus 2001	9/19	10/21		13.96%	0.99[0.52,1.9
Subtotal (95% CI)	152	191	•	100%	1.08[0.84,1.3
otal events: 69 (Monotherapy), 78 (Combination therapy	()			
leterogeneity: Tau ² =0; Chi ² =0.	92, df=2(P=0.63); I ² =0%				
Test for overall effect: Z=0.61(P	=0.54)				
10.2.5 same BL - other monot	herapy				
Piccart 1984	5/22	6/22		100%	0.83[0.3,2.3
Subtotal (95% CI)	22	22		100%	0.83[0.3,2.3
Fotal events: 5 (Monotherapy),				100 /0	0.00[0.0,2.0
Heterogeneity: Not applicable	a (somemation therapy)				
Test for overall effect: Z=0.35(P	-0.73)				
rest for overall effect: Z=0.35(P	=0.73)				
10.2.6 different BL - ceftazidi					
De Pauw 1983	11/38	24/45	+	4.36%	0.54[0.31,0.
De Pauw 1994	292/488	278/480	••••	55.66%	1.03[0.93,1.
Gibson 1989	16/52	19/50	+	3.85%	0.81[0.47,1.3
Koehler 1990	16/55	19/65	_	3.46%	1[0.57,1.
Morgan 1983	9/26	13/24	— · + – +	2.68%	0.64[0.34,1.
Novakova 1990	18/46	28/44		5.68%	0.61[0.4,0.
Pellegrin 1988	23/71	31/86	+	5.57%	0.9[0.58,1.
Piguet 1988	59/82	63/87	+	12.14%	0.99[0.82,1
Rodjer 1987	5/22	4/23		0.78%	1.31[0.4,4.2
Schuchter 1988	33/65	30/68	_ +	5.82%	1.15[0.8,1.
Subtotal (95% CI)	945	972	•	100%	0.96[0.89,1.0
Fotal events: 482 (Monotherap	y), 509 (Combination thera	ру)			
Heterogeneity: Tau ² =0; Chi ² =13	8.27, df=9(P=0.15); I ² =32.19	%			
Test for overall effect: Z=0.85(P	=0.4)				
10.2.7 different BL - imipener	n				
Ahmed 2007	28/58	23/61	++	7.53%	1.28[0.84,1.9
Au 1994	5/26	9/24	+	3.14%	0.51[0.2,1.
Cornelissen 1992	4/47	12/47		4.03%	0.33[0.12,0.
Dincol 1998	17/78	15/72	- _	5.24%	1.05[0.57,1.
Erjavec 1994	38/94	49/85		17.28%	0.7[0.52,0.
eyland 1992	48/106	52/110	-	17.14%	0.96[0.72,1.3
ieschke 1990	19/90	18/92	+	5.98%	1.08[0.61,1.
iu 1989	1/10	3/17		0.75%	0.57[0.07,4.
Matsui 1991	9/51	10/50		3.39%	0.88[0.39,1.1
Miller 1993	25/45	20/41	_ +	7.03%	1.14[0.76,1.]
Norrby 1987	35/105	46/105	_ +	15.45%	0.76[0.54,1.0
Ozyilkan 1999	6/15	6/15		2.01%	1[0.42,2
Perez 1995	14/30	19/30	_	6.38%	0.74[0.46,1.
Wade 1987	16/228	14/232	 	4.66%	1.16[0.58,2.
Subtotal (95% CI)	983	981		100%	0.88[0.78,1.0
	y), 296 (Combination thera		•	20070	



Cochrane Database of Systematic Reviews

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
Heterogeneity: Tau ² =0; Chi ² =14.44,	df=13(P=0.34); I ² =9.98	%			
Test for overall effect: Z=1.86(P=0.0	6)				
10.2.8 different BL - meropenem					
Agaoglu 2001	8/30	12/57	— <u></u>	2.25%	1.27[0.58,2.7
Akova 1999	13/40	28/43	_	7.34%	0.5[0.3,0.8
Behre 1998	15/34	17/37		4.43%	0.96[0.57,1.6
Cometta 1996	213/483	230/475	—	63.08%	0.91[0.79,1.0
De la Camara 1997	29/46	30/47	_	8.07%	0.99[0.73,1.3
Duzova 2001	11/45	16/45	+	4.35%	0.69[0.36,1.3
Hense 2000	33/58	16/26	+	6.01%	0.92[0.63,1.3
Hung 2003	11/39	16/37	+	4.47%	0.65[0.35,1.2
Subtotal (95% CI)	775	767	•	100%	0.88[0.79,0.9
Fotal events: 333 (Monotherapy), 3	65 (Combination thera	іру)			
Heterogeneity: Tau ² =0; Chi ² =8.27, d	lf=7(P=0.31); l ² =15.349	6			
Test for overall effect: Z=2.36(P=0.0	2)				
10.2.9 different BL - moxalactam					
Alanis 1983	20/46	27/48	_ _	30.04%	0.77[0.51,1.1
Bezwoda 1985	8/29	11/31		12.09%	0.78[0.36,1.
Hansen 1986	4/14	9/19	+	8.68%	0.6[0.23,1.
Pegram 1984	, 21/72	20/68		23.39%	0.99[0.59,1.
Pickard 1983	14/37	23/38	_ _	25.8%	0.63[0.38,1.
Subtotal (95% CI)	198	204	•	100%	0.77[0.6,0.9
Fotal events: 67 (Monotherapy), 90					
Heterogeneity: Tau ² =0; Chi ² =1.89, d					
Test for overall effect: Z=2.06(P=0.0					
10.2.10 different BL - piperacillin	-tazobactam				
Gorschluter 2003	25/56	35/51		82.08%	0.65[0.46,0.9
Hess 1998	9/48	8/48	—	17.92%	1.13[0.47,2.0
Subtotal (95% CI)	104	99		100%	0.74[0.53,1.0
Total events: 34 (Monotherapy), 43			-		
Heterogeneity: Tau ² =0; Chi ² =1.41, d					
Test for overall effect: Z=1.83(P=0.0					
10.2.11 different BL - cefepime					
Borbolla 2001	2/20	3/20		3.91%	0.67[0.12,3.
Corapcioglu 2005	12/25	15/25	_	19.57%	0.8[0.48,1.
Jimeno 2006	16/24	23/27		28.25%	0.78[0.57,1.4
Pereira 2009	26/62	20/63	- 	25.89%	1.32[0.83,2
Yamamura 1997	17/56	20/63		25.89%	0.98[0.56,1.]
Subtotal (95% CI)	17/56 187	17/55 190	↓	22.38% 100%	0.98[0.56,1. 0.97[0.77,1.2
			T	100%0	0.91[0.11,1.2
Fotal events: 73 (Monotherapy), 78 Heterogeneity: Tau ² =0; Chi ² =4.05, d		"			
Test for overall effect: Z=0.3(P=0.77)					
10 2 12 difforment BL athen					
10.2.12 different BL - other Conte 1996	10/21	8/19		8.46%	1.13[0.57,2.
El Haddad 1995 Gribble 1983	7/30	9/16		11.83%	0.41[0.19,0
	2/12	3/18		2.42%	1[0.2,5.



Study or subgroup	Monotherapy	Combina- tion therapy		Ris	sk Rat	io			Weight	Risk Ratio
	n/N	n/N		M-H, Fi	ixed, 9	5% CI				M-H, Fixed, 95% Cl
Petrilli 2003	20/68	13/68			+	•			13.1%	1.54[0.83,2.84]
Rodriguez 1995	15/64	22/72			•+-				20.86%	0.77[0.44,1.35]
Smith 1990	24/47	21/53			+•				19.89%	1.29[0.83,1.99]
Yildirim 2008	26/46	22/41				-			23.44%	1.05[0.72,1.54]
Subtotal (95% CI)	288	287			+				100%	1.03[0.83,1.28]
Total events: 104 (Monothera	py), 98 (Combination therap	y)								
Heterogeneity: Tau ² =0; Chi ² =	9.04, df=6(P=0.17); I ² =33.6%									
Test for overall effect: Z=0.3(F	P=0.76)									
	Favo	ours monotherapy	0.1 0.2	0.5	1	2	5	10	Favours combination	

Comparison 11. Adults vs. children

Outcome or subgroup ti- tle	No. of studies	No. of partici- pants	Statistical method	Effect size
1 All cause mortality	44	7186	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.75, 1.02]
1.1 children	9	789	Risk Ratio (M-H, Fixed, 95% CI)	0.80 [0.39, 1.64]
1.2 mixed/ undefined	6	2089	Risk Ratio (M-H, Fixed, 95% CI)	0.74 [0.52, 1.04]
1.3 adults	29	4308	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.77, 1.12]
2 Treatment failure	68		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 same BL - children	2	163	Risk Ratio (M-H, Fixed, 95% CI)	1.34 [0.95, 1.90]
2.2 same BL - mixed	3	985	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.90, 1.14]
2.3 same BL - adults	11	1685	Risk Ratio (M-H, Fixed, 95% CI)	1.17 [1.04, 1.32]
2.4 different BL - children	12	1086	Risk Ratio (M-H, Fixed, 95% CI)	1.02 [0.87, 1.18]
2.5 different BL - mixed/ undefined	11	2263	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.83, 1.04]
2.6 different BL - adults	29	4160	Risk Ratio (M-H, Fixed, 95% CI)	0.90 [0.85, 0.96]

Analysis 11.1. Comparison 11 Adults vs. children, Outcome 1 All cause mortality.

Study or subgroup	Monotherapy	Combina- tion therapy			Ri	sk Ra	tio			Weight	Risk Ratio
	n/N	n/N			М-Н, Р	ixed,	95% CI				M-H, Fixed, 95% Cl
11.1.1 children											
Agaoglu 2001	2/30	0/57				_			→	0.12%	9.35[0.46,188.82]
Ahmed 2007	2/63	3/66	_			-				0.99%	0.7[0.12,4.04]
Duzova 2001	0/45	2/45	╉	•				— .		0.85%	0.2[0.01,4.05]
	I	avours treatment	0.1	0.2	0.5	1	2	5	10	Favours control	



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Hung 2003	2/39	3/37	· · · · · · · · · · · · · · · · · · ·	1.04%	0.63[0.11,3.5
Jimeno 2006	1/23	0/26	· · · · · · · · · · · · · · · · · · ·	0.16%	3.38[0.14,7
Morgan 1983	1/26	3/24	← +	1.05%	0.31[0.03,2.7
Petrilli 2003	2/68	3/68		1.01%	0.67[0.12,3.8
Smith 1990	0/47	0/53			Not estimab
Zengin 2011	0/37	0/35			Not estimab
Subtotal (95% CI)	378	411		5.22%	0.8[0.39,1.6
Total events: 10 (Monotherap	y), 14 (Combination therapy)			
Heterogeneity: Tau ² =0; Chi ² =5	5.05, df=6(P=0.54); I ² =0%				
Test for overall effect: Z=0.62(P=0.53)				
11.1.2 mixed/ undefined					
Cometta 1996	24/483	22/475	+	7.5%	1.07[0.61,1.8
Conte 1996	1/21	1/19	← →	0.35%	0.9[0.06,13.4
Del Favero 2001	22/364	32/369	+	10.74%	0.7[0.41,1.1
Gibson 1989	3/52	5/50		1.72%	0.58[0.15,2.2
Hess 1998	1/48	5/48		1.69%	0.2[0.02,1.6
Kinsey 1990	2/77	7/83	↓ ↓	2.28%	0.31[0.07,1.4
Subtotal (95% CI)	1045	1044	-	24.29%	0.74[0.52,1.0
Fotal events: 53 (Monotherap	y), 72 (Combination therapy)			
Heterogeneity: Tau ² =0; Chi ² =4	1.59, df=5(P=0.47); I ² =0%				
Test for overall effect: Z=1.74(P=0.08)				
11.1.3 adults					
Akova 1999	1/40	0/43		0.16%	3.22[0.13,76.8
3ehre 1998	2/35	4/36		1.33%	0.51[0.1,2.6
Bezwoda 1985	7/29	11/31	+	3.59%	0.68[0.31,1.5
Cornely 2001	26/404	9/198	_	4.08%	1.42[0.68,2.9
De la Camara 1997	1/52	3/51	← → → → → → → → → → → → → → → → → → → →	1.02%	0.33[0.04,3.0
De Pauw 1994	69/488	75/480	`_ _	25.57%	0.9[0.67,1.2
Dincol 1998	3/78	2/72		0.7%	1.38[0.24,8.0
Doyen 1983	8/50	9/54		2.93%	0.96[0.4,2.2
Esteve 1997	1/39	2/46	↓	0.62%	0.59[0.06,6.2
Gorschluter 2003	5/56	8/51	·	2.83%	0.57[0.2,1.6
Hense 2000	6/61	2/26	_	0.95%	1.28[0.28,5.9
Kliasova 2001	0/22	0/20			Not estimat
_eyland 1992	14/106	11/110	+	3.65%	1.32[0.63,2.7
_ieschke 1990	13/90	10/92	+	3.34%	1.33[0.61,2.8
Matsui 1991	0/51	0/50			Not estimat
Miller 1993	2/45	2/41	_	0.71%	0.91[0.13,6.1
Norrby 1987	7/105	12/105	_	4.06%	0.58[0.24,1.4
Novakova 1990	5/46	6/44		2.07%	0.8[0.26,2.4
Novakova 1990 Novakova 1991	5/45	5/45		1.69%	1[0.31,3.2
Dzyilkan 1999	0/15	0/15		1.0070	Not estimat
Papachristodoulou 96	1/35	1/42	4	0.31%	1.2[0.08,18
Perez 1995	3/30	4/30		1.35%	0.75[0.18,3.0
Piccart 1984	1/22	2/22		0.68%	0.5[0.05,5.1
Pickard 1983	2/40	7/40		2.37%	0.29[0.06,1.2
Piguet 1988	7/82	7/87		2.3%	1.06[0.39,2.8
Rodjer 1987	5/29	1/29		0.34%	5[0.62,40
Tamura 2002	2/42	3/82	· · ·	0.69%	1.3[0.23,7.4



Study or subgroup	Monotherapy	Combina- tion therapy			Risk	Ratio				Weight	Risk Ratio
	n/N	n/N		м	I-H, Fixe	ed, 95	% CI				M-H, Fixed, 95% Cl
Tamura 2004	7/95	5/94				+ +		_		1.7%	1.39[0.46,4.21]
Wrzesien-Kus 2001	0/19	4/21	-							1.45%	0.12[0.01,2.13]
Subtotal (95% CI)	2251	2057			•					70.49%	0.93[0.77,1.12]
Total events: 203 (Monothera	py), 205 (Combination thera	py)									
Heterogeneity: Tau ² =0; Chi ² =3	15.85, df=25(P=0.92); I ² =0%										
Test for overall effect: Z=0.79((P=0.43)										
Total (95% CI)	3674	3512			•					100%	0.87[0.75,1.02]
Total events: 266 (Monothera	py), 291 (Combination thera	py)									
Heterogeneity: Tau ² =0; Chi ² =2	26.67, df=38(P=0.92); I ² =0%										
Test for overall effect: Z=1.65	(P=0.1)										
Test for subgroup differences	: Chi ² =1.42, df=1 (P=0.49), I ² =	0%									
	Fa	avours treatment	0.1	0.2	0.5	1	2	5	10	Favours control	

Analysis 11.2. Comparison 11 Adults vs. children, Outcome 2 Treatment failure.

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
11.2.1 same BL - children					
Jacobs 1993	14/46	5/45		18.27%	2.74[1.08,6.98]
Zengin 2011	24/37	22/35		81.73%	1.03[0.73,1.46]
Subtotal (95% CI)	83	80	•	100%	1.34[0.95,1.9]
Total events: 38 (Monotherapy), 27	7 (Combination therapy	/)			
Heterogeneity: Tau ² =0; Chi ² =4.44,	df=1(P=0.04); I ² =77.499	6			
Test for overall effect: Z=1.66(P=0.3	1)				
11.2.2 same BL - mixed					
Del Favero 2001	188/370	188/384	÷-	72.89%	1.04[0.9,1.2]
Kiehl 2001	14/35	12/36		4.67%	1.2[0.65,2.22]
Kinsey 1990	48/77	59/83		22.43%	0.88[0.7,1.09]
Subtotal (95% CI)	482	503	•	100%	1.01[0.9,1.14]
Total events: 250 (Monotherapy), 2	259 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =2, df=	2(P=0.37); I ² =0.01%				
Test for overall effect: Z=0.15(P=0.8	88)				
11.2.3 same BL - adults					
Doyen 1983	13/49	11/48		3.85%	1.16[0.58,2.33]
Esteve 1997	23/39	26/46	_ +	8.25%	1.04[0.72,1.5]
Kojima 1994	10/35	3/32		1.08%	3.05[0.92,10.1]
Marie 1991	67/77	50/69		18.25%	1.2[1.01,1.42]
Novakova 1991	19/36	18/33	+	6.5%	0.97[0.62,1.5]
Papachristodoulou 96	3/39	6/45		1.93%	0.58[0.15,2.16]
Piccart 1984	5/22	6/22	+	2.08%	0.83[0.3,2.33]
Rolston 1992	130/378	99/372		34.53%	1.29[1.04,1.61]
Tamura 2002	13/38	29/76	+	6.69%	0.9[0.53,1.52]
Tamura 2004	47/95	39/94	+	13.56%	1.19[0.87,1.63]
Wrzesien-Kus 2001	9/19	10/21		3.29%	0.99[0.52,1.91]
Subtotal (95% CI)	827	858	♦	100%	1.17[1.04,1.32]
	Favo	ours monotherapy 0.1	L 0.2 0.5 1 2 5 1	¹⁰ Favours combination	n



Cochrane Database of Systematic Reviews

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
Γotal events: 339 (Monothera	py), 297 (Combination ther	ару)			
Heterogeneity: Tau ² =0; Chi ² =7	7.21, df=10(P=0.71); I ² =0%				
Test for overall effect: Z=2.7(P	2=0.01)				
11.2.4 different BL - childrei	n				
Agaoglu 2001	8/30	12/57		4.21%	1.27[0.58,2.7
Ahmed 2007	28/58	23/61	++	11.4%	1.28[0.84,1.9
Corapcioglu 2005	12/25	15/25	+	7.63%	0.8[0.48,1.3
Duzova 2001	11/45	16/45	+	8.14%	0.69[0.36,1.3
El Haddad 1995	7/30	9/16		5.97%	0.41[0.19,0
Hung 2003	11/39	16/37		8.35%	0.65[0.35,1.2
Koehler 1990	16/55	19/65	+	8.86%	1[0.57,1.7
Morgan 1983	9/26	13/24		6.88%	0.64[0.34,1.2
Pereira 2009	26/62	20/63	++	10.09%	1.32[0.83,2
Petrilli 2003	20/68	13/68	++	6.61%	1.54[0.83,2.8
Smith 1990	24/47	21/53	++	10.04%	1.29[0.83,1.9
Yildirim 2008	26/46	22/41	+	11.83%	1.05[0.72,1.5
Subtotal (95% CI)	531	555		100%	1.02[0.87,1.1
Total events: 198 (Monothera	py), 199 (Combination ther	ару)			
Heterogeneity: Tau ² =0; Chi ² =1	16.89, df=11(P=0.11); l ² =34.8	38%			
Test for overall effect: Z=0.21((P=0.83)				
L1.2.5 different BL - mixed/	undefined				
Alanis 1983	20/46	27/48	+ _	6.85%	0.77[0.51,1.1
Au 1994	5/26	9/24	ŧ	2.43%	0.51[0.2,1.3
Borbolla 2001	2/20	3/20 -	e	0.78%	0.67[0.12,3.5
Cometta 1996	213/483	230/475		60.11%	0.91[0.79,1.0
Conte 1996	10/21	8/19	·	2.18%	1.13[0.57,2.2
Dincol 1998	17/78	15/72		4.04%	1.05[0.57,1.9
Gibson 1989	16/52	19/50		5.02%	0.81[0.47,1.3
Hess 1998	9/48	8/48		2.07%	1.13[0.47,2.6
Pegram 1984	21/72	20/68		5.33%	0.99[0.59,1.6
Schuchter 1988	33/65	30/68	_ +	7.6%	1.15[0.8,1.6
Wade 1987	16/228	14/232	+	3.6%	1.16[0.58,2.3
Subtotal (95% CI)	1139	1124	•	100%	0.93[0.83,1.0
Fotal events: 362 (Monothera					
Heterogeneity: Tau ² =0; Chi ² =5		1.57			
Test for overall effect: Z=1.27(
L1.2.6 different BL - adults					
Akova 1999	13/40	28/43	<u> </u>	2.65%	0.5[0.3,0.8
Behre 1998	15/34	17/37	<u> </u>	1.6%	0.96[0.57,1.6
Bezwoda 1985	8/29	11/31	ı	1.04%	0.78[0.36,1.6
Cornelissen 1992	4/47	12/47 —		1.18%	0.33[0.12,0.9
Cornely 2001	193/353	92/176	- + -	12.06%	1.05[0.88,1.2
De la Camara 1997	29/46	30/47	\rightarrow	2.92%	0.99[0.73,1.3
De Pauw 1983	11/38	24/45		2.16%	0.54[0.31,0.9
De Pauw 1994	292/488	278/480	Ļ	27.54%	1.03[0.93,1.1
	38/94	49/85		5.06%	0.7[0.52,0.9
Eriavec 1994				5.0070	0.1 [0.02,0.
Erjavec 1994 Gorschluter 2003	25/56	35/51	<u> </u>	3.6%	0.65[0.46,0.9



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
Hansen 1986	4/14	9/19		0.75%	0.6[0.23,1.57
Hense 2000	33/58	16/26	—	2.17%	0.92[0.63,1.35
Jimeno 2006	16/24	23/27	—+ 	2.13%	0.78[0.57,1.08
Leyland 1992	48/106	52/110	+	5.01%	0.96[0.72,1.28
Lieschke 1990	19/90	18/92		1.75%	1.08[0.61,1.92
Liu 1989	1/10	3/17	•	0.22%	0.57[0.07,4.74
Matsui 1991	9/51	10/50		0.99%	0.88[0.39,1.99
Miller 1993	25/45	20/41	++	2.06%	1.14[0.76,1.71
Norrby 1987	35/105	46/105	-+ +	4.52%	0.76[0.54,1.08
Novakova 1990	18/46	28/44	<u> </u>	2.81%	0.61[0.4,0.94
Ozyilkan 1999	6/15	6/15		0.59%	1[0.42,2.4
Pellegrin 1988	23/71	31/86		2.75%	0.9[0.58,1.39
Perez 1995	14/30	19/30	— + —	1.87%	0.74[0.46,1.18
Pickard 1983	14/37	23/38		2.23%	0.63[0.38,1.02
Piguet 1988	59/82	63/87	-+-	6.01%	0.99[0.82,1.2
Rodjer 1987	5/22	4/23		0.38%	1.31[0.4,4.24
Rodriguez 1995	15/64	22/72	+	2.03%	0.77[0.44,1.35
Yamamura 1997	17/56	17/55		1.69%	0.98[0.56,1.72
Subtotal (95% CI)	2163	1997	•	100%	0.9[0.85,0.96
Total events: 991 (Monotherapy), 9	989 (Combination ther	ару)			
Heterogeneity: Tau ² =0; Chi ² =40.07	, df=28(P=0.07); l ² =30.1	11%			
Test for overall effect: Z=3.26(P=0)					

Comparison 12. Sensitivity analysis (outcome in parenthesis)

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Allocation concealment (mor- tality)	44	7186	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.75, 1.02]
1.1 A	24	5489	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.73, 1.05]
1.2 B	19	1625	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.61, 1.24]
1.3 C	1	72	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Intention-to-treat vs. efficacy analysis (mortality)	44	7186	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.75, 1.02]
2.1 efficacy analysis	20	4432	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.73, 1.06]
2.2 intention-to-treat analysis	24	2754	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.66, 1.15]
3 Unit of randomisation (mortal- ity)	44	7186	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.75, 1.02]
3.1 patient analysis	19	3711	Risk Ratio (M-H, Fixed, 95% CI)	0.84 [0.66, 1.08]
3.2 episode analysis	25	3475	Risk Ratio (M-H, Fixed, 95% CI)	0.90 [0.73, 1.11]

Cochrane Library

Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
4 Publication status (mortality)	43	7110	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.75, 1.03]
4.1 jounal publication	34	5811	Risk Ratio (M-H, Fixed, 95% CI)	0.84 [0.71, 1.00]
4.2 other publication or un-pub- lished	9	1299	Risk Ratio (M-H, Fixed, 95% CI)	1.07 [0.72, 1.59]
5 Trial size (mortality)	44	7186	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.75, 1.02]
5.1 number randomised>median 94p	19	5438	Risk Ratio (M-H, Fixed, 95% CI)	0.90 [0.75, 1.07]
5.2 number randomised <median 94p</median 	25	1748	Risk Ratio (M-H, Fixed, 95% CI)	0.78 [0.55, 1.11]
6 Allocation concealment (fail- ure)	69	10357	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.93, 1.01]
6.1 same beta-lactam - A	6	1310	Risk Ratio (M-H, Fixed, 95% CI)	1.10 [0.99, 1.22]
6.2 same beta-lactam - B	9	1451	Risk Ratio (M-H, Fixed, 95% CI)	1.13 [0.99, 1.30]
6.3 same beta-lactam - C	1	72	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.73, 1.46]
6.4 different beta-lactam - A	21	4422	Risk Ratio (M-H, Fixed, 95% CI)	0.94 [0.88, 1.00]
6.5 different beta-lactam - B	31	3052	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.79, 0.96]
6.6 different beta-lactam - C	1	50	Risk Ratio (M-H, Fixed, 95% CI)	0.8 [0.48, 1.34]
7 Intention to treat vs. efficacy analysis (failure)	70		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
7.1 same BL - efficacy analysis	12	1884	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.98, 1.26]
7.2 same BL - ITT analysis	4	949	Risk Ratio (M-H, Random, 95% CI)	1.04 [0.91, 1.19]
7.3 different BL - efficacy analy- sis	38	6010	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.88, 1.01]
7.4 different BL - ITT analysis	16	1659	Risk Ratio (M-H, Random, 95% CI)	0.80 [0.71, 0.91]
8 Intention to treat vs. effica- cy analysis, assuming dropout- s=failures (failure)	68		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
8.1 same BL - efficacy analysis	5	1238	Risk Ratio (M-H, Fixed, 95% CI)	1.15 [1.02, 1.29]
8.2 same BL - ITT analysis	10	1590	Risk Ratio (M-H, Fixed, 95% CI)	1.07 [0.96, 1.19]
8.3 different BL - efficacy analy- sis	20	3037	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.89, 1.04]

Cochrane Library

Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
8.4 different BL - ITT analysis	33	4922	Risk Ratio (M-H, Fixed, 95% CI)	0.92 [0.86, 0.97]
9 Trial size (failure)	70		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
9.1 same BL no. ran- domised>median	7	2210	Risk Ratio (M-H, Fixed, 95% CI)	1.10 [1.01, 1.21]
9.2 same BL no. ran- domised <median< td=""><td>9</td><td>623</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>1.14 [0.94, 1.39]</td></median<>	9	623	Risk Ratio (M-H, Fixed, 95% CI)	1.14 [0.94, 1.39]
9.3 different BL no. ran- domised>median	28	6032	Risk Ratio (M-H, Fixed, 95% CI)	0.98 [0.92, 1.03]
9.4 different BL no. ran- domised <median< td=""><td>26</td><td>1637</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.75 [0.67, 0.84]</td></median<>	26	1637	Risk Ratio (M-H, Fixed, 95% CI)	0.75 [0.67, 0.84]
10 Unit of randomisation (fail- ure)	71		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
10.1 same beta-lactam - patient	6	1212	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.93, 1.19]
10.2 same beta-lactam - episode	10	1621	Risk Ratio (M-H, Fixed, 95% CI)	1.16 [1.04, 1.30]
10.3 different beta-lactam - pa- tient	20	3137	Risk Ratio (M-H, Fixed, 95% CI)	0.89 [0.82, 0.96]
10.4 different beta-lactam - episode	36	4656	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.89, 1.01]
11 Blinding (failure)	71		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
11.1 same beta-lactam - double blind	1	754	Risk Ratio (M-H, Fixed, 95% CI)	1.04 [0.90, 1.20]
11.2 same beta-lactam - other	15	2079	Risk Ratio (M-H, Fixed, 95% CI)	1.14 [1.04, 1.26]
11.3 different beta-lactam - dou- ble blind	3	623	Risk Ratio (M-H, Fixed, 95% CI)	1.14 [0.83, 1.55]
11.4 different beta-lactam - oth- er	52	7113	Risk Ratio (M-H, Fixed, 95% CI)	0.92 [0.87, 0.96]
12 Publication status (failure)	71		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
12.1 same beta-lactam - journal publication	12	2496	Risk Ratio (M-H, Fixed, 95% CI)	1.12 [1.02, 1.21]
12.2 same beta-lactam - other	4	337	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.79, 1.41]
12.3 different beta-lactam - jour- nal publication	44	5866	Risk Ratio (M-H, Fixed, 95% CI)	0.90 [0.86, 0.96]
12.4 different beta-lactam - oth- er	11	1870	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.89, 1.12]

Analysis 12.1. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 1 Allocation concealment (mortality).

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
12.1.1 A					
Ahmed 2007	2/63	3/66		0.99%	0.7[0.12,4.04]
Akova 1999	1/40	0/43		0.16%	3.22[0.13,76.82]
Behre 1998	2/35	4/36		1.33%	0.51[0.1,2.63]
Cometta 1996	24/483	22/475		7.5%	1.07[0.61,1.89]
Cornely 2001	26/404	9/198		4.08%	1.42[0.68,2.96]
De la Camara 1997	1/52	3/51		1.02%	0.33[0.04,3.04]
De Pauw 1994	69/488	75/480		25.57%	0.9[0.67,1.22]
Del Favero 2001	22/364	32/369	+	10.74%	0.7[0.41,1.18]
Gibson 1989	3/52	5/50		1.72%	0.58[0.15,2.29]
Gorschluter 2003	5/56	8/51	+	2.83%	0.57[0.2,1.63]
Hess 1998	1/48	5/48	↓	1.69%	0.2[0.02,1.65]
Jimeno 2006	1/23	0/26		0.16%	3.38[0.14,79]
Leyland 1992	14/106	11/110		3.65%	1.32[0.63,2.78]
Lieschke 1990	13/90	10/92		3.34%	1.33[0.61,2.87]
Matsui 1991	0/51	0/50			Not estimable
Norrby 1987	7/105	12/105		4.06%	0.58[0.24,1.42]
Novakova 1990	5/46	6/44		2.07%	0.8[0.26,2.42]
Novakova 1991	5/45	5/45		1.69%	1[0.31,3.22]
Ozyilkan 1999	0/15	0/15			Not estimable
Petrilli 2003	2/68	3/68		1.01%	0.67[0.12,3.86]
Pickard 1983	2/40	7/40	↓ · · · · · · · · · · · · · · · · · · ·	2.37%	0.29[0.06,1.29]
Tamura 2002	2/42	3/82		0.69%	1.3[0.23,7.49]
Tamura 2004	7/95	5/94		1.7%	1.39[0.46,4.21]
Wrzesien-Kus 2001	0/19	4/21	4	1.45%	0.12[0.01,2.13]
Subtotal (95% CI)	2830	2659	•	79.84%	0.88[0.73,1.05]
Total events: 214 (Monotherapy), 232 (Combination thera	іру)			
Heterogeneity: Tau ² =0; Chi ² =16.	41, df=21(P=0.75); I ² =0%				
Test for overall effect: Z=1.47(P=	:0.14)				
12.1.2 B					
Agaoglu 2001	2/30	0/57		0.12%	9.35[0.46,188.82]
Bezwoda 1985	7/29	11/31		3.59%	0.68[0.31,1.52]
Bezwoda 1985 Conte 1996	7/29 1/21	11/31 1/19	← ← ← ← ← ← ← ← ← ← ← ← ← ← ← ← ← ← ←	3.59% 0.35%	0.68[0.31,1.52] 0.9[0.06,13.48]
Bezwoda 1985 Conte 1996 Dincol 1998	7/29 1/21 3/78	11/31 1/19 2/72	<	3.59% 0.35% 0.7%	0.68[0.31,1.52] 0.9[0.06,13.48] 1.38[0.24,8.05]
Bezwoda 1985 Conte 1996 Dincol 1998 Doyen 1983	7/29 1/21 3/78 8/50	11/31 1/19 2/72 9/54		3.59% 0.35% 0.7% 2.93%	0.68[0.31,1.52] 0.9[0.06,13.48] 1.38[0.24,8.05] 0.96[0.4,2.29]
Bezwoda 1985 Conte 1996 Dincol 1998 Doyen 1983 Duzova 2001	7/29 1/21 3/78 8/50 0/45	11/31 1/19 2/72 9/54 2/45		3.59% 0.35% 0.7% 2.93% 0.85%	0.68[0.31,1.52] 0.9[0.06,13.48] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05]
Bezwoda 1985 Conte 1996 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997	7/29 1/21 3/78 8/50 0/45 1/39	11/31 1/19 2/72 9/54 2/45 2/46		3.59% 0.35% 0.7% 2.93% 0.85% 0.62%	0.68[0.31,1.52] 0.9[0.06,13.48] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26]
Bezwoda 1985 Conte 1996 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hense 2000	7/29 1/21 3/78 8/50 0/45 1/39 6/61	11/31 1/19 2/72 9/54 2/45 2/46 2/26		3.59% 0.35% 0.7% 2.93% 0.85% 0.62% 0.95%	0.68[0.31,1.52] 0.9[0.06,13.48] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 1.28[0.28,5.92]
Bezwoda 1985 Conte 1996 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hense 2000 Hung 2003	7/29 1/21 3/78 8/50 0/45 1/39 6/61 2/39	11/31 1/19 2/72 9/54 2/45 2/46 2/26 3/37		3.59% 0.35% 0.7% 2.93% 0.85% 0.62% 0.95% 1.04%	0.68[0.31,1.52] 0.9[0.06,13.48] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 1.28[0.28,5.92] 0.63[0.11,3.57]
Bezwoda 1985 Conte 1996 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hense 2000 Hung 2003 Kinsey 1990	7/29 1/21 3/78 8/50 0/45 1/39 6/61 2/39 2/77	11/31 1/19 2/72 9/54 2/45 2/46 2/26 3/37 7/83		3.59% 0.35% 0.7% 2.93% 0.85% 0.62% 0.95%	0.68[0.31,1.52] 0.9[0.06,13.48] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 1.28[0.28,5.92] 0.63[0.11,3.57] 0.31[0.07,1.44]
Bezwoda 1985 Conte 1996 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hense 2000 Hung 2003 Kinsey 1990 Kliasova 2001	7/29 1/21 3/78 8/50 0/45 1/39 6/61 2/39 2/77 0/22	11/31 1/19 2/72 9/54 2/45 2/46 2/26 3/37 7/83 0/20		3.59% 0.35% 0.7% 2.93% 0.85% 0.62% 0.95% 1.04% 2.28%	0.68[0.31,1.52] 0.9[0.06,13.48] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 1.28[0.28,5.92] 0.63[0.11,3.57] 0.31[0.07,1.44] Not estimable
Bezwoda 1985 Conte 1996 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hense 2000 Hung 2003 Kinsey 1990	7/29 1/21 3/78 8/50 0/45 1/39 6/61 2/39 2/77 0/22 2/45	11/31 1/19 2/72 9/54 2/45 2/46 2/26 3/37 7/83 0/20 2/41		3.59% 0.35% 0.7% 2.93% 0.85% 0.62% 0.95% 1.04%	0.68[0.31,1.52] 0.9[0.06,13.48] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 1.28[0.28,5.92] 0.63[0.11,3.57] 0.31[0.07,1.44] Not estimable 0.91[0.13,6.18]
Bezwoda 1985 Conte 1996 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hense 2000 Hung 2003 Kinsey 1990 Kliasova 2001 Miller 1993 Morgan 1983	7/29 1/21 3/78 8/50 0/45 1/39 6/61 2/39 2/77 0/22 2/45 1/26	11/31 1/19 2/72 9/54 2/45 2/46 2/26 3/37 7/83 0/20 2/41 3/24		3.59% 0.35% 0.7% 2.93% 0.85% 0.62% 0.95% 1.04% 2.28% 0.71% 1.05%	0.68[0.31,1.52] 0.9[0.06,13.48] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 1.28[0.28,5.92] 0.63[0.11,3.57] 0.31[0.07,1.44] Not estimable 0.91[0.13,6.18] 0.31[0.03,2.76]
Bezwoda 1985 Conte 1996 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hense 2000 Hung 2003 Kinsey 1990 Kliasova 2001 Miller 1993	7/29 1/21 3/78 8/50 0/45 1/39 6/61 2/39 2/77 0/22 2/45	11/31 1/19 2/72 9/54 2/45 2/46 2/26 3/37 7/83 0/20 2/41		3.59% 0.35% 0.7% 2.93% 0.85% 0.62% 0.95% 1.04% 2.28%	0.68[0.31,1.52] 0.9[0.06,13.48] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 1.28[0.28,5.92] 0.63[0.11,3.57] 0.31[0.07,1.44] Not estimable 0.91[0.13,6.18]



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
Piccart 1984	1/22	2/22	•	0.68%	0.5[0.05,5.12]	
Piguet 1988	7/82	7/87		2.3%	1.06[0.39,2.89]	
Rodjer 1987	5/29	1/29		0.34%	5[0.62,40.2]	
Smith 1990	0/47	0/53			Not estimable	
Subtotal (95% CI)	807	818	-	20.16%	0.87[0.61,1.24]	
Total events: 52 (Monotherapy), 59 (Combination therapy)				
Heterogeneity: Tau ² =0; Chi ² =10.25, o	df=16(P=0.85); I ² =0%					
Test for overall effect: Z=0.77(P=0.44	4)					
12.1.3 C						
Zengin 2011	0/37	0/35			Not estimable	
Subtotal (95% CI)	37	35			Not estimable	
Total events: 0 (Monotherapy), 0 (Co	ombination therapy)					
Heterogeneity: Not applicable						
Test for overall effect: Not applicable	e					
Total (95% CI)	3674	3512	•	100%	0.87[0.75,1.02]	
Total events: 266 (Monotherapy), 29	1 (Combination thera	ру)				
Heterogeneity: Tau ² =0; Chi ² =26.67, d	df=38(P=0.92); I ² =0%					
Test for overall effect: Z=1.65(P=0.1)						
Test for subgroup differences: Chi ² =	0, df=1 (P=0.98), l ² =0%	5				
	F	avours treatment 0.1	0.2 0.5 1 2 5	¹⁰ Favours control		

Analysis 12.2. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 2 Intention-to-treat vs. efficacy analysis (mortality).

Study or subgroup	tion therapy		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
12.2.1 efficacy analysis					
Agaoglu 2001	2/30	0/57		0.12%	9.35[0.46,188.82]
Bezwoda 1985	7/29	11/31		3.59%	0.68[0.31,1.52]
Cometta 1996	24/483	22/475		7.5%	1.07[0.61,1.89]
De Pauw 1994	69/488	75/480	_ _ _	25.57%	0.9[0.67,1.22]
Del Favero 2001	22/364	32/369	+	10.74%	0.7[0.41,1.18]
Duzova 2001	0/45	2/45		0.85%	0.2[0.01,4.05]
Esteve 1997	1/39	2/46	•	0.62%	0.59[0.06,6.26]
Gorschluter 2003	5/56	8/51		2.83%	0.57[0.2,1.63]
Hess 1998	1/48	5/48	↓	1.69%	0.2[0.02,1.65]
Hung 2003	2/39	3/37		1.04%	0.63[0.11,3.57]
Kinsey 1990	2/77	7/83	+	2.28%	0.31[0.07,1.44]
Kliasova 2001	0/22	0/20			Not estimable
Leyland 1992	14/106	11/110		3.65%	1.32[0.63,2.78]
Miller 1993	2/45	2/41		0.71%	0.91[0.13,6.18]
Petrilli 2003	2/68	3/68	· · · · · ·	1.01%	0.67[0.12,3.86]
Piccart 1984	1/22	2/22	• •	0.68%	0.5[0.05,5.12]
Piguet 1988	7/82	7/87		2.3%	1.06[0.39,2.89]
Rodjer 1987	5/29	1/29		0.34%	5[0.62,40.2]
Tamura 2004	7/95	5/94	· · · · · · · · · · · · · · · · · · ·	1.7%	1.39[0.46,4.21]
		Favours treatment	0.1 0.2 0.5 1 2 5	¹⁰ Favours control	



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio		
	n/N	n/N	M-H, Fixed, 95% Cl	d, 95% CI			
Zengin 2011	0/37	0/35			Not estimable		
Subtotal (95% CI)	2204	2228	•	67.21%	0.88[0.73,1.06		
Total events: 173 (Monotherapy), 1	98 (Combination thera	ру)					
Heterogeneity: Tau ² =0; Chi ² =14.48,	df=17(P=0.63); I ² =0%						
Test for overall effect: Z=1.33(P=0.1	8)						
12.2.2 intention-to-treat analysis	i						
Ahmed 2007	2/63	3/66 —		0.99%	0.7[0.12,4.04		
Akova 1999	1/40	0/43 -		0.16%	3.22[0.13,76.82		
Behre 1998	2/35	4/36		1.33%	0.51[0.1,2.63		
Conte 1996	1/21	1/19		0.35%	0.9[0.06,13.48		
Cornely 2001	26/404	9/198		4.08%	1.42[0.68,2.96		
De la Camara 1997	1/52	3/51		1.02%	0.33[0.04,3.04		
Dincol 1998	3/78	2/72		- 0.7%	1.38[0.24,8.05		
Doyen 1983	8/50	9/54		2.93%	0.96[0.4,2.29		
Gibson 1989	3/52	5/50	+	1.72%	0.58[0.15,2.29		
Hense 2000	6/61	2/26		0.95%	1.28[0.28,5.92		
Jimeno 2006	1/23	0/26	+	0.16%	3.38[0.14,79		
Lieschke 1990	13/90	10/92		3.34%	1.33[0.61,2.87		
Matsui 1991	0/51	0/50			Not estimabl		
Morgan 1983	1/26	3/24		1.05%	0.31[0.03,2.76		
Norrby 1987	7/105	12/105		4.06%	0.58[0.24,1.42		
Novakova 1990	5/46	6/44		2.07%	0.8[0.26,2.42		
Novakova 1991	5/45	5/45		1.69%	1[0.31,3.22		
Ozyilkan 1999	0/15	0/15			Not estimabl		
Papachristodoulou 96	1/35	1/42	+	0.31%	1.2[0.08,18.5		
Perez 1995	3/30	4/30		1.35%	0.75[0.18,3.07		
Pickard 1983	2/40	7/40		2.37%	0.29[0.06,1.29		
Smith 1990	0/47	0/53			Not estimabl		
Tamura 2002	2/42	3/82		0.69%	1.3[0.23,7.49		
Wrzesien-Kus 2001	0/19	4/21		1.45%	0.12[0.01,2.13		
Subtotal (95% CI)	1470	1284	•	32.79%	0.87[0.66,1.15		
Total events: 93 (Monotherapy), 93							
Heterogeneity: Tau ² =0; Chi ² =12.21,							
Test for overall effect: Z=0.99(P=0.3							
Total (95% CI)	3674	3512	•	100%	0.87[0.75,1.02		
Total events: 266 (Monotherapy), 2	91 (Combination thera				- , , ,		
Heterogeneity: Tau ² =0; Chi ² =26.67,		• • •					
Test for overall effect: Z=1.65(P=0.1							
Test for subgroup differences: Chi ² -		,					

Analysis 12.3. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 3 Unit of randomisation (mortality).

	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI	
12.3.1 patient analysis						
Akova 1999	1/40	0/43		0.16%	3.22[0.13,76.82]	
Behre 1998	2/35	4/36		1.33%	0.51[0.1,2.63]	
Bezwoda 1985	7/29	11/31		3.59%	0.68[0.31,1.52]	
Cometta 1996	24/483	22/475	+	7.5%	1.07[0.61,1.89]	
Cornely 2001	26/404	9/198		4.08%	1.42[0.68,2.96]	
De la Camara 1997	1/52	3/51		1.02%	0.33[0.04,3.04]	
Del Favero 2001	22/364	32/369	+	10.74%	0.7[0.41,1.18]	
Gibson 1989	3/52	5/50		1.72%	0.58[0.15,2.29]	
Gorschluter 2003	5/56	8/51		2.83%	0.57[0.2,1.63]	
Hense 2000	6/61	2/26		0.95%	1.28[0.28,5.92]	
Jimeno 2006	1/23	0/26		0.16%	3.38[0.14,79]	
Kliasova 2001	0/22	0/20			Not estimable	
Norrby 1987	7/105	12/105		4.06%	0.58[0.24,1.42]	
Ozyilkan 1999	0/15	0/15			Not estimable	
Papachristodoulou 96	1/35	1/42	+	0.31%	1.2[0.08,18.5]	
Piccart 1984	1/22	2/22		0.68%	0.5[0.05,5.12]	
Tamura 2002	2/42	3/82		0.69%	1.3[0.23,7.49]	
Tamura 2004	7/95	5/94	I	1.7%	1.39[0.46,4.21]	
Wrzesien-Kus 2001	0/19	4/21		1.45%	0.12[0.01,2.13]	
	1954	1757	•	42.98%	0.84[0.66,1.08]	
Subtotal (95% CI)						
Subtotal (95% CI) Total events: 116 (Monotherapy).		(עמו				
Total events: 116 (Monotherapy),	, 123 (Combination thera	ару)				
	, 123 (Combination thera 3, df=16(P=0.83); I²=0%	іру)				
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6. Test for overall effect: Z=1.37(P=0	, 123 (Combination thera 3, df=16(P=0.83); I²=0%	іру)				
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0 12.3.2 episode analysis	123 (Combination thera 3, df=16(P=0.83); l ² =0% 0.17)			0 12%	9 35[0 46 188 82]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0 12.3.2 episode analysis Agaoglu 2001	123 (Combination thera 3, df=16(P=0.83); l ² =0% 0.17) 2/30	0/57		0.12%	9.35[0.46,188.82] 0.7[0.12.4.04]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007	123 (Combination thera 3, df=16(P=0.83); l ² =0% 0.17) 2/30 2/63	0/57 3/66 —		0.99%	0.7[0.12,4.04]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996	123 (Combination thera 3, df=16(P=0.83); l ² =0% 0.17) 2/30 2/63 1/21	0/57 3/66 - 1/19 (0.99% 0.35%	0.7[0.12,4.04] 0.9[0.06,13.48]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994	123 (Combination thera 3, df=16(P=0.83); l ² =0% .17) 2/30 2/63 1/21 69/488	0/57 3/66 − 1/19 ◀ 75/480		0.99% 0.35% 25.57%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998	123 (Combination thera 3, df=16(P=0.83); l ² =0% 0.17) 2/30 2/63 1/21 69/488 3/78	0/57 3/66 − 1/19 ↓ 75/480 2/72		0.99% 0.35% 25.57% 0.7%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983	123 (Combination thera 3, df=16(P=0.83); l ² =0% 0.17) 2/30 2/63 1/21 69/488 3/78 8/50	0/57 3/66 1/19 75/480 2/72 9/54		0.99% 0.35% 25.57% 0.7% 2.93%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983 Duzova 2001	123 (Combination thera 3, df=16(P=0.83); l ² =0% 0.17) 2/30 2/63 1/21 69/488 3/78 8/50 0/45	0/57 3/66 – 1/19 (75/480 2/72 9/54 2/45 (0.99% 0.35% 25.57% 0.7% 2.93% 0.85%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997	123 (Combination thera 3, df=16(P=0.83); l ² =0% 0.17) 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39	0/57 3/66 – 1/19 (75/480 2/72 9/54 2/45 (2/45		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hess 1998	123 (Combination thera 3, df=16(P=0.83); l ² =0% 0.17) 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39 1/48	0/57 3/66 - 1/19 75/480 2/72 9/54 2/45 2/45 2/46 5/48		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62% 1.69%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 0.2[0.02,1.65]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0) 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hess 1998 Hung 2003	123 (Combination thera 3, df=16(P=0.83); l ² =0% .17) 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39 1/48 2/39	0/57 3/66 - 1/19 75/480 2/72 9/54 2/45 2/45 2/46 5/48 3/37		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62% 1.69% 1.04%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 0.2[0.02,1.65] 0.63[0.11,3.57]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0) 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hess 1998 Hung 2003 Kinsey 1990	123 (Combination thera 3, df=16(P=0.83); l ² =0% 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39 1/48 2/39 2/77	0/57 3/66 1/19 ↓ 75/480 2/72 9/54 2/45 ↓ 2/45 2/46 5/48 ↓ 3/37 7/83 ↓		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62% 1.69% 1.04% 2.28%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 0.2[0.02,1.65] 0.63[0.11,3.57] 0.31[0.07,1.44]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0) 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hess 1998 Hung 2003 Kinsey 1990 Leyland 1992	123 (Combination thera 3, df=16(P=0.83); l ² =0% 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39 1/48 2/39 2/77 14/106	0/57 3/66 1/19 75/480 2/72 9/54 2/45 2/45 2/46 5/48 3/37 7/83 11/110		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62% 1.69% 1.04% 2.28% 3.65%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 0.2[0.02,1.65] 0.63[0.11,3.57] 0.31[0.07,1.44] 1.32[0.63,2.78]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hess 1998 Hung 2003 Kinsey 1990 Leyland 1992 Lieschke 1990	123 (Combination thera 3, df=16(P=0.83); l ² =0% 0.17) 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39 1/48 2/39 2/77 14/106 13/90	0/57 3/66 1/19 75/480 2/72 9/54 2/45 2/45 2/46 5/48 3/37 7/83 11/110 10/92		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62% 1.69% 1.04% 2.28%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 0.2[0.02,1.65] 0.63[0.11,3.57] 0.31[0.07,1.44] 1.32[0.63,2.78] 1.33[0.61,2.87]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hess 1998 Hung 2003 Kinsey 1990 Leyland 1992 Lieschke 1990 Matsui 1991	123 (Combination thera 3, df=16(P=0.83); l ² =0% 0.17) 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39 1/48 2/39 2/77 14/106 13/90 0/51	0/57 3/66 - 1/19 75/480 2/72 9/54 2/45 2/45 2/46 5/48 3/37 7/83 11/110 10/92 0/50		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62% 1.69% 1.04% 2.28% 3.65% 3.34%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 0.2[0.02,1.65] 0.63[0.11,3.57] 0.31[0.07,1.44] 1.32[0.63,2.78] 1.33[0.61,2.87] Not estimable	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0) 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hess 1998 Hung 2003 Kinsey 1990 Leyland 1992 Lieschke 1990 Matsui 1991 Miller 1993	123 (Combination thera 3, df=16(P=0.83); l ² =0% 0.17) 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39 1/48 2/39 2/77 14/106 13/90 0/51 2/45	0/57 3/66 1/19 75/480 2/72 9/54 2/45 2/45 2/46 5/48 3/37 7/83 11/110 10/92 0/50 2/41		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62% 1.69% 1.04% 2.28% 3.65% 3.34%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 0.2[0.02,1.65] 0.63[0.11,3.57] 0.31[0.07,1.44] 1.32[0.63,2.78] 1.33[0.61,2.87] Not estimable 0.91[0.13,6.18]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0) 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hess 1998 Hung 2003 Kinsey 1990 Leyland 1992 Lieschke 1990 Matsui 1991 Miller 1993 Morgan 1983	123 (Combination thera 3, df=16(P=0.83); l ² =0% .17) 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39 1/48 2/39 2/77 14/106 13/90 0/51 2/45 1/26	0/57 3/66 1/19 75/480 2/72 9/54 2/45 2/46 5/48 3/37 7/83 11/110 10/92 0/50 2/41 3/24		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62% 1.69% 1.04% 2.28% 3.65% 3.34% 0.71% 1.05%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 0.2[0.02,1.65] 0.63[0.11,3.57] 0.31[0.07,1.44] 1.32[0.63,2.78] 1.33[0.61,2.87] Not estimable 0.91[0.13,6.18] 0.31[0.03,2.76]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0) 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hess 1998 Hung 2003 Kinsey 1990 Leyland 1992 Lieschke 1990 Matsui 1991 Miller 1993 Morgan 1983 Novakova 1990	123 (Combination thera 3, df=16(P=0.83); l ² =0% .17) 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39 1/48 2/39 2/77 14/106 13/90 0/51 2/45 1/26 5/46	0/57 3/66 1/19 75/480 2/72 9/54 2/45 2/45 2/46 5/48 3/37 7/83 11/110 10/92 0/50 2/41 3/24 6/44		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62% 1.69% 1.04% 2.28% 3.65% 3.34% 0.71% 1.05% 2.07%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 0.2[0.02,1.65] 0.63[0.11,3.57] 0.31[0.07,1.44] 1.32[0.63,2.78] 1.33[0.61,2.87] Not estimable 0.91[0.13,6.18] 0.31[0.03,2.76] 0.8[0.26,2.42]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0) 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hess 1998 Hung 2003 Kinsey 1990 Leyland 1992 Lieschke 1990 Matsui 1991 Miller 1993 Morgan 1983 Novakova 1990	123 (Combination thera 3, df=16(P=0.83); l ² =0% 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39 1/48 2/39 2/77 14/106 13/90 0/51 2/45 1/26 5/46 5/45	0/57 3/66 1/19 75/480 2/72 9/54 2/45 2/46 5/48 3/37 7/83 11/110 10/92 0/50 2/41 3/24 €/44 5/45		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62% 1.69% 1.04% 2.28% 3.65% 3.34% 0.71% 1.05% 2.07% 1.69%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 0.2[0.02,1.65] 0.63[0.11,3.57] 0.31[0.07,1.44] 1.32[0.63,2.78] 1.33[0.61,2.87] Not estimable 0.91[0.13,6.18] 0.31[0.03,2.76] 0.8[0.26,2.42] 1[0.31,3.22]	
Total events: 116 (Monotherapy), Heterogeneity: Tau²=0; Chi²=10.6; Test for overall effect: Z=1.37(P=0) 12.3.2 episode analysis Agaoglu 2001Ahmed 2007Conte 1996De Pauw 1994Dincol 1998Doyen 1983Duzova 2001Esteve 1997Hess 1998Hung 2003Kinsey 1990Leyland 1992Lieschke 1990Matsui 1991Miller 1993Novakova 1990Novakova 1991Perez 1995	123 (Combination thera 3, df=16(P=0.83); l ² =0% 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39 1/48 2/39 2/77 14/106 13/90 0/51 2/45 1/26 5/46 5/45 3/30	0/57 3/66 - 1/19 75/480 2/72 9/54 2/45 2/46 5/48 3/37 - 7/83 11/110 10/92 0/50 2/41 - 3/24 6/44 5/45 4/30		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62% 1.69% 1.04% 2.28% 3.65% 3.34% 0.71% 1.05% 2.07% 1.69% 1.35%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 0.2[0.02,1.65] 0.63[0.11,3.57] 0.31[0.07,1.44] 1.32[0.63,2.78] 1.33[0.61,2.87] Not estimable 0.91[0.13,6.18] 0.31[0.03,2.76] 0.8[0.26,2.42] 1[0.31,3.22] 0.75[0.18,3.07]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6; Test for overall effect: Z=1.37(P=0) 12.3.2 episode analysis Agaoglu 2001Ahmed 2007Conte 1996De Pauw 1994Dincol 1998Doyen 1983Duzova 2001Esteve 1997Hess 1998Hung 2003Kinsey 1990Leyland 1992Lieschke 1990Matsui 1991Miller 1993Novakova 1990Novakova 1991Perez 1995Petrilli 2003	123 (Combination thera 3, df=16(P=0.83); l ² =0% 0.17) 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39 1/48 2/39 2/77 14/106 13/90 0/51 2/45 1/26 5/46 5/45 3/30 2/68	0/57 3/66 1/19 75/480 2/72 9/54 2/45 2/45 4/45 5/48 3/37 7/83 11/110 10/92 0/50 2/41 3/24 6/44 5/45 4/30 3/68		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62% 1.69% 1.04% 2.28% 3.65% 3.34% 0.71% 1.05% 2.07% 1.69% 1.35% 1.01%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 0.2[0.02,1.65] 0.63[0.11,3.57] 0.31[0.07,1.44] 1.32[0.63,2.78] 1.33[0.61,2.87] Not estimable 0.91[0.13,6.18] 0.31[0.03,2.76] 0.8[0.26,2.42] 1[0.31,3.22] 0.75[0.18,3.07] 0.67[0.12,3.86]	
Total events: 116 (Monotherapy), Heterogeneity: Tau ² =0; Chi ² =10.6 Test for overall effect: Z=1.37(P=0) 12.3.2 episode analysis Agaoglu 2001 Ahmed 2007 Conte 1996 De Pauw 1994 Dincol 1998 Doyen 1983 Duzova 2001 Esteve 1997 Hess 1998 Hung 2003 Kinsey 1990 Leyland 1992 Lieschke 1990 Matsui 1991 Miller 1993 Morgan 1983 Novakova 1990 Novakova 1991 Perez 1995	123 (Combination thera 3, df=16(P=0.83); l ² =0% 2/30 2/63 1/21 69/488 3/78 8/50 0/45 1/39 1/48 2/39 2/77 14/106 13/90 0/51 2/45 1/26 5/46 5/45 3/30	0/57 3/66 - 1/19 75/480 2/72 9/54 2/45 2/46 5/48 3/37 - 7/83 11/110 10/92 0/50 2/41 - 3/24 6/44 5/45 4/30		0.99% 0.35% 25.57% 0.7% 2.93% 0.85% 0.62% 1.69% 1.04% 2.28% 3.65% 3.34% 0.71% 1.05% 2.07% 1.69% 1.35%	0.7[0.12,4.04] 0.9[0.06,13.48] 0.9[0.67,1.22] 1.38[0.24,8.05] 0.96[0.4,2.29] 0.2[0.01,4.05] 0.59[0.06,6.26] 0.2[0.02,1.65] 0.63[0.11,3.57] 0.31[0.07,1.44] 1.32[0.63,2.78] 1.33[0.61,2.87] Not estimable 0.91[0.13,6.18] 0.31[0.03,2.76] 0.8[0.26,2.42] 1[0.31,3.22] 0.75[0.18,3.07]	



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Rodjer 1987	5/29	1/29		0.34%	5[0.62,40.2]
Smith 1990	0/47	0/53			Not estimable
Zengin 2011	0/37	0/35			Not estimable
Subtotal (95% CI)	1720	1755	•	57.02%	0.9[0.73,1.11]
Total events: 150 (Monothera	apy), 168 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =	15.82, df=21(P=0.78); l ² =0%				
Test for overall effect: Z=1(P=	:0.32)				
Total (95% CI)	3674	3512	•	100%	0.87[0.75,1.02]
Total events: 266 (Monothera	apy), 291 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =	26.67, df=38(P=0.92); l ² =0%				
Test for overall effect: Z=1.65	(P=0.1)				
Test for subgroup differences	s: Chi ² =0.17, df=1 (P=0.68), I ²	=0%			
	ŀ	avours treatment 0	.1 0.2 0.5 1 2 5	¹⁰ Favours control	

Analysis 12.4. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 4 Publication status (mortality).

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
12.4.1 jounal publication						
Agaoglu 2001	2/30	0/57		0.12%	9.35[0.46,188.82]	
Ahmed 2007	2/63	3/66		1%	0.7[0.12,4.04]	
Akova 1999	1/40	0/43		0.16%	3.22[0.13,76.82]	
Behre 1998	2/35	4/36		1.35%	0.51[0.1,2.63]	
Bezwoda 1985	7/29	11/31		3.63%	0.68[0.31,1.52]	
Cometta 1996	24/483	22/475		7.58%	1.07[0.61,1.89]	
De la Camara 1997	1/52	3/51	↓	1.03%	0.33[0.04,3.04]	
De Pauw 1994	69/488	75/480		25.83%	0.9[0.67,1.22]	
Del Favero 2001	22/364	32/369	+	10.86%	0.7[0.41,1.18]	
Dincol 1998	3/78	2/72		- 0.71%	1.38[0.24,8.05]	
Duzova 2001	0/45	2/45		0.85%	0.2[0.01,4.05]	
Gibson 1989	3/52	5/50		1.74%	0.58[0.15,2.29]	
Gorschluter 2003	5/56	8/51		2.86%	0.57[0.2,1.63]	
Hess 1998	1/48	5/48	↓	1.71%	0.2[0.02,1.65]	
Jimeno 2006	1/23	0/26		0.16%	3.38[0.14,79]	
Kinsey 1990	2/77	7/83	+	2.3%	0.31[0.07,1.44]	
Leyland 1992	14/106	11/110		3.69%	1.32[0.63,2.78]	
Matsui 1991	0/51	0/50			Not estimable	
Miller 1993	2/45	2/41		0.72%	0.91[0.13,6.18]	
Morgan 1983	1/26	3/24	← +	1.07%	0.31[0.03,2.76]	
Norrby 1987	7/105	12/105	· · · · · · · · · · · · · · · · · · ·	4.1%	0.58[0.24,1.42]	
Novakova 1990	5/46	6/44		2.1%	0.8[0.26,2.42]	
Novakova 1991	5/45	5/45		1.71%	1[0.31,3.22]	
Ozyilkan 1999	0/15	0/15			Not estimable	
Perez 1995	3/30	4/30		1.37%	0.75[0.18,3.07]	
Petrilli 2003	2/68	3/68		1.02%	0.67[0.12,3.86]	
Piccart 1984	1/22	2/22	•	0.68%	0.5[0.05,5.12]	



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
Piguet 1988	7/82	7/87		2.32%	1.06[0.39,2.89]
Rodjer 1987	5/29	1/29	+	0.34%	5[0.62,40.2]
Smith 1990	0/47	0/53			Not estimable
Tamura 2002	2/42	3/82		0.69%	1.3[0.23,7.49]
Tamura 2004	7/95	5/94		1.72%	1.39[0.46,4.21]
Wrzesien-Kus 2001	0/19	4/21	•	1.46%	0.12[0.01,2.13]
Zengin 2011	0/37	0/35			Not estimable
Subtotal (95% CI)	2873	2938	•	84.89%	0.84[0.71,1]
Total events: 206 (Monotherap	y), 247 (Combination ther	ару)			
Heterogeneity: Tau ² =0; Chi ² =2	1.13, df=29(P=0.85); l ² =0%				
Test for overall effect: Z=1.92(F	P=0.05)				
12.4.2 other publication or u	n-published				
Conte 1996	1/21	1/19	+	0.36%	0.9[0.06,13.48]
Cornely 2001	26/404	9/198	— + ——	4.13%	1.42[0.68,2.96]
Doyen 1983	8/50	9/54		2.96%	0.96[0.4,2.29]
Esteve 1997	1/39	2/46	•	- 0.63%	0.59[0.06,6.26]
Hense 2000	6/61	2/26		- 0.96%	1.28[0.28,5.92]
Kliasova 2001	0/22	0/20			Not estimable
Lieschke 1990	13/90	10/92		3.38%	1.33[0.61,2.87]
Papachristodoulou 96	1/35	1/42	↓	0.31%	1.2[0.08,18.5]
Pickard 1983	2/40	7/40	↓ → →	2.39%	0.29[0.06,1.29]
Subtotal (95% CI)	762	537	-	15.11%	1.07[0.72,1.59]
Total events: 58 (Monotherapy), 41 (Combination therap	y)			
Heterogeneity: Tau ² =0; Chi ² =4.	.17, df=7(P=0.76); I ² =0%				
Test for overall effect: Z=0.33(F	P=0.74)				
Total (95% CI)	3635	3475	•	100%	0.88[0.75,1.03]
Total events: 264 (Monotherap	y), 288 (Combination ther	ару)			
Heterogeneity: Tau ² =0; Chi ² =20	6.53, df=37(P=0.9); I ² =0%				
Test for overall effect: Z=1.61(F	P=0.11)				
Test for subgroup differences:	Chi ² =1.16, df=1 (P=0.28), I ²	=13.52%			

Analysis 12.5. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 5 Trial size (mortality).

n/N	n/N	····· • • • · · · · · ·		
	11/19	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
4р				
2/63	3/66	_	0.99%	0.7[0.12,4.04]
24/483	22/475	+	7.5%	1.07[0.61,1.89]
26/404	9/198		4.08%	1.42[0.68,2.96]
1/52	3/51	+	1.02%	0.33[0.04,3.04]
69/488	75/480	_ 	25.57%	0.9[0.67,1.22]
22/364	32/369	+	10.74%	0.7[0.41,1.18]
3/78	2/72		- 0.7%	1.38[0.24,8.05]
8/50	9/54		2.93%	0.96[0.4,2.29]
3/52	5/50		1.72%	0.58[0.15,2.29]
_	24/483 26/404 1/52 69/488 22/364 3/78 8/50 3/52	24/483 22/475 26/404 9/198 1/52 3/51 69/488 75/480 22/364 32/369 3/78 2/72 8/50 9/54	24/483 22/475 26/404 9/198 1/52 3/51 69/488 75/480 22/364 32/369 3/78 2/72 8/50 9/54 3/52 5/50	24/483 22/475 7.5% 26/404 9/198 4.08% 1/52 3/51 1.02% 69/488 75/480 25.57% 22/364 32/369 10.74% 3/78 2/72 0.7% 8/50 9/54 2.93% 3/52 5/50 1.72%



Cochrane Database of Systematic Reviews

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Gorschluter 2003	5/56	8/51		2.83%	0.57[0.2,1.6
Hess 1998	1/48	5/48	← +	1.69%	0.2[0.02,1.6
Kinsey 1990	2/77	7/83	← +	2.28%	0.31[0.07,1.44
Leyland 1992	14/106	11/110		3.65%	1.32[0.63,2.78
Lieschke 1990	13/90	10/92		3.34%	1.33[0.61,2.8]
Norrby 1987	7/105	12/105		4.06%	0.58[0.24,1.4]
Petrilli 2003	2/68	3/68		1.01%	0.67[0.12,3.8
Piguet 1988	7/82	7/87		2.3%	1.06[0.39,2.8
Tamura 2002	2/42	3/82		0.69%	1.3[0.23,7.4
Tamura 2004	7/95	5/94	I	1.7%	1.39[0.46,4.2
Subtotal (95% CI)	2803	2635	•	78.81%	0.9[0.75,1.0
Total events: 218 (Monotherag					
Heterogeneity: Tau ² =0; Chi ² =1					
Test for overall effect: Z=1.17(
12.5.2 number randomised<	modian 84n				
Agaoglu 2001	•	0/57		0.12%	0 36[0 46 100 0
Agaogiu 2001 Akova 1999	2/30 1/40	0/57			9.35[0.46,188.8
		0/43		• 0.16%	3.22[0.13,76.8
Behre 1998	2/35	4/36		1.33%	0.51[0.1,2.6
Bezwoda 1985	7/29	11/31		3.59%	0.68[0.31,1.5
Conte 1996	1/21	1/19		0.35%	0.9[0.06,13.4
Duzova 2001	0/45	2/45	•	0.85%	0.2[0.01,4.0
Esteve 1997	1/39	2/46		0.62%	0.59[0.06,6.2
Hense 2000	6/61	2/26		0.95%	1.28[0.28,5.9
Hung 2003	2/39	3/37	+	1.04%	0.63[0.11,3.5
Jimeno 2006	1/23	0/26	· · · · · · · · · · · · · · · · · · ·	0.16%	3.38[0.14,7
Kliasova 2001	0/22	0/20			Not estimab
Matsui 1991	0/51	0/50			Not estimab
Miller 1993	2/45	2/41	+	0.71%	0.91[0.13,6.1
Morgan 1983	1/26	3/24	↓ ↓ ↓	1.05%	0.31[0.03,2.7
Novakova 1990	5/46	6/44		2.07%	0.8[0.26,2.42
Novakova 1991	5/45	5/45		1.69%	1[0.31,3.22
Ozyilkan 1999	0/15	0/15			Not estimab
Papachristodoulou 96	1/35	1/42	← →	0.31%	1.2[0.08,18.
Perez 1995	3/30	4/30		1.35%	0.75[0.18,3.0]
Piccart 1984	1/22	2/22	↓	0.68%	0.5[0.05,5.1]
Pickard 1983	2/40	7/40	▲	2.37%	0.29[0.06,1.2
Rodjer 1987	5/29	1/29	` _	0.34%	5[0.62,40.
Smith 1990	0/47	0/53	r i i i i i i i i i i i i i i i i i i i		Not estimab
Wrzesien-Kus 2001	0/19	4/21	4	1.45%	0.12[0.01,2.1]
Zengin 2011	0/37	0/35	•	1.1070	Not estimab
Subtotal (95% CI)	871	877		21.19%	0.78[0.55,1.1]
Total events: 48 (Monotherapy			-	21.13%	0.76[0.55,1.1
Heterogeneity: Tau ² =0; Chi ² =1					
Test for overall effect: Z=1.36(I					
Total (95% CI)	3674	3512	•	100%	0.87[0.75,1.0
Total events: 266 (Monotherap		y)			
Heterogeneity: Tau ² =0; Chi ² =2					
Test for overall effect: Z=1.65(I					
Test for subgroup differences:	Chi2=0.47, df=1 (P=0.49), I2=	0%			

Analysis 12.6. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 6 Allocation concealment (failure).

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio M-H, Fixed, 95% Cl	
	n/N	n/N	M-H, Fixed, 95% Cl			
12.6.1 same beta-lactam - A						
Del Favero 2001	188/370	188/384	+	8.51%	1.04[0.9,1.	
Kojima 1994	10/35	3/32	++	0.14%	3.05[0.92,10	
Marie 1991	67/77	50/69		2.43%	1.2[1.01,1.4	
Tamura 2002	13/38	29/76		0.89%	0.9[0.53,1.5	
Tamura 2004	47/95	39/94		1.81%	1.19[0.87,1.6	
Wrzesien-Kus 2001	9/19	10/21	_	0.44%	0.99[0.52,1.9	
Subtotal (95% CI)	634	676	◆	14.22%	1.1[0.99,1.2	
Total events: 334 (Monotherapy), 319 (Combination thera	ару)				
Heterogeneity: Tau²=0; Chi²=5.4	, df=5(P=0.37); I ² =7.45%					
Test for overall effect: Z=1.69(P=	=0.09)					
12.6.2 same beta-lactam - B						
Doyen 1983	13/49	11/48	+	0.51%	1.16[0.58,2.	
Esteve 1997	23/39	26/46	<u> </u>	1.1%	1.04[0.72,1	
Jacobs 1993	14/46	5/45	+	0.23%	2.74[1.08,6.	
Kiehl 2001	14/35	12/36		0.55%	1.2[0.65,2.	
Kinsey 1990	48/77	59/83	-+-	2.62%	0.88[0.7,1.	
Novakova 1991	19/36	18/33	_ -	0.87%	0.97[0.62,2	
Papachristodoulou 96	3/39	6/45	•	0.26%	0.58[0.15,2.	
Piccart 1984	5/22	6/22	+	0.28%	0.83[0.3,2.	
Rolston 1992	130/378	99/372	-+	4.6%	1.29[1.04,1.	
Subtotal (95% CI)	721	730	◆	11.01%	1.13[0.99,1	
Total events: 269 (Monotherapy), 242 (Combination thera	ару)				
Heterogeneity: Tau ² =0; Chi ² =12.	.08, df=8(P=0.15); l ² =33.79	9%				
Test for overall effect: Z=1.85(P=	=0.06)					
12.6.3 same beta-lactam - C						
Zengin 2011	24/37	22/35	<u> </u>	1.04%	1.03[0.73,1.	
Subtotal (95% CI)	37	35	•	1.04%	1.03[0.73,1.	
Total events: 24 (Monotherapy),	, 22 (Combination therap	y)				
Heterogeneity: Not applicable						
Test for overall effect: Z=0.18(P=	=0.86)					
12.6.4 different beta-lactam -	A					
Ahmed 2007	28/58	23/61	- +	1.03%	1.28[0.84,1.	
Akova 1999	13/40	28/43	-	1.24%	0.5[0.3,0.	
Alanis 1983	20/46	27/48	+- <u>+</u> -	1.22%	0.77[0.51,1.	
Behre 1998	15/34	17/37		0.75%	0.96[0.57,1.	
Cometta 1996	213/483	230/475	+	10.69%	0.91[0.79,1.	
Cornely 2001	193/353	92/176	-+-	5.66%	1.05[0.88,1.	
De la Camara 1997	29/46	30/47	<u> </u>	1.37%	0.99[0.73,1.	
De Pauw 1994	292/488	278/480	+	12.92%	1.03[0.93,1.	
Gibson 1989	16/52	19/50		0.89%	0.81[0.47,1.	
Gorschluter 2003	25/56	35/51	<u> </u>	1.69%	0.65[0.46,0.	
Hess 1998	9/48	8/48		0.37%	1.13[0.47,2.	



Cochrane Database of Systematic Reviews

Study or subgroup	Monotherapy Combina- tion therapy		Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI	
Jimeno 2006	16/24	23/27		1%	0.78[0.57,1.0	
_eyland 1992	48/106	52/110	+	2.35%	0.96[0.72,1.2	
ieschke 1990	19/90	18/92		0.82%	1.08[0.61,1.9	
Matsui 1991	9/51	10/50		0.47%	0.88[0.39,1.9	
Norrby 1987	35/105	46/105	— • • •	2.12%	0.76[0.54,1.0	
Novakova 1990	18/46	28/44	— + —	1.32%	0.61[0.4,0.9	
Dzyilkan 1999	6/15	6/15		0.28%	1[0.42,2	
Petrilli 2003	20/68	13/68	++	0.6%	1.54[0.83,2.8	
Pickard 1983	14/37	23/38		1.05%	0.63[0.38,1.0	
/amamura 1997	17/56	17/55	+	0.79%	0.98[0.56,1.7	
Subtotal (95% CI)	2302	2120	•	48.63%	0.94[0.88,	
otal events: 1055 (Monotherap	y), 1023 (Combination th	erapy)				
leterogeneity: Tau ² =0; Chi ² =30.	93, df=20(P=0.06); l ² =35.3	34%				
Test for overall effect: Z=2.05(P=	0.04)					
2.6.5 different beta-lactam -	В					
Agaoglu 2001	8/30	12/57		0.38%	1.27[0.58,2.7	
ntmen 2001	25/38	21/29	— + [1.1%	0.91[0.66,1.2	
u 1994	5/26	9/24		0.43%	0.51[0.2,1.3	
ezwoda 1985	8/29	11/31		0.49%	0.78[0.36,1.6	
Borbolla 2001	2/20	3/20 —		0.14%	0.67[0.12,3.5	
Conte 1996	10/21	8/19		0.39%	1.13[0.57,2.2	
ornelissen 1992	4/47	12/47 —		0.55%	0.33[0.12,0.9	
e Pauw 1983	11/38	24/45		1.01%	0.54[0.31,0.9	
Dincol 1998	17/78	15/72	_	0.72%	1.05[0.57,1.9	
Duzova 2001	11/45	16/45	_	0.74%	0.69[0.36,1.3	
El Haddad 1995	7/30	9/16		0.54%	0.41[0.19,0	
Frjavec 1994	38/94	49/85	+_	2.37%	0.7[0.52,0.9	
Gaytan-Martinez 2002	9/63	7/54	+	0.35%	1.1[0.44,2.7	
Gribble 1983	2/12	3/18		0.11%	1[0.2,5.1	
lansen 1986	4/14	9/19	+	0.35%	0.6[0.23,1.5	
lense 2000	33/58	16/26		1.02%	0.92[0.63,1.3	
lung 2003	11/39	16/37	_	0.76%	0.65[0.35,1.2	
(liasova 2001	8/23	10/20		0.49%	0.7[0.34,1.4	
Koehler 1990	16/55	19/65		0.8%	1[0.57,1.7	
iu 1989	1/10	3/17		0.1%	0.57[0.07,4.7	
Ailler 1993	25/45	20/41		0.96%	1.14[0.76,1.7	
Norgan 1983	9/26	13/24		0.62%	0.64[0.34,1.2	
Pegram 1984	21/72	20/68	·	0.95%	0.99[0.59,1.6	
Pellegrin 1988	23/71	31/86		1.29%	0.9[0.58,1.3	
Perez 1995	14/30	19/30		0.88%	0.74[0.46,1.1	
Piguet 1988	59/82	63/87		2.82%	0.99[0.82,1	
Rodjer 1987	5/22	4/23		0.18%		
Rodriguez 1995	5/22	4/23		0.18%	1.31[0.4,4.2	
chuchter 1988			-		0.77[0.44,1.3	
	33/65	30/68		1.35%	1.15[0.8,1.6	
mith 1990	24/47	21/53		0.91%	1.29[0.83,1.9	
Vade 1987	16/228	14/232		0.64%	1.16[0.58,2.3	
Subtotal (95% CI)	1522	1530		24.41%	0.87[0.79,0.9	
otal events: 474 (Monotherapy		ару)				
leterogeneity: Tau ² =0; Chi ² =29.	41, dt=30(P=0.5); l²=0%					



Study or subgroup	Monotherapy Combina- tion therapy				Risk Rati	0			Weight	Risk Ratio
	n/N	n/N		M-H	, Fixed, 9	5% CI				M-H, Fixed, 95% CI
12.6.6 different beta-lactam - C										
Corapcioglu 2005	12/25	15/25		_	-+				0.69%	0.8[0.48,1.34]
Subtotal (95% CI)	25	25		-					0.69%	0.8[0.48,1.34]
Total events: 12 (Monotherapy), 2	15 (Combination therapy)								
Heterogeneity: Not applicable										
Test for overall effect: Z=0.84(P=0	0.4)									
Total (95% CI)	5241	5116			•				100%	0.97[0.93,1.01]
Total events: 2168 (Monotherapy	y), 2150 (Combination the	erapy)								
Heterogeneity: Tau ² =0; Chi ² =90.7	'1, df=68(P=0.03); l ² =25.0	3%								
Test for overall effect: Z=1.56(P=0	0.12)									
Test for subgroup differences: Ch	ii ² =16.89, df=1 (P=0), I ² =7	0.4%								
	Favo	urs monotherapy	0.1	0.2 0.5	1	2	5	10	Favours combination	

Analysis 12.7. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 7 Intention to treat vs. efficacy analysis (failure).

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Random, 95% Cl		M-H, Random, 95% Cl
12.7.1 same BL - efficacy ana	llysis				
Doyen 1983	13/49	11/48		2.94%	1.16[0.58,2.33]
Esteve 1997	23/39	26/46	_ +	8.67%	1.04[0.72,1.5]
Jacobs 1993	14/46	5/45		1.7%	2.74[1.08,6.98]
Kinsey 1990	48/77	59/83	-+-	16.15%	0.88[0.7,1.09]
Kojima 1994	10/35	3/32	++	1.06%	3.05[0.92,10.1]
Marie 1991	67/77	50/69		20.44%	1.2[1.01,1.42]
Novakova 1991	19/36	18/33		6.52%	0.97[0.62,1.5]
Piccart 1984	5/22	6/22		1.42%	0.83[0.3,2.33]
Rolston 1992	130/378	99/372	-+	16.34%	1.29[1.04,1.61]
Tamura 2002	13/38	29/76		4.83%	0.9[0.53,1.52]
Tamura 2004	47/95	39/94	_ +	10.67%	1.19[0.87,1.63]
Zengin 2011	24/37	22/35	_ - _	9.27%	1.03[0.73,1.46]
Subtotal (95% CI)	929	955	◆	100%	1.11[0.98,1.26]
Total events: 413 (Monotherap	oy), 367 (Combination ther	ару)			
Heterogeneity: Tau ² =0.01; Chi ²	² =15.6, df=11(P=0.16); l ² =2	9.49%			
Test for overall effect: Z=1.67(F	P=0.1)				
12.7.2 same BL - ITT analysis	;				
Del Favero 2001	188/370	188/384	<u> </u>	89.76%	1.04[0.9,1.2]
Kiehl 2001	14/35	12/36		4.86%	1.2[0.65,2.22]
Papachristodoulou 96	3/39	6/45		1.06%	0.58[0.15,2.16]
Wrzesien-Kus 2001	9/19	10/21		4.32%	0.99[0.52,1.91]
Subtotal (95% CI)	463	486	•	100%	1.04[0.91,1.19]
Total events: 214 (Monotherap	oy), 216 (Combination ther	ару)			
Heterogeneity: Tau ² =0; Chi ² =1	, df=3(P=0.8); l ² =0%				
Test for overall effect: Z=0.52(F	P=0.6)				
	Fav	ours monotherapy 0.1	0.2 0.5 1 2 5	¹⁰ Favours combinatio	on
	141			. arouro compiliate	



Cochrane Database of Systematic Reviews

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Random, 95% CI		M-H, Random, 95% Cl
12.7.3 different BL - efficacy	•				
Agaoglu 2001	8/30	12/57		0.73%	1.27[0.58,2.7
Ahmed 2007	28/58	23/61		2.36%	1.28[0.84,1.9
Alanis 1983	20/46	27/48	-++	2.41%	0.77[0.51,1.1]
Au 1994	5/26	9/24		0.5%	0.51[0.2,1.3
Behre 1998	15/34	17/37		1.6%	0.96[0.57,1.6
Bezwoda 1985	8/29	11/31		0.77%	0.78[0.36,1.6
Borbolla 2001	2/20	3/20	+	0.16%	0.67[0.12,3.5
Cometta 1996	213/483	230/475	-+-	12.91%	0.91[0.79,1.0
Corapcioglu 2005	12/25	15/25	+	1.58%	0.8[0.48,1.3
Cornelissen 1992	4/47	12/47		0.4%	0.33[0.12,0.9
Cornely 2001	193/353	92/176	+	9.98%	1.05[0.88,1.2
De la Camara 1997	29/46	30/47	_ 	4.05%	0.99[0.73,1.3
De Pauw 1983	11/38	24/45		1.33%	0.54[0.31,0.9
De Pauw 1994	292/488	278/480	+	16.5%	1.03[0.93,1.1
Duzova 2001	11/45	16/45	+	1.04%	0.69[0.36,1.3
El Haddad 1995	7/30	9/16		0.72%	0.41[0.19,0.
Gaytan-Martinez 2002	9/63	7/54		0.52%	1.1[0.44,2.7
Gorschluter 2003	25/56	35/51	_ +	3.32%	0.65[0.46,0.9
Gribble 1983	2/12	3/18		0.17%	1[0.2,5.1
Hansen 1986	4/14	9/19		0.49%	0.6[0.23,1.5
Hense 2000	33/58	16/26		2.84%	0.92[0.63,1.3
Hess 1998	9/48	8/48		0.59%	1.13[0.47,2.6
Hung 2003	11/39	16/37	+ - <u>+</u> -	1.12%	0.65[0.35,1.2
Kliasova 2001	8/23	10/20		0.87%	0.7[0.34,1.4
Leyland 1992	48/106	52/110	+	4.56%	0.96[0.72,1.2
Liu 1989	1/10	3/17	+	0.1%	0.57[0.07,4.7
Miller 1993	25/45	20/41	— <u>+</u> +	2.47%	1.14[0.76,1.7
Pegram 1984	21/72	20/68		1.6%	0.99[0.59,1.6
Pellegrin 1988	23/71	31/86	+	2.17%	0.9[0.58,1.3
Pereira 2009	26/62	20/63		1.94%	1.32[0.83,2.
Petrilli 2003	20/68	13/68		1.15%	1.54[0.83,2.8
Pickard 1983	14/37	23/38		1.79%	0.63[0.38,1.0
Piguet 1988	59/82	63/87	-	8.79%	0.99[0.82,1.
Rodjer 1987	5/22	4/23		0.32%	1.31[0.4,4.2
Rodriguez 1995	15/64	22/72	— <u>+</u>	1.35%	0.77[0.44,1.3
Schuchter 1988	33/65	30/68	_ +	3.11%	1.15[0.8,1.6
Wade 1987	16/228	14/232		0.91%	1.16[0.58,2.3
Yildirim 2008	26/46	22/41	i	2.8%	1.05[0.72,1.5
Subtotal (95% CI)	3089	2921	•	100%	0.95[0.88,1.0
Total events: 1291 (Monother	apy), 1249 (Combination th	erapy)			
Heterogeneity: Tau ² =0; Chi ² =4 Test for overall effect: Z=1.63(34%			
12.7.4 different BL - ITT ana	ysis				
Akova 1999	13/40	28/43		5.74%	0.5[0.3,0.8
Conte 1996	10/21	8/19		2.98%	1.13[0.57,2.2
Dincol 1998	17/78	15/72	\	3.75%	1.05[0.57,1.9
Erjavec 1994	38/94	49/85	_+ _	14.95%	0.7[0.52,0.9
Gibson 1989	16/52	19/50	+ <u> </u>	4.88%	0.81[0.47,1.3
Jimeno 2006	16/24	23/27	. [13.37%	0.78[0.57,1.0



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Random, 95% Cl		M-H, Random, 95% CI
Koehler 1990	16/55	19/65		4.54%	1[0.57,1.74]
Lieschke 1990	19/90	18/92		4.3%	1.08[0.61,1.92]
Matsui 1991	9/51	10/50		2.17%	0.88[0.39,1.99]
Morgan 1983	9/26	13/24		3.44%	0.64[0.34,1.22]
Norrby 1987	35/105	46/105	+	11.7%	0.76[0.54,1.08]
Novakova 1990	18/46	28/44	- _	7.87%	0.61[0.4,0.94]
Ozyilkan 1999	6/15	6/15		1.86%	1[0.42,2.4]
Perez 1995	14/30	19/30	+	6.43%	0.74[0.46,1.18]
Smith 1990	24/47	21/53		7.5%	1.29[0.83,1.99]
Yamamura 1997	17/56	17/55		4.54%	0.98[0.56,1.72]
Subtotal (95% CI)	830	829	◆	100%	0.8[0.71,0.91]
Total events: 277 (Monotherapy), 33	9 (Combination thera	іру)			
Heterogeneity: Tau ² =0; Chi ² =15.16, c	df=15(P=0.44); l ² =1.06	%			
Test for overall effect: Z=3.56(P=0)					
	Favo	ours monotherapy 0	1 0.2 0.5 1 2 5	¹⁰ Favours combinatio	n

Analysis 12.8. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 8 Intention to treat vs. efficacy analysis, assuming dropouts=failures (failure).

n/N n/N M-H, Fixed, 95% Cl 12.8.1 same BL - efficacy analysis	Weight	Risk Ratio
Doyen 1983 13/49 11/48 Esteve 1997 23/39 26/46 Kinsey 1990 48/77 59/83 Marie 1991 67/77 50/69 Rolston 1992 130/378 99/372 Subtotal (95% CI) 620 618 Total events: 281 (Monotherapy), 245 (Combination therapy) 4 Heterogeneity: Tau ² =0; Chi ² =7.32, df=4(P=0.12); l ² =45.34% - Test for overall effect: Z=2.2(P=0.03) 188/370 188/384 Jacobs 1993 21/53 14/54 Kiehl 2001 14/35 12/36 Veikel 2001 14/35 12/36 Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% CI) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0%		M-H, Fixed, 95% Cl
Esteve 1997 23/39 26/46 Kinsey 1990 48/77 59/83 Marie 1991 67/77 50/69 Rolston 1992 130/378 99/372 Subtotal (95% CI) 620 618 Total events: 281 (Monotherapy), 245 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =7.32, df=4(P=0.12); l ² =45.34% Test for overall effect: Z=2.2(P=0.03) 12.8.2 same BL - ITT analysis Del Favero 2001 188/370 188/384 Jacobs 1993 21/53 14/54 Kiehl 2001 14/35 12/36 Kojima 1994 11/36 5/34 Novakova 1991 28/45 30/45 Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% CI) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0%		
Kinsey 1990 $48/77$ $59/83$ Marie 1991 $67/77$ $50/69$ Rolston 1992 $130/378$ $99/372$ Subtotal (95% CI) 620 618 Total events: 281 (Monotherapy), 245 (Combination therapy)Heterogeneity: Tau ² =0; Chi ² =7.32, df=4(P=0.12); l ² =45.34%Test for overall effect: Z=2.2(P=0.03) 12.8.2 same BL - ITT analysis Del Favero 2001188/370188/370188/370188/384Jacobs 199321/5314/54Kiehl 200114/3512/3530/45Subtotal (95% CI)764826Total events: 351 (Monotherapy), 354 (Combination therapy)Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0%	4.55%	1.16[0.58,2.33]
Marie 1991 67/77 50/69 Rolston 1992 130/378 99/372 Subtotal (95% CI) 620 618 Total events: 281 (Monotherapy), 245 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =7.32, df=4(P=0.12); l ² =45.34% Test for overall effect: Z=2.2(P=0.03) 12.8.2 same BL - ITT analysis Del Favero 2001 188/370 188/384 Jacobs 1993 21/53 14/54 Kiehl 2001 14/35 12/36 Kojima 1994 11/36 5/34 Novakova 1991 28/45 30/45 Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% CI) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0%	9.77%	1.04[0.72,1.5]
Rolston 1992 130/378 99/372 Subtotal (95% CI) 620 618 Total events: 281 (Monotherapy), 245 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =7.32, df=4(P=0.12); l ² =45.34% Test for overall effect: Z=2.2(P=0.03) 12.8.2 same BL - ITT analysis Del Favero 2001 188/370 188/384 Jacobs 1993 21/53 14/54 Kiehl 2001 14/35 12.8.2 same BL - ITT analysis Del Favero 2001 188/370 188/370 188/384 Jacobs 1993 21/53 11/36 5/34 Novakova 1991 28/45 30/45	23.25%	0.88[0.7,1.09]
Subtotal (95% Cl) 620 618 Total events: 281 (Monotherapy), 245 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =7.32, df=4(P=0.12); l ² =45.34% Test for overall effect: Z=2.2(P=0.03) Test for overall effect: Z=2.2(P=0.03) 12.8.2 same BL - ITT analysis Del Favero 2001 188/370 188/384 Jacobs 1993 21/53 14/54 Kiehl 2001 14/35 12/36 Kojima 1994 11/36 5/34 Novakova 1991 28/45 30/45 Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% Cl) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) 48/25 48/25 Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0% 46/101 46/101	21.59%	1.2[1.01,1.42]
Total events: 281 (Monotherapy), 245 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =7.32, df=4(P=0.12); I ² =45.34% Test for overall effect: Z=2.2(P=0.03) 12.8.2 same BL - ITT analysis Del Favero 2001 188/370 Jacobs 1993 21/53 14/35 12/36 Kiehl 2001 14/35 Novakova 1991 28/45 3/39 6/45 Piccart 1984 8/25 7amura 2002 17/42 35/82	40.85%	1.29[1.04,1.61]
Heterogeneity: Tau ² =0; Chi ² =7.32, df=4(P=0.12); l ² =45.34% Test for overall effect: Z=2.2(P=0.03) 12.8.2 same BL - ITT analysis Del Favero 2001 188/370 188/384 Jacobs 1993 21/53 14/54 Kiehl 2001 14/35 12/36 Kojima 1994 11/36 5/34 Novakova 1991 28/45 30/45 Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% Cl) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0%	100%	1.15[1.02,1.29]
Test for overall effect: Z=2.2(P=0.03) 12.8.2 same BL - ITT analysis Del Favero 2001 188/370 Jacobs 1993 21/53 14/54 Kiehl 2001 14/35 1994 11/36 5/34 Novakova 1991 28/45 28/45 30/45 Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 7amura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% CI) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau²=0; Chi²=5.93, df=9(P=0.75); l²=0%		
12.8.2 same BL - ITT analysis Del Favero 2001 188/370 188/384 Jacobs 1993 21/53 14/54 Kiehl 2001 14/35 12/36 Kojima 1994 11/36 5/34 Novakova 1991 28/45 30/45 Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% CI) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau²=0; Chi²=5.93, df=9(P=0.75); l²=0%		
Del Favero 2001 188/370 188/384 Jacobs 1993 21/53 14/54 Kiehl 2001 14/35 12/36 Kojima 1994 11/36 5/34 Novakova 1991 28/45 30/45 Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% Cl) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0%		
Del Favero 2001 188/370 188/384 Jacobs 1993 21/53 14/54 Kiehl 2001 14/35 12/36 Kojima 1994 11/36 5/34 Novakova 1991 28/45 30/45 Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% Cl) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0%		
Jacobs 1993 21/53 14/54 Kiehl 2001 14/35 12/36 Kojima 1994 11/36 5/34 Novakova 1991 28/45 30/45 Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% CI) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0%		
Kiehl 2001 14/35 12/36 Kojima 1994 11/36 5/34 Novakova 1991 28/45 30/45 Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% CI) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0%	54.58%	1.04[0.9,1.2]
Kojima 1994 11/36 5/34 Novakova 1991 28/45 30/45 Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% Cl) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0%	4.1%	1.53[0.87,2.68]
Novakova 1991 28/45 30/45 Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% Cl) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0%	3.5%	1.2[0.65,2.22]
Papachristodoulou 96 3/39 6/45 Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% Cl) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0%	1.52%	2.08[0.81,5.36]
Piccart 1984 8/25 8/24 Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% CI) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); I ² =0%	8.87%	0.93[0.69,1.27]
Tamura 2002 17/42 35/82 Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% CI) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); I ² =0%	1.65%	0.58[0.15,2.16]
Tamura 2004 52/100 46/101 Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% CI) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); I ² =0%	2.41%	0.96[0.43,2.15]
Wrzesien-Kus 2001 9/19 10/21 Subtotal (95% Cl) 764 826 Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); l ² =0%	7.01%	0.95[0.61,1.48]
Subtotal (95% CI)764826Total events: 351 (Monotherapy), 354 (Combination therapy)Heterogeneity: Tau²=0; Chi²=5.93, df=9(P=0.75); I²=0%	13.54%	1.14[0.86,1.52]
Total events: 351 (Monotherapy), 354 (Combination therapy) Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); I ² =0%	2.81%	0.99[0.52,1.91]
Heterogeneity: Tau ² =0; Chi ² =5.93, df=9(P=0.75); I ² =0%	100%	1.07[0.96,1.19]
Test for overall effect: Z=1.18(P=0.24)		
Favours monotherapy 0.1 0.2 0.5 1 2 5	^{5 10} Favours combinatio	n



Cochrane Database of Systematic Reviews

		Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
12.8.3 different BL - efficac					
Agaoglu 2001	8/30	12/57		1.33%	1.27[0.58,2.7
Au 1994	5/26	9/24	+	1.5%	0.51[0.2,1.3
Bezwoda 1985	8/29	11/31	+	1.7%	0.78[0.36,1.6
Borbolla 2001	2/20	3/20	•	0.48%	0.67[0.12,3.5
Corapcioglu 2005	17/30	20/30		3.21%	0.85[0.57,1.2
De Pauw 1994	292/488	278/480	*	44.93%	1.03[0.93,1.1
Duzova 2001	11/45	16/45		2.56%	0.69[0.36,1.3
El Haddad 1995	7/30	9/16		1.88%	0.41[0.19,0
Gaytan-Martinez 2002	9/63	7/54		1.21%	1.1[0.44,2.7
Gorschluter 2003	25/56	35/51	+	5.87%	0.65[0.46,0.9
iribble 1983	2/12	3/18		0.38%	1[0.2,5.1
liasova 2001	8/23	10/20	+	1.71%	0.7[0.34,1.4
egram 1984	21/72	20/68		3.3%	0.99[0.59,1.6
ellegrin 1988	23/71	31/86		4.49%	0.9[0.58,1.3
iguet 1988	59/82	63/87	+	9.8%	0.99[0.82,1
odjer 1987	5/22	4/23		0.63%	1.31[0.4,4.2
odriguez 1995	15/64	22/72	+	3.32%	0.77[0.44,1.3
chuchter 1988	33/65	30/68	++	4.7%	1.15[0.8,1.
/ade 1987	16/228	14/232		2.22%	1.16[0.58,2.3
ildirim 2008	30/49	30/50	_ +	4.76%	1.02[0.74,1
ubtotal (95% CI)	1505	1532	•	100%	0.96[0.89,1.0
2.8.4 different BL - ITT and					
hmed 2007				0.0.00	
	33/63	28/66		2.34%	
	13/40	28/43		2.3%	0.5[0.3,0.8
lanis 1983	13/40 27/53	28/43 34/55		2.3% 2.85%	0.5[0.3,0. 0.82[0.59,1.
lanis 1983 Jehre 1998	13/40 27/53 18/39	28/43 34/55 19/39		2.3% 2.85% 1.62%	0.5[0.3,0.4 0.82[0.59,1.3 0.95[0.59,1.3
lanis 1983 ehre 1998 ometta 1996	13/40 27/53 18/39 248/518	28/43 34/55 19/39 271/516		2.3% 2.85% 1.62% 23.19%	0.5[0.3,0.4 0.82[0.59,1.4 0.95[0.59,1.4 0.91[0.81,1.4
lanis 1983 ehre 1998 ometta 1996 onte 1996	13/40 27/53 18/39 248/518 10/21	28/43 34/55 19/39 271/516 8/19		2.3% 2.85% 1.62% 23.19% 0.72%	0.5[0.3,0. 0.82[0.59,1. 0.95[0.59,1. 0.91[0.81,1. 1.13[0.57,2.
lanis 1983 ehre 1998 ometta 1996 onte 1996 ornelissen 1992	13/40 27/53 18/39 248/518 10/21 7/50	28/43 34/55 19/39 271/516 8/19 15/50		2.3% 2.85% 1.62% 23.19% 0.72% 1.28%	0.5[0.3,0. 0.82[0.59,1. 0.95[0.59,1. 0.91[0.81,1. 1.13[0.57,2. 0.47[0.21,1.
lanis 1983 ehre 1998 ometta 1996 onte 1996 ornelissen 1992 ornely 2001	13/40 27/53 18/39 248/518 10/21 7/50 244/404	28/43 34/55 19/39 271/516 8/19 15/50 114/198		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07%	0.5[0.3,0.4 0.82[0.59,1. 0.95[0.59,1.4 0.91[0.81,1.4 1.13[0.57,2.4 0.47[0.21,1.4 1.05[0.91,1.4
lanis 1983 Sehre 1998 Sometta 1996 Sornel 1996 Sornelissen 1992 Sornely 2001 Be la Camara 1997	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87%	0.5[0.3,0. 0.82[0.59,1. 0.95[0.59,1. 0.91[0.81,1. 1.13[0.57,2. 0.47[0.21,1. 1.05[0.91,1. 1.02[0.77,1.
lanis 1983 ehre 1998 ometta 1996 onte 1996 ornelissen 1992 ornely 2001 e la Camara 1997 e Pauw 1983	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98%	0.5[0.3,0. 0.82[0.59,1. 0.95[0.59,1. 0.91[0.81,1. 1.13[0.57,2. 0.47[0.21,1. 1.05[0.91,1. 1.02[0.77,1. 0.67[0.41,1.
lanis 1983 ehre 1998 ometta 1996 onte 1996 ornelissen 1992 ornely 2001 e la Camara 1997 ee Pauw 1983 incol 1998	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42 17/78	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45 15/72		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98% 1.33%	0.5[0.3,0. 0.82[0.59,1. 0.95[0.59,1. 0.91[0.81,1. 1.13[0.57,2. 0.47[0.21,1. 1.05[0.91,1. 1.02[0.77,1. 0.67[0.41,1. 1.05[0.57,1.
lanis 1983 Sehre 1998 Sometta 1996 Sonte 1996 Somelissen 1992 Somely 2001 Se la Camara 1997 Se Pauw 1983 Sincol 1998 rjavec 1994	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42 17/78 38/94	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45 15/72 49/85		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98% 1.33% 4.4%	0.5[0.3,0.4 0.82[0.59,1. 0.95[0.59,1.4 0.91[0.81,1.4 1.13[0.57,2.4 0.47[0.21,1.4 1.05[0.91,1.4 1.02[0.77,1.4 0.67[0.41,1.4 1.05[0.57,1.4 0.7[0.52,0.4]
lanis 1983 ehre 1998 ometta 1996 ornel 1996 ornelissen 1992 ornely 2001 e la Camara 1997 e Pauw 1983 incol 1998 rjavec 1994 ibson 1989	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42 17/78 38/94 16/52	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45 15/72 49/85 19/50		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98% 1.33% 4.4% 1.65%	0.5[0.3,0.4 0.82[0.59,1. 0.95[0.59,1. 0.91[0.81,1. 1.13[0.57,2. 0.47[0.21,1.4 1.05[0.91,1.4 1.05[0.77,1.4 0.67[0.41,1.4 1.05[0.57,1.4 0.7[0.52,0.4 0.81[0.47,1.4]
lanis 1983 ehre 1998 ometta 1996 onte 1996 ornelissen 1992 ornely 2001 e la Camara 1997 e Pauw 1983 incol 1998 rjavec 1994 ibson 1989 ansen 1986	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42 17/78 38/94 16/52 6/16	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45 15/72 49/85 19/50 14/24		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98% 1.33% 4.4% 1.65% 0.96%	0.5[0.3,0.4 0.82[0.59,1.4 0.95[0.59,1.4 0.91[0.81,1.4 1.13[0.57,2.4 0.47[0.21,1.4 1.05[0.91,1.4 1.05[0.91,1.4 1.02[0.77,1.4 0.67[0.41,1.4 1.05[0.57,1.4 0.7[0.52,0.4 0.81[0.47,1.4 0.64[0.31,1.4]
lanis 1983 ehre 1998 ometta 1996 onte 1996 ornelissen 1992 ornely 2001 e la Camara 1997 e Pauw 1983 incol 1998 rjavec 1994 ibson 1989 lansen 1986	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42 17/78 38/94 16/52 6/16 36/61	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45 15/72 49/85 19/50		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98% 1.33% 4.4% 1.65% 0.96% 1.92%	0.5[0.3,0.4 0.82[0.59,1.4 0.95[0.59,1.4 0.91[0.81,1.4 1.13[0.57,2.4 0.47[0.21,1.4 1.05[0.91,1.4 1.05[0.91,1.4 1.02[0.77,1.4 0.67[0.41,1.4 1.05[0.57,1.4 0.7[0.52,0.4 0.81[0.47,1.4 0.64[0.31,1.4]
lanis 1983 ehre 1998 ometta 1996 onte 1996 ornelissen 1992 ornely 2001 e la Camara 1997 e Pauw 1983 incol 1998 rjavec 1994 ibson 1989 ansen 1986 ense 2000 ess 1998	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42 17/78 38/94 16/52 6/16 36/61 15/54	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45 15/72 49/85 19/50 14/24		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98% 1.33% 4.4% 1.65% 0.96% 1.92% 1.12%	0.5[0.3,0.4 0.82[0.59,1.3 0.95[0.59,1.4 0.91[0.81,1.4 1.13[0.57,2.3 0.47[0.21,1.4 1.05[0.91,1.3 1.02[0.77,1.3 0.67[0.41,1.4 1.05[0.57,1.5 0.7[0.52,0.9 0.81[0.47,1.3 0.64[0.31,1.3 0.96[0.66,1.3
lanis 1983 ehre 1998 cometta 1996 cornelissen 1992 cornely 2001 ela Camara 1997 ele Pauw 1983 corneol 1998 rjavec 1994 eibson 1989 lansen 1986 lense 2000 less 1998 lung 2003	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42 17/78 38/94 16/52 6/16 36/61 15/54 24/52	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45 15/72 49/85 19/50 14/24 16/26 13/53 27/48		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98% 1.33% 4.4% 1.65% 0.96% 1.92% 1.12% 2.4%	0.5[0.3,0.4 0.82[0.59,1.] 0.95[0.59,1.] 0.91[0.81,1.0 1.13[0.57,2.] 0.47[0.21,1.0 1.05[0.91,1.] 1.02[0.77,1.] 0.67[0.41,1.0 1.05[0.57,1.9 0.7[0.52,0.9 0.81[0.47,1.] 0.64[0.31,1.] 0.96[0.66,1.] 1.13[0.62,.] 0.82[0.56,1.]
lanis 1983 dehre 1998 cometta 1996 conte 1996 cornelissen 1992 cornely 2001 de la Camara 1997 de Pauw 1983 dincol 1998 rjavec 1994 dibson 1989 lansen 1986 lense 2000 less 1998 lung 2003 imeno 2006	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42 17/78 38/94 16/52 6/16 36/61 15/54 24/52 16/24	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45 15/72 49/85 19/50 14/24 16/26 13/53 27/48 23/27		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98% 1.33% 4.4% 1.65% 0.96% 1.92% 1.92% 1.12% 2.4%	0.5[0.3,0.4 0.82[0.59,1.] 0.95[0.59,1.] 0.91[0.81,1.0 1.13[0.57,2.] 0.47[0.21,1.0 1.05[0.91,1.2 1.02[0.77,1.] 0.67[0.41,1.0 1.05[0.57,1.9 0.81[0.47,1.] 0.64[0.31,1.] 0.96[0.66,1.] 1.13[0.6,2.] 0.82[0.56,1.2 0.78[0.57,1.0]
lanis 1983 iometta 1996 iometta 1996 iometta 1996 iometissen 1992 iomelissen 1992 iomeli 2001 de la Camara 1997 de Pauw 1983 dincol 1998 rjavec 1994 iibson 1989 lansen 1986 lense 2000 less 1998 lung 2003 iimeno 2006 ioehler 1990	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42 17/78 38/94 16/52 6/16 36/61 15/54 24/52 16/24 16/25	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45 15/72 49/85 19/50 14/24 16/26 13/53 27/48 23/27 19/65		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98% 1.33% 4.4% 1.65% 0.96% 1.92% 1.12% 2.4% 1.85% 1.49%	0.5[0.3,0.4 0.82[0.59,1.3 0.95[0.59,1.4 0.91[0.81,1.4 1.13[0.57,2.3 0.47[0.21,1.4 1.05[0.91,1.3 1.02[0.77,1.3 0.67[0.41,1.4 1.05[0.57,1.4 0.81[0.47,1.3 0.64[0.31,1.3 0.96[0.66,1.3 1.13[0.6,2.3 0.82[0.56,1.3 0.78[0.57,1.4
lanis 1983 iometta 1996 iometta 1996 iometta 1996 iometissen 1992 iomelissen 1992 iomeli 2001 de la Camara 1997 de Pauw 1983 dincol 1998 rjavec 1994 iibson 1989 lansen 1986 lense 2000 less 1998 lung 2003 iimeno 2006 ioehler 1990	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42 17/78 38/94 16/52 6/16 36/61 15/54 24/52 16/24	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45 15/72 49/85 19/50 14/24 16/26 13/53 27/48 23/27		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98% 1.33% 4.4% 1.65% 0.96% 1.92% 1.92% 1.12% 2.4%	0.5[0.3,0.4 0.82[0.59,1. 0.95[0.59,1.4 0.91[0.81,1.4 1.13[0.57,2.4 0.47[0.21,1.4 1.05[0.91,1.4 1.05[0.91,1.4 1.05[0.57,1.4 0.67[0.41,1.4 1.05[0.57,1.4 0.81[0.47,1.4 0.96[0.66,1.4 1.13[0.6,2.4 0.82[0.56,1.4 0.78[0.57,1.4 1[0.57,1.4]
lanis 1983 ehre 1998 cometta 1996 cornelissen 1992 cornely 2001 ehe la Camara 1997 ehe Pauw 1983 bincol 1998 rjavec 1994 dibson 1989 lansen 1986 lense 2000 less 1998 lung 2003 imeno 2006 coehler 1990 eyland 1992	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42 17/78 38/94 16/52 6/16 36/61 15/54 24/52 16/24 16/25	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45 15/72 49/85 19/50 14/24 16/26 13/53 27/48 23/27 19/65 90/148 18/92		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98% 1.33% 4.4% 1.65% 0.96% 1.92% 1.12% 2.4% 1.85% 1.49%	0.5[0.3,0.4 0.82[0.59,1.3 0.95[0.59,1.4 0.91[0.81,1.4 1.13[0.57,2.2 0.47[0.21,1.4 1.05[0.91,1.2 1.02[0.77,1.3 0.67[0.41,1.4 1.05[0.57,1.4 0.64[0.31,1.3 0.96[0.66,1.2 1.13[0.6,2.3 0.82[0.56,1.2 0.78[0.57,1.4 1[0.57,1.4 1.06[0.9,1.2]
kkova 1999 klanis 1983 Behre 1998 Cometta 1996 Cornelissen 1992 Cornelissen 1992 Cornely 2001 De la Camara 1997 De Pauw 1983 Dincol 1998 Grjavec 1994 Bibson 1989 Hansen 1986 Hense 2000 Hess 1998 Alung 2003 Dimeno 2006 Koehler 1990 Leyland 1992 Lieschke 1990 Jiu 1989	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42 17/78 38/94 16/52 6/16 36/61 15/54 24/52 16/24 16/55 106/164	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45 15/72 49/85 19/50 14/24 16/26 13/53 27/48 23/27 19/65 90/148		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98% 1.33% 4.4% 1.65% 0.96% 1.92% 1.12% 2.4% 1.85% 1.49% 8.08%	1.23[0.86,1.7 0.5[0.3,0.8 0.82[0.59,1.2 0.95[0.59,1.2 0.91[0.81,1.0 1.13[0.57,2.2 0.47[0.21,1.0 1.05[0.91,1.2 1.02[0.77,1.3 0.67[0.41,1.0 1.05[0.57,1.5 0.7[0.52,0.9 0.81[0.47,1.3 0.64[0.31,1.1] 0.96[0.66,1.2 1.13[0.6,2.2 0.82[0.56,1.2 0.78[0.57,1.0 1[0.57,1.7 1.06[0.9,1.2 1.08[0.61,1.5] 0.45[0.06,3]
lanis 1983 Behre 1998 Cometta 1996 Cornelissen 1992 Cornely 2001 De la Camara 1997 De Pauw 1983 Dincol 1998 Griavec 1994 Bibson 1989 Hansen 1986 Hense 2000 Hess 1998 Hung 2003 Limeno 2006 Goehler 1990 Leyland 1992 Leyland 1992 Leschke 1990	13/40 27/53 18/39 248/518 10/21 7/50 244/404 35/52 15/42 17/78 38/94 16/52 6/16 36/61 15/54 24/52 16/24 16/55 106/164 19/90	28/43 34/55 19/39 271/516 8/19 15/50 114/198 33/50 24/45 15/72 49/85 19/50 14/24 16/26 13/53 27/48 23/27 19/65 90/148 18/92		2.3% 2.85% 1.62% 23.19% 0.72% 1.28% 13.07% 2.87% 1.98% 1.33% 4.4% 1.65% 0.96% 1.92% 1.12% 2.4% 1.85% 1.49% 8.08% 1.52%	0.5[0.3,0.4 0.82[0.59,1.3 0.95[0.59,1.4 0.91[0.81,1.4 1.13[0.57,2.3 0.47[0.21,1.4 1.05[0.91,1.3 1.02[0.77,1.3 0.67[0.41,1.4 1.05[0.57,1.4 0.64[0.31,1.3 0.64[0.31,1.3 0.96[0.66,1.3 1.13[0.6,2.3 0.82[0.56,1.3 0.78[0.57,1.4 1.06[0.9,1.3 1.06[0.9,1.3 1.08[0.61,1.4]



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Morgan 1983	9/26	13/24		1.15%	0.64[0.34,1.22]
Norrby 1987	35/105	46/105	+	3.93%	0.76[0.54,1.08]
Novakova 1990	18/46	28/44	— + —	2.44%	0.61[0.4,0.94]
Ozyilkan 1999	6/15	6/15		0.51%	1[0.42,2.4]
Perez 1995	14/30	19/30	+- <u>+</u>	1.62%	0.74[0.46,1.18]
Petrilli 2003	21/69	14/69		1.2%	1.5[0.83,2.7]
Pickard 1983	17/40	25/40	+	2.14%	0.68[0.44,1.05]
Smith 1990	24/47	21/53		1.69%	1.29[0.83,1.99]
Yamamura 1997	17/56	17/55		1.46%	0.98[0.56,1.72]
Subtotal (95% CI)	2582	2340	•	100%	0.92[0.86,0.97]
Total events: 1175 (Monothera	apy), 1125 (Combination th	erapy)			
Heterogeneity: Tau ² =0; Chi ² =4	1.28, df=32(P=0.13); l ² =22.4	8%			
Test for overall effect: Z=2.92(P=0)				
	Favo	ours monotherapy 0.1	0.2 0.5 1 2 5	¹⁰ Favours combinatio	n

Analysis 12.9. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 9 Trial size (failure).

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
12.9.1 same BL no. randomised>	median				
Del Favero 2001	188/370	188/384	+	39.81%	1.04[0.9,1.2]
Doyen 1983	13/49	11/48		2.4%	1.16[0.58,2.33]
Kinsey 1990	48/77	59/83	-+-	12.25%	0.88[0.7,1.09]
Marie 1991	67/77	50/69	-+-	11.38%	1.2[1.01,1.42]
Rolston 1992	130/378	99/372		21.53%	1.29[1.04,1.61]
Tamura 2002	13/38	29/76	+	4.17%	0.9[0.53,1.52]
Tamura 2004	47/95	39/94	+	8.46%	1.19[0.87,1.63]
Subtotal (95% CI)	1084	1126	◆	100%	1.1[1.01,1.21]
Total events: 506 (Monotherapy), 4	75 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =8.64,	df=6(P=0.19); l ² =30.589	6			
Test for overall effect: Z=2.11(P=0.0	04)				
12.9.2 same BL no. randomised<	median				
Esteve 1997	23/39	26/46	_ -	22.44%	1.04[0.72,1.5]
Jacobs 1993	14/46	5/45	+	4.75%	2.74[1.08,6.98]
Kiehl 2001	14/35	12/36		11.13%	1.2[0.65,2.22]
Kojima 1994	10/35	3/32	+	2.95%	3.05[0.92,10.1]
Novakova 1991	19/36	18/33		17.66%	0.97[0.62,1.5]
Papachristodoulou 96	3/39	6/45	+	5.24%	0.58[0.15,2.16]
Piccart 1984	5/22	6/22	+	5.64%	0.83[0.3,2.33]
Wrzesien-Kus 2001	9/19	10/21		8.93%	0.99[0.52,1.91]
Zengin 2011	24/37	22/35	_ +	21.26%	1.03[0.73,1.46]
Subtotal (95% CI)	308	315	•	100%	1.14[0.94,1.39]
Total events: 121 (Monotherapy), 1	08 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =8.66,	df=8(P=0.37); I ² =7.67%				
Test for overall effect: Z=1.37(P=0.1	17)				
12.9.3 different BL no. randomis	ed>median				
	Favo	ours monotherapy 0.1	0.2 0.5 1 2 5	¹⁰ Favours combinatio	n



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Ahmed 2007	28/58	23/61		1.82%	1.28[0.84,1.9
Alanis 1983	20/46	27/48	+	2.14%	0.77[0.51,1.1
Cometta 1996	213/483	230/475		18.8%	0.91[0.79,1.0
Cornely 2001	193/353	92/176	-+-	9.95%	1.05[0.88,1.2
De Pauw 1994	292/488	278/480	+	22.72%	1.03[0.93,1.1
Dincol 1998	17/78	15/72		1.26%	1.05[0.57,1.9
Erjavec 1994	38/94	49/85	+	4.17%	0.7[0.52,0.9
Gaytan-Martinez 2002	9/63	7/54		0.61%	1.1[0.44,2.]
bibson 1989	16/52	19/50		1.57%	0.81[0.47,1.
Gorschluter 2003	25/56	35/51	+	2.97%	0.65[0.46,0.9
Gribble 1983	2/12	3/18		0.19%	1[0.2,5.
less 1998	9/48	8/48		0.65%	1.13[0.47,2.
oehler 1990	16/55	19/65	<u> </u>	1.41%	1[0.57,1.
eyland 1992	48/106	52/110	+	4.14%	0.96[0.72,1.
ieschke 1990	19/90	18/92		1.44%	1.08[0.61,1.
latsui 1991	9/51	10/50		0.82%	0.88[0.39,1.
lorrby 1987	35/105	46/105	+- <u>+</u>	3.73%	0.76[0.54,1.
egram 1984	21/72	20/68		1.67%	0.99[0.59,1.
ellegrin 1988	23/71	31/86	—	2.27%	0.9[0.58,1.
ereira 2009	26/62	20/63		1.61%	1.32[0.83,
Petrilli 2003	20/68	13/68	- <u> </u>	1.05%	1.54[0.83,2.
Piguet 1988	59/82	63/87	-	4.95%	0.99[0.82,
odriguez 1995	15/64	22/72		1.68%	0.77[0.44,1.
chuchter 1988	33/65	30/68	_ + +	2.38%	1.15[0.8,1.
Smith 1990	24/47	21/53	<u> </u>	1.6%	1.29[0.83,1.
Vade 1987	16/228	14/232		1.12%	1.16[0.58,2.
/amamura 1997	17/56	17/55		1.39%	0.98[0.56,1.
/ildirim 2008	26/46	22/41	— <u>+</u>	1.89%	1.05[0.72,1.
Subtotal (95% CI)	3099	2933	4	100%	0.98[0.92,1.
otal events: 1269 (Monothera	py), 1204 (Combination th	erapy)			
leterogeneity: Tau ² =0; Chi ² =2	5.63, df=27(P=0.54); l ² =0%				
Fest for overall effect: Z=0.82(F	P=0.41)				
12.9.4 different BL no. rando	mised <median< td=""><td></td><td></td><td></td><td></td></median<>				
gaoglu 2001	8/30	12/57		2.15%	1.27[0.58,2.
kova 1999	13/40	28/43	+	7.01%	0.5[0.3,0.
u 1994	5/26	9/24		2.43%	0.51[0.2,1.
Behre 1998	15/34	17/37		4.23%	0.96[0.57,1.
Bezwoda 1985	8/29	11/31		2.76%	0.78[0.36,1
Borbolla 2001	2/20	3/20 -		0.78%	0.67[0.12,3.
Conte 1996	10/21	8/19		2.18%	1.13[0.57,2
Corapcioglu 2005	12/25	15/25	+	3.9%	0.8[0.48,1.
Cornelissen 1992	4/47	12/47 —		3.12%	0.33[0.12,0.
e la Camara 1997	29/46	30/47		7.71%	0.99[0.73,1.
e Pauw 1983	11/38	24/45	+	5.71%	0.54[0.31,0.
Duzova 2001	11/45	16/45		4.16%	0.69[0.36,1.
il Haddad 1995	7/30	9/16		3.05%	0.41[0.19,0
lansen 1986	4/14	9/19	i	1.98%	0.6[0.23,1.
lense 2000	33/58	16/26		5.74%	0.92[0.63,1.
lung 2003	11/39	16/37		4.27%	0.65[0.35,1
					- /



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Kliasova 2001	8/23	10/20	+	2.78%	0.7[0.34,1.42]
Liu 1989	1/10	3/17	+	0.58%	0.57[0.07,4.74]
Miller 1993	25/45	20/41		5.44%	1.14[0.76,1.71]
Morgan 1983	9/26	13/24		3.51%	0.64[0.34,1.22]
Novakova 1990	18/46	28/44	+	7.44%	0.61[0.4,0.94]
Ozyilkan 1999	6/15	6/15		1.56%	1[0.42,2.4]
Perez 1995	14/30	19/30	+ _	4.94%	0.74[0.46,1.18]
Pickard 1983	14/37	23/38		5.9%	0.63[0.38,1.02]
Rodjer 1987	5/22	4/23		1.02%	1.31[0.4,4.24]
Subtotal (95% CI)	820	817	•	100%	0.75[0.67,0.84]
Total events: 299 (Monotherapy),	, 384 (Combination thera	іру)			
Heterogeneity: Tau ² =0; Chi ² =24.8	2, df=25(P=0.47); l ² =0%				
Test for overall effect: Z=5.05(P<0	0.0001)				

Analysis 12.10. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 10 Unit of randomisation (failure).

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
12.10.1 same beta-lactam - patier	nt				
Del Favero 2001	188/370	188/384		68.24%	1.04[0.9,1.2]
Kiehl 2001	14/35	12/36	+	4.38%	1.2[0.65,2.22]
Piccart 1984	5/22	6/22		2.22%	0.83[0.3,2.33]
Tamura 2002	13/38	29/76	+	7.15%	0.9[0.53,1.52]
Tamura 2004	47/95	39/94	- +	14.5%	1.19[0.87,1.63]
Wrzesien-Kus 2001	9/19	10/21		3.51%	0.99[0.52,1.91]
Subtotal (95% CI)	579	633	•	100%	1.05[0.93,1.19]
Total events: 276 (Monotherapy), 28	84 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =1.4, df	=5(P=0.92); I ² =0%				
Test for overall effect: Z=0.81(P=0.4	2)				
12.10.2 same beta-lactam - episo	de				
Doyen 1983	13/49	11/48		3.71%	1.16[0.58,2.33]
Esteve 1997	23/39	26/46	- _	7.97%	1.04[0.72,1.5]
Jacobs 1993	14/46	5/45		1.69%	2.74[1.08,6.98]
Kinsey 1990	48/77	59/83		18.96%	0.88[0.7,1.09]
Kojima 1994	10/35	3/32		1.05%	3.05[0.92,10.1]
Marie 1991	67/77	50/69	-+-	17.61%	1.2[1.01,1.42]
Novakova 1991	19/36	18/33	_	6.27%	0.97[0.62,1.5]
Papachristodoulou 96	3/39	6/45		1.86%	0.58[0.15,2.16]
Rolston 1992	130/378	99/372		33.33%	1.29[1.04,1.61]
Zengin 2011	24/37	22/35	_	7.55%	1.03[0.73,1.46]
Subtotal (95% CI)	813	808	◆	100%	1.16[1.04,1.3]
Total events: 351 (Monotherapy), 29	99 (Combination thera	ару)			
Heterogeneity: Tau ² =0; Chi ² =15.52,	df=9(P=0.08); I ² =42.02	2%			
Test for overall effect: Z=2.67(P=0.0	1)				
·					
	Favo	ours monotherapy 0.1	0.2 0.5 1 2 5	¹⁰ Favours combination	1



	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
12.10.3 different beta-lacta	•				
Akova 1999	13/40	28/43		3.76%	0.5[0.3,0.8
Au 1994	5/26	9/24	+	1.3%	0.51[0.2,1.3
Bezwoda 1985	8/29	11/31		1.48%	0.78[0.36,1.6
Borbolla 2001	2/20	3/20 —	•	0.42%	0.67[0.12,3.5
Cometta 1996	213/483	230/475	-	32.33%	0.91[0.79,1.0
Cornely 2001	193/353	92/176	+-	17.12%	1.05[0.88,1.2
De la Camara 1997	29/46	30/47	-+-	4.14%	0.99[0.73,1.3
De Pauw 1983	11/38	24/45		3.06%	0.54[0.31,0.9
Gibson 1989	16/52	19/50	+	2.7%	0.81[0.47,1.3
Gorschluter 2003	25/56	35/51	+	5.11%	0.65[0.46,0.9
Hense 2000	33/58	16/26		3.08%	0.92[0.63,1.3
iu 1989	1/10	3/17	•	0.31%	0.57[0.07,4.7
Norrby 1987	35/105	46/105	-+	6.41%	0.76[0.54,1.0
Dzyilkan 1999	6/15	6/15		0.84%	1[0.42,2
Pellegrin 1988	23/71	31/86	+	3.91%	0.9[0.58,1.3
Pereira 2009	10/29	10/28	-	1.42%	0.97[0.48,1.9
Rodriguez 1995	15/64	22/72		2.89%	0.77[0.44,1.3
Schuchter 1988	33/65	30/68	+ +	4.09%	1.15[0.8,1.6
amamura 1997	17/56	17/55		2.39%	0.98[0.56,1.7
/ildirim 2008	26/46	22/41	— , , _	3.24%	1.05[0.72,1.5
Subtotal (95% CI)	1662	1475	•	100%	0.89[0.82,0.9
Test for overall effect: Z=2.94(P=0)				
Fest for overall effect: Z=2.94(m - episode				
12.10.4 different beta-lacta		12/57		0.88%	1.27[0.58,2.7
12.10.4 different beta-lacta Agaoglu 2001 Ahmed 2007	m - episode 8/30 28/58	23/61		2.4%	1.28[0.84,1.9
12.10.4 different beta-lacta Agaoglu 2001 Ahmed 2007	m - episode 8/30		*		1.28[0.84,1.9
12.10.4 different beta-lacta Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001	m - episode 8/30 28/58 20/46 25/38	23/61 27/48 21/29		2.4% 2.83% 2.55%	1.28[0.84,1.9 0.77[0.51,1.1 0.91[0.66,1.2
12.10.4 different beta-lacta Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998	m - episode 8/30 28/58 20/46	23/61 27/48		2.4% 2.83%	1.28[0.84,1.9 0.77[0.51,1.1 0.91[0.66,1.2
12.10.4 different beta-lacta Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998	m - episode 8/30 28/58 20/46 25/38	23/61 27/48 21/29		2.4% 2.83% 2.55%	1.28[0.84,1.5 0.77[0.51,1.] 0.91[0.66,1.2 0.96[0.57,1.6
12.10.4 different beta-lacta Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25	23/61 27/48 21/29 17/37 8/19 15/25		2.4% 2.83% 2.55% 1.74% 0.9% 1.6%	1.28[0.84,1.5 0.77[0.51,1.1 0.91[0.66,1.2 0.96[0.57,1.6 1.13[0.57,2.2
12.10.4 different beta-lacta Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005	m - episode 8/30 28/58 20/46 25/38 15/34 10/21	23/61 27/48 21/29 17/37 8/19		2.4% 2.83% 2.55% 1.74% 0.9%	1.27[0.58,2.7 1.28[0.84,1.9 0.77[0.51,1.1 0.91[0.66,1.2 0.96[0.57,1.6 1.13[0.57,2.2 0.8[0.48,1.3 0.33[0.12,0.9
12.10.4 different beta-lacta Agaoglu 2001	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25	23/61 27/48 21/29 17/37 8/19 15/25		2.4% 2.83% 2.55% 1.74% 0.9% 1.6%	1.28[0.84,1.9 0.77[0.51,1.1 0.91[0.66,1.2 0.96[0.57,1.6 1.13[0.57,2.2 0.8[0.48,1.3
Azanol, 4 different beta-lactar Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992 De Pauw 1994	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47	23/61 27/48 21/29 17/37 8/19 15/25 12/47 —		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 1.28%	1.28[0.84,1.9 0.77[0.51,1.1 0.91[0.66,1.2 0.96[0.57,1.6 1.13[0.57,2.2 0.8[0.48,1.3 0.33[0.12,0.9
Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992 De Pauw 1994 Dincol 1998	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47 292/488	23/61 27/48 21/29 17/37 8/19 15/25 12/47 — 278/480		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 1.28% 29.97%	1.28[0.84,1.5 0.77[0.51,1.1 0.91[0.66,1.2 0.96[0.57,1.6 1.13[0.57,2.2 0.8[0.48,1.3 0.33[0.12,0.5 1.03[0.93,1.1 1.05[0.57,1.5
Azanol, 4 different beta-lactar Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992 De Pauw 1994 Dincol 1998 Duzova 2001	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47 292/488 17/78	23/61 27/48 21/29 17/37 8/19 15/25 12/47 278/480 15/72		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 1.28% 29.97% 1.67%	1.28[0.84,1.9 0.77[0.51,1.] 0.91[0.66,1.2 0.96[0.57,1.6 1.13[0.57,2.2 0.8[0.48,1.3 0.33[0.12,0.9 1.03[0.93,1.1 1.05[0.57,1.9 0.69[0.36,1.3
L2.10.4 different beta-lactar Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992 De Pauw 1994 Dincol 1998 Duzova 2001 El Haddad 1995	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47 292/488 17/78 11/45	23/61 27/48 21/29 17/37 8/19 15/25 12/47 278/480 15/72 16/45		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 1.28% 29.97% 1.67% 1.71%	1.28[0.84,1.5 0.77[0.51,1.1 0.91[0.66,1.2 0.96[0.57,1.6 1.13[0.57,2.2 0.8[0.48,1.3 0.33[0.12,0.5 1.03[0.93,1.1 1.05[0.57,1.5 0.69[0.36,1.3 0.41[0.19,0
L2.10.4 different beta-lactar Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992 De Pauw 1994 Dincol 1998 Duzova 2001 El Haddad 1995 Erjavec 1994	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47 292/488 17/78 11/45 7/30	23/61 27/48 21/29 17/37 8/19 15/25 12/47 278/480 15/72 16/45 9/16		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 29.97% 1.67% 1.71% 1.26%	1.28[0.84,1.5 0.77[0.51,1.1 0.91[0.66,1.2 0.96[0.57,1.6 1.13[0.57,2.2 0.8[0.48,1.3 0.33[0.12,0.9 1.03[0.93,1.1 1.05[0.57,1.5 0.69[0.36,1.3 0.41[0.19,0 0.7[0.52,0.9
L2.10.4 different beta-lactar Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992 De Pauw 1994 Dincol 1998 Duzova 2001 El Haddad 1995 Erjavec 1994 Gaytan-Martinez 2002	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47 292/488 17/78 11/45 7/30 38/94	23/61 27/48 21/29 17/37 8/19 15/25 12/47 278/480 15/72 16/45 9/16 49/85		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 1.28% 29.97% 1.67% 1.71% 1.26% 5.5%	1.28[0.84,1.9 0.77[0.51,1.1 0.91[0.66,1.2 0.96[0.57,1.6 1.13[0.57,2.2 0.8[0.48,1.3 0.33[0.12,0.9 1.03[0.93,1.1
2.10.4 different beta-lactar Igaoglu 2001 Ihmed 2007 Ilanis 1983 Intmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992 De Pauw 1994 Dincol 1998 Duzova 2001 Il Haddad 1995 Gripavec 1994 Gaytan-Martinez 2002 Gribble 1983	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47 292/488 17/78 11/45 7/30 38/94 9/63	23/61 27/48 21/29 17/37 8/19 15/25 12/47 278/480 15/72 16/45 9/16 49/85 7/54		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 1.28% 29.97% 1.67% 1.71% 1.26% 5.5% 0.81%	1.28[0.84,1.5] 0.77[0.51,1.1] 0.91[0.66,1.2] 0.96[0.57,1.6] 1.13[0.57,2.2] 0.8[0.48,1.3] 0.33[0.12,0.5] 1.03[0.93,1.1] 1.05[0.57,1.5] 0.69[0.36,1.3] 0.41[0.19,0] 0.7[0.52,0.5] 1.1[0.44,2.7] 1[0.2,5,1]
2.10.4 different beta-lactar gaoglu 2001 whmed 2007 valanis 1983 whtmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992 De Pauw 1994 Dincol 1998 Duzova 2001 El Haddad 1995 Gripvec 1994 Gaytan-Martinez 2002 Gribble 1983 Hansen 1986	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47 292/488 17/78 11/45 7/30 38/94 9/63 2/12	23/61 27/48 21/29 17/37 8/19 15/25 12/47 278/480 15/72 16/45 9/16 49/85 7/54 3/18		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 1.28% 29.97% 1.67% 1.71% 1.26% 5.5% 0.81% 0.26%	1.28[0.84,1.9 0.77[0.51,1.1 0.91[0.66,1.2 0.96[0.57,1.6 1.13[0.57,2.2 0.8[0.48,1.3 0.33[0.12,0.9 1.03[0.93,1.1 1.05[0.57,1.9 0.69[0.36,1.3 0.41[0.19,0 0.7[0.52,0.9 1.1[0.44,2.7 1[0.2,5.1 0.6[0.23,1.5]
L2.10.4 different beta-lactar Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992 De Pauw 1994 Dincol 1998 Duzova 2001 El Haddad 1995 Erjavec 1994 Gaytan-Martinez 2002 Gribble 1983 Hansen 1986 Hess 1998	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47 292/488 17/78 11/45 7/30 38/94 9/63 2/12 4/14	23/61 27/48 21/29 17/37 8/19 15/25 12/47 278/480 15/72 16/45 9/16 49/85 7/54 3/18 9/19		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 1.28% 29.97% 1.67% 1.71% 1.26% 5.5% 0.81% 0.26% 0.82%	$\begin{array}{c} 1.28[0.84].45\\ 0.77[0.51].1\\ 0.91[0.66].2\\ 0.96[0.57].16\\ 1.13[0.57].2\\ 0.8[0.48].1\\ 0.33[0.12].05\\ 1.03[0.93].1\\ 1.05[0.57].1\\ 0.69[0.36].1\\ 0.41[0.19].0\\ 0.7[0.52].0\\ 1.1[0.44].2\\ 1\\ 1[0.25].1\\ 0.6[0.23].$
L2.10.4 different beta-lactar Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992 De Pauw 1994 Dincol 1998 Duzova 2001 El Haddad 1995 Erjavec 1994 Gaytan-Martinez 2002 Gribble 1983 Hansen 1986 Hess 1998 Hung 2003	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47 292/488 17/78 11/45 7/30 38/94 9/63 2/12 4/14 9/48	23/61 27/48 21/29 17/37 8/19 15/25 12/47 278/480 15/72 16/45 9/16 49/85 7/54 3/18 9/19 8/48		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 1.28% 29.97% 1.67% 1.71% 1.26% 5.5% 0.81% 0.26% 0.82% 0.86%	1.28[0.84,1.9 0.77[0.51,1.1 0.91[0.66,1.2 0.96[0.57,1.6 1.13[0.57,2.2 0.8[0.48,1.3 0.33[0.12,0.9 1.03[0.93,1.1 1.05[0.57,1.9 0.69[0.36,1.3 0.41[0.19,0 0.7[0.52,0.9 1.1[0.44,2.7 1[0.25,1.9 0.6[0.23,1.9 1.13[0.47,2.6 0.65[0.35,1.2]
L2.10.4 different beta-lactar Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992 De Pauw 1994 Dincol 1998 Duzova 2001 El Haddad 1995 Erjavec 1994 Gaytan-Martinez 2002 Gribble 1983 Hansen 1986 Hess 1998 Hung 2003 Jimeno 2006	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47 292/488 17/78 11/45 7/30 38/94 9/63 2/12 4/14 9/48	23/61 27/48 21/29 17/37 8/19 15/25 12/47 278/480 15/72 16/45 9/16 49/85 7/54 3/18 9/19 8/48 16/37		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 1.28% 29.97% 1.67% 1.71% 1.26% 5.5% 0.81% 0.26% 0.82% 0.86% 1.76%	1.28[0.84,1.5] 0.77[0.51,1.1] 0.91[0.66,1.2] 0.96[0.57,1.6] 1.13[0.57,2.2] 0.8[0.48,1.3] 0.33[0.12,0.5] 1.03[0.93,1.1] 1.05[0.57,1.5] 0.69[0.36,1.3] 0.41[0.19,0] 0.7[0.52,0.5] 1.1[0.44,2.7] 1.6[0.23,1.5] 1.13[0.47,2.6] 0.65[0.35,1.2] 0.78[0.57,1.0]
L2.10.4 different beta-lactar Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992 De Pauw 1994 Dincol 1998 Duzova 2001 El Haddad 1995 Erjavec 1994 Gaytan-Martinez 2002 Gribble 1983 Hansen 1986 Hess 1998 Hung 2003 Jimeno 2006 Kliasova 2001	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47 292/488 17/78 11/45 7/30 38/94 9/63 2/12 4/14 9/48 11/39	23/61 27/48 21/29 17/37 8/19 15/25 12/47 278/480 15/72 16/45 9/16 49/85 7/54 3/18 9/19 8/48 16/37 23/27		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 1.28% 29.97% 1.67% 1.71% 1.26% 5.5% 0.81% 0.26% 0.82% 0.86% 1.76% 2.31%	1.28[0.84,1.9 0.77[0.51,1.1 0.91[0.66,1.2 0.96[0.57,1.6 1.13[0.57,2.2 0.8[0.48,1.3 0.33[0.12,0.9 1.03[0.93,1.1 1.05[0.57,1.9 0.69[0.36,1.3 0.41[0.19,0 0.7[0.52,0.9 1.1[0.44,2.7 1[0.2,5.1 0.6[0.23,1.5]
12.10.4 different beta-lacta Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47 292/488 17/78 11/45 7/30 38/94 9/63 2/12 4/14 9/48 11/39 16/24	23/61 27/48 21/29 17/37 8/19 15/25 12/47 278/480 15/72 16/45 9/16 49/85 7/54 3/18 9/19 8/48 16/37 23/27 10/20		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 1.28% 29.97% 1.67% 1.71% 1.26% 5.5% 0.81% 0.26% 0.82% 0.82% 0.86% 1.76% 2.31% 1.14%	1.28[0.84,1.5] 0.77[0.51,1.1] 0.91[0.66,1.2] 0.96[0.57,1.6] 1.13[0.57,2.2] 0.8[0.48,1.3] 0.33[0.12,0.5] 1.03[0.93,1.1] 1.05[0.57,1.5] 0.69[0.36,1.3] 0.41[0.19,0] 0.7[0.52,0.5] 1.1[0.44,2.7] 1.6[0.23,1.5] 0.66[0.23,1.5] 0.65[0.35,1.2] 0.78[0.57,1.0] 0.7[0.34,1.4]
L2.10.4 different beta-lactar Agaoglu 2001 Ahmed 2007 Alanis 1983 Antmen 2001 Behre 1998 Conte 1996 Corapcioglu 2005 Cornelissen 1992 De Pauw 1994 Dincol 1998 Duzova 2001 El Haddad 1995 Erjavec 1994 Gaytan-Martinez 2002 Gribble 1983 Hansen 1986 Hess 1998 Hung 2003 Jimeno 2006 Kliasova 2001 Koehler 1990	m - episode 8/30 28/58 20/46 25/38 15/34 10/21 12/25 4/47 292/488 17/78 11/45 7/30 38/94 9/63 2/12 4/14 9/48 11/39 16/24 8/23 16/55	23/61 27/48 21/29 17/37 8/19 15/25 12/47 278/480 15/72 16/45 9/16 49/85 7/54 3/18 9/19 8/48 16/37 23/27 10/20 19/65		2.4% 2.83% 2.55% 1.74% 0.9% 1.6% 1.28% 29.97% 1.67% 1.71% 1.26% 5.5% 0.81% 0.26% 0.82% 0.86% 1.76% 2.31% 1.14%	1.28[0.84,1.9 0.77[0.51,1.: 0.91[0.66,1.2 0.96[0.57,1.6 1.13[0.57,2.2 0.8[0.48,1.3 0.33[0.12,0.9 1.03[0.93,1.: 1.05[0.57,1.9 0.69[0.36,1.3 0.41[0.19,0 0.7[0.52,0.9 1.1[0.44,2.7 1.0,25,.3 1.13[0.47,2.6 0.65[0.23,1.2 0.78[0.57,1.0 0.78[0.57,1.0 0.7[0.34,1.4 1[0.57,1.7]



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Miller 1993	25/45	20/41	++	2.24%	1.14[0.76,1.71]
Morgan 1983	9/26	13/24		1.45%	0.64[0.34,1.22]
Novakova 1990	18/46	28/44	— · —	3.06%	0.61[0.4,0.94]
Pegram 1984	21/72	20/68	<u> </u>	2.2%	0.99[0.59,1.66]
Pereira 2009	26/62	20/63	- + -	2.12%	1.32[0.83,2.1]
Perez 1995	14/30	19/30		2.03%	0.74[0.46,1.18]
Petrilli 2003	20/68	13/68		1.39%	1.54[0.83,2.84]
Pickard 1983	14/37	23/38	+	2.43%	0.63[0.38,1.02]
Piguet 1988	59/82	63/87	- + -	6.54%	0.99[0.82,1.2]
Rodjer 1987	5/22	4/23		0.42%	1.31[0.4,4.24]
Smith 1990	24/47	21/53		2.11%	1.29[0.83,1.99]
Wade 1987	16/228	14/232		1.48%	1.16[0.58,2.33]
Subtotal (95% CI)	2324	2332	•	100%	0.95[0.89,1.01]
Total events: 889 (Monotherapy), 93	5 (Combination thera	ру)			
Heterogeneity: Tau ² =0; Chi ² =41.75, c	lf=35(P=0.2); I ² =16.18	%			
Test for overall effect: Z=1.6(P=0.11)					
	Favo	urs monotherapy 0.1	. 0.2 0.5 1 2 5	¹⁰ Favours combinatio	 1

Analysis 12.11. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 11 Blinding (failure).

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
12.11.1 same beta-lactam - doul	ble blind				
Del Favero 2001	188/370	188/384	-+-	100%	1.04[0.9,1.2]
Subtotal (95% CI)	370	384	•	100%	1.04[0.9,1.2]
Total events: 188 (Monotherapy),	188 (Combination ther	ару)			
Heterogeneity: Not applicable					
Test for overall effect: Z=0.51(P=0.	61)				
12.11.2 same beta-lactam - othe	r				
Doyen 1983	13/49	11/48		2.88%	1.16[0.58,2.33]
Esteve 1997	23/39	26/46	—	6.19%	1.04[0.72,1.5]
Jacobs 1993	14/46	5/45		1.31%	2.74[1.08,6.98]
Kiehl 2001	14/35	12/36		3.07%	1.2[0.65,2.22]
Kinsey 1990	48/77	59/83	-+	14.74%	0.88[0.7,1.09]
Kojima 1994	10/35	3/32		0.81%	3.05[0.92,10.1]
Marie 1991	67/77	50/69		13.69%	1.2[1.01,1.42]
Novakova 1991	19/36	18/33		4.87%	0.97[0.62,1.5]
Papachristodoulou 96	3/39	6/45		1.45%	0.58[0.15,2.16]
Piccart 1984	5/22	6/22		1.56%	0.83[0.3,2.33]
Rolston 1992	130/378	99/372		25.9%	1.29[1.04,1.61]
Tamura 2002	13/38	29/76	+	5.02%	0.9[0.53,1.52]
Tamura 2004	47/95	39/94	- +	10.18%	1.19[0.87,1.63]
Wrzesien-Kus 2001	9/19	10/21		2.47%	0.99[0.52,1.91]
Zengin 2011	24/37	22/35	_	5.87%	1.03[0.73,1.46]
Subtotal (95% CI)	1022	1057	•	100%	1.14[1.04,1.26]
Total events: 439 (Monotherapy),	395 (Combination ther	ару)			
Heterogeneity: Tau ² =0; Chi ² =16.6,	df=14(P=0.28); I ² =15.68	3%			
	Fav	ours monotherapy 0.1	0.2 0.5 1 2 5	¹⁰ Favours combination	n



Cochrane Database of Systematic Reviews

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Test for overall effect: Z=2.65(P=0.01)				
12.11.3 different beta-lacta	m - double blind				
Ozyilkan 1999	6/15	6/15		12.19%	1[0.42,2
Schuchter 1988	33/65	30/68	<mark></mark>	59.6%	1.15[0.8,1.6
Wade 1987	16/228	14/232		28.21%	1.16[0.58,2.3
Subtotal (95% CI)	308	315	-	100%	1.14[0.83,1.5
otal events: 55 (Monotherap	y), 50 (Combination therap	/)			
leterogeneity: Tau ² =0; Chi ² =0	0.09, df=2(P=0.96); l ² =0%				
Test for overall effect: Z=0.81((P=0.42)				
L2.11.4 different beta-lacta	m - other				
gaoglu 2001	8/30	12/57	+	0.52%	1.27[0.58,2.
hmed 2007	28/58	23/61		1.41%	1.28[0.84,1.9
kova 1999	13/40	28/43	İ	1.69%	0.5[0.3,0.
lanis 1983	20/46	27/48	_	1.66%	0.77[0.51,1.
Intmen 2001	25/38	21/29	<u> </u>	1.5%	0.91[0.66,1.
u 1994	5/26	9/24	_	0.59%	0.51[0.2,1.
Behre 1998	15/34	17/37		1.02%	0.96[0.57,1.
ezwoda 1985	8/29	11/31	_	0.67%	0.78[0.36,1.
Borbolla 2001	2/20	3/20		0.19%	0.67[0.12,3.
cometta 1996	213/483	230/475		14.56%	0.91[0.79,1.
onte 1996	10/21	8/19		0.53%	1.13[0.57,2.
Corapcioglu 2005	12/25	15/25		0.94%	0.8[0.48,1.
ornelissen 1992	4/47	12/47		0.75%	0.33[0.12,0.
Cornely 2001	193/353	92/176	-	7.71%	1.05[0.88,1
De la Camara 1997	29/46	30/47	-	1.86%	0.99[0.73,1.
De Pauw 1983	11/38	24/45		1.38%	0.54[0.31,0.
0e Pauw 1994	292/488	278/480	· _	17.59%	1.03[0.93,1.
Dincol 1998	17/78	15/72		0.98%	1.05[0.57,1.
Juzova 2001	11/45	16/45		1%	0.69[0.36,1.
il Haddad 1995	7/30	9/16		0.74%	0.41[0.19,0
rjavec 1994	38/94	49/85		3.23%	0.7[0.52,0.
Gaytan-Martinez 2002	9/63	7/54		0.47%	1.1[0.44,2.
ibson 1989	16/52	19/50		1.22%	0.81[0.47,1.
Gorschluter 2003	25/56	35/51		2.3%	0.65[0.46,0.
iribble 1983	2/12			0.15%	
	2/12 4/14	3/18		0.15%	1[0.2,5.
lansen 1986 Iense 2000		9/19			0.6[0.23,1.
	33/58	16/26		1.39%	0.92[0.63,1.
less 1998	9/48	8/48		0.5%	1.13[0.47,2.
lung 2003	11/39	16/37		1.03%	0.65[0.35,1.
imeno 2006	16/24	23/27		1.36%	0.78[0.57,1
liasova 2001	8/23	10/20		0.67%	0.7[0.34,1.
oehler 1990	16/55	19/65		1.09%	1[0.57,1.
eyland 1992	48/106	52/110		3.2%	0.96[0.72,1.
ieschke 1990	19/90	18/92		1.12%	1.08[0.61,1.
iu 1989	1/10	3/17	· · ·	0.14%	0.57[0.07,4.
latsui 1991	9/51	10/50		0.63%	0.88[0.39,1.
1iller 1993	25/45	20/41		1.31%	1.14[0.76,1.
lorgan 1983	9/26	13/24		0.85%	0.64[0.34,1.
lorrby 1987	35/105	46/105	 +	2.89%	0.76[0.54,1.



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Novakova 1990	18/46	28/44	— + —	1.8%	0.61[0.4,0.94]
Pegram 1984	21/72	20/68		1.29%	0.99[0.59,1.66]
Pellegrin 1988	23/71	31/86		1.76%	0.9[0.58,1.39]
Pereira 2009	26/62	20/63	- + -	1.25%	1.32[0.83,2.1]
Perez 1995	14/30	19/30		1.19%	0.74[0.46,1.18]
Petrilli 2003	20/68	13/68		0.82%	1.54[0.83,2.84]
Pickard 1983	14/37	23/38		1.42%	0.63[0.38,1.02]
Piguet 1988	59/82	63/87	-	3.84%	0.99[0.82,1.2]
Rodjer 1987	5/22	4/23		0.25%	1.31[0.4,4.24]
Rodriguez 1995	15/64	22/72		1.3%	0.77[0.44,1.35]
Smith 1990	24/47	21/53		1.24%	1.29[0.83,1.99]
Yamamura 1997	17/56	17/55		1.08%	0.98[0.56,1.72]
Yildirim 2008	26/46	22/41	<u> </u>	1.46%	1.05[0.72,1.54]
Subtotal (95% CI)	3649	3464	•	100%	0.92[0.87,0.96]
Total events: 1538 (Monotherapy),	1559 (Combination the	erapy)			
Heterogeneity: Tau ² =0; Chi ² =62.18,	, df=51(P=0.14); l ² =17.9	8%			
Test for overall effect: Z=3.38(P=0)					
	Favo	ours monotherapy 0.1	0.2 0.5 1 2 5	¹⁰ Favours combinatio	n

Analysis 12.12. Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 12 Publication status (failure).

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
12.12.1 same beta-lactam - j	journal publication				
Del Favero 2001	188/370	188/384	-	35.66%	1.04[0.9,1.2]
Jacobs 1993	14/46	5/45		0.98%	2.74[1.08,6.98]
Kinsey 1990	48/77	59/83	-+-	10.97%	0.88[0.7,1.09]
Kojima 1994	10/35	3/32	++	0.61%	3.05[0.92,10.1]
Marie 1991	67/77	50/69		10.19%	1.2[1.01,1.42]
Novakova 1991	19/36	18/33	— ,	3.63%	0.97[0.62,1.5]
Piccart 1984	5/22	6/22		1.16%	0.83[0.3,2.33]
Rolston 1992	130/378	99/372		19.29%	1.29[1.04,1.61]
Tamura 2002	13/38	29/76		3.74%	0.9[0.53,1.52]
Tamura 2004	47/95	39/94	- +- -	7.58%	1.19[0.87,1.63]
Wrzesien-Kus 2001	9/19	10/21		1.84%	0.99[0.52,1.91]
Zengin 2011	24/37	22/35		4.37%	1.03[0.73,1.46]
Subtotal (95% CI)	1230	1266	•	100%	1.12[1.02,1.21]
Total events: 574 (Monothera	py), 528 (Combination ther	ару)			
Heterogeneity: Tau ² =0; Chi ² =1	16.09, df=11(P=0.14); l ² =31.0	52%			
Test for overall effect: Z=2.52((P=0.01)				
12.12.2 same beta-lactam -	other				
Doyen 1983	13/49	11/48		21.22%	1.16[0.58,2.33]
Esteve 1997	23/39	26/46		45.55%	1.04[0.72,1.5]
Kiehl 2001	14/35	12/36		22.59%	1.2[0.65,2.22]
Papachristodoulou 96	3/39	6/45	+	10.64%	0.58[0.15,2.16]
Subtotal (95% CI)	162	175	+	100%	1.05[0.79,1.41]
	Fav	ours monotherapy 0.1	0.2 0.5 1 2 5	¹⁰ Favours combinatio	n



Cochrane Database of Systematic Reviews

Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Fotal events: 53 (Monotherapy		y)			
Heterogeneity: Tau ² =0; Chi ² =1					
Test for overall effect: Z=0.35(I	9=0.73)				
12.12.3 different beta-lactar	n - journal publication				
Agaoglu 2001	8/30	12/57		0.62%	1.27[0.58,2.7
Ahmed 2007	28/58	23/61	- 	1.67%	1.28[0.84,1.9
Akova 1999	13/40	28/43	— + — ·	2.01%	0.5[0.3,0.8
Alanis 1983	20/46	27/48	— + -	1.97%	0.77[0.51,1.1
Au 1994	5/26	9/24		0.7%	0.51[0.2,1.3
3ehre 1998	15/34	17/37		1.21%	0.96[0.57,1.6
Bezwoda 1985	8/29	11/31		0.79%	0.78[0.36,1.6
Borbolla 2001	2/20	3/20 —	+	0.22%	0.67[0.12,3.5
Cometta 1996	213/483	230/475		17.27%	0.91[0.79,1.0
orapcioglu 2005	12/25	15/25		1.12%	0.8[0.48,1.3
ornelissen 1992	4/47	12/47 —		0.89%	0.33[0.12,0.
e la Camara 1997	29/46	30/47	<u> </u>	2.21%	0.99[0.73,1.
e Pauw 1983	11/38	24/45		1.64%	0.54[0.31,0.
e Pauw 1994	292/488	278/480	+	20.87%	1.03[0.93,1.
Dincol 1998	17/78	15/72		1.16%	1.05[0.57,1.
Duzova 2001	11/45	16/45	_	1.19%	0.69[0.36,1.
l Haddad 1995	7/30	9/16		0.87%	0.41[0.19,0
rjavec 1994	38/94	49/85		3.83%	0.7[0.52,0.
ibson 1989	16/52	19/50		1.44%	0.81[0.47,1.
Gorschluter 2003	25/56	35/51		2.73%	0.65[0.46,0.
Gribble 1983	2/12	3/18	-	0.18%	1[0.2,5.
lansen 1986	4/14	9/19		0.57%	0.6[0.23,1.
less 1998	9/48	8/48		0.6%	1.13[0.47,2.
lung 2003	11/39	16/37		1.22%	0.65[0.35,1.
limeno 2006	16/24	23/27		1.61%	0.78[0.57,1.4
Koehler 1990	16/55	19/65	·	1.3%	1[0.57,1.7
eyland 1992	48/106	52/110		3.8%	0.96[0.72,1.
iu 1989		3/17		0.17%	0.57[0.07,4.]
latsui 1991	1/10 9/51	10/50		0.75%	0.88[0.39,1.
Ailler 1993	25/45	20/41		1.56%	1.14[0.76,1.
Norgan 1983	9/26	13/24		1.01%	0.64[0.34,1.
lorrby 1987	35/105	46/105		3.43%	0.76[0.54,1.
lovakova 1990	18/46	28/44		2.13%	0.61[0.4,0.
)zyilkan 1999	6/15	6/15		0.45%	1[0.42,2
ellegrin 1988	23/71	31/86		2.09%	0.9[0.58,1.
Pereira 2009	26/62	20/63		1.48%	1.32[0.83,2
Perez 1995	14/30	19/30		1.41%	0.74[0.46,1.
Petrilli 2003	20/68	13/68		0.97%	1.54[0.83,2.
iguet 1988	59/82	63/87		4.55%	0.99[0.82,1
Rodjer 1987	5/22	4/23		0.29%	1.31[0.4,4.
odriguez 1995	15/64	22/72		1.54%	0.77[0.44,1.
Smith 1990	24/47	21/53		1.47%	1.29[0.83,1.
'amamura 1997	17/56	17/55		1.28%	0.98[0.56,1.
/ildirim 2008	26/46	22/41		1.73%	1.05[0.72,1.
Subtotal (95% CI)	2909	2957	♦	100%	0.9[0.86,0.9



Study or subgroup	Monotherapy	Combina- tion therapy	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Heterogeneity: Tau ² =0; Chi ² =56.	25, df=43(P=0.08); l ² =23.	55%			
Test for overall effect: Z=3.5(P=0)				
12.12.4 different beta-lactam	- other				
Antmen 2001	25/38	21/29	-+-	7.95%	0.91[0.66,1.25]
Conte 1996	10/21	8/19		2.8%	1.13[0.57,2.26]
Cornely 2001	193/353	92/176	+	40.98%	1.05[0.88,1.24]
Gaytan-Martinez 2002	9/63	7/54		2.52%	1.1[0.44,2.76]
Hense 2000	33/58	16/26	+	7.37%	0.92[0.63,1.35]
Kliasova 2001	8/23	10/20	+	3.57%	0.7[0.34,1.42]
Lieschke 1990	19/90	18/92	+	5.94%	1.08[0.61,1.92]
Pegram 1984	21/72	20/68	_	6.87%	0.99[0.59,1.66]
Pickard 1983	14/37	23/38	+	7.57%	0.63[0.38,1.02]
Schuchter 1988	33/65	30/68		9.79%	1.15[0.8,1.65]
Wade 1987	16/228	14/232		4.63%	1.16[0.58,2.33]
Subtotal (95% CI)	1048	822	•	100%	1[0.89,1.12]
Total events: 381 (Monotherapy)), 259 (Combination ther	ару)			
Heterogeneity: Tau ² =0; Chi ² =6.3	6, df=10(P=0.78); l ² =0%				
Test for overall effect: Z=0.01(P=	0.99)				
	Fav	ours monotherapy	0.1 0.2 0.5 1 2 5	¹⁰ Favours combinatio	n

APPENDICES

Appendix 1. MEDLINE search strategy

Medline Ovid

- 1 exp Neoplasms/
- 2 Bone Marrow Transplantation/

3 (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinoma* or adenocarcinoma* or leukemia* or leukaemia* or bone marrow transplant*).mp.

- 4 1 or 2 or 3
- 5 exp Agranulocytosis/
- 6 (agranulocytosis or neutropen* or neutropaen* or granulocytopen* or granulocytopaen* or granulopaen*).mp.
- 7 5 or 6
- 8 exp beta-Lactams/
- 9 exp Anti-Bacterial Agents/
- 10 (beta-lactam* or antibiotic* or antimicrob* or anti-microb* or antibacteria* or anti-bacteria*).mp.
- 11 8 or 9 or 10
- 12 exp Aminoglycosides/

13 (aminoglycoside* or gentamicin or gentamycin or amikacin or amikacyn or tobramicin or tobramycin or kanamicin or kanamycin or netilmicin or netilmycin).mp.

- 14 12 or 13
- 15 4 and 7 and 11 and 14
- 16 randomized controlled trial.pt.
- 17 controlled clinical trial.pt.
- 18 randomized.ab
- 19 placebo.ab.
- 20 drug therapy.fs.
- 21 randomly.ab.
- 22 trial.ab.
- 23 groups.ab.
- 24 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



25 15 and 24

key:

mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier, pt=publication type, ab=abstract, sh=subject heading, ti=title

Appendix 2. EMBASE search strategy

Embase Ovid

- 1 exp neoplasm/
- 2 exp bone marrow transplantation/

3 (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinoma* or adenocarcinoma* or leukemia* or leukaemia* or bone marrow transplant*).mp.

- 4 1 or 2 or 3
- 5 agranulocytosis/
- 6 exp neutropenia/
- 7 (agranulocytosis or neutropen* or neutropaen* or granulocytopen* or granulocytopaen* or granulopen* or granulopaen*).mp.
- 8 5 or 6 or 7
- 9 exp antiinfective agent/
- 10 (beta-lactam* or antibiotic* or antimicrob* or anti-microb* or antibacterial* or anti-bacteria*).mp.
- 11 9 or 10
- 12 exp aminoglycoside antibiotic agent/

13 (aminoglycoside* or gentamicin or gentamycin or amikacin or amikacyn or tobramicin or tobramycin or kanamicin or kanamycin or netilmicin or netilmycin).mp.

- 14 12 or 13
- 15 4 and 8 and 11 and 14
- 16 crossover procedure/
- 17 double-blind procedure/
- 18 randomized controlled trial/
- 19 single-blind procedure/
- 20 random*.mp.
- 21 factorial*.mp.
- 22 (crossover* or cross over* or cross-over*).mp.
- 23 placebo*.mp.
- 24 (double* adj blind*).mp.
- 25 (singl* adj blind*).mp.
- 26 assign*.mp.
- 27 allocat*.mp.
- 28 volunteer*.mp.
- 29 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
- 30 15 and 29

key

[mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

Appendix 3. CENTRAL search strategy

CENTRAL/DARE

- #1 MeSH descriptor Neoplasms explode all trees
- #2 MeSH descriptor Bone Marrow Transplantation, this term only

#3 (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinoma* or adenocarcinoma* or leukemia* or leukaemia* or bone marrow transplant*)

- #4 (#1 OR #2 OR #3)
- #5 MeSH descriptor Agranulocytosis explode all trees
- #6 (agranulocytosis or neutropen* or neutropaen* or granulocytopen* or granulocytopaen* or granulopen* or granulopaen*)
- #7 (#5 OR #6)
- #8 MeSH descriptor beta-Lactams explode all trees
- **Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia (Review)** Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



#9 MeSH descriptor Anti-Bacterial Agents explode all trees

#10 beta-lactam* or antibiotic* or antimicrob* or anti-microb* or antibacterial* or anti-bacteria*

#11 (#8 OR #9 OR #10)

#12 MeSH descriptor Aminoglycosides explode all trees

#13 (aminoglycoside* or gentamicin or gentamycin or amikacin or amikacyn or tobramicin or tobramycin or kanamicin or kanamycin or netilmicin or netilmicin)

#14 (#12 OR #13)

#15 (#4 AND #7 AND #11 AND #14)

WHAT'S NEW

Date	Event	Description
21 September 2016	Amended	Contact details updated.

HISTORY

Protocol first published: Issue 2, 2001 Review first published: Issue 2, 2002

Date	Event	Description
11 February 2015	Amended	Contact details updated.
26 February 2014	Amended	Contact details updated.
7 June 2013	New citation required but conclusions have not changed	No change to conclusions.
10 April 2013	New search has been performed	Three new trials identified.
7 November 2007	New search has been performed	New studies found and included or excluded: 01/06/07.
		Addition of infection-related mortality as a protocol-defined out- come. Search updated and expanded the search of conference pro- ceedings (ECCMID, ASH). Deleted the limitation on inclusion of trials with >30% dropouts and assessed the effect of dropouts through sensitivity analyses. The comparisons of 'same' and 'different' beta-lactams separat- ed throughout the review for the analysis of treatment failure. Re-wrote results, discussion and implications for further prac- tice and research.
17 April 2003	New citation required and conclusions have changed	Substantive amendment

CONTRIBUTIONS OF AUTHORS

Mical Paul performed the search and article retrieval; applied inclusion and exclusion criteria; performed quality assessment and data extraction; contacted authors; analysed results and wrote the review. Yaakov Dickstein conducted the search for the 2012 update, extracted the data from new trials, entered data into RevMan and wrote the review for the 2012 update. Karla Soares-Weiser applied inclusion and exclusion criteria; performed data extraction; analysed results — all for the previous version of the review and commented on all drafts and



final version of the review. Simona Grozinsky-Glasberg assisted with search; retrieved articles; applied inclusion and exclusion criteria and assisted in data extraction — all for the previous version of the review. Leonard Leibovici performed search; applied inclusion and exclusion criteria; performed data extraction; assisted with author correspondence; analysed results; assisted in writing the review and commented on all drafts and final version of the review.

DECLARATIONS OF INTEREST

None known.

SOURCES OF SUPPORT

Internal sources

- Rabin Medical Center, Beilison Campus, Skidal Foundation, Israel.
- Tel-Aviv University, Sackler Faculty of Medicine, Israel.

External sources

• EU 5th Framework: TREAT project (grant number: 1999-11459), Not specified.

INDEX TERMS

Medical Subject Headings (MeSH)

Aminoglycosides [adverse effects] [*therapeutic use]; Anti-Bacterial Agents [*therapeutic use]; Cause of Death; Combined Modality Therapy [adverse effects] [methods]; Neoplasms [*complications]; Neutropenia [*drug therapy] [mortality]; Randomized Controlled Trials as Topic; beta-Lactams [*therapeutic use]

MeSH check words

Adult; Child; Humans